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Abstract 
Vaccine Preventable Diseases- IVlay Chiew BPharm, MPH 
Vaccination is one of the most significant public health interventions in history. In this 
thesis, I present work conducted as an Master of Applied Epidemiology (MAE) Scholar 
whilst placed at the National Centre for Immunisation Research and Surveillance 
(NCIRS) in 2012-2013. During my placement, I was involved in examining the 
epidemiology of a number of vaccine preventable diseases and also adverse events 
following immunisation (AEFI). A key requirement of the MAE is the analysis of a public 
health dataset; of which I present two analyses. Firstly, the impact of the human 
papillomavirus vaccine on high grade cervical abnormalities (HGAs) in Australia using 
screening data; the analysis found a significant reduction in HGAs in females under 20 
years post-vaccine compared to the pre-vaccine era, suggesting that the vaccine may 
have contributed to the decline in HGAs. Secondly, the epi-review on passive AEFI 
surveillance in children less than 18 years of age in 2000-2011 highlighted major 
events that occurred during this period. I also present two projects conducted as part of 
the measles outbreak in New South Wales (NSW) during 2012. The first was using a 
non-validated algorithm to identify an index case following four measles notifications 
that were linked by time and place to a paediatric hospital. The algorithm was 
unsuccessful in identifying an index case, however, may serve as a model that can be 
adapted and possibly validated for use in similar investigations in the future. The 
second was examining the epidemiology of healthcare transmissions during the 
outbreak. This study identified the importance of raising awareness of measles among 
clinicians during outbreaks and that measles control strategies may need a more 
targeted approach, particularly with limited resources. As part of my epidemiological 
study, I conducted an epi-review of measles in Australia. Since 1993, there was a 
considerable decline in measles notifications and hospitalisations; however; between 
2000 and 2011, notifications have fluctuated with a notable increase in 2011. National 
notification data (2009-2011) were also used to estimate the reproduction number (R) 
for measles. The three methods to estimate R were below one for all years suggesting 
that measles elimination had been sustained in Australia. I also calculated a measles 
discard rate in NSW; an indicator of high quality surveillance. This study further 
supported sustained measles elimination achieving the minimum standard of more than 
2 non-measles cases per 100,000 population suggesting that in NSW, endemic 
measles would be detected if wild virus was re-established. I also present another MAE 
requirement, evaluating the passive surveillance system for varicella-zoster virus 
nationally, as part of the National Notifiable Disease Surveillance System. I found that 
the sensitivity of the system in detecting the incidence of disease was poor; however, it 
was sensitive in detecting disease trends in when compared to other data sources. 
Additionally, more consistency in reporting by jurisdictions is necessary to improve the 
validity of the data. This thesis provides documentation of my MAE activities at NCIRS 
and includes how these activities have contributed to public health in Australia. 
About this thesis 
Four chapters in my MAE thesis include the four MAE projects: data analysis; 
epidemiological study; outbreak investigation and; evaluation of a surveillance system. 
Data analysis is separated into two chapters (Chapters 2 and 3), as I analysed two 
public health datasets for two very different conditions (adverse events following 
immunisation and high grade cervical abnormalities). Chapter 4 includes both the 
epidemiological study and outbreak investigations as these projects belong under the 
broader subject of measles. Lastly, Chapter 5 contains the evaluation of a surveillance 
system. 
Each chapter includes a separate table of contents and lists of figures, tables, 
abbreviations and acronyms and references, as each chapter is independent of each 
other, and is hence easier to refer to. 
On 18 September 2013, the machinery of Government changes resulted in the name 
change of the Department of Health and Ageing to the Department of Health. Please 
note that the former name is used throughout this thesis. 
Table of Contents 
Chapter 1 .Introduction 1 
Chapter 2.The impact of Human Papillomavirus Virus (HPV) vaccine on high 
grade cervical abnormalities in Australia 20 
Chapter 3.Vaccine safety in children and adolescents in Australia: the past, 
present and future 2000-2011 48 
Chapter 4. Measles in Australia: on the path to elimination 77 
Chapter 5. Evaluation of the national Varicella Zoster Virus (VZV) notification 
system in Australia 279 
Chapter 6. Teaching 359 
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Acronyms and Abbreviations 
ATAGI Australian Technical Advisory Group on Immunisation 
GDI Communicable Diseases Intelligence 
CDNA Communicable Diseases Network of Australia 
DoHA Department of Health and Ageing 
HGA High Grade Cervical Abnormalities 
HPV Human Papillomavirus 
MAE Master of Philosophy (Applied Epidemiology) 
NCEPH National Centre for Epidemiology and Population Health 
NCIRS National Centre for Immunisation Research and Surveillance 
NIP National Immunisation Program 
NSW New South Wales 
PAEDS Paediatric Active Enhanced Disease Surveillance 
PhD Doctor of Philosophy 
TGA Therapeutic Goods Administration 
WPRO Western Pacific Regional Office 
VPD Vaccine Preventable Diseases 
1.1 A field placement at the National Centre for Immunisation 
Research and Surveillance 
My first introduction to the IVIaster of Philosophy (Applied Epidemiology) (MAE) 
program was an advertisement that I received from the Australian Epidemiological 
Association. I had been contemplating whether to embark on a Doctor of Philosophy 
(PhD) in cancer epidemiology but was at a crossroads. I had always had an interest in 
infectious diseases and wanted more 'hands-on' experience in epidemiology as 
opposed to focusing solely on research. Fortuitously, I noticed the advertisement and 
took it as a sign to apply. 
National Centre for Immunisat ion Research and Surveil lance 
The National Centre for Immunisation Research and Surveillance of Vaccine 
Preventable Disease (NCIRS) was established by the Commonwealth Department of 
Health and Ageing in 1997 as part of the Immunise Australia: Seven Point Plan.' One 
initiative of the Immunise Australia program was to improve surveillance and reporting 
mechanisms for immunisation coverage, incidence of vaccine preventable diseases 
(VPDs) and outbreaks of VPDs. 
NCIRS envisages to reduce the incidence of VPDs and to increase vaccine coverage 
in children and adults. And endeavours to be the leading national source of evidence 
for immunisation policy and practice whilst upholding scientific independence and high 
credibility. NCIRS also aims to be the foremost immunisation related information 
provider for health care professionals. 
NCIRS manages and conducts epidemiological and serological research and analysis 
of VPDs and on immunisation which assists state and Commonwealth health 
departments in informing immunisation related policy. NCIRS' mission is "to promote 
the optimum control of vaccine preventable diseases in Australia through research, 
surveillance and evaluation of scientific evidence." Key activities of NCIRS includes 
surveillance, policy support, disease modelling, adverse events following immunisation 
(AEFI), the Paediatric Active Enhanced Disease Surveillance (PAEDS), vaccine 
program evaluation, clinical research, individual and social research and the provision 
of health care professional support. 
1.2 Summary of public health experiences and impact 
During my t ime at NCIRS, I was involved in a number of projects that provided me witt i 
a broad range of public health experiences, of which had signif icant public health 
impact. 
Firstly, I was involved in assessing the impact of the human papi l lomavirus (HPV) 
vaccine using screening data, which to my knowledge, was the first a detai led analysis 
has been conducted at a national level, globally. This was of particular interest to the 
Commun icab le Diseases Network of Austral ia (CDNA) HPV work ing party. The results 
of the project will also be part of the overal l evaluat ion of the HPV vaccinat ion program. 
The results of this project identif ied a reduction in high grade abnormal i ty (HGA) rates 
in females eligible for HPV vaccine under the National Immunisat ion Program (NIP). It 
also explored the strengths and l imitations of using screening data to examine the 
impact of the vaccine. A writ ten report will be provided to the Department of Health and 
Ageing (DoHA), and there is a plan to develop a manuscr ipt to submit to a peer-
reviewed journal. 
Addit ionally, I conducted data analysis on AEFI reports in chi ldren < 18 years between 
2000 and 2011. Following some major AEFI events in Austral ia during this period, the 
project reviewed the landscape of AEFI in the country, including the strengths and 
l imitations of the passive survei l lance of AEFI and how reporting has evolved over t ime. 
A review had not been conducted in Austral ia beforehand for this particular age group. 
A report will be submit ted to the Therapeut ic Goods Administrat ion (TGA) and a 
manuscr ipt submit ted to the Communicab le Diseases Intel l igence (CD!) journal. 
During 2012, I was involved in investigating two outbreaks which enabled me to fulfil 
my outbreak requirements. The first was a Staphylococcal aureus foodborne outbreak 
at an elite sport ing event ( A p p e n d i x A2). This outbreak highl ighted to me the 
chal lenges associated with investigating an outbreak with l imited resources and in a 
t imely manner. Also, it enabled me to understand that often, a source and vehicle for 
contaminat ion cannot be identified and obtaining food samples or spec imens f rom 
individuals is difficult. It also identif ied the important role that laboratories play during 
outbreaks. Co- leading this investigation equipped me with exper ience in developing a 
food exposure quest ionnaire, interviewing individuals and the analysis and 
interpretat ion of data collected. A report was developed and provided to the NSW 
Ministry of Health. There is a lack of report ing of Staphylococcal aureus foodborne 
[4] 
outbreaks in the literature and this outbreak added new knowledge to the 
understanding of Staphylococcal aureus outbreaks through a manuscript that I co-
authored with my fellow MAE published in GDI. The second outbreak investigation I 
was involved in was the 2012 NSW measles outbreak, with a specific focus on health-
care transmissions of measles. The measles outbreak provided me with an 
understanding of the operational response to an extremely infectious disease. I was 
able to gain experience in contact tracing, participating in post-exposure prophylaxis 
clinics, visiting emergency departments where transmissions occurred and working as 
surge staff in a number of local health districts and the NSW Ministry of Health. A 
manuscript was developed to highlight the importance of healthcare transmissions in 
an era where measles elimination exists and aims to raise awareness among clinicians 
in the suspicion of measles during times or measles outbreaks. A report on healthcare 
transmissions of measles during this outbreak was provided to the NSW Ministry of 
Health, and the results were also provided to the Measles Elimination working party. A 
manuscript is also planned for submission to a peer-reviewed journal. 
My epidemiological study chapter is comprised of three inter-related projects related to 
measles elimination in Australia and also includes the public health investigations on 
measles. I was fortunate not only to be involved in these three projects, but for their 
results to be used as evidence in assessing Australia's measles elimination status to 
be reviewed by the Regional Measles Verification Committed for the Western Pacific 
Region. I gained a lot of experience in cleaning and analysing data and also 
understanding the caveats in notification and laboratory data. Conducting an epi-review 
on measles notifications allowed me to familiarise myself with notification data and 
understand the national picture of measles in the country and the role of the vaccine 
program on disease incidence. I also used notification data in a modelling project which 
estimated the reproduction number (R) for measles. One aspect that I was hoping to 
understand more of before embarking on the MAE program was infectious disease 
modelling; and being involved in estimating R was a fantastic opportunity to grasp 
some understanding of modelling but also acknowledging the limitations associated 
with modelling. Furthermore, calculating the measles discard rate allowed me to gain 
an understanding on the types of testing that is conducted for measles. The measles R 
project has been accepted at the Bulletin of the World Health Organization. The 
measles epi-review will be submitted to CD! and the measles discard rate project will 
contribute to a national measles discard rate paper that is being developed by 
members of the National Measles Elimination Working Group. The results of this 
chapter is of signif icant public health impact as it adds to the argument of whether 
meas les el iminat ion has been sustained in Austral ia and will contr ibute to determining 
whether Austral ia can formal ly verify measles el imination in the country g iven the 
Region's target of measles el imination in 2012. 
I also evaluated the national notif ication of varicella zoster v i ruses (chickenpox shingles 
and unspecif ied). This project provided me with the opportuni ty to liaise with 
jur isdict ional and Commonwea l th Stakeholders, develop a quest ionnaire, col laborate 
with mult iple researchers using other data sources and examine mult iple lines of 
ev idence to generate key recommendat ions. A range of recommendat ions a im to 
improve the notif ication system, particularly the utility of it to monitor the impact of the 
vaccinat ion program. This project is of particular interest to the National Survei l lance 
Commit tee, C D N A Varicella Work ing Group and CDNA Herpes Zoster Work ing Group 
who are responsible in advising and implement ing change to the survei l lance system. 
A report will be d isseminated to Jurisdict ional and Commonwea l th stakeholders as well 
as the working groups abovement ioned. There are plans to also develop a manuscr ipt 
to submit to a peer-review journal. 
Lastly, I part icipated in the Field Epidemiology Training Program Fel lowship as a 
Rumour Survei l lance Officer at the Western Pacific Regional Off ice of the Wor ld Health 
Organizat ion (WHO) for five weeks in July and August 2013. I was responsible for 
col lect ing public health events through rumour and official channels; conduct ing rapid 
risk assessments on public health events; presenting public health events to 
col leagues work ing in the Division of Health Security and Emergencies; preparing 
reports; and liaising with survei l lance staff f rom Country Off ices within the region. 
Undertaking the fel lowship enabled me to exper ience working in a mult i lateral 
organizat ion for the first t ime. I learnt many things during my t ime there. Firstly, I learnt 
how to scan rumour channels for potential public health events of importance, 
systematical ly fo l lowed a rapid risk assessment algori thm to determine what act ions 
were required, garnered more knowledge on the International Health Regulat ions 
(2005) and Asia Pacific Strategy for Emerging Diseases (2010) and the role that the 
Wor ld Health Organizat ion plays and lastly, I learnt about many infectious d iseases 
affecting the region that I was unfamil iar with. 
1.3 Summary of core activities to meet MAE requirements 
Analyse a publ ic health dataset 
The impact of human papillomavirus vaccine on high grade cervical abnormalities in 
females < 20 years in Australia 
A twelve-year review of adverse events following immunisation in children < 18 years in 
Australia 
Outbreak invest igat ions 
Identifying the source case of measles in a paediatric emergency department in 
Sydney 
Healthcare acquired measles during the 2012 measles outbreak in NSW 
Epidemiologica l study 
A review of measles epidemiology in Australia; 2000—2011 
Estimating the measles reproduction number using notification data 
Calculating the measles discard rate in NSW 
Evaluat ion of a survei l lance system 
Evaluation of the national varicella surveillance system in Australia 
Scienti f ic manuscr ip t for a peer - rev iewed journal 
Chiew M, Gidding HF, Dey A, Wood J, Martin N, Davis N, Mclntyre P (2013) Evaluation 
of the measles reproduction number (R) as a practical means to track maintenance of 
measles elimination using routine notification data—the Australian experience. Bulletin 
of the WHO (accepted). 
Report for a public health bulletin 
Chiew M, Dey A, Martin N, Mclntyre P (2013).The epidemiology of measles in 
Australia; 2000—2011. CD! (late draft to be submitted) 
Report to a lay aud ience 
Chiew M (2013) Immunisation and changes in benefits. WebChild blog 
http://www.webchild.com.au/health/health-and-wellbeinq/immunisation-and-chanqes-in-
benefits 
Conference presentations 
Chiew M, Gidding HF, Dey A, Davis S, Mclntyre P (2012) Transmission of measles in 
an era of elimination in Australia; TEPHINET global conference, Amman, Jordan. 
I also gave several other oral presentations during the MAE program: 
NCIRS Journal Club - 29 November 2012 and 9 September 2013 
NCIRS Academic Meeting - 29 October 2013 
Infectious Disease Meeting at the Children's Hospital Westmead - 31 October 2012 
Western Pacific Regional Office, Division of Health Security and Emergencies 
meeting-30 August 2013 
Lessons from the field 
The verification of measles elimination in the Western Pacific: Has Country X achieved 
elimination? 
Teaching 
Pre-CDC Conference w/orkshop: Introduction to Epi Info™ 
MAE 2013 cohort exercises: Outbreak investigation intensives course block 
Coursework 
I completed the required MAE courses below: 
POPH8316 Outbreak investigation 
POPH8317 Public health surveillance 
POPH 8312 Research project in applied epidemiology 
POPH 8313 Analysis of public health data 
POPH 8315 Methods in applied epidemiology 
Course blocl< residential 
I attended the MAE residential blocks during March 2012, August 2012 and March 
2013. 
Other workplace activities 
Member of the National Measles Elimination Working Group Party 
Five-week Field Epidemiology Training Program Fellowship at the Western Pacific 
Regional Office in Manila, Philippines 
Co-led an outbreak investigation at an elite sporting events in 2012 in western Sydney 
Table 1: Summary of MAE course requirements included in the bound volume 
Course requirement Chapter 1 
Introduction 
Chapter 2: 
Human 
Papillomavirus 
Vaccine 
Impact 
Analysis 
Chapter 3: 
Analysis of passive 
surveillance of 
adverse events 
following 
immunisation 
Chapter 4: 
Measles-on 
the path to 
elimination 
Chapter 5: 
Evaluation of the 
passive 
surveillance of 
varicella infection 
in Australia 
Chapter 6: 
Teaching 
Analyse a public 
health dataset 
Evaluation or 
implementation of a 
public health 
surveillance system 
Conduct a field 
investigation 
Conduct and 
interpret an 
epidemiological 
study 
Literature review 
Scientific manuscript 
for a peer-reviewed 
journal 
Public health bulletin V 
Give an oral 
presentation 
Report to a lay 
audience 
Lesson from the 
field and teaching 
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Appendix A 
A1.1 Report to a lay audience 
j ^ c h i l d 
the online community for parents 
Immunisation And Changes In 
Benefits 
Writ ten by May Chiew | 24 July 2013 
May Chiew looks into the new immunisation requirements parents must meet to be eligible for the Family Tax Benefit 
Part A supplement. 
The Austral ian Government provides a number of payments to assist famil ies in the cost of raising 
chi ldren, including the Family Tax Benefit Part A supplement. To be eligible for this benefit, chi ldren need 
to be 'fully immunised ' against certain diseases by the end of the f inancial years in which they turn one, 
two and five years of age. 
W h a t A re T h e C h a n g e s ? 
As of 1 July this year, three new diseases were added to the list of d iseases chi ldren must be vaccinated 
against to receive the Family Tax Benefit Part A supplement. These are varicella (chickenpox), 
meningococca l C and pneumococca l disease. Also, the age at which chi ldren need to have their second 
dose of measles, mumps and rubella (MMR) vaccine has been brought fonj/ard from four years to 18 
months. 
To ensure they have received the required vaccines at the right t ime, a child's immunisat ion status will be 
assessed after parents lodge their tax return, by check ing the Austral ian Chi ldhood Immunisat ion Register 
- the register that records immunisat ions given to chi ldren under seven years of age. 
What Do These Changes Mean? 
Under the National Immunisation Program (NIP), three doses of vaccine against pneumococcal disease 
are recommended by six months of age. One dose of meningococcal C- containing vaccine and the first 
dose of MMR are recommended at one year of age. The vaccine against varicella (chickenpox) and the 
second dose of MMR are recommended at 18 months of age, and will now be given as a combination 
vaccine: the measles, mumps, rubella and varicella (chickenpox) vaccine (MMRV). 
If a child has already received the 18-month varicella (chickenpox) vaccine but not the 4-year MMR 
vaccine, the MMR vaccine will be given at 4 years of age. 
Why The Changes? 
These changes aim to increase the number of children who receive their recommended vaccines on time. 
Having the majority of children vaccinated means more children will be protected against these diseases, 
and that the amount of immunity In the community is high enough to protect those who can't be vaccinated 
because they are too young or because of medical reasons. Having high immunity In the community is 
also important to prevent disease outbreaks. 
Moving the second dose of MMR-contalning vaccine from four years to 18 months of age will protect 
children earlier against these three diseases. Also, the combination vaccine, MMRV, means children will 
be protected against the four diseases, with one less needle given. 
Will These Changes Cost Any th ing? 
Like all other vaccinations linked to family-assistance payments, the vaccinations against these three 
additional diseases are provided free of charge under the NIP. 
Are There Any Exempt ions? 
Parents can be given an exemption from meeting the Family Tax Benefit Part A supplement Immunisation 
requirements If their child is not 'fully Immunised' due to medical reasons, their parents' personal or 
religious beliefs, or if their child Is on a recognised catch-up plan. A form approving this exemption needs 
to be certified by a GP or an Immunisation provider. 
Where Can I Get More Informat ion? 
Further Information can be found on the Immunise Australia website at: 
http://lmmunise.health.gov.au/lnternet/lmmunlse/publlshing.nsf/Content/home 
A full list of diseases a child needs to be vaccinated against can be found at: 
http://www.humanservices.gov.au/customer/subjects/lmmunlslng-your-chlldren 
May Chlew is a Master of Applied Epidemiology Scholar for at the National Centre for Immunisation 
Research and Surveillance in Sydney. 
A2.1 Communicable Diseases Intelligence publication 
A N OUTBREAK OF STAPHYLOCOCCAL FOOD 
POISONING IN A COMMERCIALLY CATERED BUFFET 
Alenis nilsbury, >Aaf Chiew, John Botes, Vtcky Sheppeard 
Abstract 
Staph/locccca! food poisoning is a common cause 
of foodbome il'ness. in AijshTalia, since 2000, 
Gppro*ima*iely 30% of foodbome Sfop^yiococcus 
ou-reus cut-breaks reportea to OiFoodNet hove 
been associated foods pnepared by ccm-
mercia' ca^rera. VJe conducted o retrospechve 
cohcfi csnafyas of on CMjtbreak of gostrointestina 
ilJness among partidpants of on eli-^ sporting 
event during which 22 individuals became il 
after eating a corrimercjally catered buffet dinner 
in June 2012. All recoiled eoting fned rice which 
hod been intended for lunch service earlier that 
day and 20 of the 22 reported eating chicken 
stir-fry. Though no fo-od samples v/ere availoble 
for onal'f-sis, laborutor^ analysis conducted on 
four faecal sp-ecimens nesufted m 5. aoreu-s being 
cultured from one specimen and S. aureus entero-
toxin d e t e c t in another. The knov»ri epidemiol-
ogy of staphylococcal food poisoning suggests a 
food contominoted bj^  an infected food hondier 
which was subject to temperature abuse may have 
caused the outbreak. AsS. aureus fccdbcme oi-t-
breaks are often underrepcrted, this investigation 
IS a vaiuable ccntnbution to the evidence-base 
and understanding of foodbome illness due to 
S. aurew and staphybcoccol enterotoxin. 
Ke^ords : Stophylococcus oureus, eriterotoxins, 
outbreak, foodbome, rice, chicken 
Introduction 
Scaphylococcil food poisooing (SFP) is a common 
ciuse of foodbome iUneis worldwide.'*' SFP occurs 
following iogestian of staphylococcil enterotoziAs 
\K'hich heit resisciat and are produced in food 
following contamination by staphylococci, typi-
cally Stap^-lccoccus aureus. Foods including sliced 
meat meat products, salads, pastries, custards, 
raw milk and cheese products present a particular 
coataminaoon risk.^ Such a l^rge population of 
staphylococci is indicative of unhygienic food 
handling procedures and temperature abuse over a 
period of time to allow for bacterid growth.' 
In Australia, little published information ezisu 
describing past SFP outbreaks. OzFoodNet, hou'-
ever, collects information on all reported fbodborne 
illness outbreaks. Between January 2000 and March 
2012, OzFoodNet recorded 14 S.'aureus outt>reaks 
afi^ting 429 people (25 hospitalised; 1 death). In 
just under a third of these outbreaks, meals con-
taining chicken were implicated. 'Pventy-nine per 
cent of these outbreaks were associated with food 
prepared by a commercial caterer (OzFoodNet 
Outbreak Register June 2012. Unpublished data). 
The outbreak 
On 2 June 2012, 22 individuals who had par-
ticipated in an elite sporting e\'ent in Sydney 
experienced gastrointestinal symptoms alter 
eating a buflfet dinner served by the commercial 
catering company servicing the event. The day of 
the outbreak n'as the final day of the two week 
event and reportedly less busy at dinner time than 
previous meals. The 22 individuals were part of a 
larger cohon of up to 40 people who queued for 
dinner service earlier than the other SOO attendees 
due to the timing of their responsibilities at the 
event Within hours of eating, all 22 fell ill with 
symptoms including vomitiag, diarrhoea and 
abdominal cramping. Six people were transported 
to hospital. The event organiser reponed that only 
the early dining group vns aActed. 
This report summarises the epidemiological and 
microbiological investigations into the cause of 
the outbreak. 
Methods 
Ep4<lemiolooical investigation 
As this epidemiological investigation wasconducted 
as pan of the required public health response to a 
reponed outbreak, it was noc necessary to obtain 
ethical approval. 
In order to develop hypotheses regarding the cause 
of the outbreak, preliminary interviews were con-
ducted by telephone with several of the cases who 
attended the emergency department (ED) due to 
the severity of dieir symptoms. "Wfe drafted a food 
exposure questionnaire based on information from 
these interviews and information from a copy of the 
menu provided by the caterers. The questionnaire 
sought basic demographic details, food exposures 
(lunch and dinner), symptom description and 
duration, and illness history. Individuals were also 
asked whether they were <i\vare of anyone who liad 
been ill with gastrointestinal symptoms prior to or 
following the outbreak. 
A case was defined as anyone who ate the catered 
biirtet dinner on 2 lune 2012 at the early time 
(16:00 to 17:30) and experienced vomiting and/or 
diarrhoea and abdominal cramping commencing 
between 17:45 and 21:15. A confirmed case was 
someone meeting the case definition with S. aureus: 
or S. aureus toxin detected in a stool specimen. 
The names ot the cases as well as others who were 
thought to have dined early were provided bv the 
event organisers. .Ambulance Service NSW' and 
other interviewed attendees. Based on the knowl 
edge gleaned from these interviews, we conducted 
a retrospective cohort investigation to identity' 
risk factors for developing illness. Interview data 
were collated and attack rates and risk ratios were 
calculated for specific food exposures. Analysis was 
conducted using SAS® software (version 9.3). 
Microbiological and environmental 
investigations 
Xo food samples were available for resting. 
Faecal specimens were collected from 5 of the 
individuals who attended the ED. Initial testing 
tor Clostridium d i f f i c i l e . Salmonella. Shigella and 
Campylobacter species and norovirus was con-
ducted by the hospital laboratory. 
Four specimens were available to be sent to 
Queensland Health Forensic and Scientific 
Services laboratory where thev were cultured 
tor a tull range ot enteric pathogens (including 
Salmonella, Shigella and Campylobacter species) 
and toxin- mediated foodborne illness causing bac-
teria (5. aureus and Bacillus cereus). Samples were 
cultured on Baird Parker Agar for two days at 37°C 
for S. aureus and Phenol-Red Egg Volk Polvmixin 
Agar for B. cereus. Three faecal samples were tested 
for staphylococcal enterotoxin using the Tecra 
enzyme linked immunosorbent assay (TECR.\). A 
site inspection was conducted bv NSW Food Authority-
and is the subject of a separate internal report. 
Results 
Epidemiological results 
A total of 36 persons who ate an early dinner 
served bv the caterer were interviewed, with the 
majoritv interviewed 2 to 3 days after the inci-
dent. The median age of people interviewed was 
40 years (range 12 to 72 years); 78% were female. 
Among the 36 persons interviewed. 22 (61%) were 
identified as cases, including two persons with 
laboratory-cont'jrmed illnesses. 
Of the 22 cases, 18 (82%) were female, ranging 
from 12 to 69 years old (median 34 years). Of those 
who did not fall ill. 10 (71%) were female, ranging 
from 21 to 72 years old (median 46 years). 
Dinner limes reported by cases ranged from 16:00 to 
17:30. The epidemic curve illustrates the time distri-
bution of symptom onsets among cases ranging over 
a 4 hour period on 2 June (Figure 1). Incubation 
periods ranged from 1 hour to 4.75 hours (average 
2.5 hours). Illness typically began with the sudden 
onset ot vomiting, followed bv a period of concur-
rent vomiting and diarrhoea, with a median dura-
tion of 4 hours (range 2 to 13 hours). Of the 22 cases, 
21 experienced vomitn^g (96%); 17 had diarrhoea 
(77%) and 10 reported abdominal cramping (46%). 
Six people (27%) were transported to a local ED. No 
interviewees were aware of others with symptom 
onset ot gastrointestinal illness prior to or following 
the outbreak. 
Figure 1: Number of eases o fgas l ro in te s t ina l 
i l lness after the catered d inner on 2 June 2012, 
by t ime of onset (n = 22) 
I 
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Time of onset 
A number of food items were served during lunch 
and dinner. A selection of bread, cold meats (ham. 
chicken, turkev and silverside), salad and fried 
rice were available at lunch. Green salad, cole-
slaw, meatballs, cannelloni, boiled rice, fried rice, 
chicken stir fry, bread rolls, jelly and yoghurt were 
served for dinner. Fried rice intended for hmch 
service on the day of the outbreak was reportedly 
served to the early diners because the boiled rice for 
dinner service was not ready in time. 
All interviewees had eaten dinner earlv at the 
catered buffet while only 14 (39%) ate lunch there. 
Ninetv one per cent of cases ate both chicken stir -
fry and fried rice at dinner with attack rates and rate 
differences of 74% for chicken stir frv and 71% for 
fried rice (Table 1). The risk ratios for both dishes 
were undefined. Similarly, we were unable to con 
duct further analysis using stratification. Therefore 
it was not possible to identity an association with 
either chicken stir-trv or fried rice. 
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Tabic 1: Relative risks and attack rales for food items consumed by the cohort 
r vm. i f 
2 missing 
1 missing 
5 missing 
Salad 5 7 71 17 29 59 1.22(0.70-2.13) 0.68 
Coleslaw 2 2 100 20 34 59 1 70(1.28-2 25) 0.51 
Meatballs 15 24 63 7 12 58 1.07 (0.61-1 89) 1.00 
Cannelloni 14 25 56 8 11 73 0.77 (0.47-1.27) 0.47 
Fried rice 22 31 71 0 5 0 undefined 0.005 
Chicken stir-fry 20- 27 74 0 7 0 undefined 0.0006 
Yoghurt 5 8 63 17 28 61 1.03 (0.56-1.90) 1.00 
Jelly 8' 13 62 13 22 59 1.04 (0 60-1.81) 1.00 
Bread roll 11« 17 65 7 14 50 1.29 (0.69-2.43) 0.48 
Microbiological and environmental results 
Ini t ia l s c r e e n i n g re su l t s for all f ive s p e c i m e n s w e r e 
nega i i \ ' e tor n o r o v i n i s , C . dijftcile. Salmonella, Shigella 
a n d Campylobacter spec ie s . 
Q v i e e n s l a n d H e a l t h F o r e n s i c a n d Sc ient i f ic S e r v i c e s 
l abora to ry c u l t u r e d S. aureus in o n e s p e c i m e n , . • \nother 
s p e c i m e n tested pos i t ive for S. aureus enterotox in . 
T h o u g h n o f o o d s a m p l e s r e m a i n e d f o r l a b o r a t o r y 
t e s t i n g , t h e c a t e r i n g c o m p a n y c o n f i r m e d t h a t f o o d 
h a n d l i n g p o l i c i e s w e r e in p l a c e t o p r e v e n t c o n -
t a m i n a t i o n a s w e l l a s t i m e a n d t e m p e r a t u r e a b u s e . 
N o e v i d e n c e o f t i m e a n d t e m p e r a t u r e a b u s e w a s 
o b s e r v e d d u r i n g t h e s i t e i n s p e c t i o n . T h e c a t e r i n g 
c o m p a n y a l s o r e p o r t e d t h a t n o s t a f f m e m b e r s 
w e r e k n o w n to b e s u f f e r i n g f r o m g a s t r o i n t e s t i n a l 
i l l n e s s d u r i n g t h e s p o r t i n g e v e n t . 
Discussion 
5. aureus is o n e o f the m o s t c o m m o n p a t h o g e n s in 
h u m a n s , e s t i m a t e d to c o l o n i s e a p p r o x i m a t e l y 2 5 % o f 
hea l thy adults .^ M u l t i p l e p a t h o g e n i c s t ra ins p r o d u c e 
en te ro tox ins w h i c h , w h e n inges ted , c a n c a u s e ga s t ro-
enteritis.® In Aus t ra l i a , S. aureus in tox icat ion a c c o u n t e d 
for 1% o f all s u s p e c t e d a n d c o n f i r m e d foodborne 
o u t b r e a k s r epor ted to O z F o o d N e t b e t w e e n J a n u a r y 
2 0 0 0 a n d M a r c h 2012 . M e a l s i n c l u d i n g ch icken , beet; 
s e a f o o d , a n d l a m b , a s well a s p a s t a s a l a d a n d rice d i shes 
h a v e all b e e n i m p l i c a t e d a s s o u r c e o f in fec t ion in these 
S. aureus en tero tox in o u t b r e a k s ( O z F o o d N e t O u t b r e a k 
Register. J u n e 2012 . r n p u b l i s h e d d a t a ) . 
O u r findings s u g g e s t e d that c h i c k e n stir fry a n d / o r 
fr ied rice w e r e tlie f o o d vehic les r e spons ib le for i l lness . 
A l t h o u g h it w a s not p o s s i b l e to d e t e r m i n e risk rat ios for 
f r ied rice a n d c h i c k e n stir-try, the a t tack rates a n d rate 
d i f f e rences c a l c u l a t e d s u p p o r t this c o n c l u s i o n . If w a s 
not pos s ib le to c o n s i d e r these e x p o s u r e s i n d e p e n d e n t l y 
a s all c a se s w h o w e r e ab le to recollect repor ted e a t i n g 
b o t h food i tems . 
S F P o u t b r e a k s r e s u l t f r o m c o n t a m i n a t i o n o t f o o d 
w i t h S. aureus f r o m f o o d h a n d l e r s e i t h e r t h r o u g h 
s k i n i n f e c t i o n o n u n c o v e r e d h a n d s o r a r m s , o r v i a 
c o u g h i n g or s n e e z i n g o v e r t o o d t h a t i s n o t s u b -
j e c t e d t o f u r t h e r c o o k i n g . C u r r e n t i n d u s t r y g u i d e 
l i n e s r e q u i r e f o o d h a n d l e r s t o e n s u r e t h e i r b o d i e s , 
a n d a n y t h i n g f r o m t h e i r b o d i e s o r c l o t h i n g , d o 
n o t c o n t a m i n a t e f o o d or f o o d p r e p a r a t i o n a r e a s . ' 
F o r t h e b a c t e r i a to g r o w t o s u f f i c i e n t n u m b e r s , t h e 
c o n t a m i n a t e d f o o d m u s t b e le f t in t e m p e r a t u r e 
c o n d i t i o n s w h e r e t h e b a c t e r i a a r e a b l e t o p r o l i f e r -
a te . 5 . aureus p r o d u c e s p r e - f o r m e d t o x i n s t h a t h a v e 
a n e m e t i c a n d d i a r r h e a l e f fect .^ 
In t h i s i n v e s t i g a t i o n , t h e r e w a s n o e v i d e n c e o f t e m -
p e r a t u r e a b u s e a n d w e w e r e u n a b l e t o d e f i n i t i v e l y 
i d e n t i t y a c a u s e o f t h e o u t b r e a k . T h e e n v i r o n m e n -
ta l i n v e s t i g a t i o n r e v e a l e d n o f o o d s a f e t y b r e a c h e s , 
a n d t h e a b s e n c e o f f o o d s a m p l e s m a d e it i m p o s -
s i b l e t o identity- t h e f o o d v e h i c l e r e s p o n s i b l e f o r t h e 
o u t b r e a k . T h e o n l y a p p a r e n t d i f f e r e n c e in f o o d s 
s e r v e d t o t h e e a r l y d i n e r s w a s t h e f r i e d r ice w h i c h 
h a d b e e n i n t e n d e d for l u n c h s e r v i c e . 
T o p r e v e n t t o x i n - b a s e d o u t b r e a k s , it i s i m p o r t a n t 
t h a t c o m m e r c i a l f o o d p r o v i d e r s a d h e r e t o s t r i c t 
t e m p e r a t u r e p r o t o c o l s a n d e n s u r e g o o d f o o d 
h a n d l i n g p r a c t i c e s . M a n a g e m e n t a n d s t a f f n e e d 
t o b e a l e r t t o t h e p r e s e n c e o f i n f e c t e d s k i n l e s i o n s 
o r d i s c h a r g e s f r o m n a s a l p a s s a g e s , e a r s o r e y e s in 
t o o d h a n d l e r s . A p p r o p r i a t e m e a s u r e s s h o u l d b e 
t a k e n t o e n s u r e t h a t n o ill i n d i v i d u a l s c a n c o n -
t a m i n a t e f o o d o r f o o d c o n t a c t s u r f a c e s . ' ® 
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I n v e s t i g a t i o n o f t o x i n - m e d i a t e d f o o d b o r n e i l l-
n e s s i s p a r t i c u l a r l y p r o b l e m a t i c d u e t o s h o r t o n s e t 
t i m e s a n d d u r a t i o n o f s y m p t o m s . F u r t h e r m o r e , a s 
S. aureus i s n o t a n o t i f i a b l e d i s e a s e o u t b r e a k s o f t e n 
g o u n d e t e c t e d . T h i s o u t b r e a k w a s o n l y l i k e l y t o 
h a v e b e e n r e p o r t e d d u e t o t h e n a t u r e o f t h e s p o r t i n g 
e v e n t a n d t h e l a r g e n u m b e r o f i n d i v i d u a l s a f f e c t e d . 
L i m i t a t i o n s 
T h i s i n v e s t i g a t i o n w a s l i m i t e d in s e v e r a l w a y s . 
T h o u g h i n t e r v i e w s w e r e c o n d u c t e d a s s o o n a s 
p o s s i b l e f o l l o w i n g t h e o u t b r e a k , a n u m b e r o f 
i n d i v i d u a l s h a d d i f f i c u l t y r e m e m b e r i n g a l l f o o d s 
c o n s u m e d . A h i g h p r o p o r t i o n o f i n d i v i d u a l s 
w h o d i n e d e a r l y s t r o n g l y b e l i e v e d t h a t t h e f r i e d 
r i c e i n t e n d e d t o r l u n c h w a s t h e i n f e c t i o n s o u r c e . 
M o r e o v e r , p a r t i c i p a n t s h a d e x t e n s i v e l y d i s c u s s e d 
t h e o u t b r e a k a n d t h e o r i e s o n i t s c a u s e , p r e d o m i 
n a n t l y t h r o u g h s o c i a l m e d i a , p o t e n t i a l l y i n t r o d u c -
i n g b i a s t o t h e i n v e s t i g a t i o n . 
T h e m i c r o b i o l o g i c a l i n v e s t i g a t i o n w a s a l s o 
i m p a c t e d b y l i m i t a t i o n s . F i r s t ly , i n i t i a l a n a l y s e s o f 
f a e c a l s p e c i m e n s w e r e r e s t r i c t e d t o in h o u s e P G R 
a s s a y s a n d n o t c u l t u r e d a s p e r t h e N S W H e a l t h 
o u t b r e a k p r o t o c o l w h i c h s p e c i f i e s t h a t a l l f a e c a l 
s p e c i m e n s r e l a t e d t o p o t e n t i a l o u t b r e a k s u n d e r g o 
r o u t i n e e n t e r i c c u l t u r e . N e v e r t h e l e s s . S. aureus i s 
u n l i k e l y t o b e g r o w n u s i n g r o u t i n e c u l t u r e , a n d 
t h e d e l a y w h i c h e n s u e d f r o m t h e n e e d t o t r a n s p o r t 
s a m p l e s t o Q u e e n s l a n d f o r t o x i n t e s t i n g w o u l d 
h a v e d e c r e a s e d t h e y i e l d w h e n a p p r o p r i a t e l y c u l -
t u r e d t h e r e . G i v e n t h e t i m e d e l a y b e u v e e n o n s e t 
a n d r e c e i p t o f t h e s a m p l e s a n d t h e v a r i a b l e s t o r -
a g e t e m p e r a t u r e s o f t h e s a m p l e s d u r i n g t h a t t i m e , 
it i s u n s u r p r i s i n g t h a t o n l y I p o s i t i v e r e s u l t w a s 
r e t u r n e d . T h i s u n d e r l i n e s t h e i m p o r t a n c e o f g o o d 
c o m m u n i c a t i o n b e t w e e n p u b l i c h e a l t h i n v e s t i g a -
t o r s a n d l a b o r a t o r i e s s o t h a t s p e c i m e n s a r e t e s t e d 
a c c o r d i n g t o t h e c l i n i c a l a n d e p i d e m i o l o g i c a l p i c -
t u r e . A d d i t i o n a l l y , v o m i t u s s p e c i m e n s w o u l d h a v e 
b e e n p r e l e r a b l e tor a n a l y s i s a s s t a p h y l o c o c c a l 
e n t e r o t o x i n is c l e a r e d f r o m t h e g u t q u i t e q u i c k l y 
U n f o r t u n a t e l y , n o s a m p l e s o f v o m i t u s w e r e c o l 
l e c t e d a s t h i s i s n o t a r o u t i n e p r a c t i c e in E D s a n d 
v o m i t i n g h a d r e s o l v e d b e f o r e t h e p u b l i c h e a l t h 
i n v e s t i g a t i o n c o m m e n c e d . 
Conclusion 
I n f o r m a t i o n o b t a i n e d f r o m c a s e i n t e r v i e w s a n d 
t h e r e s u l t s o f m i c r o b i o l o g i c a l t e s t i n g o f h u m a n 
s p e c i m e n s s u p p o r t a c o n c l u s i o n t h a t e n t e r o t o x i 
g e n i e S. aureus b a c t e r i a w e r e r e s p o n s i b l e f o r t h i s 
o u t b r e a k . W e w e r e u n a b l e to d e t i n i t i v e l y i d e n t i f y 
a f o o d v e h i c l e in t h i s o u t b r e a k . S. aureus a s s o c i -
a t e d o u t b r e a k r e p o r t s a r e r a r e l y p u b l i s h e d in 
A u s t r a l i a d e s p i t e b e i n g s u c h a c o m m o n c a u s e o f 
f o o d b o r n e i l l n e s s w o r l d w i d e . T h i s i n v e s t i g a t i o n 
i m p r o v e s o u r u n d e r s t a n d i n g o f t h e e p i d e m i o l o g y 
ot f o o d b o r n e S. aureus o u t b r e a k s in A u s t r a l i a . 
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Abstract 
Introduction: 
In 2007, Australia implemented a national human papillomavirus (HPV) vaccine 
program, the first country in the world to fund the vaccine through a national program. 
HPV-related cervical abnormalities, are a precursor to the development of cervical 
cancer and through data from the well-established National Cervical Screening 
Program, it was timely to examine the impact of the HPV vaccine program on the 
detection of cervical abnormalities. 
Methods: 
Data on screening participation and high grade cervical abnormalities (HGAs) were 
obtained from cervical cancer screening reports published by the Australian Institute of 
Health and Welfare (2004-2011). Corresponding population estimates for these years 
were obtained from the Australian Bureau of Statistics. Absolute rates (RR) of HGAs 
detected and rate ratios comparing post-vaccine and pre-vaccine rates were calculated 
Results: 
Between 2004 and 2011, cervical screening rates for all age groups declined. The rate 
of HGAs post vaccine (2008-2011) was found to be significantly lower than during the 
pre-vaccine (2004-2007) with a 34% decline (95% CI: 30%-37%) in females <20 
years. Reductions were observed even when accounting for decline in screening 
participation among <20 years. 
Conclusion: 
Our results provide evidence that the rate of HGA among females <20 years, who were 
targeted for the HPV vaccine has significantly declined following the introduction of the 
HPV vaccine program. Although inference between the vaccine and HGA detection 
cannot be asserted due to the nature of the study, our preliminary results suggest that 
HPV vaccine is effective in reducing the incidence of HGAs. Further prospective cohort 
studies are required to provide evidence-base for the association between the two. 
Prologue 
My role 
Prior to starting the Master of Philosophy (Applied Epidemiology) (MAE), I met with Drs 
Aditi Dey, Helen Quinn and Robert Menzies, all senior researchers at National Centre 
for Immunisation Research and Surveillance (NCIRS). NCIRS are involved in policy 
and adverse event research on Human Papillomavirus (HPV) vaccines and at that time 
were in discussions with the Department of Health and Ageing (DoHA) to evaluate the 
National HPV Vaccination Program (NHVP) with a number of other collaborators. They 
wanted to gauge my interest in working on HPV vaccine related projects, of which I 
was extremely interested given my work at Cancer Council NSW on cancer screening. 
Towards the end of my first year (2012) as an MAE scholar, Aditi and I commenced a 
project looking at the impact of HPV vaccine on the rate of high grade cervical 
abnormalities (HGA) in females targeted for the vaccine. I was the primary investigator 
in this study, which was conducted as part of the evaluation of the NHVP. My role 
included developing a project proposal, reviewing the literature, conducting data 
analysis and drafting a manuscript for the project, which is included in this chapter. 
This manuscript was very much a partnership, as I worked closely with Aditi, who 
provided me with advice and guidance during all stages of the project. Aditi's role 
included reviewing the project plan, providing advice during data analysis and providing 
feedback on the draft report. Professor Peter Mclntyre, Director of NCIRS, Dr Julia 
Brotherton (Victorian Cervical Cytology Service), Dr Dorota Gertig (Victorian Cervical 
Cytology Service), Dr Bette Liu (The Sax Institute), Dr Alison Budd (Australian Institute 
of Health and Welfare), Ms Michelle Bradley (DoHA) and Mr Joel Willis (DoHA) were 
also involved in this project, reviewing drafts of the manuscript. 
Lessons learnt 
This project enabled me to learn a number of new skills. Firstly, Aditi introduced me to 
EpiBasic which is a free data analysis program available for download. It is a useful 
tool for conducting basic analysis and does not require any syntax. I learnt how to 
calculate a rate ratio using a post-vaccine period compared to a pre-vaccine period. 
I also learnt that when interpreting the results of this project, I needed to consider a 
number of factors. For example, changes in screening participation and sexual 
behaviour may be driving the changes in the decline in rate of cervical abnormalities. 
Additionally, I discovered international screening guidelines recommend that women 
<25 years of age should not be screened, yet Australia recommends screening at 18 
years or two years after sexual debut, whichever is later. I learnt that Australia also 
screens at a more frequent rate (every two years) than what is internationally 
recommended (every three years for women under 50 years of age). 
Furthermore, I learnt how to format a report to make it look presentable based on a 
common template used at NCIRS, including how to develop a table of contents in 
Microsoft Word. 
Another important lesson I learnt was the intricacies in obtaining data from reports. It 
was at times a tedious job that required careful reading of the fine print. It was a new 
experience for me, as I am used to being provided a dataset however, I have learnt 
that self-retrieval of data needs to be meticulous to prevent potential errors occurring. 
Public health action 
The project was conducted to determine if there were any changes in the prevalence of 
high-grade cervical abnormalities at a national level. The results from this study will 
form part of the national evaluation of the NHVP which aims to assess how well the 
NHVP is performing. This has policy implications; if the vaccine program is not 
performing well; for example, the prevalence of disease has remained unchanged or 
increased; it gives rise to conducting further analytical studies to determine if the 
incidence of disease is truly being affected. If further analytical studies produce strong 
evidence for the success or failure of the NHVP, there is a potential for programmatic 
change. 
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Introduction 
Persistent infection with Human Papilloma Virus (HPV) has been found to contribute to 
nearly all cases of cervical cancer.'' In Australia, cervical cancer was the twelfth most 
common cancer among females with 631 incident cases occurring in 2009.^^ Cervical 
cancer incidence and mortality in Indigenous females has been found to be twice as 
high than non-Indigenous females." In June 2006, the quadrivalent HPV vaccine, 
Gardasil®^ was registered for use in females aged 9 - 2 6 years. The following year, the 
bivalent HPV vaccine, Cervarix®® was registered for females aged 10-45 years. From 
mid-2010 the registered indication for Gardasil®in Australia was extended to females 
aged up to 45 years and males aged 9 -26 years.^ 
In April 2007, Australia became the first country to implement a fully funded National 
HPV Vaccination Program (NHVP) for females aged 12-13 years.® In addition, there 
were two catch-up phases between April 2007 and December 2009 for 13-17/18-year-
old females through school-based vaccination programs as well as 18-26-year-old 
females through general practice and community settings.® The quadrivalent HPV 
vaccine is being used for the NHVP, offered through state and territory school-based 
vaccination programs as a course of three injections over six months. A National HPV 
Vaccination Program Register (NHPVR) was established to record vaccine delivery 
and allow monitoring of the NHVP.® In February 2013, the program was extended to 
include males aged 12-13 years as part of the school-based program, with a two year 
catch-up program for males aged 14-15 years until December 2014.^° 
The National Centre for Immunisation Research and Surveillance (NCIRS), as part of 
its responsibilities under the funding agreement with the Australian Government 
Department of Health and Ageing (DoHA), has a contractual role in evaluating 
immunisation programs in collaboration with other stakeholders. As part of the 
evaluation, the effect of the NHVP on HPV-related cervical abnormalities nationally was 
assessed in this paper. 
Regular Papanicolaou smears ("Pap testing") through the National Cervical Screening 
Program (NCSP) allow for the early detection and treatment of HPV-related cervical 
abnormalities prior to the development of cervical cancer. Females are recommended 
to have regular Pap testing every two years, starting at 18-20 years (for those who 
ever have been sexually active) or two years after first sexual intercourse, whichever is 
later.^ The target age group of the NCSP is females 20 -69 years of age. ' Between 
2010 and 2011, over 3.7 million females were screened.^ During this period, Pap 
testing detected low-grade cervical abnormalities in approximately 163,050 tests and 
high-grade cervical abnormalities (HGAs) in a further 58,000 tests .^ ' Low-grade 
abnormalities were found to peak in females aged < 20 years, and HGAs were found to 
peak in females aged 25-29 years .^ ' Under screening guidelines, HGAs must be 
histologically confirmed prior to the commencement of any treatment." Since the 
implementation of the NHVP in 2007, there has been limited evidence of the effect of 
HPV vaccine on the incidence of low- and high-grade cervical abnormalities. In the 
state of Victoria, an analysis of incident cervical abnormalities in the post-vaccination 
period (1 April, 2007 to 31 December, 2009) compared with the pre-vaccination period 
(1 January, 2003 to 31 March, 2007) found evidence of a significant reduction in 
detection of histologically confirmed HGAs in the youngest age group only (< 18 years 
of age). A significant decrease of 0.38% in incidence of high grade abnormalities in this 
age group was found in the first two years after the implementation of the NHVP.^^ 
The aim of this study was to assess the prevalence of HGAs over time by age group in 
Australian females eligible and not eligible for the NHVP at a national level and by 
jurisdiction in women attending for cervical screening. This report provides a summary 
of cervical screening program statistics across all states and territories in Australia. 
Methods 
Information was taken from the Australia Institute of Health and Welfare (AIHW) reports 
Cervical Screening in Australia published during 2011-2013. ^ " All data, including 
data presented in graphs, are from these reports unless otherwise specified. These 
reports are compiled using data on the number of females screened and results of 
screening tests obtained from the eight jurisdictionally based cervical cytology 
registries {'Pap Test Registers'), all of which report standardised data on a regular 
basis to AIHW for monitoring of the NCSP. Subsequent results or clinical information 
received by the registries is not updated to the AIHW.^ Data collected from cytology 
registhes aims to monitor the effectiveness of the NCSP using performance indicators 
for participation, rescreening, cytology, histology, and the cytology-histology 
The analysis was an ecologic design with comparisons between 2004-2007 and 2008-
2011. The years, 2008-2011, were considered as the post-vaccine period as the 
NHVP commenced in April 2007. The three-dose schedule over a six-month period and 
the time required for a HPV incident infection to progress to a clinically detected high-
grade cervical abnormality would render it extremely unlikely that the vaccine would 
have any impact on HGAs during 2007. 
The annual rate of females attending screening was assessed by age group, using 
estimated resident population data by jurisdiction and at a national level from the 
Australian Bureau of Statistics as the denominator. The population was adjusted to 
include only females with an intact uterus (and cervix) using age-specific hysterectomy 
fractions derived from the National Hospital Morbidity Database (NHMD).^ The NHMD 
included public and private hospital separations. The majority of females who have had 
a hysterectomy are not at risk of cervical cancer as their cervix was removed. It is 
important to note that the NCSP recommends screening biennially and hence report 
screening participation over two years. In this report, we have calculated annual 
screening rates to assess whether any changes in screening patterns were occurring 
on a yearly basis. 
Histopathologically defined HGAs included lesions coded as cervical intraepithelial 
neoplasia of grade 2(CIN 2) or 3 (CIN 3), adenocarcinoma in situ or endocervical 
dysplasia. HGAs detected only by cytology were excluded, as a referral for biopsy, with 
subsequent histologic examination is routine, following detection of HGA by cytology.'" 
Under national guidelines, a female with Pap result of high-grade squamous 
intraepithelial lesion (including possible) is referred to a gynaecologist for colposcopy 
and targeted biopsy.^' In Australia, although colposcopy is part of the management of 
HGAs, histology is considered best practice to confirm HGA.' 11 
Data on numbers of females screened, and numbers of HGAs detected from 2004 to 
2011 (2004-2007; 2008-2011 and individual years) were tabulated by age groups (<20; 
20-24; 25-29; 30-34; 35-69) and by jurisdiction. Trends in rate of HGAs detected 
were examined. Absolute rates, rate ratios (RR) and 95% confidence intervals were 
used to quantify changes. 
A sensitivity analysis in females < 20 years was conducted to determine whether 
changes in screening participation affected HGA rates observed in this population. This 
could occur if women at high risk of abnormalities are no longer screening at the same 
rates. Females aged 18 and 19 years of age not screened (based on estimated 
resident population minus number of screened females for a particular post-vaccine 
year) were included in the analysis using pre-vaccine rates of detected HGA and 
examined by each post-vaccine year (2008-2011). Expected rates of HGA detected for 
all females in this age group had they all been screened were calculated. 
Results 
A n n u a l S c r e e n i n g R a t e s 
Trends in the AIHW data show that annual screening rates among the female 
population progressively declined, particularly among females <35 years of age. In 
particular, screening rates among females <20 years, 2 0 - 2 4 years and 2 5 - 2 9 years 
decreased from 2007 onwards (the year the NHVP commenced); whereas screening 
rates among females 35 -69 years remained relatively constant (Figure 1). 
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Overall, screening rates decreased significantly across all age groups when comparing 
the post-vaccine period with the pre-vaccine period (Table 1). The greatest reduction in 
screening observed was in females <20 years of age. There was a 15% reduction in 
screening rate during the post-vaccine period compared to the pre-vaccine period. 
Screening rates in females aged 2 0 - 2 4 years of age and 2 5 - 2 9 years of age 
decreased by 9% when comparing the post-vaccine period to the pre-vaccine period. 
Table 1. Screening rates and rate ratios, by age group, 2004-2011^"" 
Age 
group 
Pre-vaccine period Post-vaccine period Post-vaccine/ 
Pre-vaccine 
(years) 
Population Screened Rate Population Screened Rate Rate ratio 
(no) (no) (95% CI) 
<20 1107561 252953 22,8 1169551 226331 19.4 0.85 (0.84-0.85) 
20-24 2849997 758264 26.6 3090092 746681 24.2 0.91 (0.91-0.91) 
25-29 2763886 894450 32,4 3140280 923625 29.4 0.91 (0.91-0.91) 
30-34 2980738 1049064 35.2 2961738 967951 32.7 0.93 (0.93-0.93) 
35-69 14972870 5068429 33.9 16056654 5261552 32.8 0.97 (0.97-0.97) 
Source: Cervical screening in Australia 2010-2011, AIHW 
t ABS population estimates of 18-19 years as denominator for < 20 year age group 
" Screening rate per 100 female population per 4-year period 
* Comparing 2009-2011 period with 2004-2007 period, by age group, adjusted for tiysterectomy fraction 
HGAs detected 
Following the implementation of the NHVP, the number and rate ratios of HGA 
detected in females aged < 20 years and 20-24 years of age decreased (Table 2, 
Figure 2). The absolute numbers of HGAs detected in females 25-29 years increased 
and HGA rates during post-vaccine years were significantly greater than during the pre-
vaccine year. In the older age groups (30-34 years; 35-69 years), the number of HGAs 
detected and HGA rate ratio over time increased with each post-vaccine year when 
compared to the pre-vaccine year, (See Appendix B1 for rates). 
Table 2. Number of females with high-grade abnormalities detected by histology 
by age, 2004-2011 
Year 
Age group 
(years) 
2004 2005 2006 2007 2008 2009 2010 2011 
<20 915 851 803 750 653 518 416 385 
20-24 3,673 3,826 3,707 3,823 4,044 3,799 3,566 3,220 
25-29 3,879 3,931 3,861 4,186 4,379 4,464 4,524 4,543 
30-34 3,111 3,127 2,945 2,933 3,126 3,155 3,201 3,378 
35-69 4,418 4,434 4,602 4,729 4,908 4,839 5,000 5,500 
Source: Cerv ical screening in Austral ia 2010-2011, A I H W 
Figure 2. Rate ratio of females detected witli a HGA per 1000 females screened 
by age group, 2008-2011 
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The most striking reduction was observed in females <20 years, where a reduction in 
rate of HGA detected occurred during the post-vaccine period compared to the pre-
vaccine period (Figure 2). Following the introduction of the NHVP, the rate of HGA 
detected in 2008 was 10.8 (95%CI, 10.0-11.6) per 1000 females screened, an 18% 
(95% CI: 11%-25%) reduction from the rate during the pre-vaccine period (2004-2007) 
of 13.1 (95%CI: 12.7-13.6) per 1000 females screened. The rates further declined in 
2009 and 2010, with a 33% (95%CI, 26%-39%) and 41% (95%CI, 34%-47%) 
reduction in rate compared to the pre-vaccine period, respectively. In the most recent 
post-vaccine year (2011), the most pronounced decline occurred, 46% (95%CI: 40%-
51%) lower than the rate during the pre-vaccine period. 
Given limited numbers at the jurisdictional level, for example the small populations in 
the Northern Territory, successive two-year periods (2008-2009 and 2010-2011) were 
compared with data for 2004-2007 (Table 3). At the national level, a significant decline 
was observed in 2008-2009 compared to 2004-2007, and a further significant decline 
in detected HGAs per 1000 women screened from 2008-2009 in 2010- 2011. When 
stratifying by jurisdiction, the rates of HGA detected per 1000 females aged <20 years 
screened decreased in all jurisdictions by 2010-2011, three years after NHVP 
commenced (Table 3). The Northern Territory (NT) reported the highest rates of HGA 
of all the jurisdictions during the pre-vaccine period and this remained the case in the 
post-vaccine periods. Despite the high rates, in 2010-2011 in the NT, a statistically 
significant 43% reduction (95% CI, 1%-69%) in HGA rate was detected compared to 
the pre-vaccine period. 
Table 3. Rate of HGA detected per 1000 females aged < 20 years screened and 95% conf idence Intervals by jur isd ic t ion, 2004-
2011 
Jurisdiction Pre-vacclne 2004-2007 
Post-vaccine 
2008-2009 
Post-vaccine 
2010-2011 
Combined 
post-vaccine period 
2008-2011 
Rate (CI)* Rate (CI)* Rate ratio (Cl)'^ Rate (CI)* 
Rate ratio 
(CI)- Rate (CI)* 
Rate ratio 
(Cl)'^ 
NSW 16.2 10.8 0.66 8.2 0.50 9.5 0.59 
(15.3-17.2) (9.7-11.9) (0.59-0.75) (7.2-9.2) (0.44-0.58) (8.8-10.3) (0.53-0.65) 
VIC 10.8 9.7 0.90 5.9 0.55 7.9 0.73 
(9.9-11.7) (8.5-11.1) (0.77-1.06) (4.9-7.0) (0.44-0.66) (7.0-8.8) (0.64-0.84) 
QLD 
13.6 8.8 0.65 7.9 0.58 8.4 0.62 
(12.7-14.6) (7.8-9.9) (0.56-0.74) (6.9-9.1) (0.50-0.68) (7.6-9.2) (0.55-0.69) 
WA 
10.0 8.0 0.80 7.2 0.71 7.6 0.76 
(9.0-11.2) (6.7-9.5) (0.65-0.98) (5.8-8.7) (0.57-0.89) (6.7-8.7) (0.64-0.90) 
SA 
9.1 9.7 1.07 8.7 0.96 9.2 1.01 
(7.8-10.6) (7.7-12.1) (0.81-1.40) (6.8-11.0) (0.71-1.27) (7.8-10.8) (0.81-1.27) 
NT 
18.5 17.8 1.04 10.1 0.57 14.6 0.82 
(12.8-26.1) (13.9-22.5) (0.67-1.60) (5.8-16.5) (0.31-0.99) (10.8-19.3) (0.56-1.02) 
TAS 
18.1 16.8 0.93 6.0 0.33 11.7 0.65 
(15.4-21.2) (12.8-21.5) (0.68-1.25) (3,6-9.3) (0.19-0.53) (9.3-14.6) (0.49-0.85) 
ACT 
11.7 6.2 0.53 4.1 0.35 5.2 0.45 
(8.9-15.0) (3.4-10.4) (0.27-0.96) (1.8-8.1) (0.15-0.74) (3.3-7.9) (0.26-0.74) 
National 13.1 9.8 0.75 7.5 0.57 8.7 0.66 
(12.7-13.6) (9.3-10.4) (0.70-0.80) (6.9-8.0) (0.53-0.61) (8.3-9.1) (0.63-0.70) 
* Crude rates are the number of females with high grade abnormal i t ies detected by histology as a proport ion of all females screened 
[38] 
At the national level, a progressive reduction in rate of HGA in females aged 20-24 
years of age was observed each year since 2008 (Figure 2). In 2011, the rate of HGA 
detected was 17.4 (95% CI 16.8-18.0) compared to 19.8 (95% CI 19.5-20.1) per 1000 
females screened in 2004-2007. The first year that a statistically significant decline in 
rate (12%, 95% CI 9%-15%) in this age group occurred compared to 2004-2007. 
Sensitivity Analysis 
Expected rates including screened and unscreened (using pre-vaccine rates of HGAs) 
females <20 years were calculated and were compared with pre-vaccine periods to 
obtain rate ratios (Table 4). From 2009, expected rate ratios were significantly below 
one demonstrating that the patterns observed were robust to even very large (and 
implausible) changes in screening practices. 
Table 4. Sensitivity analysis of rate ratios of females < 20 years screened, 2008 
2011 
A. B. C. D. E. F. G. H. 
Year No. of 
females 
with HGA-
screened 
Expected 
no. of HGA 
by pre-
vaccine 
(2004-2007) 
ra tes" 
No, of 
females 
Screened 
No. of 
females 
not 
screened 
(B-hC)/ 
(D-i-E)xlO 
00 
Expected 
Rates* 
Expected 
Rate Ratio 
(rate ratio 
for HGA 
compared 
to 2004-7) 
95% CI 
2008 653 3006 60,612 229142 12.63 0.96 0.92-1.01 
2009 518 3113 58,307 238020 12.29 0.94 0.89-0.98 
2010 416 3151 53,297 240163 12.15 0.93 0.88-0.97 
2011 385 3095 54,115 235895 12.00 0.91 0.87-0.96 
Source: Cervical screening in Australia 2010-2011, AIHW and Australian Bureau of Statistics census data 
* Number of females not screened was calculated by subtracting ttie number of females screened by ABS population 
estimates in females 18-19 years 
» Expected number of HGAs was estimated by multiplying 2004-2007 HGA rates by ttie number of females not 
screened 
Discussion 
National data on the detection of HGAs from a mature and stable screening program 
provided a well-standardised measure to monitor the occurrence of cervical cancer 
precursors in the screened female population. 
Our analysis indicated that overall, screening rates declined in all age groups, 
particularly in females <20 years, during the post-vaccine period compared to the pre-
vaccine period. The role of vaccination on screening rates was unclear. It is important 
to note that annual screening rates cannot be interpreted as screening participation 
given the recommended two-year screening interval. Nevertheless, the decline in 
screening rate, particularly in females <20 years was unsurprising as participation in 
cervical screening nationally has gradually declined over time.^ This was in line with 
international experience of a decline in screening participation over the past decade, 
mostly amongst younger cohorts.^^ The falling screening rates; however, in very young 
females (<20 years) in Australia are probably not of immediate policy concern, given 
that Australia screens far younger and more frequently than current International 
Agency for Research on Cancer (lARC) recommendations. lARC recommends 
females < 25 years not be targeted based on the potential harm with minimal benefits 
of screening in this age g r o u p . I t must be emphasised however, that failure to 
commence regular cervical screening by a female's mid to late 20s has the potential to 
result in significant risk, particularly given that many young women vaccinated in the 
catch up program were already sexually active.'^ 
The marked decline in screening rate in our study occurred in females <20 years 
despite campaigns during and after the NHVP, promoting the need still for regular Pap 
t e s t s . C o n c e r n had previously been raised that a decline in screening 
participation may occur among females vaccinated against HPV.^° However, In a 
Victorian study conducted after the implementation of the NHVP, 96% of females aged 
18-28 years believed that Pap tests were still required following vaccination.^^ Only 8% 
of females who had never had a Pap test before, indicated that the receipt of the HPV 
vaccine made them less likely to have a Pap test in the future, suggesting it may not be 
a significant barrier to screening.^^ Other identified barriers included embarrassment, 
fear of test result, limited understanding and the lack of information.^® 
To determine the relationship between vaccination and screening, the collection of 
HPV vaccination status in women attending screening may assist in determining 
[40] 
whether there is a significant difference in the proportion of women who do not get 
screened based on vaccination status. This could ideally occur through data linkage 
between the NHPVR and the jurisdictional Pap Test Registers. This has recently been 
conducted in Victoria where the detection rates of HGA were significantly lower in 
women who received any doses of HPV vaccine compared to unvaccinated women 
(hazards ratio =0.72, 95%CI 0.58-0.95). ^^  However, a national-level study is needed 
to contribute to the evidence of whether there is a relationship between vaccination and 
screening uptake at a national level. 
Additionally, our results showed a substantial decline in the rate of HGA among women 
<20 years following the implementation of the NHVP, and in 2011, a decline among 
women aged 20-24 years. There was no decline observed among older women (25+ 
years). This was consistent with other studies including a Victorian population-based 
study that found a significant decline in HGA incidence in females <18 years post-
2007, however, found no significant change in HGA incidence among women 18-20 
years of age (p=0.7).^^ This study only utilised data until the end of 2009, during which 
the catch-up program was still being delivered, and only two years after the 
implementation of the NHVP. Our analysis included two additional post-vaccine years 
that captured the 14- and 15-year old age cohorts targeted for HPV vaccine. The 
findings of a more recent study assessing HPV DNA prevalence in Australian females 
further supported our results. A large decline in vaccine-type HPV pre-post comparison 
of 18-24 year olds attending for cervical screening at family planning clinics was 
observed.^^ Monitoring of HPV DNA prevalence has the potential to provide timely 
evidence of the impact of HPV vaccine among women who recently have become 
sexually active. ^^  Indeed, HPV vaccine effectiveness is lower in older females who are 
likely to have engaged in sexual activity by the time vaccine was a d m i n i s t e r e d . O u r 
analysis found that the reduction in HGA rate was most marked in females < 20 years 
which may have been influenced by higher vaccine coverage rates reported in younger 
age groups.^^ A significant decline in rate of HGA in females 20-24 years was only 
observed in 2011. These females would have been 16-20 years of age in 2007 and so 
many may have been vaccinated around the time of sexual debut'^ compared to the 
earlier post-vaccine years. 
A number of limitations have been discussed previously in using cervical cancer 
screening program data as a method of assessing the impact of the HPV vaccines.'^ 
Changes in screening rates, access to screening and screening behaviour have been 
[41] 
described previously as factors affecting the number of lesions detected.^" These 
factors nnay be influenced by health promotion campaigns targeting under screened 
women, which have been demonstrated to increase participation in the Australian 
setting.^® And which may subsequently raise detection rates, as under-screened 
women are more likely to have prevalent disease. This may be why a peak in 
screening rates was observed in 2007, coinciding with the commencement of the 
NHVP. We were not aware of which jurisdictions ran particular media/health promotion 
campaigns during the time periods under review, which could have influenced 
participation and detection rates. Other factors such as prominent media coverage of 
celebrities with cancer can also affect screening rates in a dramatic fashion. This was 
observed with the diagnosis and subsequent death of a young British reality television 
star from cervical cancer in 2008 and 2009, respectively.^® We attempted to consider a 
scenario whereby including non-screened women, and assumed the same rate of HGA 
detection as observed in the pre-vaccine period in our analysis. This inclusion was 
likely to be the most extreme situation, overestimating the rate of HGA detected, as not 
all females aged <20 years were sexually active. Evidence for this assumption came 
from a 2008 survey of secondary students in Year 10 and Year 12 in Australia that 
found that approximately 40% of students had experienced sexual intercourse.'^ 
Despite this likely overestimation, a reduction in rate of HGA detected was still 
observed. 
Although our analyses identified a significant reduction in rate of HGA in females < 20 
years, the known limitations of an ecologically designed study limits our ability to make 
inferences that the reduction in rates are due to the vaccine. It must also be noted that 
other factors,^" including the change to follow up guidelines for screen-detected 
abnormalities introduced in 2006, " may have played a role in the observed declines. 
Of all the jurisdictions, the NT had one of the highest rates of HGA in women aged < 20 
years and 20-24 years. One explanation for this is that the NT has the highest 
proportion of Indigenous residents of all the states and terntories.^° It has been well-
documented that the incidence of cervical cancer is twice as high among Indigenous 
women compared to non-Indigenous women.^ A study of HPV prevalence in the pre-
vaccination period did not find any significant difference in HPV prevalence or 
prevalence of vaccine preventable types between young Indigenous and non-
Indigenous Australian women.^^ Cofactors such as smoking, other STIs and early age 
of first pregnancy/high parity may be important in explaining different rates of 
abnormalities and the development of cancer. Indigenous status is not currently able to 
be collected in the national cervical screening data. If it could be captured in the future, 
that would enable research on Indigenous status and cervical screening participation to 
occur. Variations in HGA rates in jurisdictions may also be due to differences in the 
completeness of histology reporting from laboratories to the registers or the quality of 
specimen collection, processing and interpretation. However, the NCSP has standards 
for laboratories to maintain in relation to the detection rates of HGAs. Monitoring and 
feedback can result in changes in detection rates from particular laboratories over time, 
which may have the potential to influence average detection rates. 
Another limitation that might exist was including 2007 in the pre-vaccine period, despite 
the NHVP commencing in April 2007. Given the vaccine schedule and time between 
exposure and detection of HGA, we concluded that including 2007 in the pre-vaccine 
period was appropriate. Previous cohort studies have estimated the time between HPV 
infection and the development of high-grade lesions. A cohort study in the United 
Kingdom among female 15-19 years found the risk of high-grade cervical intraepithelial 
neoplasia was 18 times greater in females exposed to HPV (type 16) 6 -12 months ago 
(relative hazards ratio= 18.02 [95% Cl= 5.50-59.0]) compared to unexposed females.^^ 
Furthermore, a cohort study in the United States (US) of 241 women identified all HPV 
associated GIN 2 and 3 detected occurred within the first 24 months of initial detection 
HPV infection. ^^  
Conclusions 
Our analysis provides the first detailed analysis explicitly analysing cervical screening 
data, nationally and by jurisdiction, on changes in rates of HGA detected in women 
following the introduction of the NHVP. The rate of HGA detected in females eligible for 
HPV vaccination through the national program was found to decline. This was most 
evident in females aged <20 years, HGA rates were significantly lower following the 
implementation of the NHVP compared to during the pre-vaccine era, even after 
accounting for screening participation. While our results are encouraging, the 
ecological nature of the study prevents definitive conclusions from being made; and 
there continues to be a need for future analytical studies to be conducted. Ideally, data 
linkage studies hold the key in providing substantiated evidence of the impact HPV 
vaccination has on pre-cancerous cervical lesions. 
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Appendix B 
B1.1 Rate of cervical high grade abnormal i t ies per 1000 females screened by age group 2 0 0 4 - 2 0 1 1 
Age 
group 
(years) 
2004-2007 2008 2009 2010 2011 
Rate Rate 95% CI Rate 95% CI Rate 95% CI Rate 95% CI 
<20 13.1 10.8 10.0-11.6 8.9 8.2-9.7 7.8 7.1-8.6 7.1 6.4-7.9 
20-24 19.8 21.3 20.6-21.9 19.9 19.3-20.6 19.7 19.1-20.3 17.4 16.8-18.0 
25-29 17.7 19.3 18.7-19.8 19.0 18.4-19.5 19.9 19.3-20.5 19.4 18.9-20.0 
30-34 11.6 12.7 12.3-13.2 12.8 12.3-13.2 13.6 13.2-14.1 14.0 13.6-14.5 
35+ 3.6 3.7 3.6-3.8 3.6 3.5-3.7 3.8 3.7-3.9 4.1 4.0-4.2 
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Abstract 
Background: 
The surveillance of adverse events following immunisation (AEFI) has existed for many 
years in Australia. The primary purpose of the surveillance of AEFI is to monitor the safety of 
vaccines. Ensuring vaccine safety is crucial in instilling confidence in vaccines, particularly in 
children and infants who are the main receivers of vaccines under Australia's National 
Immunisation Program (NIP). The objectives of this report were to examine AEFI 
surveillance data over the past twelve years in infants and children (< 18 years of age 
)• 
Methods: 
De-identified data were obtained from the Australian Drug Reactions System (ADRS) on all 
vaccines administered between 1 January 2000 and 31 December 2011 suspected of 
causing an AEFI in individuals aged under 18 years. Average annual population-based 
reporting rates were estimated. 
Results: 
Overall, there were 12,885 reports of AEFI in < 18 years, of which 8.7% were considered 
serious. Peaks were observed in 2003, 2007, 2008 and 2010 (23.3, 22.0, 22.8 and 60.5 
AEFI reports per 100,000 population, respectively).The most marl<ed peak occurred in 2010 
following administration with seasonal influenza vaccine. Other peaks occurred following the 
introduction of vaccines to the NIP, particularly the Meningococcal C Conjugate Vaccine in 
2003 (MenCCV) and HPV (Human Papillomavirus) vaccines in 2007. 
Conclusions: 
The AEFI surveillance system captured a number of signals of AEFI events over the past 
twelve years. A number of these peaks were considered to be due to increased AEFI 
reporting following the inclusion of vaccines under the NIP; however the AEFI surveillance 
system detected the signal of an AEFI event associated with the seasonal influenza vaccine 
in 2010. A number of limitations, however, exist and improvements including collecting 
vaccine dosage data and standardisation of reporting are required to enable better 
interpretation of the data which will enhance the vital role the surveillance system has in 
ensuring the safety of childhood vaccines. 
Prologue 
My role 
From my practice as a pharmacist, I have always been interested in the monitoring of 
adverse drug reactions by the Therapeutic Goods Administration (TGA) and the risk 
assessment procedures that results in a drug being taken off the market. Due to my 
background, my field placement was keen to get me involved in the Adverse Events 
Following Immunisation (AEFI) Project Group. 
The project on the overview of vaccine safety in Australia (over the past twelve years) 
commenced early into my placement at NCIRS. Initially, I worked on all AEFI reports 
between 2000 and 2011, however, the project evolved quickly to have a specific focus on 
children and adolescents - as they are the receivers of the majority of vaccines under the 
National Immunisation Program. 
I conducted a project proposal for this project and sourced past annual and supplementary 
reports and TGA documents to gain an understanding of the history of AEFI surveillance in 
Australia and the many changes that have occurred over the past fifty years. I found this 
process quite challenging as much of the vaccine safety monitoring was incorporated into 
general drug safety with no difference In reporting and surveillance between the two. I also 
conducted a literature review on adverse events associated with specific vaccines and 
reviewed passive AEFI surveillance systems in the US, Canada and Denmark to consider 
the differences that existed between them and the Australia system. 
Deepika Mahajan, the Senior Research Officer who is responsible for conducting data 
analyses for AEFI annual and supplementary reports for this project provided me with SAS 
code that existed for these reports. I adapted these codes for this project and Deepika 
provided guidance during the data analysis, particularly in understanding the many variables 
that exist in the database. 
I organised and chaired teleconferences that were attended by co-authors for a paper that 
will hopefully be submitted for publication. Collaborators include NCIRS colleagues (Deepika 
Mahajan, AditI Dey, Rob Menzies and Kristine Macartney), TGA staff (Bronwen Harvey) and 
academics from the University of New South Wales (Glenda Lawrence) and the Australian 
National University (Stephanie Davis). I produced agendas and wrote minutes during the 
teleconferences. 
A manuscript to be submitted to a peer-reviewed journal has been developed for this project, 
which is what is presented in this chapter. The manuscript is at a late draft stage with further 
revisions to be made pending co-author review. 
Lessons learned 
This project provided me with a range of new skills and experiences that were incredibly 
valuable. Firstly, I feel this project was a catalyst to making me understand that it is 
imperative to have clear objectives for each project I commence. It also made me step back 
and look at the 'bigger picture' and consider the 'so what' factor of what I was doing, 
particularly for a descriptive study. This was extremely challenging and I still struggled with 
conceptualising these considerations for subsequent projects, however, I feel that the 
process itself became habitual, and was probably one of the most important lessons I have 
learnt during my MAE experience. Furthermore, I learnt that communicating these in the 
project proposal and having a clear idea of the methodology of this project would have been 
more efficient, which at times it was not. 
Secondly, I believe that the number of iterations that this paper endured allowed me to write 
better. I learnt that it is important that every paragraph has a 'take home' message. 
Further, I learnt so much from collaborating with a number of researchers from different 
organisations. They were extremely forthcoming in providing their expert knowledge on AEFI 
to me and I tried to absorb as much as I could from them. Indeed, I learnt that AEFI 
surveillance is complex and trying to understand the operation of the surveillance system 
was somewhat challenging. 
One important lesson learnt was diplomacy when working with a number of collaborators 
from different organisations. It was also a good experience to navigate the paper to ensure 
that all co-authors were content with what was produced and also learn to facilitate 
teleconferences among collaborators. 
Lastly, this project taught me many things about mentoring students. I received a great deal 
of support from different individuals for this project and it has provided me with important 
insight on how I hope to be If I was to supervise or mentor students in the future. 
Public health action 
This project describes the past and present of vaccine safety monitoring in children and 
adolescents which has policy implications for future vaccine safety. It addresses a number of 
limitations of vaccine safety monitoring and suggests possible methods to improve the 
system. Through descriptive analysis, it provides evidence of the importance of the passive 
surveillance system in allowing for signal detection and hypothesis generation. This project 
identifies passive surveillance as an vital component of vaccine safety monitoring in 
Australia. 
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Introduction 
In Australia, post-marketing surveillance and monitoring of medicines, including vaccines, 
has existed for many years through a passive surveillance system.' The Australian 
regulatory authority, the Therapeutic Goods Administration (TGA) is responsible for 
regulating medicines, including vaccines, and for monitoring their safety once they are 
available on the market.^ Nationally, passive surveillance relies on the voluntary reporting of 
suspected adverse events from vaccines to the TGA. An Adverse Event Following 
Immunisation (AEFI) is defined as any serious or unexpected adverse event following 
vaccination that may be from the vaccine itself or its handling and administration; it can be 
coincidently associated with the timing of vaccination.^ The surveillance of Adverse Events 
Following Immunisation (AEFI) primarily functions to: detect signals of suspected adverse 
events that were not detected during pre-licensure trials; identify any changes in rates of 
known adverse events; and to detect adverse events associated with program errors. This 
will ensure appropriate public health action is initiated. 
At present, Australia is one of the few countries'*"® in the world with a comprehensive 
immunisation program- the National Immunisation Program (NIP). Under the NIP, certain 
immunisations are provided free of charge to eligible Australians by the federal government 
(Table Instilling public confidence in the NIP is an important contribution of AEFI 
surveil lance.*^ Over time, the number of vaccines recommended on the NIP schedule has 
increased. In 2000, there were 16 vaccines included in the NIP schedule to protect against 
seven diseases*" in child and school programs compared to the 19 vaccines recommended 
to protect against 14 diseases in child and school programs in 2013.*^ With the addition of 
new vaccines on the schedule, it is imperative that vaccine safety monitoring occurs. This is 
particularly the case as nearly a quarter of parents have been found to believe children 
receive too many vaccines.*® 
Table 1: History of the schedule changes to the National Immunisation Program in 
children and adolescents 2000- 2011 
Year Month Intervention 
2000 March 
May 
Haemophilius B (Hib) vaccine funded; infants 2,4,6, 12 months 
Hepatitis B (HepB) vaccine funded; birth followed by 3 HepB doses of 
combined vaccine 
2001 
May 
Three doses of 7-valent Pneumococcal Conjugate Vaccine (7vPCV) 
funded for children at highest risk for Invasive Pneumococcal 
Disease)* 
A 7vPCV catch-up program became funded 
A single dose of 23-valent Pneumococcal Polysaccharide Vaccine 
(23vPPV) funded and recommended^ 
2003 
January 
September 
A single dose of meningicoccal conjugate vaccine (MenCCV) 
recommended and funded; infants 12 months 
MenCCV catch-up program funded for all children; children 2-19 
years 
4th dose of diphtheria, tetanus, acelullar pertussis (DTPa) at 18 
months of age removed from the NIP schedule 
September 
A single dose of varicella vaccine recommended at 18 months of age; 
A single dose of varicella vaccine recommended for children aged 
10-13 years with no history of varicella vaccination or clinical disease 
2004 
January 
June 
dTpa funded for adolescents, the eligible age group varied in different 
jurisdictions 
dTpa-IPV vaccine registered, for use in individuals aged >4 years 
2005 
January 7vPCV program; all infants 7vPCV catch-up program; < 2 years 
November 
Inactivated Polio Virus (IPV) became funded to replace Oral Polio 
Vaccine (OPV) 
Combined DTPa-hepB-IPV-Hib vaccine used in ACT, NSW, TAS and 
WA (for non-Indigenous children); DTPa-IPV vaccine used in other 
jurisdictions and in Aboriginal and Torres Strait Islander infants in WA 
Funded national varicella program commenced; 18 months of age 
2006 February 
October 
Funded school-based variclla catch-up program commenced, with 
routine vaccination for one cohort of children aged 10-13 years with 
no history of varicella vaccination or clinical disease 
Recommendation and funding of a 2 dose schedule of monovalent 
rotavirus vaccine and 2 and 4 months in infants using monovalent 
rotavirus vaccine (NT only) 
2007 April 
4-valent human papillomavirus vaccine (4vHPV) funded for females 
aged 12-13 years- school-based program 
4vHPV catcti-up program :females 13-26 years- schools or primary 
care providers 
July 
Funded national immunisation commenced, using a 2-dose schedule 
of monovalent rotavirus vaccine (2 and 4 months; ACT, NSW, NT, 
TAS, WA) or a 3-dose schedule of pentavalent rotavirus vaccine (2, 4 
and 6 months; OLD, SA, VIC) 
2008 
Seasonal influenza vaccination program commenced (6 months - 5 
years)-WA only 
March 
Queensland, South Australia and Victoria changed to a single 
hexavalent DTPa-IPV-HepB-Hib vaccine after using two combination 
vaccines (quadrivalent DTPa-IPV and Hib-HepB). 
May 
WA changed from using a 2-dose schedule of monovalent rotavirus 
vaccine to using a 3-dose schedule using pentavalent rotavirus 
vaccine 
September A single dose of pandemic H1N1 influenza (pH1N1) vaccine funded children; > 10 years 
2009 
October lOvalent PCV funded; infants 2,4,6,18 months of age (replaced 
7vPCV) in the NT* 
Due to an international shortage of PedvaxHib® (Hib) and Comvax ® 
(Hib-HepB) all States and Territories were using the single hexavalent 
Infanrix hexa® (DTPa-IPV-Hib-HepB) vaccine for all children at 2, 4 
and 6 months of age 
4vHPV catch-up program ceased 
December A two-dose schedule of p H I N I vaccine funded; children 6 to < 9 
years 
January 
Trivalent Influenza Vaccine (TIV) funded children; > 6 months with 
medical risk factors and all Indigenous individuals > 15 years 
April Use of TIV children < 5 years suspended 
2010 June 4vHPV registered for use in males aged 9-26 years 
August 
TIV < 5 years resumed excludingi brand (Fluvax, CSL Biotherapies) 
no longer for use in children aged 6 months to <5 years) 
December Pandemic (A/H1N1 2009) influenza vaccine no longer available 
July 
13-valent Pneumococcal Conjugate Vaccine (13vPCV) replaces 
7vPCV; infants 2,4,6 months 
13vPCV funded; children 12-35 months who completed primary 
7vPCV course. 
2011 
October 
13vPCV replaced the lOvPCV for use in the NT. A supplementary 
dose of 13vPCV was provided to those who had received the lOvPCV 
23vPPV booster dose for Aboriginal and Torres Strait Islander 
children aged 18-24 months living in NT, SA, OLD and WA ceased, 
following implementation of the 13vPCV catch-up program for 
children aged 12-35 months 
* all Aboriginal and Torres Strait Islander infants, all children with specifed underlying medical conditions that 
predispose them to invasive pneumococcal disease, and non-Indigenous children residing in Central Australia 
" non-Indigenous children residing in Central Australia <2 years of age. Aboriginal and Torres Strait Islander 
children in Central Australia <5 years of age, and Aboriginal and Torres Strait Islander children in northern NT <2 
years of age 
t Aboriginal and Torres Strait Islander children aged 18-24 months living in NT, SA, OLD, WA after completion of 
primary 7vPCV 3-dose course. Children with specific underlying medical conditions aged 12 months following 
completion of primary 7vPCV 3-dose course. School children aged 15-19 years (Grade 10 and12) in the NT 
(changed to Grade 11 and 12 in 2002). 
+ all children in the NT at age 2, 4, 6 and 18 months of age, replacing the use of the 7vPCV (3 doses) with or 
without a booster dose of 23vPPV 
Surveillance of AEFI in Australia has evolved from a reporting scheme which initially 
involved only doctor as reporters/^ to surveillance encompassing passive, enhanced and 
active approaches with numerous reporter types (e.g. general public and state and territory 
health d e p a r t m e n t s ) . ^ ' I n 2000, the Adverse Drug Reactions Unit (ADRU) of the TGA 
became responsible for collating and reviewing all AEFI notifications.^ An expert committee 
of the TGA, the Adverse Drug Reactions Advisory Committee (ADRAC) would meet at six-
weekly intervals to consider and discuss concerning AEFI reports.^ Since then, minimal 
changes the passive surveillance remained somewhat unchanged, however in 2010, 
structural changes led to the Office of Product Review replacing ADRU and the Advisory 
Committee of the Safety of Medicines (ACSOM) replacing ADRAC as the expert advisory 
committee.^" Since 2002, the National Centre for Immunisation Research and Surveillance 
(NCIRS) became responsible for analysing data, producing routine reports and also ad-hoc 
reports for AEFI when requested under an agreement with the TGA.^ In 2013, following 
recommendation of a review of passive surveillance of AEFI in Australia, the Advisory 
Committee on the Safety of Vaccines (ACSOV) was formed. This statutory expert 
committee's role is to advise and provide recommendations to the Minister of Health on 
vaccine safety Australia including conducting risk assessments and risk management. ^^  
Some diversity of vaccine safety monitoring exists between states and territories. AEFIs can 
benotified through a number of different mechanisms.^^ In 2007, the state of Victoria 
established an enhanced passive surveillance system, the Surveillance of Adverse Events 
Following Vaccination in the Community (SAEFVIC).''® More recently, the Western Australian 
Vaccine Safety Surveillance (WAVSS), based on the SAEFVIC model, was established in 
the state of Western Austral ia." A recent study found that the reporting rate of AEFI 
increased in Victoria from 2.6 per 100,000 population (2003) to 13.5 per 100,000 population 
(2009) following the implementation of SAEFVIC. Additionally, the Paediatric Active 
Enhanced Disease Surveillance (PAEDS) project is a hospital based surveillance system in 
five hospitals across the country that can detect AEFI. Detailed clinical information and 
biological samples are collected for some vaccine-related childhood conditions 
(intussusception, infantile seizures, acute flaccid paralysis and severe complications of 
varicella). 
Similarly, passive AEFI surveillance systems exist in Canada and the USA, which also 
collate voluntary reports of AEFI at a national level.^^ ^^  The American system- the Vaccine 
Adverse Events Reporting System (VAERS) was established in 1990 and accepts AEFI 
reports via the internet, mail or fax from health professionals, vaccine manufacturers, and 
the general public and are entered into the VAERS database.^" In Canada, the Canadian 
Adverse Events Following Immunization Surveillance Systems (CAEFISS) nationally collates 
voluntary reports from clinicians and also the general p u b l i c . B o t h countries also 
supplement their passive surveillance systems with enhanced and active systems. 
In Australia during 2010, an unexpected increased risk of febrile convulsions in children 
aged less than 5 years of age occurred in association with one brand of seasonal trivalent 
influenza vaccine (TIV) that had been used in Australia for many years. The events leading 
up to and surrounding the temporary nationwide suspension of influenza vaccine use in this 
age group, while evidence implicating one, but not the other registered vaccine brands was 
gathered, led to a national and state-based review of the surveillance system/s for 
monitoring vaccine safety in Australia. Recommendations from the national review have 
been adopted and will result in a number changes to the current system to further enhance 
vaccine safety surveillance. 
In light of these anticipated changes and the increasing number of vaccines administered to 
those < 18 years of age, it was timely to examine AEFI reporting data among Australian 
children and adolescents. The objectives of this report were: to examine passive AEFI 
surveillance data over the past twelve years and; to highlight major events that have 
occurred. 
Methods 
System description 
The mechanisms to report AEFI and the types of reporters of AEFI have been described 
previously.^ In short, all reports are forwarded, either directly by the individual reporter or by 
the jurisdictional health department, or in Tasmania's case, directly to the TGA where they 
are assessed using internationally consistent criteria and then entered into the Australian 
Adverse Drug Reaction Reporting System (ADRS) database (Figure 1). Information of the 
severity of outcome of the AEFI was collected, and included non-serious, not recovered at 
the time of reporting and serious. An AEFI is defined as 'serious' if the reaction meets one of 
more of the following: 1) Results in death; 2) Is life-threatening; 3) Requires inpatient 
hospitalisations or prolongation of existing hospitalisations; 4) Results in persistent or 
significant disability or incapacity; 5) Is a congenital anomaly/birth defect and; 6) Is a medical 
important event or reaction. It was assumed that AEFIs assigned as not-recovered during 
the time of reporting were not sehous. 
Figure 1:Reporting pathway of the AEFI passive surveillance system, adapted from 
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It is possible that a single adverse event can result In more than one notification/record being 
generated in the ADRS database thus the term 'AEFI record' is used. Records of AEFI 
typically list signs, symptoms and/or diagnoses that are coded by the TGA into standardised 
lower level terms (LLT) and an equivalent preferred term (PT) using the Medical Dictionary 
for Regulatory Activities (MedDRA).^^ MedDRA classifies adverse events using a 
hierarchical five-level structure from the highest level 'system organ class' (e.g. skin and 
subcutaneous disorders) to LLT, the lowest level (e.g. bruising of face).^^ Each LLT is 
related to only one PT (second lowest level terminology). A PT is a single medical concept 
and is specific enough that pathologic or etiologic information is detailed (e.g PT= Rhinitis 
seasonal versus PT= Rhinitis perennial).^^ 
Records of AEFI were assigned into 'certain', 'probable' and 'possible' causality ratings by 
medical officers at the TGA. This method of rating causality has been described previously. 
" Causality can be difficult to establish, particularly when multiple vaccines are co-
administered (which often occurs in children). When a systemic adverse event occurs in this 
instance, all vaccines co-administered are usually listed as 'suspected' of involvement. 
Data used 
We used de-identified AEFI data obtained from the ADRS database provided by the TGA in 
September 2012. ^^  All vaccines administered between 1 January 2000 and 31 December 
2011 that were 'suspected' of causing the AEFI were included in our analysis. Where date of 
vaccine administration was missing, onset date of symptoms or signs was used. Records 
were only included for those less than 18 years of age. 
Data Analyses 
Data analyses were performed using SAS ® (version 9.3, SAS Institute, Gary, NC, USA).^" 
Descriptive analyses were conducted to determine the crude number of AEFI records per 
year and numbers were further stratified by: age group; sex; level of seriousness; vaccine 
type; jurisdiction; reaction type; reporter type (state and territories, immunisation providers, 
vaccine sponsors, public and other) and; causality(certain, probable, possible). Population 
estimates were obtained from the Australian Bureau of Statistics (ABS) to estimate average 
annual population-based reporting rates.^^ 
Results 
Overall, there were 12,885 records of AEFI reported in the passive AEFI surveillance system 
in children under18 years of age between January 1, 2000 and December 31, 2011. Of 
these 1119 AEFIs (8.7%) were recorded as serious (Table 2) and 72.3% had a 'possible' 
causal rating for the vaccine resulting in an adverse event. Females accounted for 6,263 
reports (48.6%). AEFI reports did not appear to differ by sex except for a higher proportion of 
adolescent (11-17 years) AEFI reports occurring in females (75.2%). States and territories 
were the main reporters of AEFI (68.3%) followed by CPs (13.1%). The public accounted for 
5.3% of all reports. 
Table 2. Characteristics of AEFI reports in children < 18 years; 2000-2011 
Number Proportion 
(%) 
AEFI reports 12885 
Median age (years) 3 ICR: 1-5 
Sex 
Male 5986 46.5 
Female 6263 48.6 
Unknown 636 4.9 
Seriousness 
Not serious 8020 62.2 
Serious 1119 8.7 
Not recovered at the 
time of reporting 
2146 16.7 
Missing 1600 12.4 
Causality 
Possible 9316 72.3 
Certain/ probable 3569 27.7 
Reporter type 
State/Territory 8800 68.3 
General Practitioners 1684 13.1 
Hospital 954 7.4 
Public 678 5.3 
Nurse 441 3.4 
Drug company 184 1.4 
Pharmacist 81 0.6 
Specialist 45 0.4 
Other 14 0.1 
Missing 4 0.03 
The annual reporting rate of AEFIs fluctuated during this period (Figure 2). In 2000, there 
were 7.0 AEFI records per 100,000 population and peaks were observed in 2003 (23.3 per 
100,000 population), 2007 (22.1 per 100,000 population) and 2008 (22.8 per 100, 000 
population). In 2010, a substantial increase in reporting rate was observed (60.6 per 100,000 
population). Reporting rates including and excluding the public as reporters (Figure 2) were 
nearly identical except in 2010, when public reporting was higher. 
Figure 2: Adverse events fo l lowing immunisat ion, 2000-2011 by quarter < 18 years; 
2000-2011, Austral ia 
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The greatest numbers of AEFI records occurred in the 1 - 4 year age group (Figure 3). AEFI 
reporting increased following the inception of the IVlenCCV program (offering one dose for all 
1 -19 year olds from 2002) and the HPV vaccine program (2007). Overall, 73% of AEFI 
records in < 18 years occurred In children < 4 years (< 1 year; 23% and 1 - 4 years; 50%). A 
peak of AEFI records among adolescents (11-17 years) was observed in 2007 (Figure 3). 
Figure 3: Number of AEFI reports by age group in < 18 years; 2000-2011, Australia 
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The most common AEFI recorded was injection site reaction (n=3998) followed by pyrexia 
(n=3886) and rash (n=1676) (Table 3) 
There were 287 cases of Hypotonic Hyporesponsive Episode (HHE), of which 83% (n=240) 
occurred in infants (< 1 year) and 16% (n= 46) records in children aged years. Sixty-one 
cases of intussusception (IS) were reported during the 12 year period of which 98% (n=60) 
occurred in infants. There were 173 reports of febrile convulsions, most common in children 
aged 1 - 4 years (72.8%; n=126) followed by infants (24.9%; n=43).Forty-two reports of 
anaphylactic reaction occurred over the twelve year period; 43% (n=18) reportedly occurring 
in adolescents (11-17 years) followed by 33% (n=14) in children aged 1 -4 years. There 
were 284 reports of syncope during this period, 71.5% (n=203) of reports occurred in 
adolescents (11-17 years). 
Table 3. Type of selected AEFI reports by preferred terms by age groups in children < 
18 years; 2000-2011, Australia 
Age group (years) 
Preferred term < 1 1-4 5-10 11-17 Total 
n % n % n % n % 
Injection Site Reaction 403 13.3 2838 44.3 421 34.6 336 15.0 3998 
Pyrexia 843 27.8 2279 35.6 446 36.7 318 14.2 3886 
Rash 544 18.0 695 10.9 90 7.4 347 15.5 1676 
Headache 4 0.1 144 2.3 207 17.0 515 23.0 870 
Hypotonic 
Hyporesponsive 
Episode 
240 7.9 46 0.7 0 0.0 1 0.0 287 
Syncope 9 0.3 31 0.5 41 3.4 203 9.1 284 
Febrile convulsions 43 1.4 126 2.0 3 0.3 1 0.0 173 
Intussusception 60 2.0 1 0.0 0 0.0 0 0.0 61 
Anaphylactic reaction 5 0.2 14 0.2 5 0.4 18 0.8 42 
Thrombocytopenia 5 0.2 13 0.2 1 0.1 3 0.1 22 
Severity of outcome 
Over the 12 year period, 62% (n=8020) of AEFI reports were defined as 'non-serious' and 
16.7% (n=2146) were defined as not recovered at the time of the report. Sixteen deaths 
(0.12%) were temporally associated with receipt of vaccine however the causality rating for 
all deaths was 'possible'. 
Vaccine types suspected of causing an AEFI in children and adolescents are displayed 
(Figure 4). A substantial peak associated with seasonal influenza vaccine occurred in 2010. 
During the same year a peak in AEFI reports associated with p H I N I also occurred. AEFI 
reports associated with rotavirus increased after-2007. MenCCV associated AEFI peaked in 
2002-2004 and then declined from 2005. Similarly, HPV vaccine associated AEFI reporting 
peaked in 2007, however, in more recent years, has declined. 
Figure 4: Number of vaccine-specific AEFI records by vaccines in < 18 years; 2000-
2011, Australia 
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Discussion 
Passive post-marketing surveillance is an important component of monitoring vaccine safety 
as pre-licensure trials have insufficient numbers of participants to identify rare and serious 
adverse events.^® Our report provides a description of passive AEFI surveillance over the 
past twelve years in Australian children and adolescents. Over the study period, a number of 
peaks were detected. These represent both adverse events associated with specific 
vaccines, and what are most likely artefacts of vaccine programs. 
Between 2000 and 2011, the most striking peak was the 2010 peak associated with TIV; 
showing that the passive surveillance system was able to capture a signal of a true adverse 
event. Since its registration in Australia, no safety issues associated with TIV had occurred 
until 2010 when an unexpected safety signal was detected in Western Australia. An 
increase in the number of emergency department presentations in children with high fever 
and febrile convulsions was detected following receipt of TIV.^^ More in-depth investigation 
alerted the TGA to conduct an investigation which subsequently led to the suspension of all 
brands of seasonal influenza vaccine in children under 5 years of age.^® The vaccine was 
subsequently suspended by the Chief Medical Officer for children aged 5 years and under, 
pending a national investigation into the i s s u e . F u r t h e r investigations identified receipt of a 
specific brand of influenza vaccine to be significantly associated with these adverse 
events.^' Following this, a review of the passive AEFI surveillance system and its ability to 
respond to this event was undertaken. The review recommended numerous improvements 
to the system including a more consolidated, systematic approach in reporting AEFI.^® 
A number of other peaks were also observed during the study period. It is probable that most 
of these peaks were attributable to the 'Weber' effect,^® as increased reports occurred 
immediately following the introduction of a new vaccine onto the NIP. The high proportion of 
AEFI records in females from the 11-17 year age group, which peaked in 2007, was likely 
due to the introduction of the HPV vaccine offered only to females and not males. The 
increase in vaccine-specific AEFI reporting rates has been observed internationally, 
following the introduction of new vaccines including varicella, HPV and 7-valent 
pneumococcal vaccines. 
Reporting rates of AEFI by vaccine dosage is important in inferring whether a vaccine is 
indeed associated with an AEFI. Australia was the first country to establish a centralised 
Australian childhood immunisation register (ACIR) in children aged <7 years in 1996.''^ The 
number of vaccine doses from ACIR is used to calculate AEFI rates per vaccine dose given, 
allowing for the monitoring of trends. Currently, an estimated 99% of all children in the 
population are registered; a near-complete population register."^ However, there is evidence 
of underestimations in vaccine coverage."" Furthermore, although vaccination records 
remain on the register indefinitely, once a child has their seventh birthday no new vaccine 
records are added."^ For older age groups, the only source of vaccine coverage data is from 
school-based programs or surveys or jurisdictional immunisation registers. Given the lack of 
consistent coverage data for the age range used in this study, rates were reported per 
100,000 population and cannot be interpreted as incident rates per vaccine doses given 
which makes detecting a signal challenging. For example, a peak in AEFI may be correlated 
with an increase in vaccine doses rather than a true AEFI event. To enable better 
interpretation of passive surveillance data in Australia, an expanded immunisation register 
for all children under 18 years of age would allow for incident rates of AEFI to be calculated 
per vaccine doses given as in the Netherlands (where a register exists for individuals up to 
19 years of age). Expanding Australia's immunisation register to include individuals > 7 
years would enable reporting rates of AEFI to be calculated, strengthening surveillance. 
Not all AEFIs however can be detected by the AEFI surveillance system; particularly rare 
events such as intussusception. Between 2000 and 2011, there were 61 cases of IS 
detected nationwide by this system. This was an underestimate as evidenced by the 
Paediatric Active Enhanced Surveillance System (PAEDS) that captured 132 cases of IS 
between 2000 and 2006 in four states of Australia."® This demonstrated the relative lack of 
sensitivity of the passive AEFI surveillance system to detect rare AEFIs and the importance 
of complementary surveillance systems. 
Another limitation of the AEFI surveillance system is that it is possible that biased reporting 
of suspected AEFI is occurring, for example more serious AEFIs may be reported more 
than less serious AEFI, however majority of cases that were reported were 'non-serious' 
events. Co-administration of multiple vaccines also may lead to difficulties identifying a 
particular vaccine to an adverse event. Additionally, individual AEFI notifications vary 
considerably in data completeness and quality resulting in difficulties analysing data. For 
example, it is expected that reports from the public would vary in quality to reporting 
conducted by healthcare practitioners as would the level of information provided by the 
reporter. Furthermore, coding errors may occur resulting in potential misclassiflcation of 
exposure or outcome variables. Reporting forms for AEFI also differ by jurisdiction, making 
consolidation and interpretation of data extremely challenging. Forms vary in responses from 
free text responses to tick box responses. A previous New Zealand study found that opened 
ended questions used to describe reactions has been found to lead to difficulties in recording 
AEFI."" The lack of a standardised reporting form has been highlighted as a major limitation 
in the collection of AEFI data ultimately compromising internal validity.^® 
Despite these limitations, the surveillance system serves as a national data source that 
records information on reaction types and vaccines administered. Further, following the 
review of Australia's response to the 2010 seasonal influenza vaccine event, numerous 
recommendations to improve vaccine safety were formulated. These recommendations have 
resulted and continue to result in changes to the passive AEFI surveillance system. This 
includes the development of a standardised AEFI reporting form, consistent case definitions 
and the need to improve vaccine dosage data. 
To this point, we have discussed the limitations of the AEFI surveillance system in the 
context of reporting and data, however it is also important to note another limitation. The lack 
of transparency in the system during the review was considered a key limitation in the 
system, i.e. the delay to the public in being alerted to a AEFI and an understanding of the 
vaccine safety surveillance processes.^® To improve transparency, the Database of Adverse 
Event Notifications (DAEN) was launched in August 2012. DAEN is a searchable database 
available online to the public and contains reports of all adverse event reports for medicines 
(including vaccines)."® These reports are from a wide range of sources."® For vaccines, 
individual reported adverse events are reviewed by the TGA and relevant information is 
copied from the internal TGA database (ADRS) to the DAEN. 
Despite the limitations, it is important to note the strengths of the AEFI passive surveillance 
system for monitoring vaccine safety. It is a well-established system that collects detailed 
information on AEFI including demographics and vaccines administered from a diverse 
range of reporters. It has shown that it has been able to capture events of public health 
significance. With a number of improvements, the passive surveillance system has the 
potential to be better utilised and hence of even greater value. 
Conclusion 
AEFI passive surveillance is an essential component of the NIP. It has contributed to vaccine 
safety over the past 12 years, including detecting signals of increased reports of AEFI. 
Improvements in capturing vaccine dosage data and standardising reporting forms has the 
capacity to further strengthen the passive surveillance system as a vital component of 
vaccine safety and a complements other AEFI surveillance systems In Australia. 
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Preface 
During my MAE, my work on meas les related projects has led somewhat to a 
fascinat ion to measles; a d isease so infectious it has been descr ibed by Professor 
Peter Mclntyre as a 'heat-seeking m iss i l e ' - f i nd ing those most suscept ib le and infecting 
them. Such is the ferocity of the virus, that it has been attr ibuted to nearly wip ing out 
entire Indigenous populations.^ A d isease that, prior to the availabil i ty of a vacc ine 
kil led an est imated 2.6 mill ion individuals per year.^ Since the deve lopment of a highly 
effect ive vaccine, the burden of measles has reduced considerably.^ To such an 
extent that in 2012, a Measles & Rubella Initiative was developed. By 2015, a target 
date for measles eradicat ion would be given; through focusing on achieving high two-
dose vaccinat ion coverage and establ ishing high quali ty survei l lance systems." Most 
recently, South-East Asia has commit ted 2020 as the year for measles el iminat ion in 
the region, the final W H O Region to announce a set target date for meas les 
elimination.^ 
A l though measles el imination has not officially been declared in Austral ia, a number of 
indicators used to declare measles el imination were met which were used by a group 
of measles experts to justify measles el imination in Australia.® During the first year of 
my MAE, however, a large measles outbreak occurred in NSW. This outbreak has the 
potential to jeopard ise the el iminat ion status in the country. 
It was the vision of outbreak investigations, particularly conduct ing 'shoe-leather ' 
ep idemiology that led me to apply for the MAE program. I env isaged that investigating 
outbreaks would equip me with a range of new and varied skills whilst contr ibut ing to 
t imely public health action. And indeed, participating in control measures for the largest 
national measles outbreak in Austral ia in 2012 enabled me to be involved in a number 
of activities and learn a number of skills. It was a highly rewarding per iod of my MAE 
and the major highlight was gett ing to work with a mult idiscipl inary team. Including 
epidemiologists, public health nurses, infectious disease consultants, laboratory 
scientists and emergency depar tment clinical staff. 
A l though the National Centre for Immunisat ion Research and Survei l lance (NCIRS) is 
not responsible for outbreak investigation, the close relat ionship with the Western 
Sydney Local Health District (WSLHD) enabled Alexis (my fel low MAE at NCIRS) and I 
to be involved in the measles outbreak, through the generosi ty of the manager of the 
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Communicable Diseases and Immunisation branch, Dr Vicky Sheppeard. During the 
peak of the measles outbreak, we were given the opportunity to also work at the South 
Western Sydney and Sydney Local Health District (SSWLHD) and the NSW Ministry of 
Health (MoH). The measles outbreak also gave Alexis and I the opportunity to present 
our analysis to infectious disease specialists at the Children's Hospital Westmead 
infectious disease grand rounds and to colleagues at NCIRS through journal club. 
Interestingly, at the time of the measles outbreak, I was fortunate to become a member 
of the National Measles Elimination Working Group. One of my first responsibilities was 
to conduct a literature review on measles epidemiology over the past decade in 
Australia. The collation of literature enabled the Working Group to review what 
research has been conducted in Australia and facilitate the introduction and discussion 
sections of anticipated publications proposed by the Working Group. It also served me 
well, through expanding my knowledge of measles in Australia, which was important 
given the number of measles-related projects that I would be conducting as part of my 
MAE. 
Through my MAE measles related projects I have been involved in a number of diverse 
public health activities and research focussed on measles. These included: 
1. Contact tracing individuals exposed to a measles infectious case; 
2. Answering measles-related questions from individuals presenting to a measles 
post-exposure prophylaxis clinic; 
3. Examining medical charts and building maps to identify the source of a cluster 
of measles in a hospital emergency department; 
4. Conducting data analysis on infant measles cases for the NSW extraordinary 
measles expert group; 
5. Creating a line lists; 
6. Entering data into excel spread sheets of measles contacts 
7. Developing a questionnaire to identify the source of measles transmission in a 
paediatric hospital; 
8. Interviewing suspected sources of measles transmission in a paediatric 
hospital; 
9. Hypothesising the transmission of measles between two cases in an 
emergency department; 
10. Investigating cross-over times in health-care settings during the measles 
outbreak 
11. Conducting a literature review on measles epidemiology in Australia; 
12. Understanding the biases in using laboratory data to calculate a non-measles 
discard rate in New South Wales; 
13. Analysing and interpreting measles notification and hospitalisation data; 
14. Learning about the biases associated with notification and hospitalisation data; 
15. Applying infectious disease models using notification data to estimate the 
reproduction number of measles; 
16. Cleaning multiple datasets extracted from laboratories to calculate a non-
measles discard rate in New South Wales; 
17. Contributing epidemiological evidence of Australia's elimination status as a 
member of the measles elimination working group; 
18. Learning what criteria is necessary for the verification of measles elimination; 
19. Learning to develop a poster for a national conference; and 
20. Preparing and presenting a research project at an international conference; 
structure of this chapter 
This chapter encompasses reports on all the measles-related projects that I was 
involved in as part of my MAE. Section A includes an overall introduction to measles 
and a literature review of measles epidemiology in Australia. Section B comprises of an 
epidemiological review of measles between 2000 and 2011. Notification data, 
hospitalisation data and death data were analysed to provide an overview of the 
burden of measles in Australia. Section C incorporates the estimation of a measles 
reproduction number using notification data; firstly to assess Australia's measles 
elimination status and secondly, to evaluate the methodology of estimating R, 
particularly in the context of lower-income countries. Section D includes the calculation 
of a measles discard rate using laboratory data in New South Wales (NSW) to examine 
the quality of surveillance in the state. Section E incorporates two projects that were 
conducted during a measles outbreak in NSW during 2012. The first component of this 
section outlines the challenges in identifying a source measles case in a paediatric ED 
setting using a non-validated algorithm and the second component provides a review of 
the epidemiology on healthcare transmissions that occurred during the outbreak. 
SECTION A 
An Introduction to Measles 
Introduction 
Measles is a single-stranded ribonucleic acid (RNA) virus that is a member of 
Paramyxoviridae family. The Paramyxoviridae family are an important human 
pathogen, commonly causing respiratory disease among infants and children 
(respiratory syncytial virus, parainfluenza) and mumps/ Humans are the only known 
natural reservoir for measles.® 
Clinical presentation 
Initially, infection is characterised by fever, rhinitis, coughing, conjunctivitis and Koplik 
spots (prodromal phase).° Koplik spots usually occur prior to rash onset and are 
identified as small, bluish-white lesions on the buccal mucosa.® The rash begins on the 
face and behind the ears and progressively spreads to the torso, and then down to the 
extremities. The rash is characteristically maculopapular and erythematous. It 
develops due to an interaction between immune T cells and virus-infected cells' and in 
some instances, may not occur in immunocompromised individuals.® Recovery occurs 
shortly after rash onset.® 
Although in most cases, measles is self-limiting, complications can occur, and even 
result in death. Complications have been reported to occur in up to 40% of reported 
cases, the risk highest in the very young and malnourished.® Complications include 
otitis media, diarrhoea, pneumonia and encephalit is.®'^^ Pneumonia is the most 
common complication of measles that causes death^°. A rare but extremely serious 
neurological complication is sub-sclerosing panencephalitis (SSPE); a degenerative 
condition that results in persistent and prolonged infection of defective measles virus in 
the central nervous system and in most cases leads to death.®' 
Pathogenesis 
Measles is one of the most infectious human diseases known to humankind with the 
route of transmission via the upper respiratory tract.® The incubation period is usually 
7-18 days, from exposure by an infectious case to the onset of symptoms.'^ However, 
an incubation period of 23 days has previously been reported.^ I 13 
Diagnosis 
In the past, measles was often diagnosed by clinical signs and symptoms; however, as 
measles becomes rarer, challenges in clinical diagnosis exist. Previous studies have 
highlighted this through the low positive predictive value of a clinical case definition for 
measles.^" Clinicians working in places where measles is rare, may never have 
witnessed a case of measles in their career, resulting in inexperience and perhaps low 
suspicion when a true measles case presents. Additionally, a myriad of other diseases 
and conditions may present with similar signs and symptoms to measles, making 
clinical diagnosis even more challenging.'® 
Serology 
The most common diagnosis method for acute infection is serology testing to detect 
measles immunoglobulin M (IgM) antibodies. IgM are detectable from rash onset for 
6 - 8 weeks.' ' ' Enzyme-linked immunoassay (ELISA) is the most common way to test for 
antibodies. Immunoglobulin G (IgG) antibodies are also produced during rash onset 
however form more slowly and are detectable for a lifetime.''' ELISA, 
haemagglutination inhibition (HI), indirect immunofluorescence (IF), complement 
fixation testing (CFT) can be used to test for IgG antibodies.'® A four-fold rise titre of 
IgG antibody in two serum samples taken at least ten days apart indicates acute 
infection; except if an individual was vaccinated with a measles containing vaccine 
eight days to six weeks p r i o r . T h e test sensitivity for IgM by ELISA varies by disease 
progression, at four days after rash onset IgM test sensitivity is less than 50%, 
however, increases to 88-100% one to three weeks after rash o n s e t . T h e specificity 
of the test varies between 60-97%.^' 
Culture 
Virus isolation in culture is not routinely used as a diagnosis method for measles as 
sensitivity is lower than serological methods,^" however it is useful for molecular 
epidemiologic surveillance.'® Culture of measles virus from the Vero SLAM (signalling 
lymphocyte-activation molecule) cell line is currently recommended by the World 
Health Organization (WHO) laboratory network.^" 
Antigen detection 
Measles antigen detection by direct and indirect IF is a technique that can rapidly 
diagnose measles. Nasopharyngeal aspirates and respiratory secretions can be used 
as specimens and are stained with monoclonal antibodies directed against structural 
proteins of the virus. The sensitivity is approximately 50-60% and the specificity is not 
known, but around 90-95% has been reported.^^ 
RNA detection by PGR 
Rapid diagnosis can also occur through Polymerase Chain Reaction (PGR). Suitable 
specimens include respiratory secretions, early catch urine, sera, cerebrospinal fluid 
and throat secretions. Both the test sensitivity and specificity are high, approaching 
100%.^^ 
Measles vaccine 
In 1954, Edw/ard and Peebles isolated measles virus in tissue culture. ' ' Not long after, 
the attenuated Edmonston B vaccine was developed and first licensed in 1963 in the 
United States (US) . " Since then, a number of vaccines derived from the Edmonston 
strain have been further attenuated. In 1971, a combined live vaccine that included 
attenuated mumps, measles and rubella virus was licensed in the US.'® The combined 
measles-mumps-rubella (MMR) vaccine has been used in Australia for many years; 
however, more recently, the measles-mumps-rubella-varicella (MMRV) vaccine has 
become available.^^ There are currently four vaccines licensed in Australia that contain 
a measles component (two MMR and two MMRV). M-M-R II (MMR) and ProQuad 
(MMRV) use Enders' attenuated Edmonston strain for measles whilst Priorix (MMR) 
and Priorix-tetra (MMRV) use the Schwarz strain for measles." 
Vaccine eff icacy 
Measles containing vaccine induces both humoral and cellular immunity.''^ Although 
long-term immunity occurs in most individuals who receive one dose of measles-
containing vaccine, approximately 5% will not respond.^^ A second dose of vaccine in 
these non-responders however, will produce an almost complete response^" with 99% 
of individuals having sufficient antibody levels to protect against the disease after two 
doses.^^ 
There has been much debate on the optimum time to initiate vaccination against 
measles. It has been well-documented that vaccine-derived maternal antibodies wane 
at a faster rate than naturally derived maternal antibodies in infants. However, it has 
come to light that naturally derived maternal antibodies in infants also wane at a rate 
fast enough to lose protection by six months of age.^® Vaccination too soon, however, 
may interfere with existing passive antibodies resulting in vaccine failure.^^ The age to 
begin vaccination requires assessing the age of the highest rate of seroconversion and 
the risk of acquiring disease before this age.® Current recommendations range from 6 -
15 months of age.® One study comparing the humoral immune response in six-, nine-
and 12-month old infants found significantly higher seroconversion in 12-month old 
infants compared to six-month old infants following receipt of measles vaccine.^^ In 
contrast, cell-mediated immunity was similar in these age groups regardless of the 
presence of maternal antibodies prior to vaccination. 
A review of 70 vaccine effectiveness studies published between 1960 and 2010 
identified that vaccine effectiveness for one dose of vaccine was 92 % (Interquartile 
range [IQR]; 86%-96%) when administered to children >12 months compared to 77.0% 
(IQR; 62%-91%) in children administered with vaccine at 9 -11 months.^® The high 
effectiveness of the vaccine was further supported in a Cochrane review which 
concluded that one-dose of measles vaccine was > 95% effective in protecting against 
m e a s l e s . A more recent study identified that the vaccine effectiveness of one dose of 
measles vaccine was 95.9% (95% CI; 87.4%-98.7%). Interestingly, vaccine 
effectiveness was greater in two-dose recipients when the first-dose was administered 
at >15 months compared to 12-14 months (97.5% versus 93.0%).^^ 
A histot7 of measles 
Measles virus is believed be a descendent of rinderpest virus and/or the modern 
canine distemper during the Epipalaeolithic Age, a period when humans began 
domesticating cattle and dogs in the Middle East.®^ It is believed that humans became 
a host to measles around 4000 BC, spreading the virus as civilisations evolved.^^ 
Measles was established during 3000 BC in civilisations of the Tigris-Euphrates 
valley.^ From there, the disease gradually spread to other civilisations including Indus, 
Egyptian and Ganges.^^ 
By the Middle Ages, measles became established in China, Japan, the Middle East, 
North Africa and Europe.^^ During this period, Abu Bakr Muhammad Ibn Zakariya al-
Riza, a Persian physician noted for being "one of the greatest physicians Islam ever 
produced"®^ provided the first written account of measles\ In 910, in his Treatise on 
Smallpox and Measles, he was credited as the first to clearly differentiate between 
measles and sma l l pox . ^^ 
During the sixteenth century, it is believed that European explorers took measles to the 
New World where numerous epidemics occurred. As emigration occurred in America, 
measles epidemics followed. One epidemic in 1837 had particularly dire 
consequences- a 98% mortality rate resulting in the near extinction of the Mayan 
Indian tribe.' 
Measles history in Australia 
Pre-vaccine era 
It is understood that measles did not arrive to Australia until 1850.^'* Prior to this, 
restrictions on the immigration of families with children, smaller ships and a longer 
journey from Britain to Australia were likely to have prevented measles from appearing 
in Australia any earlier.^ Indeed, William Charles Wentworth, a prominent Australian 
explorer who lived in colonial NSW in 1824 noted that "infantile diseases are almost 
unknown; the measles, whooping cough, and smallpox being entirely so".^^ The first 
recorded case of measles in Australia was in 1850 in Victoria, following the voyage of 
the ship the 'Persian' from Britain. Infectious measles cases disembarked in Victoria 
(VIC) and subsequently spread the disease to others. From there, as Australia's 
population grew, so did measles cases. The first recorded deaths due to measles 
occurred in 1857 in Queensland (QLD). Prior to 1900, measles epidemics appeared to 
have been contained within states and territories, occurring at different periods. It was 
only post-1900 that interstate transmission of measles commenced, observed by 
epidemics that occurred simultaneously in a number of jurisdictions. Mortality was 
greatest in children aged <5 years (50-80% of all deaths) followed by children aged 5 -
15 years (5-20%).^^ 
Severe epidemics appeared to end within 12 months and would be separated by inter-
epidemic periods where mortality rates dropped to zero.^® Biennial epidemics were 
observed, once the accumulation of susceptible populations was large enough to 
perpetuate an outbreak. Such observations also were observed in the United Kingdom 
and the US during the pre-vaccine period.'® 
In 1909, South Australia (SA) became the first state to make the notification of measles 
mandatory.^^ Fluctuations in disease were observed during this period with a peak in 
1925 with 14,804 notifications (2742 notifications per 100,000 population) reported.^^ In 
1929, the Federal Capital Territory (Australian Capital Territory) made measles 
notifiable, and were fol lowed by Northern Australia (Northern Territory, 1931) and 
Western Australia (1940).='^ 
The vaccine era 
In 1968, a live, attenuated measles vaccine became available in Australia (Table A-
The following year, vaccination was recommended for children 12-23 months of 
age and by 1972, all states and territories subsequently funded measles vaccination for 
these age groups.^® After the introduction of measles vaccination, rates of measles 
drastically decreased to 1.4 notifications per 100,000 population in 1989. In 1991, the 
National Notifiable Disease Surveil lance System (NNDSS) was established, resulting in 
the national collation, analyses and reporting of notifiable diseases, including 
measles."" 
Table A-1. A history of measles containing vaccine policy in Australia^® 
Year Intervention 
1968 Live attenuated measles vaccine registered 
1971 Vaccine funded in children 12-23 months in all jurisdiction except NSW 
1972 Vaccine funded in children 12-23 months in all jurisdiction in NSW 
1975 Measles included in Australia's first immunisation schedule for infants 12 months 
of age 
1982 Vaccine replaced by measles-mumps (MM) vaccine 
1989 MM vaccine replaced by measles-mumps-rubella (MMR) vaccine 
1992 NHMRC recommended second dose 
1993 Second dose of MMR funded for children 10-16 years of age 
1998 Measles Control Campaign commenced 
Second dose of MMR vaccine lowered to children 4 -5 years old. 
2000 Second dose of MMR vaccine condensed to children 4 years old. 
2001 Young adult campaign funded 
2013 Second dose of MMR vaccine replaced by MMRV and lowered to children 18 
months old. 
Global measles elimination and the feasibility of eradication 
Since the development of an effective vaccine, there has been much discussion on the 
prospect of measles eradication."^ By the early 1980s, nearly all Member States of the 
WHO had included at least one dose of measles vaccine in their routine childhood 
immunisation and coverage increased to around 80% by 2000."^ Subsequently, the 
number of measles cases declined between 1983 and 2000, although, variation 
between and within WHO regions was n o t e d . B y 1994, the Region of the Americas 
had established 2000 as the target year of elimination. In 1997, the Eastern 
Mediterranean Region was the second region to set an elimination target year (2010) 
followed by the European Region (2012)."^ 
In 2000, a technical working group reviewed the current status of measles globally, and 
concluded that supplementary and routine immunisation activities should occur to 
provide a second opportunity to vaccine children who may have missed out on receipt 
of the first dose of vaccine or failed to seroconvert from the first dose."" During the 
same year, the US reported the elimination of endemic measles."^ 
A year later, the Measles Initiative was launched; it is a global partnership between the 
American Red Cross, the United Nations Foundation, the US Centers for Disease 
Control and Prevention (CDC), United Nationals Children's Fund (UNICEF) and the 
WHO. Technical and financial support is provided to national governments to increase 
and sustain population immunity through: routine immunisation and campaigns; 
monitoring measles through surveillance and; identifying and managing disease 
outbreaks." 
By 2002, the Region of the Americas had declared elimination; being the first and at 
present, the only WHO Region to have achieved and sustained measles elimination"®. 
The Western Pacific Region, of which Australia is a part of, set 2012 as the target year 
for measles elimination."^ Progress has been made towards establishing elimination in 
the region; however increasing the first and second dose of measles vaccine coverage 
in some countries is still required, in addition to introducing a booster dose to the 
vaccine schedule in Lao People's Democratic Republic, Vietnam, Solomon Islands and 
Papua New Guinea."® 
Based on the success in the Region of the Americas, the biological and technical 
feasibility of measles eradication was acknowledged by the Global Consultation of the 
Feasibility of Measles Eradication advisory panel in 2010."® However, a set target date 
is yet to be made pending review of regional measles control and elimination targets for 
2015. ' 
The will to eradicate measles garnered further support through the endorsement of the 
Global Vaccine Action Plan by the World Health Assembly (WHA) in 2012. The 
framework reiterates the goal of eliminating measles in at least 4 WHO Regions by 
2015,and as an indicator, will be reviewed in 2013 at the WHA.^° To monitor the 
progress towards measles elimination, a working group on measles and rubella as part 
of the Strategic Advisory Group of Experts on Immunisation (SAGE) developed a guide 
for Member States.^' This was endorsed by SAGE at the end of 2012. ^^  
Having reviewed the literature on the history of measles, its introduction into Australia 
and the global will to eradicate measles, I conducted a more focussed literature review 
on measles epidemiology in Australia over the last two decades- highlighting a period 
where the country transitioned from measles control to measles elimination. This 
literature review was suggested by the National Measles Elimination Working Group 
and also would enhance my understanding of measles given the numerous measles-
related projects I would be involved in. The literature review is structured to be in 
chronological order to highlight the impact of changes in vaccine policy on the 
epidemiology of measles. 
A literature review on measles epidemiology in 
Australia over the past two decades 
Research quest ion 
What changes in measles epidemiology have occurred over the last two decades in 
Australia? 
Search methods 
Medline and Informit were used to search for publications and a backward citation 
search used Web of Science. A total of 4050 measles publications and 42,140 
publications with search term 'Australia' were captured between 1992 and 2012. 
Seventy-one articles with both 'measles' and 'Australia' were found and all abstracts 
were reviewed (Table A-2). Forty-five abstracts were deemed useful in contributing to 
addressing the literature research question. 
Table A-2. Results of the literature search using Medline 
Search terms Number of records 
Measles 4050 
Australia 42140 
Measles AND Australia 71 
Measles AND Australia, between 1993 and 2012 71 
Published NNDSS Annual Reports were also accessed through the Department of 
Health and Ageing (DoHA) website. 
Literature review results 
The 1990s 
Since 1993, the incidence of measles in Australia has reduced considerably. Between 
1993 and 1998, there were over 12,000 cases of measles notified nationally 
(notification rate= 11.4 per 100,000 population),^^ the majority occurring in 1993 and 
1994 (approximately 10,000 cases).^^ Community transmission appeared to be the 
main setting for transmission during this period. Between 1993 and 1994 there were a 
number of large outbreaks that occurred around the country. In one large outbreak 
during June to December 1993, 889 notifications occurred in just one region of 
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metropolitan Sydney (western Sydney), primarily affecting the 0 -14 year age-group. A 
case-ascertainment study during this outbreak, suggested that the notification system 
captured less than half of all cases, indicating the poor sensitivity of the notification 
system duhng this per iod." In 1993 and 1994, the Northern Territory (NT) was the 
jurisdiction with the highest rates of measles.®^ During a 1994 outbreak in Alice 
Springs, 55% of 259 cases in a remote community were Aboriginal.^ The attack rate 
among Aboriginal individuals was estimated to be 12.6 per 1000 population, much 
higher than attack rates observed in non-Aboriginal individuals (4.0 per 1000 
population).^ School-based transmission was also found to be an Important setting for 
transmission during a 1994 outbreak in Western Australia (WA) affecting 53 individuals, 
a large proportion from a high-school.®® 
Consequent to the large outbreaks experienced in 1993 and 1994, a second dose of 
MMR vaccine was introduced in 1994; targeting children aged 10-16 y e a r s . B y 1995, 
measles notification rates reduced to 7.3 per 100,000 population compared to 25.7 per 
100,000 population in 1994.®® In 1996, the reduction in notification rate (2.7 per 
100,000 population) was even more marked.®^ 
A significant factor in shifting the focus from measles control to measles elimination, 
was the commencement of the Measles Control Campaign (MCC) in 1998. The MCC 
was part of the 'Immunise Australia: Seven Point Plan'; evidence that Australia was 
committed to eliminating measles in the country.®® The MCC included: ®® reducing the 
age of the second dose of MMR to four to five years; a school-based mass vaccination 
program of children aged 5 -12 years (July-December), regardless of vaccination 
status; encouraging participation in the campaign through media and education 
programs; distributing letters to parents of preschool and high-school aged children to 
encourage vaccination and; providing financial incentives to parents and general 
practitioners for vaccination. 
Following the implementation of the MCC, the measles notification rate reduced in 
1999, to the lowest rate since the inception of the NNDSS (1.2 per 100,000 
population).®" However, it was during 1999 that healthcare workers were identified as a 
susceptible population. In a Victorian outbreak, six of the 75 cases were healthcare 
workers.®' This outbreak also highlighted young adults as a susceptible group, with 
85% of cases aged 18-31 years. Community and healthcare facilities were Identified 
as important settings for measles transmission during this outbreak.®^ The impact of 
the MCC however was apparent, with a national serological survey indicating immunity 
had increased from 85% (pre-MCC campaign) to 90% after the campaign (January-
May 1999), with the greatest increase in pre-school and primary school children.®^ 
Further evidence of the success of the MCC was evident through mathematical 
modelling, which estimated that the reproduction number for measles reduced from 
0.90 pre-campaign to 0.57 post-campaign.®^ 
With further reductions in measles cases, and evidence of a successful MCC in 
increasing immunity against measles, it seemed the shift from measles control to the 
goal of elimination was in the horizon. An important indicator to assess whether an 
endemic circulating measles virus exists is through genotyping. Between 1973 and 
1998, 35 wild type viruses were circulating Australia. During 1999, a novel genotype 
G3 was identified in Queensland which was traced to a refugee population from East 
To this point, it is clear that measles notifications have declined, however, it was also 
important to establish the burden of measles through hospitalisations and deaths 
during the 1990s, particularly in the context of changes to the vaccine program. 
Between 1993 and 1998, there were 1856 hospitalisations where measles was 
recorded as the principal diagnosis (hospitalisation rate 2.1 per 100,000 population).^^ 
The most common complication reported was pneumonia (7%) and otitis media (3%). 
Children 0 - 4 years of age had the highest notification rate (11.6 per 100,000 
population) followed by children aged five to 14 years (4.2 per 100,000 population). 
Seven deaths associated with measles infection were reported between 1993 and 
1997.®' 
Assessing vaccine uptake is a useful tool to determine if there is a relationship between 
uptake and the number of cases .Coverage for the primary dose of MMR (MMR1), 
assessed at 24 months by three-month cohorts between January and December 1998, 
was less than 95% in all jurisdictions; with only Queensland reaching greater than 90% 
coverage. However, underestimates of coverage have been claimed, estimated to be 
approximately five per cent.®' 
The 2000s 
Like the year 1999, the notification rate in 2000 reduced even further (0.6 per 100,000 
population).®® During this year, however, the susceptibility of healthcare workers was 
again identified, when two ambulance officers became infected with measles following 
exposure to an infectious case.®' During a cluster of measles in Queensland, cases 
presented multiple times to a number of healthcare facilities whilst infectious.®® With 
low suspicion of measles among clinicians and no vaccine policies implemented for 
healthcare workers at the time, it was postulated®® that healthcare facilities propagated 
measles outbreaks. This was further supported by a general practice (GP) surgery 
waiting room in NSW being the setting of transmission of a cluster in 2000, involving 
five cases of measles.®® 
Measles notification rates had again reduced in 2001-2002, to 0.4 per 100,000 
population.™ A large proportion of cases during this period occurred in the 15-24 year 
age group. Young adults once more were affected by measles , the median age of a 
2001 Victorian outbreak of 51 cases was 25 years (range= 10 months-34 years). 
Another characteristic of this outbreak was the lack of suspicion of measles by 
clinicians leading to multiple presentations. A total of 62 presentations to a healthcare 
facility occurred in the 22 hospitalised cases, with measles suspected during the first 
presentation in only 13% of hospitalised cases. ' ' Of great concern however, was that 
young adults were susceptible to acquiring measles. Young adults were too old to have 
been eligible for the second dose of MMR when it was included in the vaccine 
schedule, and lacked natural immunity, as measles incidence had become rare during 
their childhood.'^ To combat the gap in immunity among young adults, the 
Commonwealth Government provided funding for MMR vaccine in adults aged 18-30 
years in 2001 and 2002.®® Vaccination was rolled-out through GPs, hospital emergency 
departments (ED) and other healthcare facilities in the Young Adult Campaign. A 
serosurvey conducted in Victoria before and after the campaign; however, found no 
significant difference in serological immunity between the two time periods'^ suggesting 
the campaign had been unsuccessful. The failure of the Young Adult Measles 
Campaign was further confirmed during two 2003 outbreaks in Adelaide where the 
median age was 23 years (range= 9 months- 36 y e a r s ) a n d in NSW where the 
median age was 24 years (range= 2 months-38 years).'® 
Despite young adults remaining a susceptible population, further reduction in measles 
notifications was providing more evidence of Australia's progress towards measles 
elimination. In 2003 to 2004, there were 92 and 54 cases of measles in Australia, 
respectively. A decrease in notification rate from 0.5 per 100,000 population in 2003 to 
0.2 cases per 100 000 population in 2004.''® By 2005, measles became even rarer, with 
only ten cases of measles nationally; the lowest rates of notifications (< 0.1 per 
100,000 population) since the NNDSS was establ ished." The progress towards 
eliminating measles was, however, disrupted in 2006. An increase in measles cases 
occurred with 125 cases notified and a notification rate of 0.6 per 100,000 population.''® 
Eighty-two cases were part of a multi-state outbreak during a tour of a spiritual leader 
from I n d i a . T h e rise in cases was short-lived however, and in 2007, only 12 cases 
(0.1 per 100,000 population) were reported, of which seven were acquired overseas. 
As expected, with declining measles notifications, a reduction in hospitalisations also 
occurred. Between July 1998 and December 2000, there were 111 measles 
hospitalisations with measles as the principal diagnosis.®^ The rate of hospitalisation 
was 0.3 per 100,000 population compared to 2.1 per 100 000 population in July 1993-
June 1998. The highest rate occurred in children 0 - 4 years old and the median length 
of stay was highest in the 15-24 year and 25-59 year age groups (both four days). No 
deaths were recorded during this period. Pneumonia was the most common 
complication among all measles hospitalisations (eight per cent) followed by 
neurological complications (five per cent).®^ 
A decline in measles hospitalisations again occurred during July 2001-June 2002 
compared to July 1998-December 2000. There were 96 hospitalisations with measles 
as a principal diagnosis and rate 0.20 per 100,000 population™ compared to a rate of 
0.3 per 100,000 population in July 1998-December 2000). The most common 
complication for all measles hospitalisations was pneumonia (7%). Similarly, no deaths 
were recorded during this p e r i o d . A s outlined above, molecular epidemiological 
evidence is important to determine whether an endemic strain of measles exists. 
During 1999-2001, there was again no evidence of a circulating genotype; nine 
different genotypes were identified including one new genotype (D9). 
Between July 2003 and June 2005, there were 72 hospitalisations with a hospitalisation 
rate of 0.12 per 100,000 population where measles was the principal diagnosis 
compared to 0.2 per 100,000 population (hospitalisation rate=0.12 per 100,000 
population) in July 2001-June 2002.®^ The hospitalisation rate was greatest in the 0 - 4 
year age group (0.76 per 100,000 population) between July 2003 and June 2005, 
however, the median length of stay was greatest in the 25-59 year age group (three 
days) where measles was the principal diagnosis.®^ No deaths were recorded during 
this period, however, there was one death in 2004 associated with S S P E . " The 
following year, another case of SSPE occurred resulting in three hospital admissions.®" 
Of all hospitalisations coded with measles, six per cent were recorded to have 
pneumonia and 13% were recorded as experiencing other complications.®^ 
Despite the increase in notifications in 2006, the rate of hospitalisations remained low, 
with 52 hospitalisations (rate= 0.13 per 100 000 population) in July 2005-June 2007. 
Similar to previous years, rates were highest in the 0 - 4 year age group (0.54 per 
100,000 population), however, length of stay was highest in individuals over five years 
of age (median=two years).Nine hospital separations were coded as experiencing 
complications, of which five were due to pneumonia. No deaths associated with 
measles were recorded during this period.®^ 
Although young adults were continuously identified as a susceptible population and 
thus jeopardising Australia's target for elimination, one area of improvement was the 
increase in measles vaccine coverage. Only Queensland exceeded 90% coverage of 
MMR1 by two years of age in previous coverage estimates (31 March 1998-31 
December 1998). In comparison, vaccine uptake of MMR1 at two years of age, 
measured between 31 March 1999 and 30 September 2001 was approximately 93% 
and remained stable during this period. South Australia was the only jurisdiction to 
reach the target of 95% coverage.'® The booster dose of MMR (MMR2) uptake 
measured at six years of age identified that coverage was lower, at around 82%, with 
little change occurring between 31 March 1999 and 30 September 2001.'° No 
comparisons were able to be made with previous years as data on vaccine coverage of 
4 - 5 years born since the ACIR commenced would only be four years of age in 2000.®^ 
There was little change in coverage during 2001-2003, remaining at around 93% for 
MMR1 at 24 months and just below 85% for MMR2 at six years.™ MMR1 coverage 
between 2003 and 2005 at 24 months of age was between 93% and 95% and 
remained steady during this period, similar to coverage of approximately 93% during 
2001-2003. Likewise, MMR2 coverage at six years between 2003 and 2005 remained 
around 85% with little change during the same period in 2001-2003 
Given the number of healthcare workers infected by measles in previous outbreaks as 
outlined above, it was important to recognise the need for healthcare workers to be 
protected against measles- particularly as an occupation health and safety issue. Each 
state and territory has their own policy and recommendations. In NSW, a policy 
directive was implemented in 2007, requiring mandatory immunisation of all NSW 
Health staff against a number of vaccine preventable diseases, including measles.®® 
Current Australian guidelines, recommend that all new staff should be assessed and 
offered vaccination for testing for certain diseases (including measles) prior to working 
in high-risk areas. 
Furthermore, coverage among children was improving. In 2007, MMR1 coverage rose 
to 94% nationally at 24 months of age with the 95% target coverage reached in 
Tasmania and the NT. MMR2 coverage at six years remained lower at 88%, Victoria 
was the only jurisdiction to achieve uptake greater than 90% (91%) however increased, 
compared to previous years.®® 
The era of measles elimination 
In 2008, a group of measles experts argued that measles had been eliminated in 
Australia since 2005, in the form of a publication.® A number of indicators were used to 
argue the case of elimination; based on indicators developed by the Western Pacific 
Regional Office (WPRO) of the WHO that aimed to assist countries in implementing a 
national plan for measles elimination.®® One of the indicators was a low incidence of 
measles (< 1 case per million population)® which in 2008, was not reached. During 
2008, 65 cases of measles were reported (0.3 per 100,000 population) of which 26% 
were reported as acquired overseas. Further progress however, was made in 
increasing vaccine coverage. In 2008, MMR1 national coverage remained stable at 
94%, with the Australian Capital Territory (ACT) and the NT the only jurisdictions to 
exceed the target uptake of 95%.®° During this year, the assessment age for MMR2 
coverage was reduced to five years of age which resulted in a sharp decrease in 
vaccine coverage nationally (79.8%).®° 
Despite the high coverage and the report of measles elimination, an increase of 
measles notifications occurred in 2009. 104 cases were notified (rate=0.5 per 100,000 
population); 34% were reported to have been acquired overseas. During this year, 
national MMRI coverage at 24 months of age was 93.8%, this time with no jurisdiction 
reaching the 95% target. The national MMR2 coverage increased from the previous 
year to 83.2% at five years of age. 
Measles notifications in 2010 was lower than the previous two years, with 70 cases 
(0.3 per 100,000 notifications) and 46% of these were reported as being acquired 
overseas. A multi-jurisdlctional outbreak involving nine cases occurred with four 
transmissions by the index case In an aeroplane. Two subsequent transmissions 
occurred in healthcare workers.®' These transmissions occurred in a Queensland 
hospital.®' In Queensland, vaccination against measles for healthcare workers is 
recommended but not mandatory.®^ Five of the nine cases from this outbreak were 
hospitalised- three with complications. The severity of measles was also highlighted 
during this year, with the publication of a report on the death of a previously healthy 22-
year old female with no history of having measles infection was diagnosed with SSPE 
during a post-mortem examinat ion." 
National notified cases are yet to be published in 2011. A number of outbreaks 
however have been reported. Firstly, a multi-country outbreak occurred when three 
index cases from New Zealand flew from Singapore to Auckland via Brisbane resulting 
in eight secondary cases.®" Transmission of measles during plane travel to Australia 
appeared to be an important setting considering four of the most recent outbreak report 
publications reporting this as the main setting for transmission.®' ^^  During this year, 
individuals of Pacific Islander origin were identified as a susceptible population during 
an outbreak in western Sydney where 46% of the 26 cases were of Pacific Islander 
origin.®® 
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Abstract 
Background: 
Since the introduction of measles vaccine to the vaccination schedule, the burden of 
measles has substantially reduced in Australia. Despite this, a number of recent 
measles outbreaks have occurred. The aim of this study was to examine the burden of 
measles in Australia through describing trends of measles infection using the most 
recent data available on measles notifications, hospitalisations and mortality. 
Methods: 
Data were obtained from the Australian National Notifiable Disease Surveillance 
System, the National Hospital Morbidity Database and National Mortality Database to 
obtain notification, hospitalisation and death data, respectively. Rates per 100,000 
population were calculated and compared over time by age group and jurisdiction. 
Results: 
Since 1993, measles notifications have reduced considerably in Australia. However, 
between 2000 and 2011, measles notification rates and hospitalisation rates fluctuated. 
Although children 0 - 4 years were the most susceptible group in 2000-2002, young 
adults (20-34 years) and children 10-19 years have appeared to be susceptible. 
Children 0 - 4 years and adults 20-34 years were the age groups to have experienced 
the greatest rates of hospitalisation over the 11 -year period. Jurisdictional variation 
occurred over the study period with differing patterns of notifications and 
hospitalisations. 
Conclus ions: 
Although a marked reduction in measles notifications and hospitalisations have 
occurred in Australia since 1993, there is still evidence measles cases are occurhng, 
and a reduction in notification and hospitalisation has not been observed over the past 
11 years. Children and young adults continue to be affected by measles infection 
highlighting gaps that continue to occur nationally. Our results suggest that enhanced 
immunisation activities are required to vaccinate susceptible individuals and incidence 
of measles needs to reduce further to be considered eliminated in the country. 
Prologue 
My role 
Upon starting the MAE, one of my first tasks was to conduct an epidemiological review 
for measles. NCIRS has a contractual arrangement with the DoHA to produce reports 
on vaccine preventable diseases and the last measles report was published as a 
Communicable Diseases Intelligence supplement in 2010, as part of the Vaccine 
Preventable Diseases in Australia report. There was discussion at this stage, however, 
that the format of the report had should be changed and include some modifications to 
how hospitalisation data were analysed (i.e. rather than conducting hospitalisation 
data analysis by financial year and separation date, calendar year and admission date 
were to be used instead). 
I was able to embark on this project immediately as notification and hospitalisation data 
had already been obtained. Aditi had previously conducted some analysis on the 
notification data which I have used the results in for Figure 1 and Figure 2. I did 
however update the number of hospitalisations for Figure 1. I used SAS® to write the 
programs for notification and hospitalisation data which was my first introduction to 
analysing notification data using this program. 
This project took more time than anticipated, due to a number of other projects that 
were prioritised due to their public health urgency (measles and Staphylococcus 
Bureaus outbreaks). However, the delay in completing this project enabled me to 
update the hospitalisation data to Include the whole of 2010. 
Lessons learned 
This project was a great introduction to measles for me, and auspicious in terms of 
what would eventuate, in respect to my other measles-related projects. Prior to this 
project I had little knowledge on the aetiology and pathogenesis of measles and I learnt 
a great deal about both of these when doing background reading for this analysis 
I learnt about the biases of notification data and the importance of standardised case 
definitions, particularly what role a change in the measles case definition may have 
played on notification data. Most importantly, I was introduced to the notion of 
underreporting of cases and the importance of interpreting results of notification data 
with the consideration of changes in surveillance activities (such as a change in case 
definition) and reporting practices. 
I learnt the complexities of measles hospitalisation data and that coding of data can at 
times be inaccurate. I also learnt that the inclusion of all diagnoses for measles in the 
analysis (i.e. principal and secondary diagnoses for a single admission) can bias the 
outcome of results. 
One important lesson I learnt, and that I previously had no idea of was about the 
sensitivities around working with small numbers in mortality data. To protect an 
individuals' confidentiality, small values were randomly assigned by the Australian 
Bureau of Statistics so that totals in some cases did not equal to the sum of their 
components. Initially I did not realise that this had been done and found it quite 
challenging trying to report the number of deaths due to measles as a range. 
I also learnt that it would have been useful to have developed a data analysis plan for 
this project as it would have provided me with clearer directions. I think this was 
definitely one of my major learning points during the MAE, and one which I think 
improved as time progressed. 
Public health act ion 
This report will be an update of measles epidemiology in Australia and aims to be 
published in the Communicable Diseases Intelligence journal as a stand-alone paper. It 
is a follow-up to a previous epidemiological review, however, is important as it provides 
a national picture of what is happening in Australia with respect to measles incidence 
and its' burden in the country which has implications towards measles elimination 
status in the country. 
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Introduction 
Nationally, measles epidemiology has been reported through NNDSS Annual Reports 
and more recently, Vaccine Preventable Diseases (VPD) Reports which provide an 
overview of VPDs including measles over a three-year period. Since 2007, an analysis 
of the epidemiology of measles nationally has not been conducted. Given the 2012 
target year for measles elimination in the region, it was timely to provide an updated 
review of the epidemiology of measles in Australia. The objective of this paper was to 
determine the burden of measles in Australia through describing trends of measles 
infection using recent data on measles notifications, hospitalisations and mortality. 
Methods 
Data Sources 
Notifications 
Measles is a notifiable condition in all jurisdictions in Australia and both confirmed and 
probable cases should be notified to health authorities.®' A confirmed case of measles 
requires laboratory definitive evidence or clinical evidence with an established 
epidemiological link. Alternatively, a probable case of measles require clinical evidence 
of measles with laboratory evidence suggesting measles infection (specifically 
measles IgM detection in an unapproved reference laboratory, except if a measles 
containing vaccine was administered eight days to eight weeks prior to the test).®® 
De-identified national data for both confirmed and probable measles notifications were 
obtained from the NNDSS from January 1993 to December 2 0 1 1 T h e following 
fields were included in the analysis: date of diagnosis, age at onset, state or territory of 
residence and genotype of measles specimen. 
Hospitalisations 
Data coded for measles using the International Statistical Classification of Diseases 
and Related Health Problems, Tenth Revision, Australian Modification International 
Classification of Disease {ICD)-10-AM/ICD-10 code BOS were obtained from the 
Australian Institute of Health and Welfare (AIHW) National Hospital Morbidity 
D a t a b a s e . T h e database collects information on patients admitted to public and 
private hospitals in Australia. Hospital admissions between January 2000 and 
December 2010 were analysed. Our analysis only includes hospitalisations by 
admission dates where measles was recorded as principal diagnosis (i.e. the diagnosis 
primarily responsible for prompting an episode of admitted/residential care or 
presentation at a healthcare institution) unless otherwise specified. The variables used 
in the analysis included date of admission, diagnosis, age on admission, state or 
territory of residence, length of stay and the mode of separation (i.e. the process by 
which an admitted patient is discharged e.g. discharge, death, transfer or change in 
care type). 
Deaths 
De-identified aggregated mortality data (2002-2011) were obtained from the Australian 
Bureau of Statistics (ABS) National Mortality Database. ' ' " Registered deaths with 
measles as the underlying cause based on the cause of death classification ICD-10 
were analysed. A more detailed explanation of the methodologies used has been 
previously described.®® To protect an individual's confidentiality, cells in the dataset 
with small values were randomly assigned meaning a range was provided. 
Data analysis 
Crude and age-specific annual rates were calculated using mid-year population 
estimates obtained from the ABS per 100,000 population. Median length of stay was 
calculated for hospital admissions by days. 
Results 
Since 1993, measles notifications and hospitalisations have reduced considerably 
(Figure B-1). During 1993 and 1994, notifications peaked with 4678 and 5184 reported 
cases, respectively. Notifications dropped dramatically over the follow/ing years to as 
low as 10 cases during 2005. Between 2000 and 2011, small peaks were observed in 
2001 (n=132), 2006 {n=125) and, more recently 2011 (n=190). 
The number of hospitalisations also decreased since 1993, and although peaks in 
hospitalisations corresponded to peaks in notifications, the number of hospitalisations 
was much lower than the number of notifications. 
Figure B-1. IVIeasles notifications and hospitalisations, Australia, 1993 to 2011, by 
month of diagnosis or admission* 
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When observing measles notification rates by age group in 2000-2011, no specific age 
group was consistently highest, and rates fluctuated considerably due to the small 
number of cases (Figure B-2). Infants < 12 months of age had the highest notification 
rates in most years, however, during 2005 and 2010, there were no infant cases 
notified. In 2011, the notification rate in infants was 3.44 per 100,000 population, the 
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highest notification rate of all age groups during the twelve-year period. During most 
years, children 1-4 years of age had the second highest notification rate followed by 
young adults aged 20-34 years. More recently, children aged 10-19 years of age have 
had the highest annual notification rates (at 1.38 per 100,000 population in 2009 and 
0.72 per 100,000 population in 2010). 
Figure B-2. Measles notif ication rates, Australia 2000-2011, by age group and 
year of diagnosis 
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State and territory variations 
Overall, there was considerable variation in notifications among State and Territories. 
(Figure B-3). Between 2000 and 2011, the three most populous states (New South 
Wales, Victoria and Queensland) accounted for 76% (752/987) of all measles cases 
nationwide. New South Wales reported the highest number of measles cases (n=335), 
of which 27% (n=90) of cases occurred during 2011. During 2009, all States and 
Territories reported at least one measles case, the only year that this occurred over the 
twelve-year period. The pattern in hospitalisations for each State and Territory follows a 
similar pattern to the number of notifications. 
Figure B-3. Measles notifications and hospitalisations by jurisdictions*^ 
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Overall, notification and hospitalisation rates remained low throughout the time period 
considered. Nationally, notification rates remained below 1 per 100,000 population for 
all years (Table B-1). For each State and Territory, variation in notification rates 
occurred with the notification rates in NSW, the NT and the ACT exceeding 1 case per 
100,000 population in 2011. 
Table B-1. Measles notification and hospitalisation rates, Australia, 2000-2011*, 
by State and Territory 
2000 Notifications 0.54 0.45 0.80 0.73 0.53 0.00 0.95 0.21 0.57 
Hospitalisations ™ 0.17 0.21 " 0.20 0.27 0.27 0.00 0.63 0.00 0.20 
2001 Notifications 0.35 1.70 0.31 0.13 0.68 0.00 0.00 0.42 0.68 
Hospitalisations 0.14 0.78 0.11 0.00 0.31 0.00 0.00 0.00 0.29 
2002 Notifications 0.11 0.29 0.22 0.13 0.00 0.00 0.00 0.00 0.16 
Hospitalisations , 0.14 0.19 0.00 0.07 0.16 0.00 0.00 0.21 0.12 
2003 Notifications M 0.26 0.80 0.29 1.58 0.00 0.50 0.00 0.00 0.47 
Hospitalisations ^ 0.17 0.29 0.11 0.39 0.00 0.00 0.00 0.00 0.18 
2004 Notifications 0.17 0.30 0.00 0.39 0.45 1.48 0.00 0.00 0.22 
Hospitalisations 0.14 0.18 0.03 0.07 0.15 0.49 0.61 0.00 0.11 
2005 Notifications 0.07 0.04 0.03 0.00 0.05 0.00 0.00 0.21 0 2 2 
Hospitalisations 0.10 0.04 0.03 0.06 0.00 0.00 0.00 0.21 0.06 
2006 Notifications 0.89 0.24 0.05 0.58 1 46 0.00 0.30 2 2 5 0.61 
Hospitalisations 0.30 0.16 0.02 0.39 0.24 0.00 0.60 0.00 0.21 
2007 Notifications 0.06 0.04 0.10 0.06 0.05 0.00 0.00 0.00 0.06 
Hospitalisations 0.00 0.12 0.07 0.00 0.00 0.00 0.00 0.00 0.04 
2008 Notifications 0.56 0.04 0.26 0.13 0.37 1.36 0.00 0.00 0.31 
Hospitalisations 0.20 0.10 0.02 0.06 0.14 0.00 0.00 0.00 0.11 
2009 Notifications 0.27 0.69 0.74 0.19 0.45 0.44 0.28 0.40 0.48 
Hospitalisations 0.18 0.26 0.12 0.19 0.09 0.44 0.00 0.40 0.18 
2010 Notifications 0.35 0.26 0.32 0.12 0.48 0.87 0.28 0.00 0.31 
Hospitalisations 0.11 0.20 0.16 0.00 0.31 0.44 0.00 0.00 0.15 
2011 Notifications 1.25 0.70 0.38 0.24 0.72 2.16 5.71 0.00 0.86 
Total number notifications 27 335 15 139 66 17 278 110 987 
Total number hospitalisations 6 107 3 34 23 4 125 34 336 
* Hospitalisation (principal diagnosis) data available through 2010 
Genotypes 
The proportion of measles notifications with data on genotype increased considerably 
since 2000. (Figure B-4). While in 2000 no specimen from the NNDSS database had 
data on genotype, by 2010, 61% of notifications were genotyped. Of those specimens 
genotyped, there was no single dominant genotype. 
Figure B-4. Proportion of measles notification by genotype, Australia 2000-2011 
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Severe morbidity and mortality 
As observed with notifications, the number of hospitalisations has substantially 
declined over the past two decades (Figure B-1). In terms of age group, the 0 - 4 year 
age group had the highest hospitalisation rates for most years (Figure B-5). With 
young adults (aged 20-34 years) having the second highest rate of hospitalisations of 
all age groups. Hospitalisations in the remaining age groups were low. Overall, adults 
aged 35+ years had the lowest hospitalisation rates. 
Figure B-2. Measles hospitalisation rates, Australia 2000-2010, by age group and 
year of admission* 
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• Hospitalisation (principal diagnosis) data available through 2010 
Of the 123 measles-related hospital admissions in 2007-2010, 107 (87%) had measles 
recorded as the principal diagnosis. Complications arising from measles infections 
were recorded for 17 (16%) admissions (Table B-2), of which five were coded as 
having measles complicated by pneumonia, two cases were coded as measles 
complicated with intestinal complications and ten as having complications other than 
pneumonia, otitis media, encephalit is and meningitis. There were no deaths recorded 
in patients hospitalised with measles between 2007 and 2010. 
Table B-2. Selected Indicators of severe morbidi ty for hospital ised cases of 
measles, Austral ia, 2007-2010*, by age group 
Age group 
(Years) 
Measles 
complicated by 
pneumonia 
Measles with complications 
other than pneumonia, otitis 
media, encephalitis or 
meningitis 
Measles without 
complications 
n % Total+ n % Total+ n % Total+ 
0-4 1 3.6 2 7.1 25 89.3 
5-9 0 - 0 - 1 100.0 
10-19 1 5.6 1 5.6 16 88.9 
20-34 2 4.3 2 10.5 40 85.1 
35+ 1 7.7 4 30.8 8 61.5 
All ages 5 4.7 12 11.2 90 84.1 
* Hospitalisation (principal diagnosis) data available through 2010 
1 of total in t t ie age g roup 
Length of stay per admission by age group is displayed in Table B-3. Between 2007 
and 2010, hospital separations accounted for 306 bed days. The median length of stay 
was three days with adults aged 35+ years age group having the longest median 
length of stay in hospital (four days). 
Table B-3. Length of stay per admission of measles hospitalisation by age group, 
2007-2010® 
Age group (year) 
Hospital admissions Median length of stay (days) 
n rate per 100,000* n 
range 
0 - 4 28 0.50 1.5 1 -6 
5 -9 1 0.02 1 1-1 
10-19 18 0.16 2 1 -6 
20-34 47 0.25 3 1 -8 
35+ 13 0.03 4 1 -8 
Total 107 0.12 3 1 -8 
§ Principal diagnosis (hospitalisations) 
t Average annual age-specific rate per 100,000 population 
Between 2002 and 2011, there were one to four deaths reported in the National 
Mortality Database with measles as the underlying cause of death. These deaths were 
registered in 2010 and occurred in males only. 
Discussion 
Our results provide an overview of the burden of measles in Australia over the last 
tw/elve years. Overall, the notification rate fluctuated reducing to less than one case per 
nnillion population twice during the study period, a previous indicator of low incidence 
set by the WHO required to reach elimination.®® More recently however, this indicator 
was updated to not include a threshold. The revised indicator states countries where 
measles should have very low incidence of confirmed cases - which our results 
indicate have occurred. 
From our results, it was evident that the 0 - 4 year age group is a vulnerable population 
for measles infection and hospitalisations. It has been well-documented that measles is 
predominantly a childhood disease. However, from our data, infants younger than 12 
months of age, in most years have been the age group most affected by measles, 
highlighting their susceptibility. One explanation for this could be the decline in 
maternal antibodies in infants, with a minimum level at 7 - 9 months of age observed. 
Moreover, the concentration of antibodies against measles in pregnant women derived 
from vaccine has been found be significantly lower than antibodies derived from natural 
infection.^® In addition, a modelling study has predicted that by six months of age, 95% 
of infants with naturally derived maternal antibodies would be susceptible to measles 
due to the waning of maternal antibodies. It has been postulated that because measles 
is becoming rare, the lack of natural boosting through exposure of wild virus in both 
vaccinated women and women with past infection has consequently resulted in infants 
becoming more susceptible. It is thus important that timely vaccine uptake among 
infants occurs at the recommended 12 months of age. During outbreaks, the first dose 
of measles can be administered early, with two subsequent doses required after 12 
months of age due to concerns of interference with maternal antibodies. 
In the above discussion, the susceptibility of infants was outlined but it is also important 
to consider the susceptibility in children aged 1 - 4 years. Previously under the NIP, the 
booster dose of MMR was administered at 4 years of age. In 2008, it was 
recommended that the booster should be brought forward to 18 months given the 
number of notifications in the 1 - 4 year age group and the potential to improve vaccine 
uptake. " This recommendation was not implemented under the NIP until July 2013 
and aims to protect children against measles at an earlier age.^^ 
Interestingly, between 2009 and 2010, individuals aged 10-19 years had the highest 
notification rates which increased in 2011. This age group would have been born 
between 1990 and 2001 and should have been captured during the MCC. However, it 
might be that a proportion of individuals in this age group (those born between 1990-
1992) were too young to be eligible for MMR2 given at 10-14 years between 1995 and 
1998 and too old for MMR2 when the dose was brought forward to four to five years of 
age in 1998, and thus missed out on the booster dose of vaccine. This was highlighted 
during a recent high-school based outbreak (ten cases in a single high-school).®® 
Additionally, detailed demographic information on the 10-19 year age group would 
assist in considering risk factors that may be associated with infection such as ethnicity 
(eight of the ten cases were of Pacific Islander origin^®). This would allow for more 
targeted interventions to be piloted promoting vaccination uptake in this age group. 
Our study supports previous literature which identified young adults as susceptible 
cohort. Those born between 1968 and 1982 ( 2 1 ^ 5 years) are particularly susceptible 
as low vaccine coverage existed when they were infants and natural immunity against 
infection was waning.'^ Furthermore many in this cohort were ineligible for the booster 
dose as they exceeded the 10-16 year eligibility age when it was offered between 
1994 and 1998. Young adults are often mobile and well-travelled with a number of past 
outbreaks occurred following the importation of measles by a young adult traveller from 
measles endemic countries.®' " Although a targeted young adult measles campaign 
was conducted in 1999, it was deemed to be unsuccessful in changing immunity, 
possibly due to the lack of funding for advertising and planning. 
As most outbreaks in Australia begin with an importation of measles from an endemic 
country, it is essential that measles immunity status be assessed when patients attend 
clinics to receive vaccinations for international travel. Currently, all individuals born 
during or after 1966 who have not acquired natural immunity or received two doses of 
MMR are recommended to be vaccinated before travelling.^^ Of further concern is 
whether travellers present to a healthcare facility for pre-travel advice. In a study of 17 
353 ill returned travellers who presented to one of the 30 participating travel or tropical 
medicine clinic around the globe, 50% had documented pre-travel health advice.'"^ 
Given the low proportion of travellers seeking pre-travel health advice, it is necessary 
to think of other mechanisms to raise the awareness of the risk of measles in 
unvaccinated individuals travelling to measles endemic countries. Health advice upon 
booking a flight or travel insurance may be possibilities; however, further research is 
necessary. 
Moreover, an Australian-based study found that 4% of recently returned travellers who 
presented to two hospitals were vaccinated against MMR over a six-year period 
(1998-2004) in a group of 917 travellersT^ Although MMR is currently recommended 
in travellers born after 1966 who have not had two doses of measles containing 
vaccine,^^ the proportion travellers in this category who receive MMR is unknown. 
Moreover it is unclear whether immunisation providers recommend vaccination. It 
would be of value to conduct a qualitative survey on the attitudes and behaviour of 
general practitioners towards pre-travel advice, particularly for measles. 
Clearly, a number of susceptible populations exist in Australia and consequently this 
may lead to outbreaks in these populations. To determine whether cases are linked, it 
is important that genotyping of specimens occurs. Additionally, genotyping of 
specimens indicates the origins of the genotype and examines whether there are 
particular strains circulating in a country- especially important in the verification of 
measles elimination.^' Our results on completeness of the data field 'genotype' indicate 
that during the earlier years, genotyping was not conducted. A previous study, 
however, suggest that genotyping did indeed occur and during 2000 and 2001. 
Between 2000 and 2001, D7, G2, HI and D5 were observed to be circulating in 
Australia®^ but for some reason, were not captured in the NNDSS dataset. A review of 
the NNDSS measles dataset to assess the quality of this data field is recommended. 
This is because the completeness is of particular importance in demonstrating whether 
a circulating measles strain exists. 
A number of limitations in the analysis warrant caution in interpreting the results. 
Firstly, in general notification data is considered not representative of all cases in the 
community due to not all cases presenting for health care and/or having the correct 
diagnostic test taken. However, this is unlikely to occur for measles as it is assumed 
most cases would attend a healthcare facility due to the signs and symptoms of the 
disease. 
Secondly, a unique identifying code which links NNDSS and AIHW morbidity data does 
not exist. 
In general, coding errors may occur in hospitalisation data, particularly when coding 
conditions that an individual is hospitalised for. A Victorian based study found that the 
discrepancy rate in coding field amongst hospital morbidity data increased the rarer the 
condition. Our data also highlighted these discrepancies as in some instances, the 
number of hospitalisations exceeded number of notifications suggesting either the 
under-reporting of measles notifications and/or the miscoding of hospitalisations as 
measles. 
Lastly, the case definition for measles was amended in 2004. Prior to 2004, a 
confirmed case of measles could include a clinical diagnosis of an illness characterised 
by measles. As many conditions may present with similar symptoms to measles, the 
specificity of this case definition is likely to have been low and subsequently led to an 
overestimation of true measles cases. 
Although the last reported death due to measles occurred in 1995, between 2002 and 
2011 period, one to four deaths were recorded in 2010. Unfortunately, we have no 
further information on which complications occurred, and whether there were specific 
factors that made these cases more susceptible such as pre-existing co-morbidities 
and/or extremes of age. A recent publication®^ indicated that during the study period, a 
22-year old died from SSPE in Western Australian hospital, however, this was not 
captured in the AIHW morbidity and National Mortality dataset based on sex and age. 
It is not known how sensitive the dataset is in capturing deaths where the main cause 
is measles 
Conclusions 
The rates of notification and hospitalisation of measles in Australia have fluctuated over 
the last 12 years, with gaps in immunity continuing to occur in children years and 
more recently, those aged 10-19 years. This suggests that enhanced immunisation 
activities would be beneficial for certain groups. . Measles notification rates have 
remained above previous WHO criteria of below one per million population in ten of the 
12 years of the study period.. 
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Abstract 
Background: 
Global targets for measles elimination have now been established by all World Health 
Organization (WHO) regions. Demonstrating that R, the average number of secondary 
cases from an infectious case remains below one is a widely accepted means to track 
maintenance of measles elimination. We evaluated three methods to calculate R using 
routinely collected notification data. 
Methods: 
Using data from Australia's National Notifiable Disease Surveillance System, R was 
estimated for the years 2009-2011. Three methods were used to estimate R: 1) 
Proportion of imported cases; 2) Distribution of outbreak sizes; and 3) Distribution of 
generations of spread. Proportions of completeness of the required notification data 
fields were also examined. 
Results: 
Between 2009 and 2011, there were 367 notified cases in Australia, a mean annual 
rate of 5.5 per million population. Data completeness was 100% for importation status 
but 77% for outbreak reference number. We estimated R to be below one for all years 
and methods used. Based on the proportion of imported cases, R = 0.65 (95% 
CI=0.60-0.70), based on distribution of outbreak size R=0.64 (95% 01=0.56-0.72), and 
based on generation of spread R=0.47 (95% 01=0.38-0.57). 
Conclusions: 
We obtained consistent estimates of R by all three methods, enhancing confidence in 
their validity. Importation status is the most straightfonward surveillance data element to 
collect and should be applicable to a wide range of countries as a practical means to 
monitor elimination status. 
Prologue 
My role 
Heather Gidding, a past MAE scholar and former epidemiologist at NCIRS, in Apnl 
2012, returned to work one day a week at NCIRS on a number of projects. Due to my 
work on an epi-review of measles in Australia at that time, she approached me to work 
on a project using measles notification data to estimate the reproduction number (R) for 
measles. Heather has conducted numerous studies using serosurveillance data to 
estimate R, as a co-author on a landmark study in Australia providing evidence of 
measles elimination and has authored numerous studies on measles control. 
This project would involve the use of sub-branching critical models to estimate R which 
was unfamiliar territory to me and a difficult concept to grasp. It was however a 
collaborative project, including Heather, Aditi, Dr James Wood a modeller from 
University of New South Wales and Ms Nicolee Martin from the Department of Health 
and Ageing (DoHA). 
I was involved in conducting the literature review for this project, developing the first 
draft of the project proposal, cleaning the data, conducting descriptive analysis, 
developing the algorithm to identify potentially missed outbreaks, using the algorithm in 
preparation for the modelling analyses and drafting the manuscript. 
It must be made clear that the estimates of R were a collaborative effort and close 
guidance was provided by Heather and James during the analysis. I conducted the 
analyses to estimate R for the methods proportion of imported cases and distribution of 
outbreak sizes whilst James conducted modelling analysis to estimate R by distribution 
of generations of spread. I had no involvement in the analysis that James conducted. 
Lessons learned 
One of the primary lessons that I learnt due to this project was the potential use of 
national notification data beyond the scope of what I had previously known, when a 
high quality surveillance system exists. 
I also feel I have grasped some sense of modelling, due to this study, including the 
complexities of modelling and that is about estimations rather than 'the truth'. 
This project enabled me to witness and belong to an extremely supportive and 
encouraging environment. I have learnt, in many respects, how I hope to be further 
down in my career if ever I were to mentor students. Communication between main co-
authors was an important reason this project progressed incredibly smoothly and it has 
made me realise how important communication is in the success of your work. 
Additionally, the process of preparing a manuscript for this project allowed me to 
understand that the choice of journal for submission is extremely important in how the 
paper is framed and ultimately, the main messages of the paper. 
Public health action 
The results of this project will form part of the lines of evidence that is being compiled 
by the measles elimination working group for the verification of measles elimination in 
Australia. The potential impact of measles elimination in Australia, if formally verified, 
will contribute to the World Health Organisation (WHO) Western Pacific Regional Office 
(WPRO) in their target for measles elimination in the region in 2012. Furthermore, the 
priority of measles elimination in all WHO regions is high, with worldwide measles 
eradication considered feasible in the not too distant future. 
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Introduction 
Between 2000 and 2010, the global burden of measles reduced considerably, with 
annual measles incidence and mortality decreasing by 66% and 74%, respectively.^ 
The implementation of childhood and supplementary immunization activities by World 
Health Organization (WHO) Member States has largely contributed to these declines. 
As a result, all WHO Regions have set target dates for measles elimination^"®, most 
recent being the South-East Asian Region.® At present, the Region of the Americas is 
the only WHO Region to have achieved elimination, reporting the interruption of 
endemic measles transmission in 2002.^°® 
Three years after the declaration in the Americas, the WHO Regional Office for the 
Western Pacific (WPRO) adopted a resolution, setting 2012 as the target year for 
measles elimination in the region."^ Several countries have made significant progress 
towards this goal, including Australia.^"® Over the past two decades, the national 
incidence of measles has declined dramatically, following a number of national 
measles strategies, including the 1998 Measles Control Campaign and lowering the 
second dose of measles containing vaccine to four years of age.'® This led to a 
report that indigenous measles transmission had been eliminated in Australia® with the 
authors' reasoning that Australia had satisfied most of the WPRO criteria to justify the 
elimination of measles.® 
One approach to monitoring measles elimination is by estimating the reproduction 
number (R). R is the average number of secondary cases that results from an 
infectious case in a particular population (Box 1). When R is below one, the number 
of cases reduces with every generation and, if maintained, elimination is considered to 
have occurred 
There are a number of methods to estimate R, including the use of serosurveillance 
data, the early epidemic phase growth rate and notification d a t a . ® ^ - I n Australia, 
three national serosurveys have been conducted previously."^ "^Serosurveys 
however, can be time consuming and c o s t l y a n d in developing countries, may not be 
feasible,. Alternatively, routinely collected notification data can be used to estimate R 
on a regular basis with minimal resources required. These methods were described by 
De Serres et and uses the following data to estimate R: 1) the proportion of cases 
imported; 2) the distribution of outbreak sizes and; 3) the distribution of the number of 
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generations of spread in eacli outbreak.^"® An assumption required when using these 
methods is that elimination has already been achieved. 
Methods based on routinely collected notification data have been used to differing 
extents internationally""' and in Australia. The United States (US) and Canada both 
reported the interruption of indigenous measles transmission by 1998 and used the 
methodology described by De Serres et al. to assess e l i m i n a t i o n . " " ' E n g l a n d and 
Wales also claimed elimination and used the distribution of outbreak sizes (1995-2001) 
to estimate R."® In the Australian state of Victoria, notification data (1998-2003) were 
used to estimate R using the distribution of outbreak size and generation of spread 
(R=0.87 and R=0.73, respectively)." ' More recently, National Notifiable Diseases 
Surveillance System (NNDSS) data (2001-2006) in Australia were used to estimate R 
using the proportion of imported cases (R=0.90); the authors concluded, however, that 
the incompleteness of data may have resulted in the overestimation of R.® There have 
been considerable improvements in completeness of notification data since 2009. 
Therefore, the aim of our study was to apply three methods for estimating R using 
routinely collected notification data and highlight the utility of these methods in lower 
resource countries as a practical means to monitor elimination status. 
Methods 
Notification data 
In Australia, measles is a notifiable disease in all States and Territories. Under public 
health legislation, clinicians and laboratories are required to notify their respective 
health authorities of a suspected, probable or confirmed case of measles.®' Additional 
information on confirmed measles cases are collected by health authorities during 
follow-up investigations and fonwarded to the NNDSS. Confirmed cases of measles 
require either laboratory definitive evidence of measles infection or both clinical and 
epidemiological evidence.®' 
De-identified data were obtained from the NNDSS dataset for all notified measles 
cases between 2009 and 2011. Data fields used in the analysis included 'place 
(country) of acquisition', 'outbreak reference number' (Box 1), date of symptom onset 
(if missing, diagnosis date was used). 
Box 1. Definitions 
1. Importat ion'": a case public health authorities believe was acquired overseas 
based on international travel in the period prior to rash onset. 
2. Generation of spread of an outbreak"^: 
• Same generation : disease onset date between the first and last case was 0-6 
days apart 
• One generation of spread: disease onset date between the first and last case 
was 7-14 days apart 
• Two generations of spread: disease onset date between the first and last 
case was 15-24 days apart 
• Additional generation of spread: 10 days difference between the disease 
onset date of the first and last case added an extra generation 
3. Outbreak reference number: a unique identification number assigned to cases 
which were determined to be part of the same outbreak based on epidemiological (and/ 
or virological) evidence. 
4. Reproduction number (R)"": 
• R= 1: a state of endemic equilibrium exists where on average, one case results 
in one secondary infection 
• R > 1: the number of cases increases from one generation to the next, 
potentially resulting in an epidemic 
• R < 1: the number of cases reduces with each generation and if maintained 
elimination occurs 
An algorithm was developed to link cases together where data field 'outbreak reference 
number' was missing '(Figure C-1). 
Figure C-1. Algorithm link cases together where data 'outbreak reference 
numbers' was missing to identify possible measles outbreaks 
If 'place (country) of acquisition' was overseas, cases were considered sporadic 
unless they had the earliest onset date of an identified outbreak and all other cases 
were locally acquired. If more than one case was acquired overseas in the same 
outbreak, the imported case most temporally similar to locally acquired cases was 
considered the index case whilst the other imported case was considered sporadic. All 
remaining cases where 'place of acquisition' was local and 'outbreak reference number' 
was missing were defined as sporadic. For cases belonging to the same outbreak, the 
generation of spread of infection was derived from a previous algorithm (Box 1). 
Estimating R 
Three methods were used to estimate R for the combined years 2009 to 2011 and for 
each individual year (2009; 2010; 2011). In method one, R was estimated as 1 - p, 
where p=proportion of cases imported (using the data field 'place of acquisition'). This 
method is based on the observation that if each initial case infects R persons, the 
second generation will contain R^ persons and so on, with the total number of cases 
forming a geometric sum with value 1/(1-R). And hence, with some simple algebra'™ R 
can be estimated 
For the second and third methods, R was estimated through fitting a subcritical 
branching process that models the spread of infection with reproduction number R to 
the observed distributions of outbreak sizes and generations of spread, respectively."® 
For details of the branching process model, please refer to the paper by De Serres.''"® 
Maximum likelihood estimation was used to obtain estimates for R. Stata version 12 ® 
™ was used to estimate R for the distribution of outbreak sizes, while estimates of R 
using the distribution of the generations of spread were calculated in Matlab version 
For all three methods, 95% confidence intervals were estimated using a normal 
approximation based on the estimated standard errors. 
All of these approaches are based on the assumption that R<1 and are only 
appropriate in settings where measles incidence is low. In addition, for the second and 
third methods, it is assumed that the reproduction number for each individual is 
Poisson distributed with mean R and thus (non-random) heterogeneity between 
individuals is ignored. 
As larger outbreaks may be more likely to be detected by the surveillance system than 
smaller outbreaks, a sensitivity analysis was conducted to include only outbreak sizes 
of > 3 cases. 
Results 
Notification data 
Between 2009 and 2011, there were 367 notifications of measles in Australia (nnean 
notification rate 5.5 per million population) with 105 cases In 2009 (notification rate 4.8 
per million population), 69 cases in 2010 (notification rate=3.1 per million population) 
and 193 cases in 2011 (notification rate=8.5 per million population). Most cases 
occurred in individuals aged 10-19 years and 2 0 - 3 4 years (Figure C-2). Thirty-five per 
cent (n=128) of cases were acquired overseas and 41% (n=150) were 
epidemiologically linked to an imported case. The data fields 'place of acquisition' and 
'outbreak reference number' were 100% (n=367) and 77% (n=283) complete, 
respectively. Fifteen sporadic cases had a complete 'outbreak reference number'. 
Figure C-2. Distribution of confirmed measles cases by age group in Australia, 
2009-2011 
Source: National Notifiable Diseases Surveillance System, Australia 
Of the 84 cases with missing 'outbreak reference number', 19 (23%) were reclassified 
as belonging either to an identified outbreak or were linked together as part of an 
outbreak previously not identified. Seven cases were linked based on jurisdiction, t ime 
and identical genotype compared to 12 cases that were linked by jurisdiction, t ime and 
proximity of residence. The remaining 65 cases with missing 'outbreak reference 
number' were considered to be sporadic. Of these, 83% were acquired overseas and 
25% had missing genotype, 21% were genotype D8 and 16% were genotype D9. The 
algorithm was also applied to the 15 sporadic cases with a complete 'outbreak 
reference number' with 2 sporadic cases linked to a cluster of two cases based on 
jurisdiction, time and identical genotype and subsequently considered an outbreak of 
four cases 
Overall, there were 55 outbreaks (range: 2 -25 cases) and 78 sporadic cases in 2009-
2011. The longest duration of an outbreak was seven generations (67 days). 
Estimation of R 
The values of R for the combined years 2009-2011 for all methods were significantly 
below 1. Little difference was observed between using the methods proportion of 
importations and outbreak size to estimate R (Figure C-3). Further, R estimates, when 
restricting outbreak size to three or more cases and when no restrictions were applied 
appeared similar (R=0.67 95% Cl= 0.56-0.78 and R=0.64 95% 01=0.56-0.72, 
respectively). However, the generations of spread method provided a lower R estimate 
(0.47 95% 01= 0.38-0.57) than the other methods used. 
Figure C-3. Estimates of the reproduction number including 95% confidence 
intervals in Australia, 2009-2011 
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Similarly, for individual years all estimates of R were below 1 and there was little 
difference in estimates across time and method (Table C-1). Again, the method of 
generations of spread provided the lowest annual estimates. The lowest value of R was 
observed in 2009 for the distribution of generations of spread (0.38 95% CI: 0 . 1 9 -
0.56). The highest value of R was observed from the sensitivity analysis conducted on 
outbreak size in 2009 (0.78 95% CI; 0.57-1.00). This estimate was the only result 
where the upper confidence interval reached 1.00. Similar R estimates were obtained 
when including and excluding outbreaks with three or more cases. 
Table C-1. Est imation of R in Austral ia by individual year, 2009-2011, NNDSS data 
Methods 2009 2010 2011 
R 95% CI R 95% CI R 95% CI 
Proportion of 
imported 
cases 
0.66 0.57-0.75 0.55 0.43-0.67 0.68 0.62-0.75 
Distribution of 
outbreak sizes 
0.65 0.49-0.80 0.59 0.41-0.78 0.65 0.53-0.76 
Distribution of 
outbreak sizes 
s 3 cases 
0.78 0.57-1.00 0.65 0.40-0.90 0.62 0.47-0.76 
Distribution of 
generations of 
spread 
0.38 0.19-0.56 0.50 0.29-0.70 0.50 0.38-0.63 
Discussion 
During 2009 to 2011, R estimates using national notification data remained below one, 
providing good evidence that measles elimination is being maintained in Australia. 
These findings are consistent with estimates obtained using the 2002 serosurvey data, 
which estimated R to be 0.69 and the prediction that between 2003 and 2012, R would 
remain below 0.80.^^^ Our conclusion that measles elimination is being maintained is 
further supported by high measles vaccine coverage rates and the absence of an 
endemic circulating genotype for many years in Australia.®^ 
Similarities in R estimates between the three methods used in this study and that of the 
serosurvey suggest that estimates of R using Australia's surveillance data are valid. 
Additionally, there was little difference between the estimates of R when restricting 
outbreak size s 3 cases and when no restrictions were applied, which indicates a high 
level of sensitivity of the surveillance system in detecting both small and large 
outbreaks. 
There was however, some variation for the estimates of R between the three methods 
used. The highest value of R was observed in 2009 for the distribution of outbreak size 
> 3 cases per outbreak and this was the only value where the upper confidence interval 
reached 1.00. A large proportion of cases in 2009 were sporadic or clusters of two 
resulting in only seven outbreaks left in the analysis, the largest outbreak throughout 
the time period (n=25) also occurred during this year. Consequently, this method 
resulted in wide confidence intervals and a high R estimate. 
It was expected that the R estimates would be highest using the proportion of imported 
cases method due to an underestimation of the number of cases arising from contact 
with international visitors, as was observed in similar studies conducted in the US and 
C a n a d a . " " The estimate of R based on importation status in the US was 0.68 
(95%CI=0.30-0.78) compared to 0.51 {95%CI=0.44-0.59) using the distribution of 
outbreak s ize." " Similarly, the estimate of R based on importation status in Canada 
was 0.87 (95%CI= 0.76-0.98) compared to 0.82 (95%CI=0.72-0.93) using the 
distribution of outbreak size."® Our estimates, however, were comparable to the 
estimates obtained from the other two methods. The 100% ascertainment of 'place of 
acquisition' is possibly the reason for our comparable results. In contrast, the 
completeness of reporting imported cases (1997-2001) in the US was only 40%.^^" It 
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is likely that estimates of R using the proportion of imported cases method provided an 
accurate R estimate for Australia due to a sensitive surveillance system and complete 
data on place of acquisition. 
An important difference to consider when comparing our estimates with those from the 
US and Canada relates to the definition of an imported case. An importation in the US 
required travel outside the US 18 days prior to rash onset (unless date of symptom 
onset was > 7 days following the symptom onset date of a travelling companion)."" An 
importation in Canada required exposure outside Canada 7 -21 days prior to rash onset 
not linked to a local transmission.'^^ Australia's definition of an importation (Box 1) 
involves assessment on a case-by-case basis using epidemiological and virological 
evidence and may have been more sensitive and less specific than either of these 
definitions. For example, a case with prior travel to the Philippines, 23 days before 
symptom onset in Australia was considered imported." In the US and Canada, 
however, this case would not be considered imported."" Nevertheless, 
overestimations are unlikely as health authorities usually conduct extensive 
investigations for each case . " The use of a consistent definition for importation status 
among health authorities both in Australia and internationally would provide more 
comparable R estimates. As recording of importation status requires minimal additional 
resources and any underestimation of the proportion imported would only overestimate 
R, we recommend low- to middle-incomes countries initially focus on collecting this 
variable to monitor their elimination status. 
R estimates obtained from the distribution of generations of spread were consistently 
found to provide lower estimates in Australia and the US (R=0.44 95%CI=0.36-0.52) 
compared to the other methods used. One explanation for the lower estimates is that 
the generations of transmission for both countries were derived from an algorithm, 
possibly making R estimates using this method less val id."" For example, in 2009-
2011, the longest duration of an outbreak (67 days) in Australia was calculated to be 
seven generations. However, based on an incubation period of 18 days, the 
generations of transmission of this outbreak could have been as low as four 
generations. Recording the number of generations of transmission would improve the 
validity of estimates of R using this method. 
In our study, R estimates for the distribution of outbreak size and distribution of the 
generations of spread may also have been an overestimate of the true value. Nineteen 
cases with a missing 'outbreak reference number' were assigned to a particular 
outbreak based on an algorithm (Figure 1). We also used the algorithm on sporadic 
cases with a complete 'outbreak reference number' to assess whether they may have 
been part of an outbreak. This was conducted as some health authorities automatically 
assign an 'outbreak reference number' to all cases of measles regardless of whether 
the case was known to belong to an outbreak or not. These cases may have wrongly 
been assigned to an outbreak potentially overestimating R. However, as measles is 
such a rare disease in Australia, it is likely that cases with temporal and geographical 
similarities are indeed linked. Moreover, the high sensitivity of the surveillance system 
made the detection of most measles cases likely. Hence, it is unlikely that a large 
number of cases were missed, which would have resulted in an underestimation of R. 
Completeness of surveillance data is imperative to obtain accurate estimates of R. In 
comparing our results with Canada and the US, it is important to note that our data 
were more recent (2009-2011) than those used in Canada (1998-2001)"^ and the US 
(1997-1999) "^ It is likely that the completeness of data for both countries have 
improved since these studies were conducted. However, to date these studies are the 
most recent to be published. In Australia, over the three-year period analysed, 
completeness of the data field 'place of acquisition' was 100%. The data field 'outbreak 
reference number', however, was incomplete. This in part is because most 
jurisdictional health authorities do not assign unique outbreak reference numbers to 
known sporadic cases (personal communication, Nicolee Martin). If all known sporadic 
cases were assigned reference numbers they could be more accurately differentiated 
from cases where a link to an identified outbreak was undetermined providing a more 
accurate R estimate. However, recording 'outbreak reference number' and the number 
of generations of spread requires more extensive case follow-up to enable linkage 
between cases, and may be more challenging to collect in low- and middle-income 
countries. 
The models used in our study have a number of potential limitations. We assumed 
homogeneity in susceptibility and the mixing of populations.^"® Past outbreaks have 
identified susceptible sub-populations in Australia, including young adults and infants 
too young to be i m m u n i s e d . ^ ^ ^ Therefore, R may exceed one in certain sub-
populations. However, our results are similar to R estimates using serosurveillance 
data, which take into account population dynamics. Despite these limitations, these 
methods provide a suitable means to monitor the status of elimination in Australia as a 
whole, on a regular basis through the use of high quality national notification data and 
could potentially be applied in lower-re source settings too. 
Notification data have the potential to play an important role in verifying measles 
elimination, especially when all WHO Regions are working towards elimination by 2020 
^ As high quality surveillance is an essential criterion for verification,^' it should be 
feasible for all countries aiming for verification to produce valid R estimates using the 
methods described in this paper, particularly through collecting importation status; as 
ongoing evidence for the maintenance of a country's elimination status. 
Conclusions 
Our results provide evidence of sustained measles elimination in Australia and suggest 
the validity of using notification data to monitor measles elimination where a sensitive 
surveillance system exists. Collecting the importation status of all cases during case 
investigations in low- and middle-income countries is simple and the methodology to 
estimate R straightforward. As global measles activities shift focus from measles 
control to measles elimination, the use of notification data, particularly importation 
status to estimate R has the potential to be an important component of the verification 
process by WHO Regional Offices, particularly in low-resource countries. 
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SECTION D 
Measuring discard rates for measles in 
New South Wales; an indicator of 
quality surveillance 
Abstract 
Background: 
A measurement of the qualityy of measles surveillance includes examining the rate of 
suspected measles cases that end up as negative results (laboratory discard rate). 
Ensuring adequate investigation of suspected measles {> 2 non-measles cases per 
100,000 population) is imperative to high quality surveillance which forms part of the 
criteria necessary to verify measles elimination. The objective of this study was to 
measure the discard rate in NSW to determine whether NSW is satisfying one of the 
criteria necessary for measles elimination. 
Methods: 
NSW laboratory measles test data (2009-2012) were obtained from the Institute of 
Clinical Pathology and Medical Research (ICPMR), South Eastern Area Laboratory 
Services (SEALS) and Hunter Area Pathology Service (HAPS) in NSW. The number of 
negative episodes was collated and annual discard rates were calculated using mid-
year population estimates from the Australian Bureau of Statistics. 
Results: 
From 2009 to 2012, the laboratory discard rate exceeded > 2 non-measles cases per 
100,000 population suggesting that adequate investigation occurred in NSW during this 
period. The rate appeared to increase over time which may be due to an increase of 
testing conducted or be reflective of the increase in cases over the 4-year period, 
including large outbreaks during 2011 and 2012 in the state. 
Conclusions: 
NSW laboratory discard rates are well above the target for measles elimination 
suggesting that high quality surveillance is occurring in the state. Our results will 
contribute to the calculation of a national discard rate to determine if Australia is 
meeting the criteria for high quality surveillance as a nation. 
Prologue 
My role 
In April 2012, a number of discussions with experts in measles epidemiology around 
Australia and the DoHA, led to the formation of the Measles Elimination Working Party. 
I was most fortunate to be included in this working group, as during this time I had 
embarked on a number of measles related projects. The role of this working party is to 
provide technical expertise and evidence to the measles national verification committee 
who will assess Australia's measles elimination status. An essential criterion for the 
verification of measles elimination is high quality surveillance. One method to 
determine this is through measuring the number of suspected cases of measles that 
are ultimately confirmed to not be cases based on laboratory testing - known as 
discarded cases. To obtain a national rate of discarded measles cases, members of 
the working party were requested to obtain data from laboratories in their jurisdictions 
between 2009 and 2012. I was approached to be responsible for calculating the NSW 
laboratory discard rates, which I was keen to do as I had not previously worked with 
laboratory data and I saw this as an opportunity to analyse laboratory data for the first 
time. I accessed data from 2 laboratories; the Institute of Clinical Pathology and 
Medical Research (ICPMR) and South Eastern Area Laboratory Services {SEALS)and 
collated the results from these 2 laboratories with results from Hunter Area Pathology 
Service (HAPS) to calculate a state discard rate. David Durrheim was responsible for 
conducting the data analysis for HAPS and provided me with the results of his analysis. 
Lessons learned 
This project taught me a number of lessons that I am sure will help me in the future. 
Firstly, this was the first time that I was given data very much in its raw extracted form. 
There were many discrepancies in the data that I needed not only to clarify with 
laboratory staff but also needed to clean in SAS. It taught me that the process of data 
cleaning can take a long time, and in this instance, much longer than the actual 
calculation of the discard rate. As time-consuming as it may be however, I learnt how 
important data cleaning is to the validity of your results. In SAS, I learnt a number of 
new functions including: Proc Transpose, splitting your dataset into two (one with 
duplicates and one without) and recoding variables using new techniques. 
I also learnt the limitations inherent to laboratory data, particularly that it is difficult to 
ascertain whether individuals who are tested for IgM (without knowledge of whether 
they were tested for IgG) may in fact not be suspected cases but individuals being 
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screened for measles immunity. Another lesson learnt, was in regards to the type of 
laboratory test used. I learnt that they type of testing that is conducted by laboratories 
is very much based on the preference of the chief virologist and that test type varies 
within NSW. And what test type used is important as test results may be affected by 
the sensitivity and specificity of each test type used. I learnt that the best method to 
measure discard rate is to have additional information on each individual's clinical 
symptoms to ensure that the analysis did only include suspected cases of measles. 
Public health act ion 
The results of this project will be included into a national discard rate calculation as an 
indicator of the quality of measles surveillance in Australia. The discard rate will provide 
evidence as to whether measles elimination can be formally declared in Australia. This 
is the first time that a national discard rate has been calculated in Australia. 
Furthermore, this project is expected to be part of a publication of the national discard 
rate in the country. 
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Introduction 
To verify the sustained elimination of measles in a country, a number of criteria need to 
be satisfied.®' This includes: the documentation that endemic measles transmission 
has not occurred in > 36 months; the presence of a high quality surveillance system 
and the interruption of endemic measles through genotypic evidence.®' One indicator of 
high quality surveillance is achieving an annual reporting rate of > 2 non-measles 
cases per 100,000 per population. Achieving this is suggestive that adequate 
investigation of suspected measles cases (i.e. individuals with measles-like-illness) is 
occurring and would be sufficient to detect an endemic strain of measles virus, if this 
was occurring. In Australia, information on suspected case investigations does not 
exist on the NNDSS. An alternative method to measure the reporting rate of suspected 
measles cases is through the use of laboratory data. Harpaz and Papania concluded 
that IgM testing in the United States was a valid index of measuring measles-like-
lllness incidence.'^® The author's posited a standard of at least 1 measles-like-illness 
case per 100,000 population to be used as a minimum standard rate of investigation.'^® 
In Australia, the rate of discarded non-measles cases has been calculated in Victoria; 
between 1998 and 2003, 72% of measles notifications were discarded following testing 
providing a median annual discard rate of 2.9 per 100,000 p o p u l a t i o n . T h e discard 
rate has never been calculated in NSW, the most populous state in Australia. The 
objectives of this study were to calculate the rate of discarded measles cases in NSW 
between 2009 and 2011 and assess whether the results met the minimum standard of 
case follow-up and laboratory testing. 
Methods 
NSW laboratory measles test data between 2009 and 2012 were obtained from the 
Institute of Clinical Pathology and Medical Research (ICPMR), South Eastern Area 
Laboratory Services (SEALS) and Hunter Area Pathology Service (HAPS) for the 
following test types: immunoglobulin M (IgM); immunoglobulin G (IgG; HAPS only and 
ICPMR in 2012); nucleic acid detection by Polymerase Chain Reaction (PGR) and; 
antigen detection by Immunofluorescence (IF). Other variables used in the analysis 
included a unique patient identifier, sex, postcode (ICPMR and HAPS), date of birth, 
specimen collection date and test result. 
The three laboratories where data were obtained encompassed parts of metropolitan 
and regional NSW. ICPMR services hospitals and laboratories in western Sydney,''^® 
SEALS services all public hospitals in the South Eastern Sydney area and other private 
hospitals, laboratories and community-based GPs'^® and HAPS provides services to 
the Hunter New England area.'® 
Exact duplicates (unique patient identifier, test type, specimen collection date and test 
result) were removed. If entries were duplicated by test type and specimen date but 
differed by test result, only the entry with a positive result was kept. 
A temporary patient identifier was assigned to records where a unique patient identifier 
was missing; if sex, postcode (if available) and date of birth were identical to another 
record, the same temporary patient identifier was assigned. 
Measles episodes were calculated and an episode of measles was defined as an event 
of suspected measles infection in an individual. An episode of suspected measles was 
considered the same if the specimen collection date was within 28 days of the earliest 
specimen collection date for the same unique patient identifier. Multiple test results 
were carefully scrutinised to determine whether they may have represented testing in 
the convalescent period. If the number of days between samples exceeded 28 days, 
episodes of suspected measles were considered different unless the first episode 
produced a positive result. 
For ICPMR and SEALS data, only episodes involving PCR and/or IF tests were 
included in the analysis (Table D-1). For HAPS data, episodes not including PCR that 
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were IgM negative/ IgG positive or IgG equivocal were excluded from the analysis. 
These exclusions were conducted to prevent an overestimation of the discard rate due 
to the inclusion of individuals who might have been screened for immunity rather than 
being tested for suspected measles. 
Table D-1. Tests used to define a measles episode by laboratory, NSW 
Laboratory 
ICPMR HAPS SEALS 
PGR PGR PGR 
IF lgM+/lgG- IF 
lgM-/ lgG-
A sensitivity analysis was also conducted on 2012 ICPMR data comparing negative 
test results using the two different inclusions of what an episode was (i.e. 
ICPMR/SEALS versus HAPS) , to determine if there was a difference in results. 
A positive result from any test listed above (except IgG) was considered to be a 
positive episode whilst if all tests were negative the episode was considered negative. 
If a test result was equivocal, it was considered to be a negative result. 
The year of specimen collection and the final result for each episode of suspected 
measles were used to calculate testing rates per population and positive measles 
rates. To calculate the rate of non-measles (discarded) cases by year, the sum of 
negative results from the three laboratories was divided by the NSW mid-year 
population estimate for the corresponding year. Mid-year population estimates were 
obtained from the Australian Bureau of Statistics. SAS and Microsoft Excel were used 
to clean the data and calculate rates, respectively. 
Results 
Between 2009 and 2012, there were 2188 suspected measles episodes tested at 
ICPMR with 56.5% (n=1236) of these episodes occurring in 2012 (Table D-2). Measles 
antigen detection by IF was the most common test used to diagnose a suspected 
measles episode, 92.8% of all tests used IF only. 
Table D-2. Measles result by test type 2009-2012, ICPMR 
Tes t 
type 
2009 2010 2011 2012 
negative posit ive Total negative positive Total negative positive Total negative positive Total 
IF only 135 3 138 284 2 286 457 463 1123 21 1144 
PCR 
only 
0 0 0 1 0 1 3 4 0 1 
IF/IgM 3 1 4 7 1 8 20 15 35 70 16 86 
IglWPCR 0 0 0 1 0 1 3 3 1 4 
IF/PC R 0 0 0 0 0 0 2 2 0 0 
IF/ lgWP 
C R 
0 0 0 0 1 1 5 6 0 1 
Total 138 4 142 293 4 297 490 23 513 1198 38 1236 
In contrast, there were 624 measles episodes tested between 2009 and 2012 at 
SEALS (Table D-3), of which 55% (n=343) of tests were conducted in 2012. The most 
common test used was a combination of IF and PGR tests, with 54% (n=335) of all 
episodes being tested with these two tests. 
Table D-3. Measles result by test type 2009-2012,SEALS 
Test type 
2009 2010 2011 2012 
negative positive Total negative positive Total negative positive Total negative positive Total 
IF only 15 1 16 29 0 29 0 0 0 87 0 87 
PCR_only 
C 0 0 
8 1 9 8 2 10 24 4 28 
IF/IgM 4 0 4 6 0 6 0 0 0 10 0 10 
IF/PGR 0 0 0 31 1 32 99 16 115 139 49 188 
IglWPCR 0 0 0 0 0 0 0 0 0 
1 1 2 
IF/lglWCFT 5 3 8 1 1 2 0 0 0 0 0 0 
IF/lgWPCR 0 0 0 0 0 0 
15 3 18 20 8 28 
IglWPCR/CFT 
0 0 0 0 0 0 
2 1 3 
0 0 0 
IF/lglWPCR/CFT 0 0 0 1 0 1 15 13 28 0 0 0 
Total 24 4 28 76 3 79 139 35 174 281 62 343 
Measles testing was lowest In HAPS (Table D-4) with 272 measles episodes during 
this period. Testing number by year did not appear as disparate as the other 2 
laboratories with 32.3% (n=88) of tests occurring in 2012. 
Table D-4. Total tests conducted and positive/negative results by laboratory 
2009-2012*, NSW 
* Only including IF/PGR results except for HAPS which included IgM/IgG serology results (apart from those that were 
IgM -/ + (or equivocal) IgG 
Overall, in 2009-2012, the rate of negative measles cases (i.e. discard rate) remained 
above 2 non-measles cases per 100, 000 population in NSW (median= 7.9 per 
100,000 population; range= 2.9-21.4 per 100,000 population) and, increased with year 
(Table D-5). The rate of measles cases also increased by year, with 14 cases per 
million population observed in 2012, ten times the rate observed in 2009 (1.4 cases per 
million). Testing rate also increased by year with 1667 tests conducted in 2012 (22.9 
test per 100 000 population) compared to 214 tests in 2009 (3.0 per 100,000 
population). 
Table D-5. Measles test ing, negative and posit ive rates for NSW by year, 2009-2012* 
Tests Rates 
Location Year Total tests Positive Negative Population 
Testing 
Rate (per 
100 000) 
Positive 
Rate (per 
million) 
Negative 
Rate (per 
100 000) 
NSW 2009 214 10 204 7134421 3.0 1.4 2.9 
2010 447 14 433 7232589 6.2 1.9 6.0 
2011 756 60 696 7211468 10.5 8.3 9.7 
2012 1667 102 1565 7290345 22.9 14.0 21.4 
' Only includes tests where a PCR and/or IF test was performed (ICPMR & SEALS), Includes lgM+/-lgG results except where IgM -/ + (or equivocal) IgG (HAPS) 
The sensitivity analysis found that by using the inclusion criteria of episodes by test 
type from the HAPS methods, 157 more negative test results were captured from this 
method compared to the inclusion criteria used for episodes in the ICPMR/SEALS 
methods (Table D-6) 
Table D-6. Sensitivity analysis on measles result by test type using ICMPR/ 
SEALS versus HAPS methods, ICPMR 2012 data'^ 
Test type Final Result (ICPMR/SEALS 
method) 
Final Result (HAPS method) 
negative positive Total negative positive Total 
IF only 1122 21 1143 1122 21 1143 
PGR only 1 0 1 1 0 1 
IgM only excluded excluded excluded 144 2 146 
IgM/lgC^ excluded excluded excluded 13 7 20 
IgM/PCR 1 0 1 1 0 1 
IF/IgG 1 0 1 1 0 1 
IF/IgM 34 10 44 34 10 44 
IF/lgM/IgG 36 6 42 36 6 42 
IF/lgM/PCR 1 0 1 1 0 1 
IgM/PCR/IgG 2 1 3 2 1 3 
Total 1198 38 1236 1355 47 1402 
Only IgM-ve/ IgG-ve and IgM+ve/lgG-ve were included in the analysis 
The only difference between HAPS and ICPMR methods to obtain negative tests were 157 more discard cases for the 
HAPS methods which included IgM only and IgM/IgG tests 
Discussion 
Our results provide evidence that NSW met the minimum discard rate > 2 non-measles 
cases per 100,000 population®^ for the years 2009-2012. This suggests that adequate 
measles surveillance is occurring in NSW, and will contribute to the national measles 
discard rate calculation to assess the national adequacy of surveillance; an essential 
criteria for the verification of measles elimination.®' 
The calculation of a measles discard rate to assess the performance of a surveillance 
system was first proposed in 2004.'^® The authors' recommended minimum standard of 
one discarded case per 100 000 population per year was applied in Victoria, where the 
enhanced surveillance system was found to exceed the minimum standard. Between 
1998 and 2003, the annual discard rate was consistently > 2 cases per 100,000 
population. Our results are in line with the Victorian study, the only known published 
Australian study to have used discard rates to assess the quality of measles 
surveillance. A similarity between the two studies which also had been noted 
globally, was the increase in the discard rate during epidemics. During 2011 and 
2012 the testing of suspected measles cases in NSW increased. This is likely to be due 
to heightened awareness among clinicians when an individual presents with measles 
like illness; as supported by Harpaz and Papania'^" resulting in more suspected 
measles cases being tested and subsequently an increase in non-measles discard 
rates. 
A number of limitations to this study must be noted. Firstly, our results for New South 
Wales excluded measles testing from private laboratories. It is not known what 
proportion of measles diagnostic testing is conducted in private versus public 
laboratories. We however, used the entire NSW population estimate as the 
denominator whilst the numerator included three public laboratories. This calculation 
was an underestimate of the true discard rate. Despite this underestimation, our results 
exceeded the minimum requirement of > 2 non-measles cases per 100,000 population 
providing strong evidence that NSW has high quality surveillance, with suspicion high 
enough to detect a wild strain of measles, if it was circulating in the state. 
Additionally, diagnostic tests conducted differed by laboratory. As the sensitivity and 
specificity of tests differ, particularly depending on the stage of disease, this might limit 
the validity of our results. For example, ICPMR primarily used IF as their diagnostic test 
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for measles. The sensitivity of IF has been suggested to be 50—60%. This has the 
potential to overestimate the discard rate as true positive cases may be classified as a 
negative result. Our results indicate that most suspected cases only have an IF test 
conducted. Given the low sensitivity, recommendations should be in place that an 
alternative test such as PGR is conducted (based on its high sensitivity and specificity) 
or a number of different tests to increase the sensitivity of detecting a true measles 
case. More standardised routine testing procedures state-wide would also increase the 
validity of the discard rates. 
A strength of the study is that attempts were made to minimise the overestimate of 
negative cases through the conservative approach to what tests were included in our 
analysis. Firstly, an episode of measles was only included in our analysis if an IF or 
PGR test was conducted. Data were not collected on IgG testing during from ICPMR 
(2009-2011) and SEALS (2009-2012). Concerns were raised that if the IgM results 
were included in the analysis, it may overestimate the discard date as IgM testing may 
have been conducted as a concurrent test for immunity screening ( IgG) rather than 
testing due to a suspected measles case. It was therefore important that these tests 
were not included in our analysis. Moreover, an episode of measles was only included 
in the HAPS analysis if the individual had a PGR test or was IgG-ve/lgM+ve or IgG-
ve/lgM-ve. This again was a conservative approach, trying to account for immunity 
screening. This method however, would include individuals tested for immunity who 
were found to be susceptible (i.e. IgG-ve/lgM-ve), potentially overestimating measles 
discard rate. We conducted a sensitivity analysis to determine how our results would 
change given the two different inclusion criteria we had for IGPMR/SEALS versus 
HAPS data. Our results identified that the inclusion criteria for IGPMR/SEALS data was 
more conservative, providing a lower number of negative measles cases and 
subsequently a lower measles discard rate. Despite this conservative approach, the 
negative discard rate for NSW in 2012 was still well above the minimum threshold with 
21.4 non-measles cases per 100,000 population. 
Additionally, using laboratory non-measles discard rates as a measure of the adequacy 
of a surveillance system in itself has a number of challenges. Firstly, it is well 
documented that in regions where measles is rare, clinicians may not suspect 
measles.'^' Low suspicion and the subsequent non-referral for a measles test will 
affect not only testing rates but also non-measles discard rates. This limitation has 
been described previously. Despite this, during 2009-2012, our rates far exceeded 
the minimum standard of > 2 non measles cases per 100,000 population. 
There has been previous discussion on whether caution is required when measuring 
the quality of surveillance using measles discard rates. Suspect measles cases may 
vary largely by region and are dependent on, among other things the local 
epidemiology of measles like illness. Such large variation makes establishing a 
minimum reference standard challenging and suggestions have been made that a 
reference standard be dependent on the region of a country. However, the minimum 
standard of > 1 non-measles case per 100,000 population was intended not to measure 
the sensitivity of a surveillance system but rather, identify whether a surveillance 
system was weak."^ Indeed, it is important to note that the calculation of a discard rate 
is not a sole measure to quantify the performance of a surveillance system. More 
recently, other indicators for high quality surveillance have been included to assist 
countries in assessing this. These include: the timeliness and representativeness of 
reporting; the proportion of suspected cases with a specimen collected to be tested in 
an accredited laboratory; the proportion of laboratory confirmed outbreaks with 
adequate samples submitted for viral detection; and the adequacy of investigation 
within 48 hours of notification.^^ 
Conclusions 
The calculation of laboratory discard rates is an important component in measuring the 
quality of measles surveillance. Our results provide evidence that since 2009, New 
South Wales has achieved and surpassed the minimum standard of s 2 non-measles 
cases per 100,000 population and in turn, surveillance w/ould likely detect endemic 
measles if it was circulating in the state. A national measles discard rate will be 
calculated, incorporating our results for NSW, which subsequently will contribute to the 
evidence submitted to assess the verification of measles in Australia. 

SECTION E 
Public health action during a measles 
outbreak in New South Wales 
"For the things we have to learn before we can do them, we learn by 
doing them." 
- Aristot le 
Challenges in identifying a source of measles transmission in 
an emergency department 
Abstract 
Background: 
At the beginning of the 2012 NSW measles outbreak, four cases, of which three were 
infants too young to be immunised, were notified to health authorities in metropolitan 
Sydney. All had attended a tertiary paediatric hospital ED on 11 May 2012; however, a 
source case had not been identified. The objective of this project was to identify the 
source of the four measles cases. 
Methods: 
An algorithm to detect the suspect source case was developed and comprised of 
reviewing patient notes of all children who had attended the ED on 11 May 2012. 
Patients were assessed by time and symptom presentation. Vaccination status was 
obtained, (where possible) from the Australia Childhood Immunisation Register (ACIR). 
A suspect source case was defined as any patient that presented with fever and other 
symptoms consistent with measles (cough, coryza, conjunctivitis or rash) that were 
unvaccinated or partially vaccinated for measles. A questionnaire was developed and 
the parents of suspect cases interview over the phone. 
Results: 
There were 162 patients that presented to the ED on 11 May. The medical notes of 40 
patients were reviewed and eight febrile suspect cases were identified of which three 
were excluded based on alternative diagnoses. From parent interviews, none of the 
five suspect source cases identified were found to be the source case. 
Conclusions: 
This outbreak highlighted the challenges of identifying the source of measles and also 
provided further evidence of infants' susceptibility to measles using a non-validated 
algorithm. As healthcare associated transmissions increasingly become common in an 
era of measles elimination, this algorithm the potential to be further developed and 
used in identifying a source case of measles if a similar scenario is to occur in the 
future. 
Prologue 
My role 
In 2012, during May, four cases of measles were notified to the Western Sydney Public 
Health Unit (PHU) within a four-day period. Following case investigations, all four cases 
were linked by time and place to an ED at a paediatric teaching hospital in Sydney. Dr 
Vicky Sheppeard, the manager of the PHU approached Alexis (my fellow MAE 
colleague at NCIRS) and I to investigate the source of the four cases. Our role was to 
liaise with ED staff, examine ED charts, develop a questionnaire and interview suspect 
source cases to try to Identify the index case. Alexis and I communicated our findings 
at a weekly Infectious Disease Meeting at the paediatric hospital and also for Journal 
Club at NCIRS. Additionally, we wrote a report of our findings for dissemination to the 
PHU and ED within two months of the investigation commencing to document the 
incident, the investigation that occurred and lessons learned that may reduce measles 
cases in the future in this setting. 
Lessons learned 
There were abundant lessons to be learned during this project. Most notably that 
despite all efforts to attempt to identify a cause or source, you can be unsuccessful. It 
was challenging to interview parents of patients who we suspected may be the index 
case without explicitly inferring anything that may upset the parents. I learnt that when 
communicating with parents, it is important to listen to their concerns, be clear in 
getting your message across and ask questions in a sensitive manner. 
At times, Alexis and I were unsure of how to go about conducting the investigation and 
what the next steps should be. We were fortunate that during this investigation we had 
access to experienced public health experts who had a wealth of experience in 
measles outbreaks who provided guidance and advice. One thing that I believe we 
could have done better was documenting all stages of the investigation and organising 
records more systematically to be more efficient. Upon reflection, I realised that this 
was a weakness of the project and put this into practice for the MAE projects 
subsequent to the outbreak investigation. 
The ED staff displayed a wealth of knowledge and it made me realise that you should 
take advantage of their experience and ask any questions you may have. They related 
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to me that there were many unrecorded people in the ED including wards persons, 
visitors and family members and were for thcoming in informing us of the chal lenges of 
what we were trying to do i.e. that we would have diff iculty in contact ing every 
individual that had passed through the ED on that day. 
Public health action 
Unfortunately we were unable to f ind the source of infection at the paediatr ic hospital. It 
highl ighted though the chal lenges in trying to identify a source case and also indicated 
that with current procedures it is difficult to monitor the movements of every individual 
present in the ED ward. Our report may impact future ED practice on infection control 
including the documentat ion of individuals that enter the ED. 
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Introduction 
In countries where measles is a rare condition, transmission of the virus often occurs in 
healthcare settings, usually crowded and busy environments frequented by those most 
susceptible; infants too young to be immunised and the immunocompromised." ' The 
positive predictive value of a diagnosis based on clinical symptoms is low and without 
laboratory confirmation or suspicion by clinicians,'® misdiagnosis can lead to the delay 
of the implementation of control strategies to prevent further infection. 
In Australia, clinicians and laboratories are legislatively required to notify their 
respective health authorities of a suspected, probable or confirmed case of measles. 
Guidelines exist to provide health authorities with a protocol to assist containment 
efforts in an attempt to prevent a measles outbreak from occurring. A confirmed case of 
measles requires laboratory definitive evidence of measles infection, or clinical and 
epidemiological evidence. 
Although there has been a drastic reduction of measles over the past two decades, a 
number of outbreaks have occurred in recent times, most notably the 2012 outbreak in 
New South Wales (NSW). This outbreak was the largest outbreak to have occurred in 
fifteen years, and, since measles elimination was reported to have been achieved in 
Australia®. The index case was a 25 year old Australian-born male who had returned to 
Australia from a trip to Thailand in AphI 2012. There were 168 cases identified, of 
which the last case had symptom onset during November 2012. Most cases were from 
western and south-western Sydney .Transmission by this individual resulted in three 
known secondary cases and molecular genotyping identified the strain to be D8. 
A month later, four cases of measles (Cases A, B, C and D) were notified to two public 
health units (Western Sydney and Northern Sydney) within a six-day period. (Figure 
E-1). 
Figure E-1 Chain of transmission by date of onset fol lowing likely exposure at a 
Sydney paediatric hospital, May 2012 
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Upon further investigations, it was revealed that within the incubation period, all four 
cases had presented or accompanied a sibling to the ED of a large paediatric hospital 
at around the same time on 11 May 2012. Of the four cases, three were too young to 
have been vaccinated (Cases A, B and C; range: 7-11 months old). The remaining 
case (Case D) was a 17 year old girl with no record of receipt of measles vaccination 
(Table E-1). Case B was exposed to a sporadic case of measles within his incubation 
period and had been contacted for this exposure however the genotype of this case 
was later identified as B3. 
Table E-1 .Time spent by secondary measles cases in the Sydney paediatric 
hospital ED, 2012 
Case Sex Age Estimated arrival 
time at ED 
Discharge time 
Case D Female 17 years 14:45 01:40(nextday) 
Case C Female 10 months 17:40 21:19 
Case A Female 11 months 17:55 21:37 
Case B Male 7 months 20:55 23:54 
Specimens from Case A and Case C were transferred to the Victorian Infectious 
Diseases Reference Laboratory (VIDRL) for genotyping and both returned genotype 
D8. No genotype specimens were available for Case B and Case D. The only other 
known measles cases with a D8 genotype in NSW at the time was the 25-year old 
index case and the three secondary cases identified a month earlier. The four 
nosocomial acquired cases were assumed to have been linked to the index case based 
on identical genotypes, time and place . This assumption was made due to the 
rareness of measles in Australia and the only other confirmed cases during this period, 
being a case with genotype B3). The paediatric hospital was located within the same 
local health district (LHD) as the residence of the index and secondary cases. . The 
aim of this study was to identify the source case that presented to the ED on 11 May 
2012 and to report on the methodology used in an attempt to identify the source of 
infection. 
Methods 
The algorithm 
An electronic list of all ED attendances for 11 May 2012 which included Medical Record 
Number (MRN), date of birth, times of arrival, triage and departure and summary of 
presenting problem was provided by the ED director. Electronic ED patient notes were 
used to gather information on presenting condition, medical history, provisional 
diagnosis at time of discharge and whether transfer as an in-patient occurred. The 
Australian Childhood Immunisation Register (ACIR) was consulted for individuals' 
immunisation status when appropriate. 
Following the provision of the list of ED attendances, an algorithm was developed to 
identify the source case by time, place and person (symptom presentation and 
vaccination status). The development of the algorithm was aided by the national 
outbreak guidelines and documented symptoms of m e a s l e s . ' ^ ' T h e complete list of 
attendees at the ED for 11 May was reviewed by time of arrival and departure. Current 
national protocols stipulate that contacts be followed up for up to 2 hours after the 
index case has departed."" Thus, the time range of exposure to measles was 
estimated to be 2 hours before the last case arrived in the ED waiting room and one 
and a half hours after the first secondary case was discharged from the ED (i.e. 18:55 
to 22:49). On average, patients waited an hour and a half in the waiting room before 
the time of arrival is entered into the electronic ED patient notes (personal 
communication, ED director) and hence all patients were given an estimated arrival 
time one and a half hours before the entered time of arrival in patient notes. 
The complete list of attendees was further restricted by presenting condition. Patients 
who presented with trauma, mental health issues, central nervous system, urological 
symptoms, constipation, appendicitis, routine childhood examination and dental 
concerns were excluded. 
Having excluded children who did not fit the timeframe detailed above or those whose 
conditions were not compatible with measles, review of the remaining patients by 
symptoms recorded in hospital notes and immunisation status from ACIR was 
conducted. Suspect cases were defined as any patient that presented with fever and 
other symptoms consistent with measles (cough, coryza, conjunctivitis or rash) who 
were unvaccinated or partially vaccinated for measles. Children listed as 'did not wait' 
were reviewed by immunisation status and symptoms and if no information was 
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present, their parents were contacted for an interview. We developed a questionnaire 
(Appendix) to gather infornnation about the patient's symptoms, recovery, vaccination 
status, movements in the ED to determine whether or not they might be the source 
case. 
Additionally, in an attempt to determine whether a more precise location of exposure 
within the ED could be determined, attempts to recreate the movements of cases within 
the ED using ED notes, an ED map and the hospital's official incident report occurred. 
The hospital's official incident report was an internal document that compiled 
information supplied to the Infection Control Team which was circulated to a number of 
staff members and public health unit staff including paediatricians, infectious disease 
specialists and occupation health and safety staff. It outlined the event and the action 
taken by Infection Control at the hospital. 
Results 
General public health response 
Following receipt of the four notifications, control measures for each confirmed case 
were implemented as per national guidelines.^® Interviews with parents of cases were 
conducted by public health unit staff and a number of settings were Identified where 
cases may have potentially exposed individuals during their infectious period. This 
included household members; in-patients who had been in the same ward as cases; 
contacts from the ED and medical centre waiting rooms, schools and retail outlets. 
Public Health Unit and surge staff conducted contact tracing to assess the risk of 
infection of individuals exposed; determine current health and vaccination status; 
recommend and explain interventions and detail appropriate actions required upon 
becoming symptomatic. Measles fact sheets were emailed or posted to provide 
additional information. In total, 270 individuals were contacted; either through a phone 
Interview to determine their risk and provide advice or if individuals were unable to be 
contacted, a letter was posted to their address. 
Post Exposure Prophylaxis (PEP) clinics were held due to the high number of 
susceptible individuals exposed at the paediatric hospital ED by three of the four cases 
(Cases A, B and D) . Prophylaxis administered at the clinic included Measles, Mumps, 
Rubella (MMR) vaccine or Normal Human Immunoglobulin (NHIG). Each individual 
was reviewed using post exposure guidelines to determine the appropriate prophylaxis 
to be administered.'^" Overall, 18 individuals were administered NHIG and 8 individuals 
received MMR. 
As an additional control measure, public health alerts were issued to the paediatric 
hospital staff, general practitioners in the area and media outlets warning measles 
occurring (Appendix). 
Investigation to Identify the source case 
ED staff had conducted preliminary investigations to identify the source of infection 
shortly after establishing the link of the four cases to the ED. However, their efforts 
were unsuccessful and we were requested to conduct a comprehensive investigation 
following the completion of control measures 
Figure E-2 shows the steps used to try to identify the source case. There were 162 
children who presented to the ED on 11 May 2012 (Figure E-2) of which we excluded 
92 due to the timing of their presentations. 
Figure E-2. Algorithm to identify suspect source measles case presenting at a 
Sydney paediatric hospital ED, 11 May 2012 
Based on guidelines followed,''^'' individuals were included as possible source cases if 
they were discharged two hours (18:55) before the last case (Case D) arrived at 20:55 
and if they arrived in the ED waiting room one and a half hours (22:49) after the first 
case (Case C) was discharged at 21:19 (Figure E-3). 
Figure E-3.Overlap times of secondary measles cases and time that source case must have been present in the Sydney 
paediatric hospital ED, 2012 
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The four confirmed measles cases (Cases A, B, C and D) were also excluded resulting 
in 66 remaining children. Additionally, we excluded 17 children who presented with 
conditions which were incompatible with measles (i.e. patients who presented with 
trauma, mental health issues, central nervous system, urological symptoms, 
constipation, appendicitis, routine childhood examination and dental concerns). And 
nine patients who did not wait: 3 fully immunised patients, 3 afebrile patients and 3 
patients who presented with symptoms unrelated to measles (n=2 trauma, n=1 blood in 
stool) were also excluded. 
We reviewed ED medical charts for the remaining 40 patients. Of these, a number of 
patients were excluded as they were afebrile (n=17); had received 2 doses of MMR 
(n=9); or had a definitive diagnosis of a non-measles condition (typhoid fever or 
Salmonella serotype Enteritidis (n=2); allergic reaction (n=1);) were followed up by ED 
staff and not considered suspect cases (n=2); and had suffered a febrile convulsion 
following vaccination (n=1 ).One patient was admitted as an in-patient following ED 
presentation and treated for suspected meningococcal septicaemia (PGR negative for 
Neisseria meningitides but urine culture positive for enterococcus species) thus was 
excluded 
We conducted phone interviews with parents of 5 suspect source cases (Table E-2). 
The median age of suspect index cases was 17 months (range; 9 months-7 years). All 
5 patients were reported to have recovered soon after presentation. One patient had 
previously been exposed to a sporadic case of measles at a local medical centre; 
however, this case was later identified as genotype B3. 
Table E-2. Demographics and symptoms of suspect source measles cases In the Sydney paediatric hospital ED, 2012 
Case Age Sex Symptoms Vaccination 
status 
Other comments 
Suspect 
case one 
16m Female Coryza, fever, cough, otitis media, rash 
on face. 
MMR1 Exposed to measles genotype B3 7 May 2012 at a medical 
centre. Received antibiotics at CHW and parents reported 
improvement soon after. No new symptoms or ill household 
contacts. 
Suspect 
case two 
10m Female Fever, cough, coryza. Ineligible Patient recovered soon after attendance at ED. Also attended 
GP after ED presentation. Ongoing itchy scalp. Represented 25 
May with same symptoms. 
Suspect 
case 
three 
7y Female Rash, fever, cough, possible 
conjunctivitis. 
Unknown- later 
identified as 
MIVIR2 
Patient was ill for 1 -2 days and diagnosed with flu. No 
household contacts had prior or post-illness. Parents' state fully 
vaccinated. 
Suspect 
case four 
4y Female Fever and vomiting, diagnosed with a 
Urinary Tract Infection (UTI) 
No record Patient was diagnosed with UTI and did not acquire any new 
symptoms. No household contacts had prior or post-illness. 
Suspect 
case five 
9m Male Fever, cough, coryza, vomiting and 
diarrhoea 
Ineligible Patient was not prescribed any medications post presentation 
and recovered soon after discharge. No household contacts had 
prior or post-illness. 
Following a review of the 5 cases with colleagues and the manager of comnnunicable 
diseases at the western Sydney LHD, it was concluded that the five suspected source 
cases were unlikely to have been measles considering their recovery time occurred 
soon after discharge. Three of the five suspect cases were not observed to experience 
rash. Although suspect case one had a rash on her face, it reportedly did not spread to 
her torso or extremities. Due to unknown reason, ascertainment of the vaccination 
status of suspect case three was not recorded during preliminary investigations on 
ACIR, and her parents were interviewed. Their report of her vaccination status was 
later verified on ACIR. 
Cases A, B and D had waited in the ED waiting room for approximately one and a half 
hours before being examined by ED staff (Figure E-4). The remaining case (Case C) 
was brought in by ambulance using an alternative entrance. It is not known how long 
children sat in the waiting room to how long they were in cubicles or rooms being 
assessed. Three of the cases (Cases A, B and D) have near identical movements 
around the ED whilst Case C was completely different. Based on these four cases' 
movements however, it is likely that the source case entered into the ED to have 
transmitted face-to-face to Case C. It is difficult to ascertain where transmission was 
most likely for each case; considering the source case could have been moved around 
the ED. Given the varying times of arrival to ED by Cases A, B and D; it is unlikely that 
all three occurred in the waiting room. Case C would most likely have acquired 
measles in the ward area where she was located before being moved to a ward 
external from the ED. 
Figure E-4 Recreation of movements by the 4 secondary cases In the Sydney paediatric hospital ED, 11 May 2012 
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Discussion 
We investigated a cluster of four measles cases that were linked by time and place to a 
paediatric emergency department on 11 May 2012. We developed an algorithm to 
identify the source of infection and even though we were unable to identify the source 
case during this investigation, our algorithm may be improved upon and validated to 
assist future outbreaks with a similar scenario. 
Although the focus was on identifying the index of the case, this event also emphasised 
the susceptibility of infants in acquiring measles, particularly in a healthcare setting. 
During the outbreak, three of the four secondary cases were too young to be 
immunised, the youngest being seven months of age. Susceptibility among infants is 
not a new observation^®' however it suggests that more focus needs to occur in 
preventing such transmission. Though there have been suggestions to move fonward 
the primary dose of MMR to less than 12 months seroconversion of measles 
antibodies have been found to be highest in older infants (> 15 months) compared to 
younger infants (9-11 months).'^® Further, a more recent study found vaccine 
effectiveness to be greater at 15 months compared to 12-14 months.^^^ The immaturity 
of the humoral immune response in young infants, particularly those less than 6 
months^' indicates the complex nature in identifying the optimal time for the first dose 
of MMR. Vaccination of infants 9 -11 months of age is currently only recommended 
when exposure to an infectious case has occurred.^^^ A more practical approach in 
ensuring protection to infants in healthcare settings is perhaps to focus on establishing 
an isolation room during periods of outbreaks for all individuals presenting with fever 
and rash. Measles notifications had begun in the local health district the previous 
month, and heightened awareness by ED in containing suspicious measles cases may 
have prevented transmission, this however, will be discussed in more detail in the 
below project. 
Our failure to identify the source case may be due to the limitations of our investigation. 
Firstly, the algorithm used was based on the use of ED notes. The validity of ED notes 
is not known and to my knowledge, no publications exist on measuring the validity of 
this information for this type of public health investigation. It must be stressed however 
that ED notes are not intended as a data source for epidemiological studies, its main 
purpose is to document clinical information of patients. Information on time of arrival 
and departure, signs and symptoms, temperature, location treated and diagnosis are of 
utmost importance in applying this algorithm and if even one variable is not accurately 
captured the true index case of measles may have been missed. For example, the 
reliability of recording temperature or stating whether a patient was febrile in the 
electronic ED notes was not known. Seventeen patients were excluded based on being 
afebrile; had one of these in fact been febrile it is possible that further Investigation 
would have revealed that they were the index case. Data are entered by qualified 
nursing or medical staff which makes error improbable but errors can occur. ED notes 
have the potential to play an important role in identifying index cases in infectious 
disease outbreaks believed to be transmitted in the ED and while it would be ideal to 
validate ED notes for this type of public health investigation how this could be done 
(given the variability between and within persons that also may be influenced by time of 
day or level of activity in the ED) as well the usefulness of doing this in the overall 
scheme of patient management needs to be considered. 
A more pragmatic approach would be to validate the measles-specific algorithm itself. It 
was unfortunate that we did not validate the algorithm during the investigation due to 
time constraints. This was the first time that the algorithm developed was used we are 
unaware of existing algorithms to identify a source case in the past. We were however, 
guided by contract tracing guidelines and known symptoms of measles whilst 
developing the algorithm. 
The first stage of excluding cases was by the time frame of likely measles transmission 
using current national protocols that recommend contacts be followed up for up to two 
hours after the index case has departed.^® Since the index case was unknown, all 
patients who presented two hours before the last case arrived in the ED waiting room 
and one and a half hours after the earliest case was discharged from ED were 
included, with the remaining patients on the list excluded. As highlighted in the next 
report of this thesis, there has been much discussion of the likelihood of transmission 
of measles two hours after the departure of an infectious case. The timeframe in this 
algorithm is conservative as it includes the possibility of lingering aerosols. Previous 
outbreaks in Australia,'^® including this outbreak (described in more detail in the next 
report) have generally found measles transmission in healthcare facilities to have 
occurred when both the index case and secondary case were present in the facility at 
the same time. Hence it is likely that based on time, the algorithm would have captured 
the true index case, if they were a person that attended the ED. 
Another important consideration that may have assisted in identifying the index case is 
if the movements of all patients whilst in the ED were known. Movement of patients in 
the ED of the four secondary cases (Cases A, B, C and D) were collected in an incident 
report based on information collected for Infection Control. However, in the remaining 
patients that had attended the ED during this time, there was narrative text entered in 
some of them of their location however it varied considerably. In some countries like 
the United Kingdom, contact tracing is based on whether an individual was present in 
the same room as an infectious case of measles.'^® Given that the risk of measles 
transmissions in susceptible individuals is greatest when direct exposure occurs, it 
would have been useful if ED notes were able to capture the location and time of 
patients in the ED and indicate any movements within the ED and potentially 
incorporate this into the algorithm. 
In the above discussion, time and place have been addressed in identifying the index 
case, and it was also important to exclude patients on the ED list by their signs and 
symptoms. After excluding potential source cases by time, symptom presentation was 
examined. A summary of the presentation problem was used 
(provided by the Director of ED) due to time constraints to review in-depth narrative text 
in ED notes to exclude patients by symptom presentation. Patients discarded were 
recorded as having an acute problem (such as trauma injury) which was completely 
unrelated to measles and thus unlikely to be the index case but possibly may have 
been during pre-prodrome. 
Clearly use of symptom presentation in the development of an algorithm is an 
important factor in attempting to identify the index case of the outbreak. In some 
instances though, excluding by symptoms may not capture the index case if they 
happen to be pre-prodrome or a sub-clinical measles case. In some instances, partial 
immunisation can result in sub-clinical infection where symptoms are milder and may or 
may not include f e v e r . E v e n in fully vaccinated individuals, there is a possibility that 
measles infection can o c c u r . S i b l i n g s exposed to measles on an aeroplane became 
infected despite records indicating they received 2 doses of MMR. Vaccine 
administration occurred at different times suggesting that it was not a cold chain issue 
or defective batch but possibly a genetic i s s u e . I f the true index case presented 
without fever, our algorithm would have excluded them, however, it is highly unlikely 
that a sub-clinical case of measles was the source of infection as there have been no 
reports of measles transmission to household contacts by subclinical measles cases.'"" 
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Moreover, transmission may have occurred one day prior to prodrome'^ of a patient 
who presented to the ED with trauma or a problem not measles related. Given the time 
constraints of this investigation, we were unable to thoroughly review these patients. 
Following recommendations by clinicians and public health experts, we focussed on 
patients that had presented to the ED with a fever. We do not believe that any of these 
cases were the source case based on subsequent measles cases over the next few 
months that did not come from families known to have attended the ED on 11 May 
(other than the 4 confirmed cases identified). 
Rather than a sub-clinical case being responsible for this measles outbreak. It is highly 
possible that the index case was not a patient presenting to the ED but an individual 
accompanying a patient or a hospital worker. The ED does not record visitors that enter 
the ED or non-medical staff such as ward persons that enter the ED. Given that 
hospital workers have been reported to continue working whilst infectious with 
measles^\ it is a possibility that a worker was the source case. In 2007, however, the 
NSW Department of Health (now the Ministry of Health) issued a policy directive 
requiring health facility staff (newly recruited and existing) and students to be 
vaccinated against certain vaccine preventable diseases including measles, (unless 
they have been screened and found to be protected against measles).'® How much this 
policy is adhered to is unknown, however the existence of a mandatory policy suggests 
that a hospital worker was less likely to be the source case. On the other hand, an 
individual accompanying a patient may indeed have been the source case; however 
there was no way to assess this as no records are taken of individuals entering the ED 
other than patients. Therefore one recommendation would be that all individuals 
accompanying an ill individual are recorded in the ED notes and a log book exists to 
collect information of all hospital workers that enter into the ED. This would not only be 
of benefit when attempting to identify a source case but would also come in useful 
during contact tracing if an individual with an infectious disease exposed others in the 
ED. Whilst this would be useful for public health, it may be difficult to implement in a 
busy ED setting which needs to be considered. 
To this point, it is clear that many factors need to be taken into account in developing 
an algorithm to identify an index case of measles in a healthcare facility. Time, place 
and symptom presentation were used, and although the algorithm was guided by 
existing measles literature, it proved unsuccessful in identifying the index case. Despite 
this, the algorithm can serve as a guide for others to use and improve on, particularly 
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given the importance of healthcare transmissions during measles outbreaks that will be 
mentioned in more detail in the second part of this section. 
Further studies on validating a refined version of the algorithm would assist in 
identifying an index case if a similar situation was to occur in the future. One example 
could be to apply the algorithm to past outbreaks that have occurred in a healthcare 
facility with a known index case and determine whether following the algorithm, that the 
index case would have been identified. 
After following the algorithm, five interviews were conducted with suspected source 
cases. Interviews were conducted up to six weeks after the suspected transmission 
event date. Of the five suspect index cases, four were contacted within two weeks of 
the transmission event whilst it took five attempts of contacting the parent of one 
suspect case before an interview could be conducted (six weeks later). This is likely to 
have led to difficulty in recollecting the event by the parent of the one suspected case. 
However, it was assumed that having a child present to an ED would be traumatic and 
stressful for parents and hence resulted in remembering the event well. It is also 
noteworthy to mention that parents may have been concerned that their child was a 
'suspected' source of measles. Their responses to the questionnaire may have 
reflected this however we drafted our questionnaire to not suggest or implicate 
individuals as the source of infection during interviews. 
Conclusions 
Though Australian measles vaccination coverage rates are high EDs are an 
important transmission setting for measles, particularly in infants. Healthcare setting 
transmission has been a common characteristic of recent measles outbreaks in 
developed countries and presents an obstacle to securing and maintaining measles 
elimination."^ The investigation of four cases of measles identified on 1 day 
from a Paediatric Emergency Department was unsuccessful in identifying the source of 
infection; which may have been due to using a non-validated algorithm. As healthcare 
settings are considered the predominant mode of transmission in countries where 
measles is rare, developing a validated algorithm to identify an index case would be 
useful to guide healthcare facilities in identifying an unknown index case of measles. 
The algorithm developed in this investigation serves as a guide to be used in the future 
to refine and validate an algorithm that has the potential to be applied in healthcare 
settings. 
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Abstract 
Background: 
Increasingly, healthcare facilities are becoming common settings for measles 
transmission in countries where elimination has occurred. In 2012, seven years after 
measles elimination was reported in Australia, the country experienced its largest 
measles outbreak in 15 years. Indeed, a high proportion of cases in this outbreak were 
healthcare acquired.. The objective of the study was to highlight key characteristics of 
healthcare acquired cases and in a post-elimination setting, consider whether the 
epidemiology of measles may be changing. 
Methods: 
A healthcare-acquired measles case was defined as a confirmed case Apri l-
November 2012 who had a coincident attendance with a measles-infected individual 
(source case) at a healthcare facility 7-18 days before symptom onset. We conducted 
descriptive analyses using case series data from the metropolitan Sydney region to 
examine demographic characteristics, including age, sex .vaccination status and the 
time of presentation. The number of presentations, time of presentation, symptoms 
upon presentation and isolation information were obtained for source cases. The 
number of contacts exposed to source cases was provided by health authorities. 
Results: 
There were 36 cases of healthcare acquired measles and 16 source cases (of which 
14 could be identified). All source and secondary cases overlapped in time, and source 
cases, on average presented three times to a healthcare facility before being 
diagnosed. Eighty-four per cent of secondary cases acquired measles from a case with 
rash. 
Conclusions: 
The most recent measles outbreak in Australia has indicated that measles 
epidemiology post-elimination may differ to that during a period of measles control. 
Given that healthcare facilities are common settings for measles transmission in 
countries nearing or who already have reported elimination; understanding 
characteristics of healthcare setting transmissions can assist in effectively targeting 
prevention strategies. 
Prologue 
My role 
Alexis and I were fortunate to commence the MAE during the year which would 
experience the biggest national measles outbreak in 15 years. Subsequently, we were 
part of the health department's surge staff, being on hand to assist at a local and state 
level. Our role started in April when we were introduced to contact tracing, interviewing 
individuals exposed to the index case of the outbreak. Following this we assisted in 
post-exposure prophylaxis clinics set up by Parramatta public health unit, this included 
weighing babies to ensure the appropriate volume of normal human immunoglobulin is 
received and also administration duties at the clinics. We also were mobilised to the 
Ministry of Health to conduct descriptive analysis on measles cases for the NSW 
Expert Working Group and also entered data for contact tracing lists. We also were 
mobilised to South West Sydney public health unit to enter data on cases into a new 
database they developed. 
During the outbreak, a high proportion of cases were found to be acquired at a 
healthcare facility. As we were heavily involved in public health action from the 
beginning of the outbreak, Vicky suggested that we should be part of a team 
conducting analysis of healthcare acquired infections with the aim to submit a 
publication to a peer-reviewed journal. We would be responsible for drafting the paper 
which included conducting data analysis, interpreting the results and preparing the 
manuscript. Sophie Norton and Kirsty Hope were responsible for developing Table E-3 
that is presented in this paper. 
Lessons learned 
This outbreak occurred one month after commencing the MAE program and it provided 
me with many lessons about working at a public health unit at a state and local level. 
Firstly, it was my first introduction into contact tracing. I was fortunate enough to have 
Vicky listen to my first interview. This was an extremely daunting experience however 
her feedback was invaluable. I learnt that I had to communicate succinctly and 
confidently and ensure that I provided correct information to individuals. I also learnt 
that it is important how one delivers a message, in some circumstances individuals 
may feel panic and anger at the potential of being exposed to an infectious individual. 
During the post-exposure prophylaxis clinic, I learnt the algor i thm for when the MMR 
vaccine is administered compared to the administrat ion of NHIG. It was also clear that 
it teamwork is imperative to the clinic running smoothly and ensur ing everyone has 
clear roles and responsibi l i t ies al lows greater eff iciency. 
I also was able to exper ience how it would be work ing at a local level and state level. It 
was interesting to see how they interacted together as well as the di f ferences in 
priorit ies and public health action each had. 
I learnt about the caveats of the data used for analysis. Wi th the attack rate calculated, 
only heal thcare contacts of index cases that t ransmit ted infection at a healthcare 
sett ing were used as the denominator to calculate attack rates. This would have 
overest imated the overall attack rate for healthcare t ransmissions as there reports that 
120 healthcare presentat ions of infectious cases of measles resulted in no 
transmissions. This calculation will be revised for the manuscr ipt however at the t ime of 
writ ing my thesis; data of the number of contacts f rom these 120 healthcare 
presentat ions have not been extracted. Hence, the reasons that the attack rate was 
calculated as abovement ioned. 
In terms of the deve lopment of the manuscript, I learnt that it is important to choose 
what journal you want to submit the manuscr ipt to before writ ing up, so you have an 
idea of the 'angle', structure and word count of the manuscript. It was also enl ightening 
to col laborate with a number of public health units and try and overcome dif ferent 
expectat ions that each public health unit had for the evolution of the manuscript . 
During course block, Mahomed was instrumental in teaching us that messages that 
you want to communicate differ between a presentat ion and a manuscript. Wi th much 
thought, we requested help f rom Mahomed into guiding us through the preparat ion of 
the manuscript . He taught me a great deal on how to write a manuscr ipt and made me 
think outside the box on the key messages of the paper. This project al lowed me to 
gain insight on how to write a paper and the important components of each section. He 
taught us that the strength of our study is determined by the validity of our data. 
Public health action 
This outbreak resulted in the exposure of numerous individuals to measles in a 
heal thcare facility. The public health action was almost immediate fol lowing the 
conf i rmat ion of a measles case. Firstly, contact tracing occurred as soon as contact 
lists f rom medical centres and EDs were suppl ied. Individuals who were known to be 
infants < 12 months and pregnant were priorit ised. Post-exposure prophylaxis clinics 
were organised at the paediatr ic hospital to administer MMR vaccine and NHIG if 
exposure occurred < 5 days beforehand. 
Our report highl ighted the importance of healthcare transmission, particularly in an era 
of meas les el imination. It descr ibes the epidemiology of measles in this setting and has 
the potential to inform policy. This includes removing the 2-hour rule that is 
recommended in current guidel ines for contact tracing in a healthcare facility, 
consider ing new approaches to raise awareness of measles among clinicians during 
per iods of outbreaks and reconsider ing when measles is most infectious. 
W e aim to submit the report below to the British Medical Journal as we believe that our 
observat ions are highly relevant for cl inicians and public health staff in England and 
Wales. Our results provide lessons learned for Austral ia but also other countr ies 
striving for measles el imination and suggest that similar epidemiological observat ions 
will occur dur ing periods of outbreaks once this has been achieved. 
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Introduction 
Between 2003 and 2008, Australia, England and Wales claimed to have eliminated the 
indigenous transmission of measles.® Despite this, all three countries have 
experienced a number of measles outbreaks in recent t i m e s . T h i s includes 
Wales' largest measles outbreak in 18 years, affecting 1325 individuals (at the time of 
writing).'"'® For both England and Wales, a consequence of their large scale and 
persistent outbreaks has been the re-introduction of indigenous measles in 2008.'®° 
Australian outbreaks have comparably remained relatively small and it Is likely that 
measles elimination has been sustained despite the largest outbreak in 15 years 
occurring in 2012. The United States (US) where measles elimination was declared in 
2000,"® has also witnessed recent outbreaks, with over 222 cases in 2011 ,the largest 
outbreak in the US since 2006.^®' 
One key characteristic observed to have perpetuated the 2012 Australian outbreak 
was the numerous transmission which occurred in healthcare settings. Indeed, 
healthcare facilities have been reported as a prominent setting for measles 
transmissions in countries where measles is rare or e l i m i n a t e d . ' ^ ' ' R e a s o n s for this 
are well documented, and include the low suspicion of infection among clinicians 
unfamiliar with the disease. This is further exacerbated by the difficulties inherent in 
diagnosing illness characterised by the non-differential symptoms shared by a myriad 
of other conditions.'® Additionally, measles is highly infectious and busy, highly dense 
environments like hospital EDs are optimal settings to propagate outbreaks. ' " Of 
concern is that the immunocomprised often frequent healthcare facilities, particularly 
hospitals and if infected, experience more severe disease outcomes than 
immunocompetent individuals.'^' 
Contact tracing to identify susceptible individuals exposed to measles is often resource 
intensive.'®" Measles virus has been demonstrated to remain viable in air for up to 
two hours in a controlled e x p e r i m e n t P r e v i o u s published outbreaks have supported 
this finding, however are somewhat out-dated and occurred in an era where measles 
was still endemic.'®^ These publications have dictated contact tracing guidelines in 
Australia which suggest all individuals present for up to two hours after a confirmed 
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measles case departs a healthcare facility should be contacted (referred to as the 'the 
two-hour rule') ."" 
Although numerous measles outbreak reports have been published describing 
healthcare transmissions/" many reports often lack detailed case demographics 
and characteristics of transmissions are scarce. The 2012 outbreak in north-west 
England identified that nearly 30% of confirmed cases reported before March were 
exposed to a measles case in a healthcare setting.''"® A separate publication on this 
outbreak questioned why suspected cases were not isolated which resulted in 'a 
significant number' of secondary c a s e s . N o further details were provided from these 
two reports. Similarly, little is known on the epidemiology of healthcare measles 
transmissions in Australia, particularly in the context of measles elimination. Because 
little has been published on the characteristics of healthcare transmissions during 
measles outbreaks, and because of the need for this type of evidence to inform 
prevention strategies and policies appropriate to a post-elimination setting, the 
objective of this study was to describe key characteristics of the 2012 NSW outbreak, 
focusing on healthcare acquired transmissions because of their prominent role fuelling 
outbreaks in countries where measles cases are rare. The three key characteristics 
described include: 1) The nature of exposure and exposure time between the source 
and secondary case; 2) The delay in diagnosis of measles in the source case and; 3) 
The stage of measles infection when transmission typically occurred. 
Methods 
Case series data describing confirmed measles cases were obtained from metropolitan 
Sydney Local Health Districts in Australia's most populous state, New South Wales, 
between April and November 2012. Western Sydney, where the majority of outbreak 
cases resided, is culturally diverse. A third of its two million population were born 
overseas and it also includes the largest urban population of Aboriginal and Torres 
Strait Islander people in the country. 
A confirmed measles case required laboratory evidence or clinical signs of infection 
with an established epidemiological link.'®' Clinicians and laboratories are legislatively 
required to notify public health authorities of suspected and confirmed measles cases. 
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All confirmed cases temporally and regionally similar to the index case (i.e. the 25 year 
old Australian-born male who had returned to Australia from a trip to Thailand in April 
2012) with genotype D8 or unknown were considered as belonging to this outbreak. 
Genotyping of specimens was conducted at the Victorian Infectious Diseases 
Reference Laboratory (VIDRL). 
Health authorities interviewed cases using a standardised questionnaire to obtain 
demographic information (age, sex, ethnicity, and vaccination status), symptom onset 
date and movements during exposure and infectious periods. The exposure period was 
defined as seven to 18 days prior to rash onset whilst the infectious period was defined 
as five days prior to and four days after rash onset. 
Electronic patient notes (including clinical history, movements in hospital, number of 
individuals exposed) were acquired from hospital ED files if cases had presented to an 
ED seven to lB days preceding onset of symptoms during either the exposure or 
infectious period as defined above. For all ED cases, detail regarding arrival, triage, 
time seen and discharge times were available 
A healthcare facility was defined as any premises that delivered healthcare services 
including hospital EDs, inpatient wards and GPs. A healthcare-acquired infection was 
a confirmed case between April and November 2012 who had a coincident attendance 
with a measles-infected individual at a healthcare facility seven to 18 days before 
symptom onset. These measles-infected individuals were defined as source cases of 
healthcare-acquired transmission. 
Analysis was conducted using Stata®^" to describe demographic characteristics of 
source and secondary cases. Overlap times of source and secondary cases during 
presentation at a healthcare facility were calculated for each transmission event. 
For source cases, proportions were calculated for type of healthcare facility of first 
presentation, number of presentations, number of cases isolated and symptoms during 
presentations. The average time spent by the source case in the healthcare facility was 
calculated. For each transmission event, a crude attack rates was calculated with 
number of individuals exposed used as the denominator. Crude attack rates were 
stratified by Local Health District to account for the different contact tracing procedures 
implemented by the districts. 
Ethics approval was not required as this study was part of the public health response of 
the outbreak. 
Results 
There were 168 confirmed and 2 probable cases of measles, of which 36 (22%) were 
health-care acquired (Figure E-4). 
Figure E-5. Confirmed and probable measles cases in the NSW outbreak by 
setting of transmission, Apr i l -November 2012 
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The median age of the healthcare-acquired cases was nine years (range: 5 months -37 
years). Eleven cases (31%) were infants too young to be vaccinated, fourteen cases 
(39%), were unvaccinated and two cases (6%) received a dose of measles-mumps-
rubella vaccine (MMR) following exposure as part of contact follow-up. One case (5%) 
had records of receiving two doses of MMR and three cases (8%) had received one 
dose of MMR. One case (5%) was a healthcare worker. 
Thirty-three transmissions (33/36=92%) occurred in hospital, of which 29 transmissions 
(29/33=81%) occurred in an ED or ED waiting room and 4 transmissions (4/33=11%) In 
a ward. Three transmissions (3/36=8%) occurred at a GP. 
Source cases 
The median age of known source cases (n=14) was 16 years (range: 7 months-39 
years). Two source cases acquired measles in a healthcare setting and were also 
included as a healthcare acquired case. Nine source cases (64%) were unimmunised 
and three source cases (21%) were too young to be immunised. One source case had 
documented evidence of a primary dose of MMR and the vaccination status of another 
source case was unknown. Two source cases could not be identified. 
Overlap time between source and secondary case 
The median overlap time between source and secondary cases was 4 hours and 24 
minutes (range: 59 minutes-35 hours 31 minutes). All secondary cases were present 
at the same time of the source case and no transmissions occurred after the departure 
of the source case. 
Of the known source cases that occurred in a GP clinic, presentation and departure 
times of patients were not recorded. However, one of the three secondary cases that 
were acquired in a GP reported that a measles case was known to be present during 
their attendance at the GP. For the 5 secondary cases that occurred in an ED where 
the source case remained unknown, 4 of the secondary cases overlapped with each 
other by time and place whilst the remaining secondary case overlapped in time with 3 
possible source cases. 
Delay in diagnosis 
On average, source cases presented 3 times to a healthcare facility before being 
suspected of measles. The median number of days from symptom onset to notification 
was 5 (range:2-23) days and the median number of days from rash onset to 
notification was 2 (range:0-18) days A total of 1251 contacts were subsequently 
exposed to measles from the 14 known source cases. 
Of the 38 known healthcare presentations by a source case, isolation occurred upon 
initial presentation to an ED twice. Two other source cases were isolated after eight 
hours or more in the ED. A presentation of a source case to a GP resulted in isolation 
there; however, the source case re-presented at an ED on the same day and was not 
isolated. Three source cases were isolated upon admittance to a ward. Isolation 
patterns from the 14 known source cases did not appear to improve as the outbreak 
progressed (Table E-3). 
Transmission characteristics 
Of the known source cases, a total of 38 presentations to a healthcare facility occurred. 
Eighteen presentations occurred prior to rash onset and led to 5 transmissions (Table 
E-3). Twenty presentations occurred following rash onset and resulted In 25 
transmissions. Sixteen per cent (n=6) of secondary cases acquired measles from a 
case without rash compared to 84% (n=30) of secondary cases who acquired measles 
from a case with rash. 
In Western Sydney Local Health District, the crude attack rate for measles was 0.8% if 
the source case had no rash compared to 0.4% when the source case had a rash. In 
Sydney South West Local Health District, the crude attack rate for measles was 5.1% if 
the source case had no rash compared to 11.0% if the source case had a rash. 
T a b l e E-3 . H e a l t h c a r e p r e s e n t a t i o n o f s o u r c e c a s e by d a y o f r a s h o n s e t , N S W 2 0 1 2 
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Discussion 
A key driver of the 2012 NSW measles outbreak was numerous healthcare setting 
transmissions, which occurred in part because of delayed diagnosis and 
implementation of control procedures. Key characteristics of healthcare acquired 
transmissions during the 2012 outbreak in N S W - t h e largest in Australia since 1997, 
have prompted health officials to reconsider public health response practices during 
measles outbreaks. Indeed, the results of this study suggest that a re-assessment of 
current knowledge in measles epidemiology is required, particularly in an era of 
measles elimination. 
Contact tracing and the two-hour rule 
The value of contact tracing individuals up to two hours after an infectious case has 
departed a healthcare facility is questionable. Australia's two-hour contact tracing rule 
appears to have been based on literature obtained during the 1960s to the 1980s. 
Under experimental conditions, measles virus was found to persist in air for up to 2 
h o u r s . T h i s was further supported by airborne transmission occurring up to two hours 
after an infectious case departed on a number of occasions,'®® ^^ However, the 
number of transmissions from these reports was low (total of 6 secondary cases)'®® 
and all reports occurred in the United States at a time when measles was endemic, 
which would make identifying the source of infection challenging. Moreover, many of 
these reports described source cases who were vigorously coughing and likely to be 
'superspreaders'.'®® Reviews on nosocomial measles transmissions continue to use 
these out-dated sources as evidence of virus persisting in air for up to two hours, even 
in updates'®' 
Among the known source cases in this study, no transmissions were observed to occur 
outside the direct time of exposure between the source case and susceptible individual 
in the healthcare setting. Although the overlap times between source and secondary 
case were missing for 8 transmissions, anecdotal evidence purports that an overlap 
time existed for one of these transmissions whilst another transmission had 3 possible 
source cases, all of whom overlapped in time with the secondary case. The overlap 
time for the remaining 6 transmissions cannot be precisely ascertained. Four of these 
were infected at the same time from an unknown source case. Though the source case 
remained unidentified, all secondary cases overlapped succinctly in time and place; 
however, we believe sufficient evidence still exists to question the necessity of 'the two-
hour rule'. Hope et al 2013 also found all source and secondary cases to overlap in 
time during a 2011 measles outbreak and concluded changes to the 'two-hour rule' 
may be warranted.'^® In England and Wales, only contacts with face-to-face exposure, 
exposure time excessive of 15 minutes or immunocompromised individuals with any 
contact (including over a short period after the measles case departed) are followed-
A potential limitation in this study, however was the differing contract tracing 
procedures that occurred in local health districts (LHD) in Sydney. One LHD contact 
traced according to the recommended 'two-hour rule' whilst another contact traced up 
to 15 minutes after the infectious case departed the healthcare facility. If a transmission 
had indeed occurred after 15 minutes, it would likely be captured by surveillance as 
measles is rare and Australia has a sensitive surveillance system. Furthermore, 
exposure at a healthcare facility would have been identified through case 
investigations. 
To this point, it may be that the two-hour rule is unnecessary, moreover contributes to 
substantial proportion of costs of measles control efforts. An estimated USD 10 376 
was spent in the US in 2008 for investigation and control efforts per measles case 
We suggest more targeted approach to contact tracing in Australia is adopted, 
particularly in the midst of an outbreak. Focusing only on individuals that are present at 
the same time as an infectious measles case in a healthcare setting would ideally 
minimise resource utilisation and be more appropriate for countries where measles is 
rare or eliminated. 
Infectious stage of measles 
It has long been recognised that infectiousness of measles is greatest during 
prodrome^®® whereas the appearance of a rash indicates the beginning of viral 
clearance from blood and tissue.''®® In this study however, a large proportion of 
healthcare transmission appeared to occur after the rash onset of the source case. 
Other reports have documented similar f i n d i n g s . T h i s may suggest that 
infectiousness could be just as high during the rash stage of illness as during the 
prodromal stage, through there are a number of caveats to this interpretation, including 
the small number of transmission events, variable wait times and times of exposure for 
the secondary cases. Additionally, there was one source case in this study that 
infected 11 secondary cases and this outlier may have skewed results. Nevertheless, 
attack rates were calculated by the number of individuals exposed at each presentation 
which may partially control for wait-times. It is unfortunate; however, that we were 
unable to obtain information on the number of susceptible individuals at each 
presentation to obtain more valid attack rates. 
Moreover, the attack rate may be an overestimate of the true attack rate. The 
denominator only included contacts of known source cases that transmitted in a 
healthcare setting. It excluded the healthcare contacts of index cases that were 
infectious whilst presenting to a healthcare facility that did not result in any known 
transmissions. During this outbreak, 120 (personal communication) presentations were 
reported to have occurred at a healthcare facility without any secondary transmission; 
however, at the time of writing, the number of contacts from these presentations was 
unknown. 
Despite these limitations, the observation that, for this study, more secondary cases 
acquired measles from source cases that had rashes than source cases that were in 
the prodromal stage of infection may serve as a reminder of the importance of 
increasing suspicion when a patient presents with rash during times of outbreak. 
Additionally, infection can occur without presentation of a rash , particularly in the 
immunocompromised.'"" If this was to occur, it is likely more secondary cases would 
have resulted after a source case presented without rash, however, this was not 
observed. 
One hypothesis to our results is that cough may be a stronger predictor of 
infectiousness than rash which is biologically plausible, given the route of transmission 
and documentation of index cases with rash and vigorous coughing resulting in a 
number of explosive outbreaks'^® however, more recent outbreak reports have 
limited information on cough severity. The frequency and rigour during this outbreak 
was not captured upon presentation In clinical notes during the 2012 outbreak and this 
kind of detail would have aided our understanding of transmission and it is therefore 
recommended that description of cough be better recorded in clinical notes. 
Delayed diagnosis 
Delayed diagnosis of measles cases was an ongoing issue during A recent review 
found that up to 50% of cases in developed countries, particularly where measles 
elimination was established had been acquired in a healthcare setting On first 
presentation, only a low proportion of cases are suspected of having measles.''®. 
Measles is difficult to clinically distinguish from other viral systemic illnesses. A patient 
in the early stages of measles may present with a combination of non-differential 
symptoms including fever and perhaps only one of the following cough, coryza and 
conjunctivitis with differential diagnoses including influenza and other common 
respiratory viral infections and allergic rhinitis. Even with the characteristic 
maculopapular rash, a measles diagnosis may be overlooked because of the disease's 
rareness and similarities to adeno- and enteroviral infection, other exantha of childhood 
and drug allergy."' Lacking diagnosis, most cases presented multiple times to both 
the same healthcare facility of their first presentation and to other healthcare facilities .It 
is noteworthy to mention that although public health alerts were disseminated to 
healthcare facilities during this outbreak, including faxing and telephoning GPs in 
particularly affected areas, awareness did not appear heightened as multiple 
healthcare presentations by source cases were observed to occur even during the 
peak of the outbreak. More innovative approaches may be needed including alerts that 
are triggered when 'fever' and 'rash' are entered into electronic health records of 
primary health centres, however, such measures are yet to be evaluated.''^' 
Our results identified that even during the peak of the outbreak, a number of measles 
cases were not suspected of having measles despite having a rash and subsequently 
were not isolated. Although a number of source cases were documented as being 
isolated, it was either too late as transmission had already occurred or isolation was 
ineffective. While isolation of an infectious case in a negative pressure room is the 
preferred method"" in many situations this may not be feasible. More feasible options 
might include confinement of suspect cases in a single private room with a face mask 
although busy EDs during winter, single rooms are scarce. Nevertheless, isolation 
practices were documented to have differed not only between hospitals but also within 
hospitals. Isolation practices could be more effective if procedures were more 
standardised and consistent. 
Though several key limitation of this study have been detailed above, others are worth 
briefly noting. Though presentations by source cases to a healthcare facility may have 
been missed (presented at another GP/ ED) this is unlikely as cases were interviewed 
using a standardised questionnaire and are likely to recall seeking medical attention. 
There is a possibility that isolation of a suspected case could have occurred but was 
not captured in ED/GP medical records. If this was missing, the information would have 
been collected by public health authorities though communication with the clinician of a 
measles case. Ultimately, if time and resources permitted, it would have been ideal to 
compare the source cases who presented multiple times to a control group of 
individuals who were recognised immediately at a healthcare facility to determine if any 
risk factors led to misdiagnosis of measles. New approaches are essential during 
periods of outbreaks to heighten awareness of disease among clinicians. 
Conclusions 
As more countries progress towards elimination, the predominant role of transmission 
in healthcare facilities must be noted. The most recent measles outbreak in Australia 
has indicated that measles epidemiology in an era of elimination may differ to that 
during a period of measles control. Contact tracing procedures based on out dated 
evidence may be revised to be more appropriate to the post-elimination context. 
Continual strengthening of the evidence base with outbreak reports such as this report 
will assist in improving the understanding of the pathogenicity of measles and 
consequently how best target awareness and education. Moreover improving clinician 
recognition and suspicion of measles - particularly during times of outbreak must 
continue to be prioritised with innovative strategies required. Without attempting to 
improve understanding of the current epidemiology of measles in an era of measles 
elimination may result in out dated and irrelevant measles control strategies. And the 
lack of relevant strategies may result in an increase in measles cases jeopardising the 
elimination status in Australia, and elsewhere. 
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Appendix B 
B1 .Literature Review- Measles over the last two decades in Australia 
Outbreaks 
Authors Year/Source Location Study Design Results 
1. Lush et al 1995/ The NT 
Communicable 
Diseases Bulletin 
NT Outbreak report 259 cases- that occurred in 1994. 55% cases were 
Aboriginal. The overall attack rate in Alice Springs region 
was 6.8 per 1000 population. Attack rates were 12.6 per 
1000 population among Aboriginal people compared to 
4.0 per 1000 population in non-Aboriginal people in Alice 
Spring. 8 confirmed measles cases occurred in 
Aboriginal infants aged < 6 months. 
2. Jeremijenko, Kelly & 
Patel 
1996/Journal of 
Paediatrics & Child 
Health 
WA Retrospective cohort 53 cases- 21 serological confirmed, 23 epi-linked & 9 
cases clinically diagnosed. Mean age =12yrs (range 9 
mths-21yrs) Index case acquired in Japan- transmission 
predominantly occurred at a high school (24). 91.7% of 
high school cases were unvaccinated. Ten cases had 
further complications and five were admitted to hospital. 
3. Gidding et al 1999/001"' QLD Retrospective cohort 46 cases- 10 serologically confirmed. Median age= 9yrs 
(range 11 mths-34yrs). Transmission occurred primarily 
at an education seminar during 1997 A vaccine efficacy 
study found that for children who had at least one dose 
of MMR, VE= 81.3% (84.6% for validated only). Source 
of infection unknown. 
4. Holland & Hall 2000/CDl'" SA Outbreak report 7 cases- all serologically confirmed. Median age= 32yrs 
(range 3-41 yrs). Two of the cases were ambulance 
officers and one case was a patient assistant. 
Vaccination status for the three cases was unknown. 
Notification of all cases occurred after confirmation of 
diagnosis. Index had no history of recent travel. 
5. Hanna et al 2000/CDl'"' QLD Outbreak report 5 cases (siblings) aged between 2.8yrs and 11.5yrs and 
all unvaccinated. 4/5 cases measles antigen detected in 
throat swabs. Symptoms of case 1 occurred in England, 
12 days after leaving Sri Lanka. Four cases PGR- throat 
swab positive for the 'Sri Lankan genotype'. Two cases 
presented to a healthcare facility, one case presented 
three times to a general practice before being suspected 
of havina measles. 
6. Lambert et al 2000/MJA'' ' VIC Case series using 
enhanced measles 
surveillance data in 1999. 
75 cases- 74 were lab confirmed and 1 was epi-l inked. 
Median age was 22 years (range 10 months- 31 years 
old). 85% of cases were aged between 18 and 31 years. 
The Index case recently travelled to Bali and 
transmission occurred primarily at the cinema complex 
where the index case worked. Over a third of cases 
required hospitalisation and 6 healthcare workers were 
infected. 
7. South Eastern Sydney 
PHU 
2001/001"" NSW Outbreak report 5 cases- 2 cases were serologically confirmed & 2 
cases measles antigen detected in throat swabs. Source 
of index case unknown however assumed to be acquired 
through occupational exposure in a health care setting. 
Transmission occurred primarily in a GP waiting room. 
8. Blake et al 2001/MJA'" ' NSW Letter 3 cases- all serologically confirmed. Index case (23 year 
old female) recently travelled to Hong Kong and was 
hospitalised with rash-associated febrile illness. Second 
case epi-linked to index as visited her whilst in hospital. 
Genotyping did not occur as attempts to culture measles 
virus unsuccessful in 3 patients. Third case (one-year old 
male) was epi-linked to index case whose sibling 
attended general- practice within 25 mins of index case. 
9. Hanna, Symons & 
Lyon 
2002 /CDl ' " QLD Outbreak report 7 cases-1 case serological confirmed, 4 cases measles 
RNA detected by PCR on samples taken & 1 case epi-
linked. Median age= 14 years (range 11mths-19yrs). 
Suspected source of infection from a 16 year old female 
who recently travelled to Thailand who stayed with the 
index case. Genotyping of 5 cases identified genotype 
D5. 
10. Kelly, Riddell & 
Andrews 
2002/MJA'" ' VIC, WA 
and NSW 
Editorial The authors discuss a number of measles transmissions 
in healthcare settings around the country. Predominantly, 
cases were acquired overseas and presented at general 
practices or emergency departments in hospitals. Health 
care professionals were among the cases that occurred 
in these outbreaks. The importance of outbreak control 
was discussed. 
11. Davidson et al 2002/CDr' VIC Outbreak report 51 cases- 50 were lab confirmed. Median age= 25yrs 
(range 10 mths-34yrs). Transmission occurred at a 
number of restaurants, a nightclub, shopping centres and 
on public transport in 2001. One healthcare worker was 
infected. One case was too young to be vaccinated, 4 
cases had received one dose of MMR and the remainder 
had no evidence of MMR vaccination. 
12. Fielding 2005/ CDI" SA Outbreak report 22 cases- all cases were lab, clinical and epi confirmed. 
Median age= 23yrs (range 9mths-36yrs). Transmission 
occurred at a concert, supermarket and at a hospital. 
Index case recently travelled to New Zealand. Sixty per 
cent of cases were unvaccinated and 27% of cases had 
evidence of one MMR. 
13. Weston et al 2006/CDl" NSW Outbreak report 9 cases- all cases had at least one lab test confirming 
measles. Median age= 24 years (range 2mths-38yrs). 
Index case recently travelled to Nepal via Bangkok. One 
case had documented evidence of one measles 
containing vaccine administered overseas. Nosocomial 
infection occurred during presentation at ED as well as in 
the community. 
14. Riddelletal 2006/ 
Eurosurveillance'" 
VIC Short report 1 case of measles imported from Europe - suggested to 
be linked to an outbreak in Stuttgart, Germany. No 
further cases were identified. Genotyping of specimen 
identical to a strain identified in the UK. 
15. Sheppeard et al 2009/NSW Public 
Health Bulletin"" 
NSW Retrospective cohort 57 cases, 1760 contacts and 553 susceptible individuals. 
Measles prophylaxis efficacy was calculated using data 
on all cases of measles notified between 1 March and 31 
May 2006. Prophylaxis effectiveness (MMR/ NHIG) was 
83.3%. 
16. Martin & Foxwell 2009/CDl"' National Outbreak report National outbreak data identified 78 cases between 1 
Jan and 31 March 2009. Ninety three per cent of cases 
had not received any dose of measles containing 
vaccine of the cases of known vaccine status (57). 
Twenty two per cent of cases were acquired overseas, 
predominantly in young adults. 
17. Bowen 2009/ Emergency 
Medicine Australasia''*' 
NSW Outbreak report The authors describe the control and prevention 
processes followed after an unvaccinated 15 month old 
presented at ED. There were 111 individuals exposed to 
the case of which 9 individuals were administered NHIG. 
Ninety-three contacts were identified as immune. 
18. Coleman & Markey 2010/ Epidemiology & 
Infection'^ 
NT Outbreak report 4 cases- all serologically confirmed. Median age 
14.5years (range 11-17 years). Index case flew from 
China-Singapore-Darwin-Melbourne. Transmission likely 
to have occurred during the flight from Singapore-Darwin 
(2 cases) and during transit (1 case). Two of the cases 
were fully vaccinated on ACIR records. 
19. Beard et al 2010/ Western Pacific 
Surveillance and 
Response Journal'" 
VIC, OLD 
& NSW 
Outbreak report 9 cases- 7 cases measles antigen detected by PGR, all 
genotype. Two cases were serologically confirmed. 
Median age= 33 years (range 11-62 years). Index case 
administered MOV 5 days prior to flight; all other cases 
had no documented evidence of vaccination. Four cases 
likely to have become infected on flight Australia- South 
Africa. Other exposures include ED and GP clinic. 
20. Hoskins 2011/MMWR"'' QLD Outbreak report 11 cases- 3 cases serologically confirmed; 6 cases 
measles RNA detected by PCR and 2 cases clinically 
diagnosed. Three index cases (from New Zealand) flew 
Singapore-Brisbane-Auckland resulted in 8 further 
cases. Transmission suspected to have occurred during 
the flight. Eight cases were unvaccinated, 2 cases 
vaccination status was unknown and 1 case was 
reported to be vaccinated. 
21. Flego, Sheppeard & 
McPhie 
2011/CIDM Broad 
Street Pump" 
NSW Outbreak report 26 cases- 22 cases were lab and clinically diagnosed, 4 
cases had clinical symptoms and were epi-linked. Age 
range was 8 months to 35 years. Transmission likely 
occurred in a high school however all cases resided in 
the same suburb and 46% were of Pacific Islander origin. 
All confirmed cases had no documented evidence of 2 
MCV. 
Incidence 
Authors Year 
A/Source 
Location Study Design Results 
22. Mclntyre et al 2000/CDP- National Epi review of notification data 
from the NNDSS 1 Jan 1993 to 
31 Dec 1998 and hospitalisation 
data using AIHW National 
Hospitality Morbidity data for 1 
July 1993 to 30 June 1998. 
Between 1993 and 1998 the annual notification rate was 
11.4 per 100,000 population. During this period there were 
12,404 notified cases of measles. The notification rate was 
highest in the 0-4 year age group (45.4 per 100,000 
population) followed by the 5-14 year age group (31.8 per 
100,000 per 100,000 population). Notification rates were 
highest in the NT (51.7 per 100,000 population). 
There were 2223 hospitalisations due to measles and the 
average annual hospitalisation rate of 2.5 per 100,000 
population. 20% of hospitalisations had complications due 
to measles. Hospitalisation rate during this period was 
highest in the 0-4 year age group (14.6 per 100,000 
population). 
23. Mclntyre et al 2002/CD 
1"' 
National Epi review of notification data 
from the NNDSS 1 Jan 1999 to 
31 Dec 2000 and hospitalisation 
data using AIHW National 
Hospitality Morbidity data for 1 
July 1998 to 30 June 2000. 
Between 1999 and 2000 the notification rate for measles 
was 0.9 per 100,000. There were 336 notified cases during 
this period. Notification rates were highest in the 0-4 year 
age group (4.3 per 100,000 population) and 15-24 year age 
group (2.0 per 100,000) during this period. Notification 
rates were highest in Victoria, all states and territories 
reported cases of measles during this period. 
During 1998/1999 to 1999/2000, there were 145 
hospitalisations of which complications occurred in 19%. 
Hospitalisation rates were highest in the 0-4 year age 
group. 
24. Brotherton et 
al 
2004/CD 
, 70 
National Epi review of notification data 
from the NNDSS 1 Jan 2001 to 
31 Dec 2002 and hospitalisation 
data using AIHW National 
Between 2001 and 2002 the notification rate for measles 
was 0.4 per 100,000 population. Measles notifications-
2000 (n=107), 2001 (n=139) and 2002 (n=32). 
Notification rates were highest in aqe groups 0-4 years and 
Hospitality Morbidity data for 1 
July 2000 to 30 June 2002 
15-24 years during this period. Victoria had the highest 
notification rate (1.7 per 100,000) and all other states 
reported measles cases. Both ACT and NT did not report 
any measles cases during this period. 
During 2000/2001 and 2001/2002 there were 105 hospital 
separations due to measles and 11 % of these led to 
complications due to measles. Hospitalisation rates were 
highest in the 0-4 year age group. 
25. Brotherton et 
al 
2007/CD 
,83 
National Epi review of notification data 
from the NNDSS 1 Jan 2003 to 
31 Dec 2005 and hospitalisation 
data using AIHW National 
Hospitality Morbidity data for 1 
July 2002 to 30 June 2005. 
Between 2003 and 2005 the notification rate for 
measles was 0.25 per 100,000 population. Measles 
notifications- 2003 (n=93) ;2004 (n=45); 2005 {n=10). 
Notification rates were highest in children < 5 years and 
individuals aged 15-54 years of age. 
Notification rates were highest in SA and the NT (0.65 
per 100,000 and 0.67 per 100,000, respectively). 
Dunng 2002/2003 to 2004/2005, there were 94 hospital 
separations and 21% of separations had complicat ions due 
to measles. Hospitalisation rates were highest in 
individuals < 5 years old and 20-35 years old groups. 
26. Chiu e t a l 2010/CDl ' ' National Epi review of notification data 
from the NNDSS 1 Jan 2005 to 
31 Dec 2007 and hospitalisation 
data using AIHW National 
Hospitality Morbidity data for 1 
July 2005 to 30 June 2007. 
Between 2006 and 2007 the notification rate for measles 
was 0.33 per 100,000 population. Of the 137 cases, 93% 
were confirmed cases. Measles notifications- 2005 (n=10), 
2006 {n=125) and 2007 (n=12).Notif ication rates were 
highest in < 5 years of age. Between 2006 and 2007, 
measles cases were notified in all jurisdictions excluding 
NT. 
138 hospital separations due to measles occurred between 
July 2005 and June 2007. Hospitalisation rates were 
highest in children < 5 years of age in this period. 
Complications due to measles occurred in 16% of hospital 
separations. 
Immunisation Coverage 
Authors Year/Source Locati 
on 
Study Design Results 
27. Mclntyre et al 2000/CDl" National Epi review using data from the 
ABS survey in 1995 and ACIR 
data from 1996-1998. ACIR 
coverage estimates for MMR1 
assessed at 2 years of age (by 3 
month cohort born in children born 
1 January 1996 to 31 March 
1996). The vaccination status of 
each cohort is estimated at 12 
months and 24 months of age. 
Trends in MMR coverage used 
four cohorts of 2 year olds by 
jurisdiction. 
MMR coverage was found to increase in all jurisdictions. 
OLD vaccine coverage estimate was greater than 95 % 
whilst the rest of the states and territories were below 
the target of 95% coverage. 
Underestimates of ACIR coverage is likely by at least 
5%. 
28. Mclntyre et al 2002/CDl" National Epi review using data from ACIR 
data from 31 March 1999 to 30 
September 2001 ACIR coverage 
estimates for MMR1 assessed at 2 
years of age (by 3 month cohort 
born in children born 1 January 
1998 to 30 September 2000). 
Trends in MMR coverage used 
four cohorts of 2 year olds by 
jurisdiction. 
Vaccination coverage of MMR1 at 2 years of age 
increased over the period with South Australia being the 
only jurisdiction to reach the target of 95% coverage 
(2001). 
29. Lawrence et 
al 
2003/ ANZJPH"" National Cross-sectional study of all 
children born 1 Oct to 31 Dec 1995 
who were registered on the ACIR 
on 4 May 2001. Parents of a 
sample of children with no record 
of MMR2 were phone interviewed 
to determine reasons for non-
uptake of MMR2 and to assess 
under-reporting. 
Parents of 22% of children registered on the ACIR as 
not having MMR2 were reported to have been 
immunised before 5 years of age and 42% of children by 
5.5 years of age. Reports from parents identified under-
reporting in the ACIR data and vaccine coverage was 
4.3% higher ( 5 year olds) and 8.2% (5.5 year olds) than 
ACIR coverage estimates Correction of coverage 
estimates resulted in 93% of the group being immunised 
(MMR2). 
Lack of knowledge of the MMR vaccine schedule was 
the most cited reasons to non-uptake of MMR2. 
30. Brotherton et 
al 
2004/CDl" National Epi review using data from ACIR 
data from 31 IVIarch 2001 to 31 
December 2003. ACIR coverage 
estimates for MMR1 assessed at 2 
years (by 3 month cohort born in 
children born 1 January 1999 to 31 
March 2001). Two years of MMR2 
coverage data for six year 
milestone of age were available 
between 31 March 2002 and 31 
December 2003 (by 3 month 
cohort born in children born 1 
January 1996 to 31 December 
1997). 
Between 2001 and 2003, vaccine coverage remained 
stable and approximately 93%. 
Vaccination coverage of MMR2 at age 6 years was 
observed to be steady (slight increase) during this 
period hovering towards 85%. 
31. Brotherton et 
al 
2007/CDI National Epi review using data from ACIR 
data from 31 March 2003 to 31 
December 2005. ACIR coverage 
estimates for MMR1 assessed at 2 
years (by 3 month cohort born in 
children born 1 January 2001 to 31 
March 2003). MMR2 Coverage 
data for six year milestone was 
estimated between 31 March 2003 
and 31 December 2005 (by 3 
month cohort born in children born 
1 January 1997 to 31 December 
1999). 
MMR1 coverage estimates at 24 months of age 
remained relatively stable during this period and was 
below the target of 95% coverage. Timeliness of MMR1 
was measured by jurisdiction for the cohort born from 1 
January 2003 to 31 March 2003. Timeliness in WA and 
the NT were observed to be the poorest in uptake of 
MMR1. By 18 month, all jurisdictions appear to have the 
same cumulative coverage. 
MMR2 coverage also remained steady with coverage 
being approximately 85% during this period. 
32. Hul le ta l 2009/CDl" National Epi review using 2007 data from 
ACIR data. ACIR coverage 
estimates for MMR1 assessed at 2 
years and MMR2 at 6 years of 
age. For 24 month milestone (by 3 
month cohort born in children born 
1 January to 31 December 2005) 
94.1% of children on the ACIR had MMR1 by 24 months 
of age. Tasmania and the NT achieved the 95% target 
whilst WA had the lowest coverage (93%). MMR2 
coverage at 6 years of age was lower with 88.4% of 
children having been vaccinated. Victoria was the only 
state to achieve higher than 90% coverage (90.9%). 
and six year milestone (by 3 month 
cohort born in children born 1 
January to 31 December 2001). 
Trends in vaccination coverage found that there was a 
steady increase in MMR1 vaccine uptake between 31 
Mar 1998 and 30 Sep 2007. Whereas there was a sharp 
increase in MMR2 uptake mid-2006. 
33. Hul letal 2010/CDl''" National Epi review using 2008 data from 
ACIR data. ACIR coverage 
estimates for MMR1 assessed at 2 
years and MMR2 at 5 years of 
age. For 24 month milestone (by 3 
month cohort born in children born 
1 January to 31 December 2006) 
and five year milestone (by 3 
month cohort born in children born 
1 January to 31 December 2003). 
MMR1 coverage in Australia was found to be 94% with 
the ACT and NT being the only jurisdictions to reach the 
target of 95% coverage. The lowest coverage was 
observed in WA (90.8%). 
MMR2 coverage in Australia was found to be 79.8% 
with ACT having the highest coverage of 85.9% and SA 
the lowest (74.7%). 
MMR1 coverage trend appears to be steady since mid-
2002 whilst there was a sharp decrease in MMR2 
coverage at the end to 2007 which was due to the 
change in assessment age 
34. Hull et al 2011/CDl"" National Epi review using 2009 data from 
ACIR data. ACIR coverage 
estimates for MMR1 assessed at 2 
years and MMR2 at 5 years of 
age. For 24 month milestone (by 3 
month cohort born in children born 
1 January to 31 December 2007) 
and five year milestone (by 3 
month cohort born in children born 
1 January to 31 December 2004). 
MMR1 coverage was 93.8% in Australia and no 
jurisdiction reached the 95% coverage target. WA had 
the lowest coverage with 92.9% uptake. 
MMR2 coverage was 83.2% in Australia and SA had the 
lowest coverage of 79.3%. 
Population Immunity 
Authors Year/Source Location Study Design Results 
35. Ferson et 1998/Journal of NSW Population based seroprevalence 62.4% of the 689 study participants provided a blood 
al Paediatrics & Child 
Health'" 
survey using two different enzyme 
immunoassays on plasma in 
children 1-4 years of age between 
February to March 2005. 
sample and of these, adequate plasma remained for 
347 subjects. 80.4% of children were immune. 
36. Causer et 
al 
2000/ Journal of 
Paediatrics & Child 
Health""' 
NSW Analysis of a clustered sample of 
sera in children 18 months- 5 years. 
Seroprevalence was measured 
using enzyme immunoassays 
between 1992 and 1994. 
Adequate plasma remained for 580/726 children 
whose parents agreed to participate in the study. 
Measles immunity was found to be 88.8% and 
documented evidence of measles in 88.4% of 
children. 91.6% of children with documented 
evidence of measles vaccination had detectable 
measles antibody. 
37, Gidding & 
Gilbert 
2001/CDr- National Analysis of a clustered sample of 
sera collected opportunistically 
between July 1996 and November 
1998. Seroprevalence was 
measured using enzyme 
immunoassays. 
2126 sera samples in 19-49 year olds. Immunity was 
highest in subjects born before 1968 (98.3%). 
Immunity was lowest in subjects born in 1994-1998 
(83.6%) and in subjects born in 1974-1980 (88.9%). 
38. Gilbert e ta l 2001/ Epidemiology 
and Infection''-
National Analysis of a clustered sample 
of sera collected opportunistically 
before and after the 1998 
Australian Measles Control 
Campaign. Samples were collected 
2 years before the campaign and 
between January and May 1999. 
4400(1-49 years) and 3000 (1-18 years) samples 
were collected before and after the campaign, 
respectively. Measles immunity in those 1-18 years 
increased from 85% before, to 90% after the 
campaign. The greatest increase was in preschool 
(7%) and primary school (10%) children. 
39. Kelly e ta l 2001/CDl" ' VIC Comparative analysis of blood 
samples in healthy subjects aged 
18-30 years and 312 sera samples 
stored at VIDRL following 
diagnostic testing. Sera from health 
subjects were collected in March 
1999. Immunity was measured 
using a standard enzyme 
immunoassay. 
No significant difference in measles immunity 
between healthy adults and subjects with sera stored 
were observed. 88.4% of individuals born in 1968 to 
1974 were found to be immune to measles whilst 
74.1% born in 1975 to 1981 were immune to 
measles. 
40. Hogg et al 2006/Journal of 
Paediatrics & Child 
Health'"" 
National 
excluding 
NSW 
Analysis of a clustered sample of 
sera of children aged 1-4 years. 
Samples were collected between 
February and April 1995. Immunity 
was measured using an enzyme 
923 subjects provided blood samples and 86% of 
children were immune to measles. Of those who 
were reported to have been immunised against 
measles, 91% tested seropositive. 
immunoassay. 
41. Kelly e ta l 2007/ BMC Public 
Health" 
VIC Population based seroprevalence 
survey in young adults (20-34 years 
old) using enzyme immunoassays 
in 2002. Results were compared to 
the 1999 Victorian state 
serosurvey. Evaluation of the young 
adult MMR campaign compared 
results from the Victorian results of 
the two national serosurveys in 
1996-1999. 
No significant change was observed in immunity in 
young adults following the young adult MMR 
campaign (83.9% before and 85.5% after the 
campaign) in the state serosurveys. 
The Victorian component of the national serosurveys 
found a significant decline in immunity (91% before 
and 84.2% after the campaign). 
Estimation of R 
Authors Year/Source Location Study Design Results 
42. Maclntyre et 
a! 
2002/IJID" National Mathematical modelling to 
calculate R used serosurvey 
results before and after the 
Measles Control Campaign from 
subjects 1-49 years of age and 
vaccine coverage estimates 
Before the campaign R was estimated to be 0.90 
After the campaign R was estimated to be 0.57 
ACIR data suggested that R would exceed 1 by 
2007-2008 nationally and sooner in some regions of 
Australia. 
43. Maclntyre et 
al 
2003/ NSW 
PH Bulletin"" 
NSW Mathematical modelling of 
vaccine coverage was used to 
predict measles control in 2001 
for the doses given at 12 months 
and four years by divisions of 
general practice. Serosurvey data 
was used to estimate 
susceptibility. Susceptibility in 
some age-specific cohorts was 
estimated by coverage and 
vaccine efficacy. The average, 
best and worst R values over time 
were calculated by division of 
By the age of 5, 11 % of children had not received a 
dose of MMR, and 35% had only received a single 
dose. 
In inner Sydney, the average R value was projected to 
exceed 1 in 2003 compared to the average R values 
in outer Sydney and South and West NSW exceeding 
1 in 2005. Northern NSW was observed to have the 
best measles control with the average R value 
estimated to exceed 1 in 2006. 
general practice if vaccination 
coverage remained the same. 
44. Becker et 
a r " 
2005/ANZJPH VIC Mathematical modelling was used 
to estimate the probability of R 
exceeding 1 using Poisson 
offspring and geometric 
distributions. Outbreaks that were 
notified between 1998 and 2003 
were used. 
The probability that R exceeds 1 was found to be 
0.044 under the geometric model and 0.026 under the 
Poisson offspring model. 
Individuals aged 19 to 32 years and children < 2 years 
were identified as the most susceptible populations. 
45. Gidding et 2007/ Vaccine National Mathematical modelling of 
vaccine coverage was used to 
calculate R and predict R until 
2012. 2002 serosurvey data was 
used to estimate susceptibility. 
Comparison of serosurvey results 
were conducted with previous 
serosurveys. Susceptibility of new 
birth cohorts were projected using 
vaccine coverage. 
2002 population seroprevalence was found to be 
significantly lower (93.9% versus 95.0%; p = 0.004) 
than the estimate from the first serosurvey (1996-
1999). 
R was calculated to be 0.69, predicted to remain 
below 0.8 between 2003 and 2012 however an 
upward trend was predicted to occur after 2010. 
46. Woode ta l " " ' 2009/ Vaccine National Modelling was used to estimate R 
using a contact matrix based on 
UK data to include patterns of 
contact in the community in 
addition to serosurvey data and 
vaccine coverage data if MMR2 
was moved from 4 years to 18 
months. The effect of this shift 
was modelled on population 
susceptibility. 
R was predicted to remain below 1 until 2028 and be 
slightly lower if MMR2 is given at 18 months. 
If 6% of vaccinated who initially seroconvert and then 
became susceptible after 10 years, R was estimated 
to exceed 1 past 2015 for both schedules. 
R was estimated to remain below 1 until 2028 if the 
one MMR dose coverage of 96%. 
Measles susceptibility was predicted to reduce 
considerably in the 2-4 year age group and reduce 
slightly in the overall population if the MMR2 was 
brought forward to 18 months. The model suggests 
that the long-term trend for susceptibility is increasing. 
Circulating measles genotype 
Authors Year/Source Location Study Design Results 
47. Chibo et 
al 
2000/ Journal of 
General 
Virology" 
VIC Molecular epidemiological study 
conducted between 1973 and 
1998. 
35 wild-type measles viruses were identified however the 
continuous replacement of genotypes without temporal 
overlap suggests that transmission of an indigenous 
genotype of measles in Australia has ceased. 
48. Chibo et 
al 
2002/ Emerging 
Infectious 
Disease''^ ^ 
QLD& VIC Short report of a novel genotype 
identified in Australia in 1999. 
A novel genotype of measles (G3) was identified in 1999 
and found to be circulating in Queensland. Importation of 
this genotype was also observed following measles 
cases among refugees from East Timor. 
49. Chibo et 
al 
2003/ Virus 
Research'-
VIC, NSW, 
QLD, N T & 
WA 
Molecular epidemiological study 
conducted between 1999 and 
2001. 
9 different genotypes of measles were identified including 
1 new genotype. There was no evidence of a circulating 
indigenous genotype in Australia. Young adults appeared 
to be the highest risk of infection. Most index cases were 
found to acquire infection from overseas. 
Discard rate 
Authors Year/Source Location Study Design Results 
50. Wang, Andrews & 
Lambert 
2006/ Bulletin of WHO"" VIC Epidemiological review 
of measles notifications 
between 1998 and 
2003. Discarded 
notifications during 
epidemic and 
interepidemic periods 
were used to calculate 
discard rates. 
Discarded measles notifications were estimated to 
be 41% (422) during interepidemic periods and 
59% (608) during epidemic periods. Highly 
sensitive algorithms of sentinel measles cases 
were developed to detect sentinel cases during 
interepidemic periods potentially saving the 
resources required to perform enhanced 
surveillance on a high number of discarded 
notifications. 
51. Wange ta l 2007/ Epidemiology & 
Infection'" 
VIC Epidemiological review 
of measles notifications 
between 1998 and 
2003. 
Seventy two per cent of measles notifications were 
found to be discarded after testing. The median 
annual discard rate was calculated to be 2.9 per 
100,000. The annual rate of discarded notifications 
in Victoria was above the minimum recommended 
standard. The annual rate of discard was higher 
during epidemic periods compared to 
interepidemic periods and infants < 1 years of age. 
Surveillance 
Authors Year/Source Location Study Design Results 
52. Person et al 1 9 9 5 / M J A " NSW Case survey between December 
1990 and August 1993 
49 cases that had no/not yet been serologically conf i rmed 
but clinically diagnosed with measles were assessed. A 
clinical diagnosis was found to have a false positive rate of 
51%. Of subjects confirmed with measles, a cough and 
febrile on the day of rash onset were more likely than 
individuals with no definite diagnosis. 
53. Lambert 1998/CDr*" ' VIC Epi review looking at notification 
and laboratory testing data for 
measles and public hospital 
discharge codes between 1992 and 
1996. 
Notification data- The notification rate of measles 
decreased in the five year period. Notification rates were 
highest for children below the age of five years. Lab 
confirmation was received for 16.2% of notifications. 
Lab testing- 11 % of tests performed for measles were 
positive with the highest proportion positive in 1993 and 
1994. 
Hospital data- 102 discharges with a primary 
diagnosis relating to measles 
54. The Enhanced 
Measles 
Surveil lance 
Working Party 
1999/CDl' ' " VIC Surveillance summary of the 
implementation of an enhanced 
surveillance system for measles in 
1997-1998. Attempts to interview all 
notified case of measles (or 
guardians) through a structured 
telephone questionnaire were 
made. Serological samples were 
collected at the case's home by a 
paediatric phlebotomist. 
There were 317 notifications of measles during this t ime 
period. After the introduction of the phlebotomy service, 
serological confirmation for all notifications increased from 
69% (July - Dec 1997) to 90% (July-Dec 1998). The 
median delay between illness onset and notification was 7 
days and the median t ime from notification to specimen 
collection was 1 day (July 1997-December 1998). Data on 
immunisation status was obtained in 97% of the 317 
notifications of measles. 
55. Heath et al 1999/CDl ' ' " National Surveillance plan To prepare for measles elimination, a number of 
recommendations were made including: 
Revising control targets (vaccination coverage and 
population immunity) to align with ability to 
achieve elimination 
Develop standardised, sensitive and simple case 
definitions 
All suspected measles cases should undergo 
serological testing. Positive serological results 
from a sporadic case should be confirmed at a 
reference laboratory. 
Specimens to culture at least 2 cases in an 
outbreak should occur to allow for genotyping 
Uniform case investigation and consistent data 
collection (including vaccination status), 
investigation of measles outbreaks 
Active surveillance and standard indicators to 
monitor the quality of surveillance data 
Enhancing AEFI surveillance 
Conducting national serological surveys 
56. Lambert at al 2000/MJA" VIC Case series using enhanced 
measles surveillance data between 
July 1997 and 1998 (interepidemic 
period). 
In the six months preceding July 1997, 23% of notified 
measles cases had sera collected. Following the 
employment of a paediatric phlebotomist, 81% of measles 
cases had their sera collected (July 1997-Dec 1998). Of 
these samples, 19% were lab confirmed measles; the 
remainder were found to be human parvovirus or rubella. 
This report highlighted the importance of a lab confirmed 
diagnosis of measles particularty during an interepidemic 
period. 
57 Brotherton 2000/ NSW 
PH Bulletin'" 
NSW Epi review of measles notifications 
and hospital separations between 
1991 and 2000 
6390 measles cases were reported during the 10-year 
period of which 18.5% were lab confirmed. The proportion 
of lab confirmed cases as lowest in 1991 (4%) and highest 
in 2000 (61%). The highest number of notifications 
occurred in 1993 (2348) and the lowest in 1999 (32). Most 
notifications were reported in children less than 5 years of 
age. 431 Hospitalisations occurred during calendar year 
from 1994 to 1999 and 3 deaths were recorded. 
58. Durrheim & Speare 2000/CDI National Editorial The authors note the importance of enhanced surveillance 
of measles during a measles elimination phase. 
Specifically, a standardised, highly sensitive case 
definition that is not ambiguous. 
59. Turnbul letal 2001/Bulletin 
of WHO-"' 
National Evaluation of the 1998 Measles 
Control Campaign. Overall 
coverage of MMR was measured in 
Over 1.33 million children (5-12 years old) were 
vaccinated at school An estimated 1 7 million doses were 
administered during the campaign. Prior to the campaign 
children < 7 years of age using 
ACIR data. ACIR data was also 
used to identify pre-school children 
whose first dose of MMR was 
overdue and reminder letters sent. 
Effect of letter measured by 
checking ACIR data and random 
telephone interviews. A cluster 
sampling method of primary 
schools was also used to measure 
coverage. 
Data on adverse events 
following immunisation (AEFIs) 
during the campaign were obtained 
from three sources. Immunity was 
estimated by serosurveys 
conducted before and after the 
campaign. Incidence of disease 
was measured using NNDSS data 
immediately after the campaign { 
Jan-June 1999) 
84% of school children were immune to measles and after 
the campaign, this increased to 94%. Among pre-school 
children, 82 % were immune to measles prior to the 
campaign and 89% were immune after the campaign. 89 
AEFIs were reported during the campaign (5 per 100 000 
doses). A marked reduction in measles incidence 
immediately after the campaign was observed in the age 
groups targeted. 
60. Lawrence et al 2001/GDI' VIC Surveillance report. 
Data from the Victorian Inpatient 
Minimum Dataset between 1 Jan 
1997 and 30 June 1998 was 
compared to the Victorian 
enhanced measles surveillance 
database. Hospital case notes of 
measles cases hospitalised 
however not entered in the 
surveillance dataset were examined 
to determine whether these cases 
met a lab or clinically diagnosis of 
measles. 
1 case was lab confirmed and 2 cases were clinically 
diagnosed with measles. These patients were not notified 
to the health authorities highlighting inadequacies in 
notification of measles by hospital staff. 
61. Gidding 2005/Epidemio 
logy 
Infection"" 
National Epi review of measles surveillance 
data between 1993 and 2002 
Reduction in measles notification and hospitalisation rates 
started to decline following the introduction of the second 
dose of MMR. A peak was noted to have occurred in 1997 
due to an outbreak. Notification rates among 10-19 year 
olds (targeted in the campaign) declined the most and this 
was also reflected in hospitalisation rates. In 1998, the age 
of second dose was lowered to 4 years and notification 
and hospitalisation rates were further reduced. The 
highest notification rates were observed in children < 5 
years however notifications among young adults were 
increasing 
Elimination 
Authors Year/Source Location Study Design Results 
62. Roche, Spencer & 
Merianos 
2001/CDl''"' National Editorial The authors concluded that if the criterion for elimination 
of measles was based on the end of an endemic 
circulating genotype of measles, Australia has achieved 
measles elimination. 
63. Kelly etal 2009/ Eurosurveillance''" National Perspective Key elimination criteria are considered by the authors- 1. 
Molecular evidence that no circulating endemic genotype 
of measles for at least one year 2.Vaccine coverage of 
one dose MCV is maintained at 95%. The authors 
propose that elimination status should be reviewed 
annually and that four principles should guide the 
development of formal declaration of measles elimination: 
1. Elimination criteria should be met by countries 
that have eliminated measles 
2. Elimination of measles should not be defined by 
quality surveillance criteria 
3. Elimination criteria should quality surveillance 
criteria 
4. Elimination criteria should be standard across 
WHO regions unless for good reason 
64. Heywood et al 2009/ Bulletin of WHO' National Epi review The authors describe the WHO criteria for measles 
elimination and demonstrate that Australia is not fulfilling 
these criteria. They argue however that specific criteria 
have been met to justify the formal declaration of measles 
elimination and provide evidence to support this. 
65. Kohlhagen, Massey 2011/WPSAR"" NSW Surveillance 63 notifications were identified in the region and six of the 
& Durrheim Project between 
June 2006 and 
June 2008 
ten measles indicators established by the WPR of WHO 
for elimination were met. Three were not applicable and 
two doses of MCV coverage was found fell below the > 
95% indicator (91.9%). 
Vaccine Effectiveness 
Authors Year/Source Location Study 
Design 
Results 
66. Patel & Lush 1998/ANZJPH'-' NT Retrospective 
cohort 
Vaccine effectiveness was measured during an outbreak 
in Alice Springs in 1994. There were 109 individuals that 
were eligible (children aged 9 months and 10 years 
residing in a particular remote community) to participate in 
the study. 108 children were immunised and 7 developed 
measles. . Overall vaccine effectiveness was 93.5% (95% 
CI 86.7%-- 96.8%). Vaccine effectiveness was 92.2% 
(95% CI 83.2—96.4%) in children vaccinated < 12 
months compared to 96.8% (95% 01 77.8—99.5%) in 
children vaccinated > 12 months. However, this difference 
was not statistically significant 
67. Sheppeard et al 2009/CDr'''' NSW Retrospective 
cohort 
Vaccine effectiveness was measured during a NSW 
outbreak in 2006. There were 33 cases aged 12 months 
to 7 years and of these, 6 received at least one dose of 
MMR. The age adjusted vaccine effectiveness for one 
dose of MMR was 96% (77.8%- 99%). 
68. Shiell et al 1998/ANZJPH National Decision-
analytic model 
to estimate cost 
effectiveness of 
outbreak control 
procedures. 
In a hypothetical scenario of an outbreak occurring in a 
primary school (5—10 years of age) setting of 500 
students and their younger siblings, 6 control strategies 
and their cost-effectiveness were examined. Vaccinating 
only unvaccinated students would lead to $32.90 cost to 
prevent one case whilst if you were to also vaccinate 
siblings all siblings > 6 months irrespective of vaccination 
status, the cost per case prevented was estimated at 
$6795.70. Vaccinating all school children irrespective of 
vaccination status would cost $836.00 to prevent one 
case. 
69. Rosewell et al 2010/CDl'"' NSW Retrospective 
cohort 
328 GPs participated in the study to measure 
awareness of a measles outbreak and the impact of 
receiving a faxed alert from the health department or the 
Australian General Practice Network. GPs were more 
likely to be aware of a measles outbreak when sent a fax 
alert by the health department (RR 1.18; 95% CI 1.02— 
1.38) and report that susceptible staff were offered MMR 
vaccine during the outbreak (RR 1.55; 95% CI 0.99— 
2.45) than those not sent an alert. They were also more 
likely to isolate patients with suspected measles (RR 
3.30; 95% CI 1.83—5.97) and notify suspected cases (RR 
4.26; 95% CI 1.93—9.41). 
70. Jayamaha et al 2012/Joumal of Clinical 
Virology 
NSW Retrospective 
descriptive 
study 
Between February and May 2011, 34 individuals were 
suspected of measles and 16 cases were confirmed at 
SEALS. The mean age was 22.4 years (range 1-35 
years). 11 of the cases were young adults. Two cases 
were acquired overseas there was one hospital based 
cluster whilst the remaining were community based. The 
most common genotype was D9 (11 cases). One case 
was fully vaccinated by age. 
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Background: Measles 
• Paramyxovirus 
Highly infectious 
Clinical signs- fever, cough, coryza. conjunctivitis, 
maculopapular rash 
Complications 
Rare disease in Australia 
Elimination since 2005' 
B a c k g r o u n d : R e p r o d u c t i o n n u m b e r 
• Elimination 
• Eradication 
• Reproduction number(R) 
R > 1: Epidemic 
R= 1: Endemic 
R < 1 maintained: Elimination 
Measles case definition 
Laboratory definitive evidence 
OR 
Clinical evidence ( generalised maculopapular rash 
lasting three or more days and fever at the time of rash 
onset and cough or coryza or conjunctivitis or Koplik 
spots) and epidemiological evidence 
Aim 
To examine the current ep idemio logy of 
meas les and to provide ev idence that 
meas les e l iminat ion is being mainta ined in 
Austra l ia 
Methods 
• Measles notifications National Notifiable Disease 
Sun/eillance System (NNDSS) 
• Trends (2000-2011) 
• Estimation R 
Data fields used 
• Importation status (N N DSS 2008-2011) 
• Outbreak reference number (N N DSS 2009-2011) 
Algorithms developed where data fields missing 
Methods- Estimation of R 
1 Proportion of imported cases (2008-2011) 
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Resul ts : Meas les no t i f i ca t i on rates by year of d i a g n o s i s . 2000-
2011 
Results: Estimation of the reproductioii number (R) of measles by year 
12008-2011) 
t ) to 
MM 2009 m o 2011 
Resul ts : E s t i m a t i o n of the r e p r o d u c t i o n n u m b e r (R) o f meas les 
(2009-2011) 
Interpretation of findings 
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Background 
in 2005. the World Health Organisation Regional Office for the Westerr* Pacific (WPRO) set 2012 
as the target year to eliminate measles in the region.' Based en several criteria set by WPRO, 
iludmg maintenance of a reproduction number (R) below 1, indigenous transmission of measles 
s argued to have ceased in Australia since 2005.^ However, other WPRO criteria, such as very 
low incidence and meeting specific surveillance cntena have not been met. 
Aim 
To examine recent trends in measles notifications 
and estimate R using routinely collected 
surveillance data in order to provide evidence that 
measles elimination is being sustained in 
Australia. 
Methods 
Measles surveillance data obtained from the National Notifiable Disease Surveillance System were used to: 
- Examine trends (2000-2012) in notifications 
- Estimate R (2009-2011) based on: 1) Proportion of imported cases 
2) Distribution of outbreak sizes (and a sensitivity analysis of outbreaks 2 3 cases) 
3) Distribution of generations of spread 
R, the average number of secondary cases from an infectious case, can be used to monitor measles elimination. R is required to be maintained below 1 to 
meet cntena for elimination. Completeness of data fields required to estimate R were assessed and where incomplete, algorithms were developed to 
determine if these cases belonged to another outbreak. Analyses were performed using the statistical software Stata ® version 12 and MatLab^. 
Results Figure 1. The fluctuating annual measles notification ratesin Australia, 2000-2012 
Between 2009 and 2011, there were 367 notifications of measles, 
35% ( n : l 2 8 ) of cases were acquired overseas. Only 77%(ns283) 
of cases had complete information about whether they belonged 
to an Identified outbreak. Following an algorithm to identify 
possible clusters, a further 5% (n=19) were considered to be part 
of an outbreak. Overall, there were 55 outbreaks (range:2-25 
cases) and 76 sporadic cases during 2009-2011 The longest 
duration of an outbreak was estimated to be 7 generations (67 
days). 
Figure 2. R estimates remained Delowi for all three methods, 2009-2011 
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Table 1 R esllmoles remained be lowl for all three methods by Indlvldualyear. 2009-2011 
+ + 
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•Genaralion 
ktetriod* 2009 2010 2011 
R 95%ConMence Interval R 
05S Confklerce 
mten/si R 
9SS Confidence 
Interval 
Propoojon of imported 066 0 57-0 76 055 0 43-0 67 068 0 62-0 75 
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$IZ«S 
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Conclusion 
Even though Australia did not meet the WPRO cnteria for measles elimination during (his penod 
(annual notification rate was > 1 case per million for most years and other required sun/eillance 
data such as testing discard rates are not routinely available); R was shown to be substantially 
below 1 by a range of different methods, supporting the contention that elimination continues to be 
maintained. This is consistent with the 2002 serosurvey results which estimated R to be 0,69.' 
These results provide evidence that measles elimination is being maintained in Australia and are 
further supported by high measles vaccine coverage rates and the absence of an endemic 
circulating genotype in Australia for many years,^ 
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SECTION 1: CONTACT DETAILS 
Surname: 
First name: 
Telephone: 
INTERVIEWER SCRIPT: 
"Good morning/afternoon. My name is and I'm calling from the 
Parramatta public health unit in Sydney. I i/i/as hoping to speak with the 
parents/guardian of . I am calling in regards to your child being at 
the emergency department at the Children's Hospital at Westmead in May. Records 
from the emergency department indicate u/as present on 11'" May. A 
number of children who were at the ED on the same day as became 
infected with measles. We are trying to investigate the source of Infection and whether 
there might have been other children who became infected with measles. We would 
like to ask you a few questions, it should take approximately ten minutes to complete. 
All the information we collect is confidential and only authorised public health staff will 
have access to this Information. Would it be possible for you to answer our questions"? 
* If parent/guardian unavailable, ask what is the best time to call back_ 
Verbal consent given for interview/: 
Y e , • 
• 
No 
SECTION 2: PERSONAL DETAILS 
Age: 
Address: 
Immunisation status (measles): _ 
Number/s and age/s of sibling/s: 
"Does attend childcare/preschool"? 
Yes n No I I 
If yes, where (name)? 
SECTION 3: HEALTH INFORMATION 
"How is he/she going"? 
"l-iow long was unwell for after being discharged from hospital"? 
"Did the doctor prescribe any medicine upon discharge"? 
Yes No [ ~ ] 
"If yes, what medicines"? 
"Did he/she get better after taking the medicine"? 
Y e s | ^ N o Q Unsure] | 
"Did get any new symptoms after being discharged from hospital"? 
Y e s | ^ Unsure I | 
"If yes, could you please describe the symptoms"? 
"How long did these symptoms last for"? _ 
"Did you take them to see a doctor or need to return to hospital following his/her ED 
visit"? 
Yes Q N o [ ] Unsure [ ] 
[246] 
"If yes, which doctor/hospital"? 
"Prior to his/her visit on 11"" May. did you visit any other doctor's surgeries or 
hospital"? 
Yes Q N O Q Unsure] | 
"If yes, which doctor/hospital"? 
SECTION 3: POTENTIAL EXPOSURE INFORMATION 
"How long you were in the hospital for on the 11'" May"?_ 
"How long did you wait in the ED waiting room? 
"Thanks for your time to day, would you mind if we contacted you in the future to 
clarifying anything else? Please do not hesitate to contact the infectious disease control 
team at the Parramatta public health unit on 9840 3603 if you have any further 
questions. 
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Abstract 
Introduction 
Primary varicella zoster infection (chickenpox) is a childhood disease that is generally 
mild. Shingles is the reactivation of dormant varicella zoster, most often occurring in the 
elderly. Both conditions may develop complications, leading to severe morbidity and 
mortality. In November 2005, universal varicella vaccination commenced in Australia 
for children 18 months of age, followed soon after by a catch-up program in children 
10-13 years. In 2006, the Communicable Diseases Network of Australia (CDNA) 
recommended that chickenpox and shingles should be nationally notifiable through the 
National Notifiable Disease Surveillance System (NNDSS). By the end of 2008, all 
jurisdictions except NSW had adopted these recommendations. The aim of this 
evaluation was to determine whether the NNDSS for varicella zoster virus 
(NNDSSVZV) is achieving its objectives, primarily whether the NNDSSVZV is 
measuring the impact of the vaccine program. 
Methods 
Data were obtained from the NNDSS (2006-2012) for varicella zoster (chickenpox), 
varicella zoster (shingles) and varicella zoster (unspecified) and stakeholders were 
consulted. The system attributes were examined using evaluation frameworks for 
surveillance systems published by United States Centers for Disease Control (CDC) 
and Health Canada. The utility of the NNDSSVZV, and the sensitivity, predictive 
positive value, representativeness, data quality, stability, simplicity and flexibility were 
measured. The sensitivity and representativeness of the NNDSSVZV were assessed 
by comparison with the Bettering the Evaluation and Care of Health (BEACH) 
database, the Emergency Department Data Collection (EDDC) data from the NSW 
Ministry of Health and the Paediatric Active Enhanced Surveillance (PAEDS) network. 
Results 
The NNDSSVZV has a number of shortfalls which limits the utility of the system. It is 
unable to meet the objective of measuring the impact of the vaccine given that 
jurisdictions (except South Australia) began notifying disease after the implementation 
of the varicella vaccine program. The case definition for chickenpox and shingles is not 
being consistently applied among the jurisdictions, which affects the ability to interpret 
the data. Due to chickenpox being a generally mild illness, the sensitivity for individual 
notifications, overall is poor. As some jurisdictions only include laboratory notifications, 
the overall sensitivity is likely to be even lower. The sensitivity of the NNDSSVZV for 
trends appears sufficient, when comparing the system to other data sources, although 
this varies by age group. Despite NSW not notifying chicl<enpox or shingles, the 
NNDSSVZV appears to be representative of disease patterns occurring in NSW 
emergency department presentations. One of the major strengths of NNDSSVZV is 
that it belongs to the NNDSS, a well-established surveillance system, and hence is 
stable, simple and potentially flexible. The data quality of the NNDSSVZV is high for 
notifications of chickenpox in patients less than seven years however could be further 
improved by conducting follow-up in all notifying jurisdictions. Data quality is not as 
good outside this age group. Among stakeholders, the acceptability of the system 
varies and the usefulness of system is a concern with suggestions that other 
surveillance systems may be more useful in meeting the objectives of varicella 
surveillance. 
Conclusion 
The NNDSSVZV in Australia does not appear to meet its objective of measuring the 
impact of universal varicella vaccine. Although notifications on chickenpox and shingles 
are captured by the current system, the large proportion of unspecified disease limits 
the utility of the system. The lack of resources among jurisdictions is a major barrier as 
follow-up cannot be conducted, therefore compromising the sensitivity and data quality 
of the NNDSSVZV. Review of the case definition and standardised reporting is 
recommended to ensure consistency among jurisdictions, which would improve the 
ability to interpret the data. 
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Prologue 
My role 
I was responsible for reviewing the literature, formulating an evaluation plan and 
developing structured questionnaires for jurisdictional and Commonwealth 
stakeholders. I communicated with stakeholders to clarify responses to the 
questionnaire and requested enhanced data. I also liaised with researchers and 
stakeholders to obtain data from other sources. I analysed data from the National 
Notifiable Disease Surveillance System (NNDSS) and Paediatric Active Enhanced 
Disease Surveillance (PAEDS) and calculated rates obtained from the NSW Ministry of 
Health Emergency Department Data Collection (EDDC). I wrote a report on the 
evaluation, and with guidance from my supervisors developed suggested 
recommendations from the evaluation. 
Lessons learned 
I had always envisaged that the evaluation of a surveillance system component of the 
Master of Applied Epidemiology (MAE) program would be straight-fonward and 
relatively quick. Unexpectedly, this project was perhaps the most challenging and time 
consuming of all my projects. 
In hindsight, there were a number of things I would have done differently. However, 
despite the challenges and frustrations of this project, I have learnt so much from the 
evaluation. 
Firstly, as with previous projects, I learnt the importance of formulating specific, 
measurable, achievable, realistic and time-based (SMART) objectives for the 
evaluation in addition to considering why this project was important. The project 
appeared large and the time to complete it short. Through direction and support from 
my supervisors, I learnt how to examine the available data sources systematically and 
how these sources could be useful in the context of the national surveillance system. 
I learnt that every analysis and its interpretation in this chapter needed to be relevant to 
answering the objectives of the evaluation or enhancing the reader's understanding of 
varicella to justify its inclusion in the chapter. Being exposed to numerous data 
sources also allowed me to gain an understanding of the limitations of each data 
source. 
I also learnt how to use SurveyMonkey® (https://www.survevmonkev.com/, online 
questionnaire software) which included developing an evaluation questionnaire and 
collecting and analysing the data. 
An important lesson learned was the use of a framework to guide an evaluation. 
Sometimes however not all evaluations can easily be 'moulded' to a framework, thus I 
considered two frameworks during this evaluation. 
I collaborated with many stakeholders during this project. This enabled me to improve 
my communication skills through discussions about the evaluation. Liaising with other 
researchers from the Family Medicine Research Centre (FMRC) and Paediatric Active 
Enhanced Disease Surveillance (PAEDS) to obtain their data improved my 
understanding of the nuances of the data from both sources. 
Public health act ion 
This evaluation has resulted in the formulation of numerous recommendations to assist 
the varicella surveillance system in meeting its objectives and improve the system's 
attributes. These recommendations will be fonwarded to CDNA to consider and the 
report in the chapter will be sent to jurisdictional and Commonwealth stakeholders. A 
related manuscript will also be submitted to Communicable Diseases Intelligence for 
wider distribution to the public health community in Australia. 
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Introduction 
Varicella zoster virus (VZV) is one of eight herpes viruses that belongs to the 
Herpesviridae family. Primary infection with VZV manifests as varicella (chickenpox). 
Herpes zoster (shingles) occurs following endogenous reactivation of VZV from its 
latent state in the sensory nerve ganglia of the dorsal root.^ 
Clinical features 
Chickenpox typically affects young children and presents with a generalised pruritic 
rash, mild headache, low-grade fever and malaise, the rash is commonly the first sign 
of disease in children.^ In adults, a prodome consisting of fever and malaise may 
precede the chickenpox rash by approximately 24-48 hours.^ The lesions often appear 
in crops, initially on the head, and then on the trunk and later the extremities. Lesions 
evolve rapidly to papules, then vesicles, before erupting to form pustules which 
subsequently crust. Most crusts disappear within 20 days of the onset of prodrome. ' 
The most common complication in children <5 years is secondary bacterial infection 
and in adults S20 years is pneumonia."^ Adults, immunocompromised individuals and 
neonates are particularly susceptible to complications. Varicella infection in pregnant 
women can result in intrauterine transmission to the foetus or neonate and lead to 
congenital varicella syndrome or neonatal varicella.® Rare complications of chickenpox 
include encephalitis, aseptic meningitis and cerebellar ataxia.^ 
Shingles is more common in the elderly and can occur decades after primary infection 
with chickenpox.^ Disease generally presents as pain and parathesiae along the 
dermatome corresponding to where reactivation occurs, followed by vesicular eruption 
2 - 3 days later. Vesicles are often unilateral and continue to form for approximately 3-5 
days.'' Complications of shingles occurs in approximately 13-26% of patients, with the 
most common being postherpetic neuralgia; a painfully debilitating condition which 
greatly reduces the quality of life of those a f f e c t e d . O t h e r complications include 
encephalitis, myelitis, cranial-nerve palsies and peripheral-nerve palsies.^ 
Pathogenesis 
Chickenpox is highly contagious. The virus is transmitted through aerosol and droplets 
from the nasopharynx during the prodrome and from skin lesions for a period of 5 - 7 
days after rash onset. The Incubation period is 14-15 days (range 10-21 days)^ and 
attack rates among susceptible household contacts have ranged from 61-100%.^ 
Shingles occurs primarily due to a decline in cellular immunity to VZV. Risk factors 
include aging, immunosuppression or having chickenpox <12 months of age.'° 
Transmission of VZV from lesions via contact and airborne route can occur and lead to 
primary infection in susceptible individuals. Infectiousness begins one day prior to rash 
onset and remains until lesions have crusted over (usually five days), but may be 
prolonged in individuals with altered immunity.° 
Diagnosis 
Chickenpox is mainly diagnosed on clinical grounds; namely the characteristic 
vesicular rash. This diagnosis can be further supported by a history of recent exposure 
to a varicella (or herpes zoster) case.^ ' " Similarly, herpes zoster diagnosis is primarily 
through clinical diagnosis of characteristic skin eruptions accompanied by pain.^ 
When there is uncertainty of a diagnosis solely on clinical and epidemiological grounds, 
a laboratory diagnosis can be conducted, but depends on the availability of a clinical 
specimen (primarily skin lesions). Methods include: culturing the virus; identifying viral 
DNA through polymerase chain reaction (PGR); antigen detection by 
immunofluorescence (IF); and serology tests of Immunoglobulin (lg)G, IgM and IgA 
antibodies through enzyme linked immune-sorbent assay (ELISA).^^ 
Treatment and prevention 
Symptomatic management is the mainstay for chickenpox and shingles treatment as a 
curative treatment for both conditions does not exist. In some instances acyclovir is 
recommended for chickenpox." In comparison, all patients with shingles are 
recommended antiviral treatment within 72 hours of rash onset. 
Prevention options following significant exposure to an infectious chickenpox or 
shingles case is limited to varicella vaccine or zoster Immunoglobulin (ZIG), depending 
on the time since exposure. Varicella vaccine should be administered within five 
(preferably three) days of exposure to non-immune children and adults who have had 
significant exposure to chickenpox or shingles. ZIG should be given within 96 hours 
(but some efficacy has been reported up to ten days) of exposure'" and is prepared 
from fiuman plasma containing high VZV antibody titre. ZIG can prevent and attenuate 
disease among neonates, immunosuppressed children and pregnant women. ' " 
The vaccine 
In 1974, the first live attenuated monovalent vaccine (Oka strain) was developed'^ and 
to date, is the only strain available (although genetic differences exists between 
vaccines).' Initially, one dose of vaccine was recommended in the United States (U.S.) 
in 1995. A two-dose schedule however was recommended following a number of 
varicella outbreaks,'®"'® and of post-licensure trials which showed that vaccine 
effectiveness was significantly higher with two doses (98%) compared to one dose 
(94%).^° Findings that the risk of breakthrough disease was higher In individuals 
administered only one-dose further supported the two-dose recommendation.^' 
The vaccine program in Australia 
In Australia, two varicella monovalent vaccines have been registered for use in children 
since 1999 (Varilrix® and Varivax®).'" In 2003, the Australian Technical Advisory Group 
on Immunisation (ATAGI) recommended a single dose of vaccine for children 18 
months of age and children 10-13 years of age with no history of vaccination or clinical 
disease. In November 2005, the national funding of one dose of vaccine for children 
18 months of age commenced The following year, a national catch-up program for 
children 10-13 years of age with no history of vaccination or clinical disease was 
introduced. ^^  Each jurisdiction decides the school grade(s) when vaccines are offered, 
guided by the national recommended age for vaccination.^' Both the primary and 
catch-up dose continue to be funded under the National Immunisation Program (NIP).^" 
Although a two-dose schedule is currently recommended in Australia, it is not funded 
under the NIP schedule.'" On 1 July 2013, a quadrivalent combination vaccine 
containing measles, mumps, rubella and varicella (MMRV) was added to the NIP for 
children aged 18 months.^® 
The zoster (shingles) vaccine was licensed in Australia in 2006 and is recommended 
for use in adults aged 60-79 y e a r s . T h e r e has however, been a shortage of this 
vaccine and it only recently became available in Australia.'" Given this, the effect of the 
vaccine using surveillance data could be estimated with pre- and post-vaccine 
surveillance data collected-an important impetus for the passive surveillance of 
shingles. 
Passive surveillance of varicella zoster 
Despite this incentive for the passive surveillance of varicella zoster, there has been 
much debate on whether to include VZV onto the notifiable disease list in Australia.^''^® 
A nnajor impediment to the system is the difficulty in calculating the incidence of 
chickenpox given that only a small proportion of cases seek medical attention. In 2002 
however, three years before the commencement of the varicella vaccination program. 
South Australia (SA) became the first jurisdiction to make VZV infection a notifiable 
disease.^® 
Four years after being notifiable in SA, the Communicable Disease Network of 
Australia (CDNA) included varicella zoster (chickenpox), varicella zoster (shingles) and 
varicella zoster (unspecified) in the National Notifiable Disease List. By the following 
year, all states and territories (except Victoria and New South Wales) included varicella 
zoster in their public health legislation as a notifiable disease following the 
recommendation by CDNA.^° In 2008, Victoria adopted CDNA's recommendations and 
VZV became notifiable. Thus, 2009 was the first complete year where data were 
transferred to the National Notifiable Diseases Surveillance System (NNDSS) from all 
jurisdictions except New South Wales (NSW), the only jurisdiction in Australia where 
VZV continues not to be notifiable.^® 
For the purposes of this evaluation, from this point forward, the passive surveillance 
system for VZV at a national level will be described as the National Notifiable Disease 
Surveillance System for Varicella Zoster Virus (NNDSSVZV). 
Objectives of varicella surveillance 
A joint National Immunisation Committee and CDNA Jurisdictional Executive Group 
committee was established in 2005 and given the task of managing the implementation 
of varicella surveillance. This encompassed establishing objectives of varicella 
surveillance which they formulated and included:' 
o to measure the impact of universal varicella vaccine on the incidence of 
varicella infection in the Australian population; 
o to measure the potential impact of the varicella vaccine program on the 
prevalence of varicella infection among specific populations such as 
unimmunised older children, adults and adolescents and Indigenous children 
and adults; 
o to measure vaccine failure and provide data to measure vaccine effectiveness 
over time by age group; and 
o to monitor possible changes in epidemiology of zoster infections in Australia as 
a result of the varicella vaccination program. 
Alternative data sources 
Given the infancy of the NNDSSVZV, other surveillance systems and data sources 
have been used to assess chickenpox and shingles epidemiology in Australia, mainly 
sentinel surveillance systems (Appendix E1.1). 
Firstly, emergency departments (EDs) are used in some states and territories to 
monitor presentations due to chickenpox or shingles, particularly in NSW where VZV is 
not n o t i f i a b l e . " ' F o r more serious cases requiring hospitalisation, the incidence 
and morbidity of VZV can be estimated using hospitalisation data."-^'' 
Secondly, the Virology and Serology Laboratory Reporting Scheme (LabVISE) has 
collected data since 1982. Laboratories around the country provide voluntarily reports 
on VZV which are collated and analysed quarterly.^® Limitations exist however, as no 
information is collected that differentiates between chickenpox and shingles. Moreover, 
the uncertain validity and inconsistent reporting protocols of participating laboratories 
have been reported.^® 
' CDNA varicella working group- internal discussion document 
[279] 
Thirdly, the Australian Sentinel Practice Network (ASPREN) is a network of general 
practitioners around Australia who report on a number of medical conditions, including 
chickenpox and shingles, on a weekly b a s i s . I n a previous state-based evaluation of 
varicella surveillance in South Australia, it was recommended that collection of 
ASPREN data be terminated as it did not increase knowledge on the impact of varicella 
vaccine on VZV epidemiology.^' Considering that little is known about the population 
presenting to sentinel GP sites, the data collected is of limited use, particularly for 
calculating the incidence of both conditions.^® 
Additionally, active surveillance has been used to monitor severe infection in infants 
and children. Active surveillance of congenital varicella syndrome (CVS) and neonatal 
varicella has existed for many years through the Australia Paediatric Surveillance Unit 
(APSU).^® Monthly report cards are sent to participating paediatricians and child 
health specialists to detect infant cases who match the case definition for the 
abovementioned conditions (Appendix £5.1)."° The ongoing collection of reports at a 
national level has made APSU surveillance an important data source to monitor 
changes in CVS and neonatal varicella, particularly comparing pre- and post-vaccine 
periods.^® The APSU, in collaboration with the National Centre for Immunisation 
Research and Surveillance (NCIRS) coordinates Paediatric Active Enhanced Disease 
Surveillance (PAEDS). PAEDS commenced in 2007 and consists of a network of five 
paediatric teaching hospitals across Australia who participate in reporting any child (1 
month-15 years) who is hospitalised due to varicella.''' 
Public Health Importance 
In Australia, the burden of chickenpox and shingles has been substantial. Prior to the 
availability of vaccine, it was estimated that 250,000 individuals (one birth cohort) 
would be infected with chickenpox each year."^ Chickenpox in Australia was generally 
seasonal, peaking during late winter, spring and early summer."^ Severe disease was 
also observed with an average annual hospitalisation rate of 8.5 per 100,000 
population. Nearly a quarter of these experienced complications; and between 1993 
and 1997, there were 36 deaths reported."" Although chickenpox is known to be more 
severe in adults, hospitalisations were greatest in children 0 - 4 years; however, adults 
60+ years experienced the longest median length of stay in hospital (seven days)."" 
The significant burden of chickenpox can result in substantial economic and societal 
costs. It was estimated that in children <15 years of age, the direct cost of hospitalised 
cases of chickenpox was over 1.9 million Australian dollars per year. However, this did 
not take into account the indirect and social costs of infections, such as a parent's time 
off work."® Given the significant costs of infection, a cost-effectiveness study in 
Australia found that the direct costs of a one-dose varicella vaccine program, 
particularly in infants was less than the direct costs of no vaccine program at all."® 
There has, however, been discussion on whether a one-or two-dose schedule should 
be funded. As previously mentioned, one-dose of varicella vaccine is free in Australia 
under the NIP. Due to the occurrence of breakthrough disease, which can be 
contagious and even lead to large outbreaks,"' a two-dose schedule is recommended 
in Australia but currently not funded.'" An Australian study found that a funded two-
dose schedule would reduce both the Incidence of natural and breakthrough disease 
and thus lead to lower morbidity."" To inform policy on the funding of two-doses of 
varicella vaccine, further epidemiological evidence In Australia is still required, and 
hence it is important to monitor the burden of chickenpox at a national level. 
The burden of disease of shingles has been reported to be even higher than 
chickenpox.®^ Prior to availability of varicella vaccine, there were approximately 
150,000 new cases of shingles per year in Australia.®® Seasonal patterns have not 
been observed in shingles.^ Hospitalisations for shingles occurred most often in older 
adults (mean=68.6 years) and mean length of stay was 12.7 days. In July 1999 to June 
2000 in hospitalised cases where shingles was the principal diagnosis, 51% of cases 
experienced complications and 22 deaths were recorded.®® The severe morbidity of the 
disease has led to high healthcare costs. Between 2001 and 2005, the cost of shingles 
to Australia was estimated to be $19-30 million."® In 1999 alone, around 59 200 of 
shingles cases were treated with antivirals in the community.®® 
Following the availability of varicella vaccine, concern was raised of the change in 
shingles epidemiology following the availability of varicella vaccine. Hope-Simpson first 
postulated that exposure to wild varicella virus boosts the Immune system, and without 
this exposure; may render an individual susceptible to shingles.®" An Australia study 
using general practice data found that there had been a significant Increase in the 
management of shingles between 1998 and 2009.®' In Victoria, hospitalisation rates 
due to herpes zoster appeared to increase between 1998 and 2007 (5% per year); 
however it was not clear what was behind the increase due to the ecological nature of 
the study.®^ Given that shingles is most common In older age groups; the observed 
Increase needs to be considered in the context of Australia's ageing population.®® 
It is clear from what is outlined above, that chickenpox and shingles are of public health 
importance and need to be monitored, particularly in light of the introduction of 
universal varicella vaccine and the more recent availability of zoster vaccine. Given that 
it has been five years since the first complete year of Victorian data was submitted to 
the NNDSS, it is timely to evaluate the performance of the NNDSSVZV. Public health 
surveillance system evaluations are imperative to ensuring that health conditions of 
public health importance are being monitored efficiently and effectively.^" 
Rationale for the evaluation of the NNDSSVZV 
The aim of evaluating the NNDSSVZV was to highlight what (if any) improvements are 
required in monitoring VZV, specifically using varicella zoster notification data from 
jurisdictions. In light of the addition of the MMRV vaccine to the NIP in July 2013, the 
evaluation is timely and will inform the Australia Technical Advisory Group on 
Immunisation (ATAGI) Varicella Zoster Working Party and the CDNA Varicella Zoster 
Working Group. These groups will be considering surveillance of varicella in Australia 
in the context of the change from MMR and MMRV and also the possible public funding 
of zoster vaccine in the future. 
Objectives of the evaluation of NNDSSVZV 
o To ascertain how the NNDSSVZV is performing against the stated CDNA 
objectives of the passive surveillance of VZV; 
o To examine the sensitivity of the NNDSSVZV in comparison with 
hospitalisation, PAEDS and Bettering Evaluation and Care of Health (BEACH) 
data; 
o To assess the representativeness of the NNDSSVZV in comparison with NSW 
ED data; 
o To determine the strengths and limitations of the current NNDSSVZV and 
consider any improvements required; 
o To assess the usefulness of the NNDSSVZV, particularly the degree of public 
health action resulting from data collected by the NNDSSVZV; and 
o To assess other attributes of the NNDSSVZV including data quality, 
acceptability, simplicity, stability and flexibility. 
Methods 
The following evaluation framework was adapted from frameworks for the evaluation of 
health surveillance systems published by the U.S. Centers for Disease Control and 
Prevention (CDCf® and Health Canada.®® 
Stakeholder consultations 
Two electronic self-administered jurisdictional and Commonwealth questionnaires were 
developed on Surveyl\/lonkey®and included a subset of the jurisdictional survey for 
NSW (Appendix E2; E3; E4). In order to maximise response rates, stakeholders were 
followed-up with a telephone interview. One of the main purposes of consulting with 
stakeholders was to gain an understanding of the specific operation of the NNDSSVZV, 
particularly the notification process between jurisdictions and the Commonwealth. 
Document review 
To assess the operation of the NNDSSVZV and system components on a national 
level, NNDSS annual reports were reviewed to determine the operation of the system 
as a whole. 
Data Analyses 
NNDSS data 
NNDSSVZV data for VZV (chickenpox), VZV (shingles) and VZV (unspecified) were 
obtained from the NNDSS database (2006-2012). SA notification data (2002-2005) for 
VZV were obtained from the SA Department of Health. 
PAEDS data 
Data were obtained from PAEDS on cases of hospitalisations due to varicella (2007-
2012). Cases were patients from three tertiary paediatric hospitals in Victoria (Royal 
Children's Hospital), SA (Women's and Children's Hospital) and Western Australia 
(Princess Margaret Hospital). Year of diagnosis of varicella disease (chickenpox or 
shingles), date of birth, postcode and sex were used to examine whether cases were 
notified to the NNDSS; if the data of these variables were identical in both data 
sources, they were assumed to be the same individual. Whether a laboratory test was 
ordered for each case was also obtained from the investigators of the PAEDS study 
group. 
Bettering Evaluation and Care of Healtli (BEACH) data 
Data from the BEACH study (April 1998-March 2013) were obtained on encounters 
that were coded by the International Classification of Primary Care, version 2 as A72: 
Chickenpox and S70:Herpes Zoster.^' New encounters (i.e. the first time a patient 
sought medical care for the problem managed) were collected as well as all total 
encounters (new and old problems managed). The number of varicella zoster tests 
(culture and serology) was collected. Additionally, number of PCR tests ordered was 
obtained for encounters where chickenpox and herpes zoster were managed. 
NSW Emergency Department Data Collection (EDDC) data 
As VZV infections are not notifiable in NSW, ED presentations of chickenpox and 
herpes zoster (1998-2012) based on International Classification of Diseases (ICD)-10-
AM/ICD-10 codes B01 and 802 by age group were obtained from the NSW Ministry of 
Health (1998-2012). Data were collected from 45 NSW EDs that consistently reported 
to the Emergency Department Data Collection (EDDC) during this period. 
The type and timing of data used for each jurisdiction are summarised in Table 1. 
Table 1. Data sources compared by year and jurisdiction, 1998-2012 
Jurisdiction NNDSSVZV 
Notifications 
PAEDS' ' BEACH* ED data 
NSW - - 1998-2012 1998-2012 
VIC 2009-2012 2009-2012 1998-2012 -
QLD 2006-2012 - 1998-2012 -
SA 2002-2012 2007-2012 1998-2012 
WA 2006-2012 2007-2012 1998-2012 -
NT 2006-2012 - 1998-2012 -
ACT 2006-2012 - 1998-2012 -
TAS 2006-2012 - 1998-2012 -
*BEACH year was from April to March 
•OLD joined the PAEDS networl* in July 2012 and was not included in data analysis 
Surveillance System Utility and Attributes 
Utility 
The utility of a system is the measure of the system's contribution in preventing and 
controlling an adverse health-related event. Its utility may also be in identifying the 
importance of an adverse health-related event w/hich previously was not recognised as 
important and or through its contribution to performance measures.®^ 
The utility of the NNDSSVZV was measured by how well it performed against Its 
objectives and the public health action that occurred as a result of the NNDSSVZV. 
Firstly, notification rates from the NNDSSVZV were calculated to determine if the 
impact of the varicella vaccine program could be measured for chickenpox and 
shingles in the Australian population and also among specific populations. Secondly, 
NNDSSVZV data were reviewed to determine whether vaccine effectiveness could be 
measured over time. Additionally, VZV (unspecified) notification rates by age group 
were calculated to assist in conjecturing whether these notifications were chickenpox or 
shingles, based on the known epidemiology of both diseases. Stakeholders were also 
consulted to determine whether they thought the objectives of the NNDSSVZV were 
being met and what public health action had occurred because of the system. 
The following system attributes were selected on the basis of their relevance to the 
objectives of the NNDSSVZV: sensitivity; data quality; representativeness; 
acceptability; stability; flexibility; and positive predictive value. 
Sensitivity 
The sensitivity of a surveillance system refers to the proportion of cases of a health 
event detected by the surveillance system and the system's ability to detect 
outbreaks.®' With no known estimates of the number of chickenpox cases that occur In 
the post-vaccine era, a denominator data does not exist to calculate the sensitivity of 
the NNDSSVZV. A proxy of the measurement of sensitivity of the surveillance system 
was obtained through calculating the proportion of laboratory tests that were requested 
for chickenpox and shingles managed In the BEACH dataset. 
Firstly, rates of ED presentations for chickenpox and shingles per 100 000 population 
in NSW by age group were compared to NNDSSVZV rates. 
Secondly, chickenpox and shingles notification rates from all jurisdictions and at a 
national level (excluding NSW) were compared to SA notification rates. SA was 
considered the 'gold standard' as notifications commenced in 2002. 
Thirdly, chickenpox notifications rates by age group (<1 year; 1 -4 years; 5-9; 10-19 
years; 20-39 years; and 40+ years) were compared to rates of chickenpox and 
shingles managed from the BEACH study and NSW EDDC dataset. Prior to comparing 
NNDSSVZV annual rates with BEACH annual rates, seasonality of disease 
notifications were assessed to see if comparison of BEACH year (April to March) with 
calendar year may impact on the results. 
Additionally, to further determine the ability of the NNDSSVZV to capture severe 
disease, notification rate were compared to national hospitalisation rates for 
chickenpox from an unpublished manuscript.®' Lastly, severe cases of chickenpox 
and shingles in children < 15 years old from the PAEDS dataset were obtained to 
determine whether cases in the PAEDS system were captured by passive surveillance 
and used as an index of sensitivity of severe infection with chickenpox. Chi squared 
tests were used to determine whether a significant difference in proportion of PAEDS 
cases with a positive test result were notified compared to cases with no test result. 
Data Qualitv 
Data quality refers to the completeness and validity of the data in the s y s t e m . T o 
assess the data quality of the NNDSSVZV, completeness of the following fields were 
assessed: demographic data including vaccination status, onset date of symptoms and 
Indigenous status. 
Representativeness 
The representativeness of the system is the ability of it to accurately describe the 
occurrence of disease over time and its distribution by place and p e r s o n . T o 
measure the representativeness of the NNDSSVZV, rates of ED presentations for 
chickenpox and shingles per 100 000 population in NSW by age group were compared 
to NNDSSVZV rates. 
Acceptability 
The willingness of persons and organisations to participate in the surveillance system 
is imperative to the accuracy, consistency and completeness of data.®^ Acceptability 
was primarily determined through stakeholder consultations. However, a measure of 
acceptability was also conducted through the calculation of the proportion of the 
number of VZV unspecified cases over the total number of VZV (chickenpox and 
shingles) cases. In some jurisdictions, clinicians are requested to provide clinical 
information to health authorities following a laboratory notification. Anecdotally, it is 
widely accepted that majority of notifications come from laboratories. It was assumed 
that all notifications would result in efforts by health authorities to contact the clinician. 
And if a case was unspecified, clinicians did not respond to requests by the health 
authority. 
Simplicitv 
Simplicity is defined as the ease of operation and structure of a surveillance system.^^ 
The simplicity of the NNDSSVZV was determined through stakeholder consultations 
and includes responses on the operation of the system and review of NNDSS annual 
reports. The simplicity of the CDNA case definitions for VZV infection were also 
reviewed. 
Stability 
The stability of a system is its reliability and availability.®® To determine the stability of 
the system, relevant stakeholders were consulted. 
Flexibility 
The flexibility of the system is its ability to adapt to changing information needs or 
operational procedures with limited additional time, human resources or funds.®® The 
flexibility of the NNDSSVZV was measured through stakeholder consultations. 
Positive predictive value 
The positive predictive value (PPV) refers to the proportion of reported cases that 
actually have the health-related event under surveillance.®® Case definitions for 
varicella disease were reviewed to consider whether there is a possibility of false 
positives occurring. The proportion of probable cases over total cases (by year) was 
calculated from NNDSSVZV data to determine whether testing for VZV had increased 
over time for all jurisdictions (except NSW). Lastly, NNDSSVZV cases were examined 
by the laboratory method used to diagnose disease, in the context of the sensitivity and 
specificity of the laboratory methods used. 
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Results 
A total of nine stakeholder were consulted, and included jurisdictional and 
Commonwealth stakeholders. 
Operation and System Components 
Legislation 
Under the provision of public health jurisdiction in states and territories, notifications of 
varicella zoster (chickenpox), varicella zoster (shingles) and varicella zoster 
(unspecified) are electronically fonwarded to the DoHA on a daily basis. Prior to 
September 2007, there was no legislative requirement for jurisdictions to forward 
notifications to the Commonwealth.^® However, from September 2007, the National 
Health Security Act 2007 received royal assent, providing a legislative basis to 
authorise the exchange of health information between the Commonwealth and 
jurisdictions. De-identified data on a nationally agreed list of communicable diseases 
are voluntarily forwarded to the Commonwealth for the purposes of surveillance of 
communicable diseases at a national level. As part of the core dataset of the NNDSS, 
mandatory data fields include: a unique record reference number; the notifiying 
jurisdiction; disease code; confirmation status; and the date of notification to 
jurisdictional health authorities.^® 
Data flow 
The structure and flow of data of VZV notifications through the NNDSS is displayed in 
Figure 1. Data transfer occurs through the Data Acquisition System (DAS) on a daily 
basis, and data are automatically transferred into the Microsoft Access NNDSS 
database.Not i f icat ions requiring updates can occur at any time and quality control 
measures are in place through data constraints to monitor the validity of data. 
Figure 1. Flow chart of the varicella zoster virus noti f ication system 
Outputs: 
Internet 
GDI quarterly journal 
GDI annual report 
All notifications reported from Tasmania and the Australian Capital Territory (ACT) 
were from laboratories (Table 2). In the ACT, notifications were sent to ACT Health by 
laboratories. If the clinical notes section of the form had 'query shingles' or 'query 
chickenpox', cases were classified as varicella zoster (shingles) or varicella zoster 
(chickenpox), respectively. In Tasmania, laboratory notifications were fonwarded to the 
health department who subsequently sent out a form via fax to the clinician to collect 
clinical information on the case. This is similar in the Northern Territory (NT) where a 
questionnaire is sent to clinicians to record clinical and demographic information 
following a laboratory notification. Although Queensland health authorities can receive 
notifications from laboratory and clinicians, almost all notifications were from 
laboratories. In Victoria, Western Australia (WA), SA and the NT, both clinical and 
laboratory notifications occur. 
In 2006, a national notifiable case definition for varicella zoster (chickenpox), varicella 
zoster (shingles) and varicella zoster (unspecified) was first developed and 
implemented by a working group of CDNA (Appendix E1.2). Since then, no changes 
have been made to the case definitions despite a review occurring during August 2008. 
In most instances, jurisdictions follow CDNA case definitions for VZV. In SA however, it 
was discovered during the stakeholder consultation that cases without a laboratory test 
notified by a clinician to the health department were considered a confirmed case 
(Table 2). WA also differed in their use of the CDNA case definition, including a VZV 
positive result from a cerebrospinal fluid (CSF) as a VZV (unspecified) case. 

Table 2. Case definitions, reporters and degree of follow-up of varicella notifications by jurisdictions 
Jurisdiction CDNA case definition Notified 
by Lab 
Notified by 
clinician 
Follow-up 
NSW - - - -
VIC • No follow-up conducted, however, if chlckenpox notifications 
occur in a closed setting, an outbreak investigation will be 
conducted and cases are contacted. 
QLD • Chickenpox notifications in children <8 years old. Follow-up of 
10% of a sample of chickenpox also occurs periodically. Follow-
up is through clinician interview. 
SA • 
But defines cases with 
'clinical evidence' only as 
confirmed cases 
• Case-by-case basis and risk assessment conducted to 
determine whether follow-up should occur. Case and clinician 
interviews are conducted if follow-up occurs. 
WA •/ 
Accepts VZV positive 
cerebrospinal fluid 
specimens as VZV 
(unspecified). 
• • Follow-up of children 0 - 5 years occurs, healthcare and chlldcare 
workers and asylum seekers. Case and clinician interviews are 
conducted. 
NT • •/ All chickenpox notifications are followed up by faxing the 
clinicians following a laboratory notification to obtain clinical 
information, particular to verify vaccination status of notifications. 
TAS Case-by-case basis, usually follow-up is the provision of 
advice to individual clinicians with no direct public health 
action conducted in the majority of notifications. 
ACT • Case-by-case basis, in some instances follow-up with 
clinician to recommend specific public health action (for 
example the administration of ZIG). 
The degree of follow-up of cases varied among notifying jurisdictions. Some 
jurisdictions conducted follow-up through case and clinician interviews. However, in 
most cases, notifications were reviewed on a case-by-case basis to determine whether 
public health follow-up should be conducted. 
In the NT, all cases were followed up. Clinicians were contacted following a laboratory 
notifications with a focus on identifying high-risk contacts. The level of risk in contacts 
was also examined in clinician notifications. The aim of the follow-up of high-risk 
contacts was to implement preventative measures. Similarly in SA, risk assessments 
were conducted to identify high-risk contacts. In SA, clinicians were encouraged to 
conduct follow-up and enforce control and preventative measures themselves. In WA, 
follow-up was prioritised depending on age and other identified risk factors. In contrast, 
Queensland focused on following-up notifications in children under eight years of age 
and also periodically follow-up 10% of all notifications. Prior to 2010, attempts were 
made to follow-up all VZV in Queensland however with limited resources and capacity 
poor completeness occurred. 
Tasmania and the ACT follow-up on a case-by-case basis. In Tasmania, this occurred 
through the provision of information and advice to clinicians who were responsible for 
the follow-up of cases and the implementation of preventative measures with 
assistance in public health measures, available on request. Victoria reported not 
conducting any routine follow-up, however in the past had investigated an outbreak 
that occurred in a closed setting.®^ Similarly, if a notification occurred in a healthcare 
worker or childcare worker, follow-up was reported to occur. 
Surveillance System Utility and Attributes 
Utility 
Overall, the NNDSSVZV is not performing well against its objectives; and little public 
health action has occurred as a result of the surveillance system. 
Performance of the system against its objectives 
Objective 1: To measure the impact of universal varicella vaccine on the 
incidence of varicella infection in the Australian population 
NNDSS data 
The utility of the NNDSSVZV to measure the impact of the varicella vaccine on the 
incidence of disease is generally weak as varicella only became notifiable in six of the 
seven notifying jurisdictions after the implementation of the vaccine program. 
Therefore, at a national level, notification rates pre- and post-vaccine cannot be 
calculated using the NNDSSVZV data. On a jurisdictional basis, only SA data can be 
used to measure vaccine impact as they began notifying VZV in 2002 and it is 
worthwhile noting that since 2005, a decline in notification rate of chickenpox in SA has 
occurred, suggesting that the varicella vaccine may have led to a reduction in disease 
(Figure 2). 
Figure 2 Notification rate of varicella zoster (chickenpox), Australia 2002-2012*^^ 
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stakeholder consultations 
From the stakeholder consultations (notifying jurisdictions and the Commonwealth), six 
of the eight respondents believed that the current NNDSSVZV was measuring the 
incidence of varicella infection in the Australian population whilst two were neutral. 
One jurisdictional stakeholder however, commented: 
While I have ticked 'agree' it doesn't mean the notification data are 
either accurate of complete or that the measures are fool proof. A 
range of data needs to be considered, not just that of the NNDSS 
Given the infancy of the NNDSSVZV, more time may be required to improve its 
usefulness. Indeed, the increase in the rate of chickenpox in the NT (Figure 2) was 
acknowledged by one stakeholder who suggested that the increase may be due to the 
increased testing of cases rather than an increase in disease. It was mentioned that 
clinicians may have previously been unaware of diagnostic tests for chickenpox (for 
example PGR) however; more recently have become more aware of these tests which 
has resulted in an increase in testing. 
The first calendar year that data from all notifying jurisdictions were received occurred 
in 2009. One jurisdictional stakeholder commented: 
Our plan for varicella zoster virus surveillance when we made VZV 
notifiable at the end of 2008, was to basically let the surveillance 
system run as a passive system (with no follow-up for at least 5 years), 
to allow for clinicians (and, to a lesser extent, laboratories) to get used 
to the idea that VZV is notifiable, let the data settle into a pattern, and 
then to evaluate what the data looked like... 
Objective 2: To measure the potential impact of the varicella vaccine program on 
the prevalence of varicella infection among specific populations such as 
unimmunised older children, adults and adolescents and Indigenous children 
and adults 
NNDSS data 
Objective 2 is dependent on the completeness and validity of specific variables that will 
be discussed in more detail under the system attribute 'data quality'. Notification rates 
by age-group are shown (Figure 3). These were highest in children < 1 year, 1 - 4 years 
and 5 - 9 years. In the 1 - 4 year age group, notification rates appeared to be decreasing 
until 2009 when it plateaued. Universal vaccine is recommended at 18 months, 
suggesting that this reduction may be due to more children in the 1 - 4 year age group 
having been vaccinated against varicella and thus leading to a reduction in susceptible 
individuals in this age group and subsequently a decline in cases of chickenpox. Again 
the significance of this in the context of the vaccine program is impossible to state at 
this stage. 
Figure 3 Notification rate of varicella zoster (chickenpox) by age group, 2006 -
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Stakeholder consultation 
Five of the eight respondents (notifying jurisdictions and the Commonweal th) agreed or 
strongly agreed that the incidence of varicella infection was being measured in 
unimmunised children and Indigenous children, whilst two respondents were neutral 
and one disagreed. In unimmunised adults and Indigenous adults, three agreed that 
the incidence of varicella infection was being measured by the NNDSSVZV, three were 
neutral and two disagreed. 
Given that adult cases were not followed-up in most jurisdictions, one stakeholder felt 
that the incidence of adult cases would not be captured well and that the jurisdictions 
that do follow-up adults had small populations and due to this would not be 
representative at a national level. 
Objective 3: To monitor the impact of the varicella vaccination program on the 
epidemiology of zoster infection 
NNDSS data 
The occurrence of zoster is being measured by the NNDSS and overall rates by 
jurisdiction are shown (Figure 4). Nationally, rates show a slight increase, however 
whether this reflects a true effect or an artefact is impossible to determine given that 
the disease only became notifiable after the vaccine program started. As for 
chickenpox. South Australian notification data could potentially be used to monitor the 
vaccine impact; interestingly these rates have been increasing over time - whether this 
indicates a true increase (due to decreased circulating virus and subsequently 
decreased immunity due to natural boosting) or an artefact due to increased reporting 
is unclear (Figure 4). Notification rates by age-group are shown (Figure 5). These 
were highest in adults > 75 years and in the three oldest age groups (45-59; 60-74; 
75+ years). In these age groups, notification rates appeared to be increasing with a 
peak in notifications observed in 2008 - again the significance of this in the context of 
the vaccine program is impossible to state at this stage. 
Of importance however, is that with the recent availability of a herpes zoster vaccine in 
Australia, pre-vaccine notification data on shingles will be useful in determining if the 
vaccine has impacted on the burden of shingles at a national level. 
Figure 4 Notification rate of varicella zoster (shingles), Australia, 2002-2012*'^ 
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stakeholder consultation 
Among the jurisdictional stal<eholders which notify varicella infection and the 
Commonwealth, seven of the eight respondents agreed that the NNDSSVZV is 
monitoring the changes in the epidemiology of shingles in Australia. 
Objective 4: To measure vaccine failure and provide data to measure vaccine 
effectiveness over time by age group 
Another objective of the NNDSSVZV was to measure vaccine effectiveness over time 
by age group. This is dependent on the quality of the data on vaccination status which 
will be discussed in more detail later. However, from stakeholder consultations, under 
the Vaccine Preventable Diseases Surveillance Project Agreement, jurisdictions are 
encouraged to achieve at least 95% in completeness of the vaccination status data 
field in chickenpox cases aged < 7 years. 
Of the notifying jurisdictional and Commonwealth stakeholders, five of the eight 
respondents agreed or strongly agreed that this objective was being met by the current 
system. 
Additional objectives 
Two additional objective of the surveillance system that a jurisdictional stakeholder 
identified was: 
To identify/monitor outbreaks (for example in settings such as child-
care) and to assess morbidity, at least crudely based on hospitalisation 
data to the extent recorded in notifications. 
However they were unsure as to whether the current surveillance system in place was 
able to meet this objective. Additionally, it was identified that not all jurisdictions collect 
information on hospitalisations, hence it would be difficult to examine morbidity on this, 
particularly if the completeness of this field was poor. 
Overall, there was no over-riding agreement that the notification system was 
meeting its objectives. In relation to the national notification system, one 
jurisdictional stakeholder remarked: 
Many of the objectives of varicella surveillance are being met through 
alternative systems. 
The users of notification data 
Stakeholder consultation 
Stakeholders believed that the main users of national notification data were 
jurisdictional and Commonwealth surveillance officers and researchers. However, one 
stakeholder commented that although they assumed there were multiple users of the 
NNDSSVZV it didn't necessarily mean that the NNDSSVZV was helpful. 
Public health action 
Stakeholder consultation 
An important measure of the usefulness of a surveillance system is whether any public 
health action or changes in public health policy occurs. Stakeholders from three 
jurisdictions reported that the only use for varicella notifications in their jurisdiction was 
the production of routine reports. Five of the respondents were unsure whether the 
NNDSSVZV led to any public health action at a national level, and the remaining three 
believed no public health action had occurred. Similarly, six of the eight respondents 
were unsure whether the NNDSSVZV had led to changes in public health policy at a 
national level; one believed that it had led to changes, whilst another believed no public 
health policy changes had occurred. Despite this, a number of stakeholders felt that as 
the NNDSSVZV becomes more established, future policy changes are likely. 
I'm not aware that policy has changed as yet based on the varicella zoster 
notification data per se, but presumably it may do as time goes by, 
depending on what the data reveal and in concert with data from other 
sources (hospitalisation data, overseas studies, etc.) 
Early days yet ...but ongoing prioritised follow-up of certain cases may 
prompt policy changes - we'll see... 
Of the notifying jurisdictional stakeholders, three of the seven respondents were aware 
that NNDSSVZV data were used to generate national reports, whilst three were unsure 
and one respondent believed no reports were generated. 
The usefulness of a surveillance system is also determined by the following system 
attributes: sensitivity, data quality, representativeness and acceptability. This will be 
discussed in more detail below. 
Attributes of the system 
The following section addresses the attributes of the system in relation to the 
NNDSSVZV's objectives, guided by the CDC evaluation framework.^^ 
Sensitivity 
The sensitivity of the NNDSSVZV is likely to be poor for a number of reasons. Figure 6 
demonstrates the notification process to the NNDSS for all notifiable diseases and 
shows the high proportion of cases not notified to the NNDSS. Specific attributes of 
varicella decrease the likelihood of sensitivity. Given that mild disease is generally 
experienced by most cases, only a small proportion may seek medical care. 
Additionally, several jurisdictions collect all, or the vast majority of their notifications 
from laboratories, further reducing the sensitivity of a system that is assumed to 
capture only a small proportion of disease occurring in the community. 
Figure 6. Notifiable fraction of communicable diseases 
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The poor sensitivity of the NNDSSVZV is demonstrated by the low proportions of 
laboratory tests that were requested for chickenpox and shingles managed in the 
BEACH dataset (Table 3). This suggests that in a community setting, the majority of 
cases of chickenpox and shingles are clinically diagnosed and thus not notified to the 
NNDSSVZV. The proportion of test requests however, appeared to be increasing, 
indicating that sensitivity may be increasing over time. Between 2000 and 2012, there 
were no PGR tests for chickenpox encounters and eight PGR test requests for shingles 
encounters in the BEACH dataset. Given that the main laboratory method used to 
diagnose chickenpox and shingles is PGR in the NNDSS (discussed in more detail 
below under positive predictive value), demonstrates the poor sensitivity of the 
NNDSSVZV at capturing individual notifications in the community. 
Table 3. Number (weighted) and proportion of GP-patient encounters at which chickenpox and shingles was managed as a new 
problem where a confirmatory laboratory test (serology or culture or PGR) was ordered.* 
Year 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
Total number of 
tests ordered 
6.2 14.4 34.0 24.5 29.8 31.9 38.9 26.3 55.3 75.2 63.2 69.4 49.7 
Total new 
encounters of 
chickenpox and 
shingles 
231.3 174.7 191.5 206.2 199.4 176.6 180.4 208.6 159.6 149.0 139.4 143.1 151.4 
Proportion of 
encounters with 
test request (%) 
2.7 8.2 17.7 11.9 15.0 18.0 21.6 12.6 34.7 50.5 45.3 48.5 32.8 
• Numbers are not whole numbers as weighting occurred 
Moreover, the proportion of tests by year was consistently highest in the 5-59 year age 
group; which indicates the uncertainty among clinicians in diagnosing varicella zoster in 
this age group (Table 4). It does suggest that in the 0-4 year and 60+ year age groups, 
few tests are being requested and the proportion of test requests have been sporadic 
with no real pattern observed ( although it appears to be increasing in the 0-4 year age 
group). Given this fluctuation in the BEACH data, it is possible that the sensitivity in 
notifications is also changing. 
Table 4. Proport ion (%) of GP-patient encounters at which chickenpox and shingles was managed as a new problem where a 
serology or culture or PGR test was ordered by age group, 2000-2012, BEACH data 
Age group Year 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
0—4 years 0.0 0.0 2.5 0.9 1.9 0.0 13.5 0.0 9.8 6.4 15.6 45.5 14.2 
5-59 years 5.1 12.5 29.0 22.0 27.4 29.3 34.1 20.7 51.2 91.0 72.1 82.0 72.3 
60+ years 0.0 0.0 0.0 0.0 1.1 4.3 3.2 1.2 17.5 1.9 14.4 8.7 2.8 
Furthermore, without clinical information on positive laboratory results of varicella 
zoster, a large proportion of tests were not classified as chickenpox or shingles which 
further contributed to the lower sensitivities of both diseases. Unspecified varicella 
disease does not provide information on the epidemiology of disease. However, 
calculating the rates of notifications by jurisdiction and age group still provided valuable 
insight on the performance of the NNDSSVZV Nationally, a slight increase in VZV 
(unspecified) notifications was observed which may suggest that the sensitivity of the 
NNDSSVZV for each disease is decreasing (Figure 7). 
Figure 7 Notification rate of varicella zoster (unspecified), Australia, 2003-2012*' 
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When stratifying by age, notification rates were highest in adults >60 years and 
increased over time (Figure 8) In contrast, VZV (unspecified) notification rates in 
children 0-14 years of age appeared to be decreasing. The trends in notification rates 
by age group differed, which might be due to a change in follow-up over time. The 
reduction observed in children 0—14 years may have occurred due to increased follow-
up of notifications in children <7 years as part of the Vaccine Preventable Diseases 
Surveillance Project Agreement. If this was the case, it would suggest that the 
sensitivity of the system was increasing over time. In adults aged >60 years however, 
an increase in notification rate of unspecified disease may suggest that the sensitivity 
of the NNDSSVZV for this age group was decreasing based on the increase in rate 
over time. If these rates were indeed a true depiction of disease, based on our 
understanding of VZV, it would be likely that unspecified disease in 0-14 years were 
chickenpox and >60 years were shingles notifications. If this was the case, the 
unspecified disease trends were similar to the national trends that were observed for 
chickenpox (Figure 2) and shingles (Figure 4) suggesting that although there were a 
high number of VZV unspecified notifications, the sensitivity of the system in capturing 
trends for chickenpox and shingles is occurring. 
Figure 8 Notification rate of varicella zoster (unspecified), Australia by age 
group, 2006-2012* 
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Further evidence of the poor sensitivity of the NNDSSVZV existed when comparing it to 
NSW ED data. Despite only collecting ED data from 45 hospitals In NSW and using the 
entire NSW population to calculate disease rates, the rates were comparable to 
NNDSS notification rates, nationally (Figures 15 and 16). As ED presentations would 
capture more severe disease, it would be expected that the sensitivity of the ED 
surveillance system would be lower than the NNDSS. Although these rates may be 
interpreted as NSW having a higher burden of disease for chickenpox and shingles, it 
suggests that the sensitivity of the NNDSS for chickenpox and shingles is extremely 
poor. 
Of more importance is the consistency in the reporting of disease in the NNDSSVZV, to 
allow the true pattern of disease to be captured. The sensitivity of the NNDSSVZV in 
captuhng disease patterns was better in some age groups compared to other age 
groups. 
In specific age groups, patterns of notification rates for chickenpox were similar to rates 
of chickenpox managed in GPs, indicating that the NNDSSVZV was sensitive enough 
to capture the pattern of disease that is occurring in the community (Figure 9). This 
was most evident in the 1 -4 year age group, where patterns of disease from the three 
data sources corresponded closely to each other. In the older age groups (10-14 
years; 15-19 years and 20-39 years), patterns were observed to be similar when 
comparing BEACH (new encounters) rates to notification rates. The pattern of 
NNDSSVZV notification rates and BEACH (all encounters) rates were also similar in 
the older age groups; except for the 15-19 year age group in 2009 where a peak 
occurred in the BEACH dataset. In children 5 - 9 years, divergence between the three 
sources existed. Peaks occurred in 2008 and 2011 in the BEACH and NNDSS 
datasets; however, these peaks did not occur in the ED dataset. A four-year increase in 
chickenpox presentations occurred in the GP setting, which was not reflected in the 
NNDSSVZV or in NSW ED data. 
Figure 9. A comparison of rates of disease of chickenpox by age group from 
multiple data sources, 1998-2012*''# 
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The sensitivity of ttie NNDSSVZV for shingles in capturing pattern of disease varied by 
age group, in comparison with BEACH and NSW ED data (Figure 10). The notification 
rate of shingles in the younger age groups (0-14 years and 15-29 years) differed by 
data source, particularly between notification data and BEACH data. It suggested that 
the NNDSSVZV was not sensitive in capturing the burden of shingles in the community 
for these age groups. BEACH data in the younger age groups fluctuated substantially 
whilst NSW ED data appeared to be more stable. Similar patterns of disease in the 
older age groups ( 3 0 ^ 4 years; 45-59 years; 60-74 years; 75+ years) occurred. It 
suggested that the NNDSSVZV for shingles was sensitive in capturing disease patterns 
in older age groups but not the younger age groups. 
Figure 10. A comparison of rates of disease of shingles by age group from 
multiple data sources, 1998-2012*' '# 
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Another data source that has been used to examine the impact of vaccine in Australia 
has been hospitalisation data. Since 2001/2002, a reduction in rate occurred, with the 
greatest reduction observed after the implementation of the vaccine program (Figure 
11). A slight decline of NNDSS VZV chickenpox rates was observed from 2006 (Figure 
2) which was consistent with the pattern of hospitalisation rates during the same time 
period suggesting that the NNDSSVZV was sensitive in capturing the burden of severe 
disease for chickenpox. 
Figure 11. Hospital isat ion rate of chickenpox in Austral ia, 1998-2010" 
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The sensitivity of tlie NNDSSVZV was poor in capturing severe disease in infants and 
children. Between 2007 and 2012, a total of 111 varicella hospitalisations (96 
chickenpox and 15 shingles) were reported in SA, WA and Victoria through the PAEDS 
network (Table 5). A notification to the NNDSS occurred in 54% (n=52) of PAEDS 
chickenpox cases and 73% (n=11) PAEDS shingles cases. Among PAEDS chickenpox 
cases, 80% (47/59) of cases with a positive test result were notified to the NNDSS 
compared to 14% (5/47) of cases with no test result ( x M o . 1 , p<0.001). Additionally, 
89% (8/9) PAEDS shingles cases with a positive test result were notified to the NNDSS 
compared to 50% (3/6) of cases with no test result (Fisher's exact=0.24). 
Table 5. Number and proport ion of PAEDS cases notif ied to the NNDSS 2007-
2012 from Victoria, South Australia and Western Australia* 
Disease 2007 2008 2009 2010 2011 2012 Total 
n(%) n(%) n(%) n(%) n(%) n(%) n 
Chickenpox 3 (75.0) 10(62.5) 11 (61.1) 7 (33.3) 13 (61.9) 8 (50.0) 96 
Shingles 2 (100.0) 1 (100.0) 3(100.0) 2 (66.7) - 3 (50.0) 15 
stakeholder consultation 
During the stakeholder consultations, a number of jurisdictions raised concerns of an 
idiosyncrasy of the CDNA case definition, which may lower its sensitivity. In Western 
Australia, positive PGR tests for varicella zoster from a cerebrospinal fluid (CSF) 
specimen without lesions are notified. Under the CDNA case definitions (Appendix 
E1.2) these cases would not be considered a probable or confirmed case of 
chickenpox, shingles or unspecified disease. Although these WA cases did not meet 
the CDNA case definition, they were notified to the NNDSS as varicella zoster 
(unspecified) cases. 
Data Quality 
Overall, the data quality of chickenpox and shingles notifications in the NNDDSVZV is 
high but poor for unspecified disease. The key issue hindering the data quality of 
varicella surveillance was the high proportion of all VZV notifications that were 
unspecified (Table 6). Consequently, a large proportion of VZV notifications cannot be 
interpreted; not only because it was not known whether a notification was chickenpox 
or shingles, but also due to the low completeness of demographic information (Figure 
12). Moreover, the proportion of unspecified disease as a total of all varicella zoster 
notifications did not change, indicating that data quality was not improving. 
Table 6.Number and proportion of notifications by disease and year, 2006-2012 
Disease 
Year 
2006 2007 2008 2009 , 2010 2011 2012 Total 
N % tn % N % n % n % n % n % n % 
chickenpox 1,621 24.7 1,667 22.2 1,566 19.6 1,755 15.6 1,748 14.7 2,092 15.2 1,953 13.1 12,402 16.8 
shingles 1,178 18.0 1,560 20.8 2,148 26.9 2,721 24.2 2,993 25.2 3,999 29.0 4,405 29.6 19,004 25.7 
unspecified 3,764 57.4 4,284 57.0 4,261 53.4 6,785 60.3 7,147 60.1 7,720 55.9 8,524 57.3 42,485 57.5 
Figure 12. Data completeness of varicella zoster (unspecified) notifications, 2006-2012 
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However, for notifications which were coded as chickenpox and shingles, data quality 
was good, particularly for onset date of symptoms and Indigenous status. It is important 
to note, that completeness was found to vary by age for vaccination status. The 
completeness of Indigenous status was high for chickenpox notifications (Figure 13). 
Similarly, completeness of the field date of onset was high, however, appeared to be 
declining over time. For vaccination status for NNDSSVZV chickenpox notifications, 
completeness was higher in children < 7 years compared to all ages. 
Figure 13. Data completeness of varicella zoster (chickenpox) notif ications, 
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For NNDSSVZV shingles cases, the completeness of data fields Indigenous status and 
onset date of symptoms were high. Completeness over time increased slightly for 
Indigenous status and decreased for onset date of symptoms (Figure 14). The 
completeness of vaccination status w/as much lower; completeness was highest in 
2006 however since then declined. 
Figure 14. Data completeness of varicella zoster (chickenpox) notifications, 
2006-2012 
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Stakeholder consultation 
Although SA has a well-established passive surveillance in place and actively follow-up 
notifications, between 2006 and 2012, the vaccine status field was 25% complete in the 
state. It is understood that a data extraction issue exists with SA notifications in the 
NNDSSVZV that might be influencing the completeness of vaccination status. At a 
national level, this is of concern as it reduces the validity of the data and hence makes 
it difficult to interpret the results of any analysis. Further, the extent of this issue is not 
known. 
Representativeness 
The pattern of NNDSSVZV rates for chickenpox with rates in chickenpox presentations 
from NSW EDs was similar, suggesting that disease rates captured in the NNDSSVZV 
reflected what was occurring at a national level (Figure 15). 
Figure 15. Comparison in rate of shingles notifications versus NSW emergency 
department presentations, 1998-2012 
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Furthermore, comparison between notification rates for shingles and rate of shingles 
presentations in NSW EDs over time shared a similar pattern, with an increase 
observed over time. It indicated that the NNDSSVZV represented what was occurring 
nationally, despite NSW not notifying disease (Figure 16). In 2008, a peak of shingles 
notifications in the NNDSSVZV occurred which was not reflected in NSW ED data. 
Apart from this particular year, the similar patterns suggested that NNDSS shingles 
data was representative of the national picture. 
Representativeness is also related to data quality and system operations (including 
reporting mechanisms). Inconsistent case definitions and reporting by jurisdictions to 
the Commonwealth have been discussed in detail above; however can additionally 
compromise the representativeness of a surveillance system. 
Figure 16. Comparison in rate of shingles notifications versus NSW emergency 
department presentations, 1998-2012 
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Stakeholder consultations 
From jurisdictional stakeholders, the main limiting factor communicated was the poor 
representativeness of surveillance data given NSW does not notify and the second 
most populous state Victoria does not routinely follow-up cases. It was noted however, 
that the intensity of follow-up by jurisdictions was limited by the resources available to 
them. 
Despite stakeholder concerns of the representative of the NNDSSVZV, from the 
comparisons between NSW ED and NNDSS data, NNDSS data appeared to provide a 
representative picture of what was occurring at a national level, including in NSW. 
Acceptability 
The acceptability of the NNDSSVZV was generally good, however there were a 
number of issues identified that could increase the acceptability of the system. 
Following a laboratory notification of chickenpox or shingles, clinicians receive a fax 
from health authorities (NT and Tasmania) requesting clinical details to determine 
whether the notification was chickenpox or shingles. The low proportion of unspecified 
VZV infections suggests that acceptability in these two jurisdictions was high (Table 7). 
However, appeared to decline based on the increased proportion of unspecified 
disease over time. It is important to mention that in the NT, health authorities will ring 
the clinician to return the form if they had not responded by 4 - 7 days. In Tasmania; no 
resources were available to chase up forms not sent back. The number of unspecified 
disease thus would depend on how actively jurisdictions follow-up clinicians after 
sending off a fax 
Table 6. Proportion of varicella zoster (unspecified) notifications of total varicella 
notifications in Tasmania and the Northern Territory, 2006-2012 
Year 2006 2007 2008 2009 2010 2011 2012 
Proportion of VZV unspecified/ VZV total 
notifications) [%] 4.2 6.6 10.5 21.0 16.8 12.6 15.7 
Stakeholder consultations 
Among the notifying jurisdictional and Commonwealth stakeholders, five of the eight 
respondents believed that varicella was of public health importance whilst one was 
neutral and one felt that it was unimportant. Similarly, five of the eight stakeholders 
thought that notifying varicella was a good use of their time whilst the remainder were 
unsure. One respondent commented: 
I think the importance lies in the future. Notification and the vaccination 
program have probably not been in place for long enough as yet for the 
data collected to be readily interpretable. 
Whilst another commented: 
There could be other ways of doing this surveillance. 
One stakeholder stated that there was a 
Lower public health priority for mild form of disease. 
Five of the eight notifying jurisdictional and Commonwealth stakeholders believed that 
the current requirements for chickenpox reporting nationally were adequate however 
some believed that completeness of data needed to be improved with suggestions to 
focus on vaccination status in children < 5 years. 
One stakeholder also commented 
Data completeness and quality probably needs to be improved. 
Important to evaluate the system as it currently operates. 
To improve the acceptability of the NNDSSVZV, jurisdictional stakeholders suggested 
that: more national consistency was required; a series of national guidelines for 
varicella should be developed; better reporting methods were needed (particularly for 
clinicians (e.g. online reporting)) and; a focus on clinician notifications was required in 
the NNDSSVZV. 
Simplicity 
Stakeholder consultations 
One of the major strengths of VZV surveillance was that it is part of the well-
established NNDSS which is connected to all states and territories (although NSW 
does not notify VZV disease). Six of the seven notifying jurisdictional stakeholders felt 
that reporting VZV notifications to the NNDSS was easy and that the flow of information 
to and from the NNDSS was adequate. In a previous evaluation of the NNDSS, the 
structure of the NNDSSVZV was deemed simple however, it was noted that it had 
taken some time to develop a national standardised database.^® 
The CDNA case definitions were not simple to administer based on the lack of 
consistency in applying the case definitions by the jurisdictions. The interpretation of 
NNDSSVZV data at a national level is thus difficult. Whilst some jurisdictions accept all 
cases as confirmed, others require laboratory evidence and the degree of follow-up 
varies which leads to variations in the level of completeness of data fields. A 
resounding sentiment among stakeholders was the limited resources available with 
which compromised their ability to follow-up cases. 
Stability 
Stakeholder consultations 
Another major strength of the NNDSSVZV was how stable the system is, being part of 
a well-established and stable surveillance system infrastructure. Data transfer, back-
up, storage and the release of data are considered to be stable. Unscheduled outages 
do not occur. Having existed from many years, the NNDSS is maintained regularly and 
runs efficiently. Reports are prepared every quarter and annual reports are also 
developed that include VZV notification data. 
Flexibility 
The flexibility of NNDSSVZV is particularly important. However, it is not known how 
flexible the NNDSSVZV will be until a major change occurs. Following the introduction 
of universal varicella vaccine, the incidence of chickenpox is expected to decline and 
become rarer. It is possible that in the future, the objectives of the NNDSSVZV will 
expand to include the detection of chickenpox outbreaks. It was concluded by 
stakeholders that the NNDSSVZV had the potential to be able to detect outbreaks 
however it would be challenging to start genotyping specimens and collecting 
additional information. Moreover, the NNDSSVZV would need to be flexible in 
conducting vaccine failure analysis in outbreaks. Improvements would need to be 
made in collecting vaccination status for this to occur. 
Positive predictive value 
Although varicella zoster (chickenpox) and varicella zoster (shingles) are predominantly 
clinically diagnosed,®^ a number of laboratory tests exist to confirm cases of chickenpox 
and shingles as part of the CDNA case definition.®^ These include detection of virus 
antigen by direct immunofluorescence (IF), viral isolation through cell culture, detection 
of viral nucleic acid by PGR or detection of virus-specific antibodies using serology 
(Appendix £6.1).®"'®® 
The most commonly used laboratory methods to test for varicella zoster in the NNDSS 
was PGR. Detection of viral nucleic acid by PGR can occur rapidly and is the most 
sensitive of all diagnostic tests for varicella zoster ( -100%) but can be affected by the 
number of copies of target. The specificity of the test is dependent on the primer/probe 
design. The PPV is high in symptomatic individuals however in asymptomatic or 
immunosuppressed individuals, may be reduced due to low or no viral load. For 
varicella zoster (shingles), sensitive is higher if the specimen is an older lesion.®' 
Based on the assumption that most cases would be symptomatic when seeking 
medical attention, the PPV is likely to be high. 
Of the 12,402 chickenpox notifications between 2006 and 2012, 43.7% of notifications 
had a PGR conducted. However, no laboratory diagnosis methods were used in 55.2% 
chickenpox notifications. For shingles notifications, 66.2% of the 19,004 notifications 
had a PGR test conducted whilst no laboratory diagnosis method was used in 33.0% of 
notifications. Given that PGR was the most used test coupled with the requirement of 
clinical evidence, and in some cases, an epidemiological link to a laboratory confirmed 
case; the PPV of a confirmed case was high. 
The PPV of a clinical diagnosis chickenpox (probable case) is unknown; however, the 
existence of a characteristic vesicular rash suggests that it would be high. Other 
conditions that may be considered during differential diagnosis include allergic skin 
reactions, herpes simplex infection, herpes zoster infection and enteroviruses^ 
suggesting that without laboratory diagnosis, or an epidemiological link to a case, there 
is a possibility of false positives from a clinical diagnosis. There is a possibility though 
that misdiagnosis may occur, particularly if modified disease occurs in a vaccinated 
individual. Moreover, there is a possibility that as disease becomes rarer due to the 
introduction of universal vaccination, clinicians may become unfamiliar with the disease 
and clinical diagnosis may not be valid. The proportion of probable cases of chickenpox 
in the NNDSSVZV decreased over time (Table 7). Although this Is unlikely to be of a 
concern as chickenpox is still a common disease, it may be of concern in the future 
when chickenpox becomes rarer. 
The PPV from a clinical diagnosis of herpes zoster is also assumed to be high. In a 
primary healthcare setting in the Netherlands, the PPV was found to be 91%; (95% CI: 
87%-94%).®® This suggests that the probable cases of shingles from the NNDSSVZV 
were likely to be true cases of shingles. As with chickenpox, the proportion of probable 
cases in shingles notifications increased over time which suggests that testing has 
decreased (Table 7). 
Table 7.Proport ion (%) of probable cases by disease, 2006-2012, NNDSS 
Disease 2006 2007 2008 2009 2010 2011 2012 Total 
Chickenpox 15.9 18.8 16.4 36.4 35.1 34.9 35.1 28.2 
Shingles 4.2 4.6 6.2 14.0 12.7 11.9 12.7 10.8 
Unspecified 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 
Total disease 4.7 5.1 4.9 9.1 8.4 8.7 8.4 7.5 
Discussion 
Strengths of the NNDSSVZV 
The main strength of the NNDSSVZV is that it forms part of Australia's well established 
and well performing national notifiable diseases surveillance system. Overall, attempts 
are being made for the NNDSSVZV to achieve its objectives, specifically through 
providing jurisdictions financial incentives to collect the vaccine status of at least 95% 
in children under seven years. Increasing completeness of vaccinations status would 
allow a more valid measurement of vaccine failure. Vaccination status data were better 
for children under seven years (although 95% target was not reached) than all ages; 
however, this may be due to an issue with data extraction between jurisdictions and the 
Commonwealth which needs further investigation. 
The NNDSSVZV was simple, stable and appeared representative. It is not a sensitive 
system, but was sensitive in capturing disease patterns at a national level in certain 
age groups (i.e. younger age groups for chickenpox and older age groups for shingles) 
when compared to long-standing data sources. The NNDSSVZV was useful in 
producing output based on reports published quarterly in the CDI and in the NNDSS 
annual report. 
Limitations of the system 
The NNDSSVZV had a number of limitations which need to be considered when 
interpreting the data. Firstly, notification data could not assess the impact of the 
varicella vaccine as the disease only became notifiable in most jurisdictions after the 
implementation of the vaccine program. 
Although the sensitivity of the NNDSSVZV was poor, the system does not aim to 
capture all disease in the community and hence is not an important attribute. Rather, it 
was more important that the NNDSSVZV's sensitivity remained constant so that trends 
in disease notifications were interpreted appropriately. The sensitivity of the 
NNDSSVZV; however, varied due to the inconsistency in reporting mechanisms among 
jurisdictions. Some jurisdictions only collected laboratory notifications; others also 
collected notifications from clinicians. Follow-up differed by jurisdiction and the case 
definition agreed to by CDNA was not being consistently implemented in all notifying 
jurisdictions. Lower sensitivity would occur in jurisdictions only notifying through 
laboratories. Moreover, it was difficult to understand the national picture of disease 
when some jurisdictions defined a clinical diagnosis of disease as a confirmed case 
whilst others include cases that, under the national case definition, were not defined as 
a case of chickenpox or shingles. Any changes to the methods by which a jurisdiction 
reported notifications over the time period analysed would also make rates difficult to 
interpret. This is because any changes in disease epidemiology observed may be more 
an artefact of changes in the sensitivity of the system rather than a true change in 
disease. 
Another limitation was the acceptability of the NNDSSVZV. The representativeness of 
the surveillance system could be improved if NSW began notifying disease; however, 
there was a low acceptance of the utility of the current system. A number of notifying 
jurisdictions also questioned the utility of the system and consequently suggested that 
the acceptability of the NNDSSVZV was not high. There were a number of 
stakeholders who mentioned that other data sources should be considered instead of 
using the NNDSSVZV. Moreover, some stakeholders were not aware of any reports 
using data from the NNDSSVZV. Without knowledge of public health action or the 
implementation of public health policy, acceptability is likely to be even poorer. 
Measuring vaccine effectiveness was described as an objective of the NNDSSVZV. 
Due to the poor sensitivity of the surveillance system, vaccine effectiveness cannot be 
measured reliably. A previous publication discussed observational study methods used 
to calculate vaccine effectiveness and concluded that cohort studies during outbreak 
investigations are the simplest and most accurate of observational study designs in 
calculating vaccine effectiveness.®® Cohort studies have previously been conducted in 
Australia to calculate varicella vaccine effectiveness.®^ ™ Conducting retrospective 
cohort studies during outbreaks may be a better approach in achieving this objective 
compared to using notification data.®® 
Other data sources to meet the system's objectives 
From stakeholder responses, it was stated that other data sources are needed to 
compliment the NNDSSVZV and perhaps be better alternatives to the current system. 
However, the strengths and limitations of these data sources, in the context of the 
evaluation of the NNDSSVSV need to be considered. 
PAEDS data 
The PAEDS data provided an important data source to examine severe cases of VZV 
in infants and children using an active surveillance system and to compare with the 
NNDSSVZV. Comparisons made between NNDSSVZV data and PAEDS data 
highlighted that even severe paediatric cases of varicella, specifically chickenpox cases 
were not notified to the NNDSS. Additionally, it identified that a positive test result was 
significantly associated with whether it was notified to health authorities. This is of 
concern, given that in a number of instances, specimens could not be taken to confirm 
a diagnosis. It has been emphasised in this evaluation that the purpose of the 
NNDSSVZV is not to capture every case of chickenpox or shingles, nationally, rather, 
the system should be sensitive in capturing severe varicella cases, which from our 
results the notification system is not achieving. 
To interpret PAEDS data, it was important to consider the limitations of the PAEDS 
dataset. Firstly, data were from three separate paediatric hospitals, which may have 
affected the representativeness of severe varicella cases in children. The three 
hospitals were large paediatric tertiary hospitals and likely to be representative of their 
states, moreover, the objective of analysing PAEDS data was to calculate proportions 
of PAEDS cases that were notified to the NNDSSVZV, which could be calculated 
regardless of the representativeness. 
Additionally, a number of changes to the case definition for VZV infection have 
occurred in the PAEDS data since 2007 (personal communication: Jocelynne McRae, 
PAEDS). Prior to November 2012, the age of cases collected was between >1 month 
and 14 years. In November 2012, the age of cases was lowered to include neonates 
(infants < 1 month old). Also, cases could also include individuals without complications. 
For this evaluation, data were collected until December 2012 (one month of data where 
the case definition was different). There were only five PAEDS cases between in 
December 2012, and all were >1 month of age; of which four suffered complications. 
The change in case definition may have led to only one additional case during our 
study period so was thus unlikely to have affected our results. 
A case definition to include herpes zoster infection was only officially applied in May 
2013, and hence it is difficult to interpret shingles cases from the PAEDS dataset as it 
was likely to be underreported. Furthermore, shingles cases may have been reported 
as a 'complication' of varicella. The PAEDS network was not explicitly intended to 
capture herpes zoster cases and thus may not have reported consistently resulting in a 
possible underestimation of shingles cases. This change occurred after our study 
period; and whether the case was chickenpox or shingles should not impact on the 
main finding from the PAEDS data; that is, a positive test result was an important 
determinant to whether a PAEDS case was notified to health authorities. 
Laboratory diagnoses were also limited by the inability to obtain vesicle fluid as the 
vesicles had healed by the time of hospitalisation. Although a clinical diagnosis of 
chickenpox or shingles may lead to false positives, this was unlikely given the 
characteristic illness of disease and also that cases were admitted to tertiary paediatric 
hospitals where paediatricians were highly experienced. Despite the limitations outlined 
above, PAEDS provided an important data source to assess the sensitivity of the 
NNDSSVZV, particularly in collecting information on severe cases of disease In 
children. 
BEACH data 
The analysis of BEACH data enabled the community burden of chickenpox and 
shingles to be examined. When comparing disease in a community setting to 
NNDSSVZV data, a number of conclusions were established. Firstly, requests for 
laboratory confirmation of chickenpox and shingles were poor, particularly in the ages 
<5 years and 60+ age groups. In contrast, test requests between 5 -59 years were 
increasing over time and much higher than the other two age groups, which suggested 
that there was uncertainty in making a clinical diagnosis for this age group. Secondly, 
over the 13-year period from the BEACH data, only eight PCR test requests were 
made for shingles encounters. Given that PCR was the main laboratory test method for 
chickenpox and shingles in the NNDSSVZV, it indicated that the sensitivity of the 
NNDSSVZV was extremely low i.e. the cases collected in the BEACH dataset would 
not have been captured in the NNDSS dataset. Despite the poor sensitivity, the pattern 
of disease between the two data sources was similar, particularly in children 1 - 4 years 
and 5 - 9 years. Similarly, for shingles, the comparison between BEACH and NNDSS 
data suggested that the NNDSSVZV was sensitive in capturing community disease 
patterns in all age groups over 30 years. 
BEACH data were found to be an important data source in examining varicella disease 
in the community, particular as data has been available since 1998 (pre-vaccine). 
BEACH data were obtained from 1000 randomly selected GPs that differ every year.^' 
Although the response rate was 30%, comparisons of the sampling frame using 
Medicare data occurred and led to adjustments to ensure the BEACH sample was 
representative of GP activity in Australia.''' Furthermore, although BEACH use a 
clustered sample study design (100 consecutive encounters per GP), rates were 
adjusted to account for the cluster design.'^ 
A number of limitations of the data need to be considered in the context of comparison 
with NNDSS data. A limitation of the study was that NNDSSVZV data and BEACH data 
years were compared using different months (i.e. January to December versus April to 
March, respectively). The seasonality of disease patterns from the NNDSSVZV were 
examined and based on the peaks observed, would not have affected the analysis. 
From our results, the number of disease encounters stratified by age group was quite 
small which contributed to the considerable fluctuations in rates of disease in the 
BEACH data, making it difficult to monitor varicella in the community. Lastly, a patient 
may have been double counted if they returned to their GP within the 100 encounters 
captured by a GP, overestimating the encounters associated with chickenpox or 
shingles. New and total encounters were collected to overcome this possible 
overestimation and to determine if there was a difference in rates between the two. 
NSW EDDC data 
It was important to examine the burden of disease in NSW to provide an understanding 
of the patterns of chickenpox and shingles occurring in a significant proportion of the 
Australian population. By comparing NSW ED data and NNDSSVZV data, it was 
possible not only to consider the sensitivity of the NNDSSVZV in capturing the patterns 
of disease from a well-established data source that existed prior to the vaccine 
program implementation, but also to assess the representativeness of the NNDSSVZV. 
NSW not notifying VZV disease was considered to be a major impediment in 
interpreting NNDSSVZV as it would not be representative of the national picture of 
disease. From the comparisons in this study however, it suggested the opposite. That 
even without NSW notifying, the NNDSSVZV was capturing trends in disease that was 
similar to NSW and hence was representative in capturing disease trends at a national 
level. 
An important limitation to consider in interpreting ED data was the participation of EDs 
in the NSW ED Data Collection (EDDC) database. Participation of EDs increased over 
time, from 46 EDs participating in 1996 to 97 EDs in 2013 (personal communication; 
Sophie Norton, NSW Ministry of Health). Data analysed in this report included only 46 
EDs that consistently participated during 1998 to 2011. Data were only analysed from 
these hospitals to ensure increases in rates of disease was not associated with an 
increase in participation for a particular year. Approximately 150 public hospital EDs 
exist in NSW, and therefore it was possible that the reporting EDs used in this 
evaluation was not representative. Moreover, the EDDC database does not collect any 
data from private hospitals. Although this may mean that the rates of disease were an 
underestimate, further exacerbated by the use of the total NSW population as the 
denominator in estimating rates, the consistency in the numerator (disease from the 46 
EDs) and denominator ( NSW population) would still have captured changes in disease 
patterns. Moreover, most of the larger EDs in the state are participants of EDDC 
resulting in a large proportion of the NSW population being covered by this system and 
hence likely to be a representative system. An important consideration of the NSW 
EDDC dataset is that variation on completeness of diagnosis reporting occurred over 
time in some hospitals of which the extent of this is unknown. 
Recommendations 
Following this evaluation, CDNA may want to consider the following recommendations 
to assist the NNDSSVZV in meeting its objectives and improving the system's 
attributes. 
1. Consistent follow-up of chickenpox and shingles notifications. Currently, follow-
up of cases varies substantially by jurisdiction. The inability to determine 
whether a notification was chickenpox or shingles hampers the ability to 
interpret NNDSS data. 
2. Demographic information is not collected e.g. vaccination status in a number of 
jurisdictions to aid the system in meeting its objectives. To improve this, a 
number of options exist including: 
• Provide more resources for states and territories to conduct follow-up, 
however this needs to be considered in the context of other issues 
that may be of greater public health importance in each jurisdiction. 
• Update laboratory reporting forms to include a field indicating whether 
the test is for chickenpox or shingles and also what the patient's 
vaccination status is. 
• Develop an automated communication system for all VZV unspecified 
cases and cases missing vaccination status to automatically follow-up 
clinicians. A standardised varicella-specific follow-up form could be 
sent to clinicians through a fax or email system that does not require 
any extra time of surveillance staff. 
3. Revise the national case definitions for chickenpox, shingles and unspecified 
disease to include VZV positive test results obtained in a CSF specimen as a 
case of disease. 
4. Audit the data extraction process between jurisdictions and the Commonwealth 
in light of the poor completeness of vaccination status observed in one 
jurisdiction known to conduct comprehensive follow-up in children < 7 years. 
5. Consistent application of the case definitions so that a clinically diagnosed case 
of chickenpox and shingles without laboratory evidence and without an 
epidemiological link are considered probable cases. 
6. Recommend NSW make VZV notifiable to improve the representativeness of 
the NNDSSVZV which will allow for a better understanding of the burden of 
chickenpox and shingles. This is of particular importance in light of the 
increased availability of zoster vaccine. 
7. Development of a national guideline to guide jurisdictions in follow-up including 
implementing control and preventative measures, particularly in response to the 
anticipated decline in Incidence of chickenpox following the vaccine program 
implementation. 
8. For future vaccine preventable diseases, a strategy should be in place to 
establish surveillance to assess the impact of universal vaccine, prior to the 
implementation of the vaccine program. 
Conclusions 
The surveillance system for chickenpox and shingles in Australia does not appear to 
meet its main objective of measuring the impact of universal varicella vaccine. Although 
notification rates on chickenpox and shingles are being captured by the current 
NNDSSVZV , the poor sensitivity and the non-existence of notification rates pre-vaccine 
limits the utility of the system. Resources among jurisdictions are a major barrier to 
improving the NNDSSVZV , due to limited capacity to conduct follow-up which has 
compromised the sensitivity and quality of the data. A review of the case definition and 
standardised reporting is recommended to ensure that consistency among jurisdictions 
will allow for the accurate interpretation of data. 
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Appendix E 
E1.1 The surveillance of varicella zoster virus in Australia 
E1.2. Austral ian national notif iable disease case definit ions 
Varicella zoster 
(chickenpox) 
Confirmed case 
Laboratory definitive AND clinical evidence 
OR 
Clinical AND epidemiological evidence 
Probable case 
Clinical evidence only 
Laboratory definitive evidence 
Isolation of varicella-zoster virus from a skin or lesion 
swab OR detection of varicella-zoster virus by nucleic 
acid testing from a skin or lesion swab OR detection of 
varicella-zoster virus antigen by direct fluorescent 
antibody from a skin or lesion swab OR detection of 
varicella-zoster virus-specific IgM in an unvaccinated 
person. If the case received varicella vaccine between 5 
and 42 days prior to the onset of rash the virus must be 
confirmed to be a wild type strain. 
Clinical evidence 
Acute onset of a diffuse maculopapular rash developing 
into vesicles within 24 -48 hours and forming crusts (or 
crusting over) within five days 
Epidemiological evidence 
Contact between two people involving a plausible mode 
of transmission at a t ime when one of them is likely to be 
infectious AND the other has illness ten to 21 days after 
contact AND at least one case in the chain of 
epidemiologically-l inked cases is laboratory confirmed. 
Varicella zoster (shingles) Confirmed case 
Laboratory definitive AND clinical evidence 
Probable case 
Clinical evidence only 
Laboratory definitive evidence 
Isolation of varicella-zoster virus from a skin or lesion 
swab OR detection of varicella-zoster virus from a skin or 
lesion swab by nucleic acid testing from a skin or lesion 
swab OR detection of varicella-zoster virus antigen from 
a skin or lesion swab by direct fluorescent antibody from 
a skin or lesion swab. 
Clinical evidence 
A vesicular skin rash with a dermatomal distribution that 
may be associated with pain in skin areas supplied by 
sensory nerves of the dorsal root ganglia. 
Varicella zoster Confirmed case 
(unspecified) Laboratory definit ive in the absence of clinical 
ev idence 
Laboratorv definitive evidence 
Isolation of varicella-zoster virus from a skin or lesion 
swab OR detection of varicella-zoster virus from a skin or 
lesion swab by nucleic acid testing from a skin or lesion 
swab OR detection of varicella-zoster virus antigen from 
a skin or lesion swab by direct fluorescent antibody from 
a skin or lesion swab OR detection of varicella-zoster 
virus-specific IgM in an unvaccinated person. 
E2.1 Notifying Jurisdictional Stakeholder Questionnaire 
Instructions on answering 
The National Centre for Immunisation Research and Surveillance (NCIRS) is 
currently undertaking an evaluation of the national varicella notification. 
The aim of the evaluation is to assess the current notification surveillance 
system for varicella zoster in Australia. 
All questions refer to varicella (chickenpox) and varicella (shingle) unless 
otherwise stated. 
All information you provide will be confidential and de-identified. 
The questionnaire should take approximately 15 minutes to complete. 
Question 1. What jurisdiction are you from? 
O Victoria 
• Queensland 
• Soutti Australia 
• Western Australia 
• Tasmania 
• Northern Territory 
• Australian Capital Territory 
Question 2. What is your role in varicella notifications in your jurisdiction? 
Question 3. Within your jurisdiction, how is a confirmed varicella zoster (chickenpox) 
case defined? 
This section aims to measure how well the objectives of the varicella notification 
system are being met. 
Question 4. Please rate you s on the following objectives of the national notification of 
varicella: 
Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
The incidence of varicella infection 
in the Australian is being measured. 
-specifically in unimmunised 
children 
-in unimmunised adults 
-in Indigenous children. 
-in Indigenous adults 
Vaccine effectiveness over time 
can be measure by age group. 
Vaccine effectiveness over time 
can be measured by vaccine 
schedule. 
The changes in the epidemiology of 
zoster in Australia are being 
monitored. 
Further comments 
Question 5. Apart from the objectives listed above, are there any other objectives of the 
varicella notification system that you can think of? 
• Yes 
• No 
• Unsure 
Question 6. Please list these objectives. 
Question 7. 
Are these objectives being met by the current varicella notification system? 
• Yes 
• No 
O Unsure 
USEFULNESS 
This section aims to determine how helpful the notification system is to public health 
staff. 
Question 8. Who are the main users of varicella notification data? 
• Jurisdictional Surveillance Officers 
• Jurisdictional Immunisation Coordinators 
• Commonwealth Surveillance staff 
• Commonwealth Immunisation staff 
• Researchers 
• Qther 
If other (please specify) 
Question 9. What are the uses of notification data in your jurisdiction? 
Question 10. Has national notification system for varicella led to public health action in 
the following? 
Yes No Unsure 
Your jurisdiction 
National 
Question 11. Please provide details (if relevant). 
Question 12. Has the national notification system for varicella led to changes in public 
health policy in the following? 
Yes No Unsure 
Your jurisdiction 
National 
Question 13. Please provide details (if relevant). 
Question 14. To your knowledge, has varicella notifications led to the generation of 
national reports? 
• Yes 
• No 
• Unsure 
Question 15. Please provide details. 
Question 16. Does follow-up occur if the following individuals are notified varicella 
(chickenpox) cases? 
Yes No Unsure 
Neonates 
Infants 
Children aged 1—5 years 
School children 
Pregnant women 
Indigenous individuals 
Other 
If other (please specify) 
Question 17. If yes, please select what follow-up is conducted. 
Yes No Unsure 
Case interview 
Clinician interview 
Verification of vaccination status 
Other (please specify) 
Question 18. If follow-up differs depending on groups specified in Question 17, please 
describe what differences exist. 
Question 19. Are varicella (chickenpox) outbreaks that occur recorded by your 
jurisdiction. 
• Yes 
• No 
• Unsure 
Question 20. Please provide examples what information is collected. 
Question 21. Do you collect any extra information from varicella cases that are not sent 
to the NNDSS? 
• Yes 
• No 
• Unsure 
Question 22. Please provide details. 
ACCEPTABILITY 
The aim of this section is to measure how willing you are to participate in the current 
notification system. 
Question 23. In your view, please rate the public health importance of varicella 
• Extremely important 
• Important 
• Neutral 
• Unimportant 
• Extremely unimportant 
Question 24. Do you think notifying varicella is a good use of you time? 
• Yes 
• No 
• Unsure 
Question 25. Please provide details (if any). 
Question 26. Do you think the current requirements for varicella (chickenpox) case 
reporting in States and Territories is adequate? 
• Yes 
• No 
• Unsure 
Question 27. Please provide details. 
Question 28. What do you think could be done to improve the acceptability of the 
national varicella notification system? 
SIMPLICITY 
This section aims to ascertain the structure of the system and its ease of operation. 
Question 29. Please describe how varicella notification data gets from your jurisdiction 
to the national system. 
Question 30. Compared to other notifiable disease, is it easy to report varicella to the 
NDDSS? 
• Yes 
• No 
• Unsure 
Question 31. Please give your reasons. 
Question 32. Do you think that the flow of information on varicella notifications to and 
from the NNDSS is adequate? 
• Yes 
• No 
• Unsure 
Question 33. Please provide details. 
Question 34. What are the reasons for not making varicella notifiable in your 
jurisdiction? 
This section seeks information on your views on the national notification system for 
varicella. 
Question 35. In your opinion, what are the strengths of the national system for varicella, 
for Australia overall? 
Question 36. In your opinion, what are the limitations of the national notifications 
system for varicella, for Australia overall? 
Question 37. In your opinion, l iow could the national varicella notification system be 
improved, for Australia overall? 
Question 38. Do you think that varicella should be notifiable in your jurisdiction? 
• Yes 
• No 
• Unsure 
Question 39. Please give your reasons. 
Question 40. Further comments. 
Thank you for completing the questionnaire 
E2.2 Noti fying jur isdict ions quanti tat ive responses f rom quest ionnaire 
1. What jurisdiction are you from? 
Victoria 
New South Wales 
Queensland 
South Australia 
Western Australia 
Tasmania 
Northern Territory 
Australian Capital Territory 
1. USEFULNESS 
Please rate your agreement on the following objectives of the national 
notification of varicella: 
i i l ! 4 mmm 
14.3% 
0.0% 
14.3% 
14.3% 
14.3% 
14.3% 
14.3% 
14.3% 
I Strongly disagree 
I Disagree 
I Neutral 
I 
I Strongly agree 
i m 
Hi I I 
Apar t f rom the objectives listed above, are there any other objectives of the 
varicella notification s y s t em that y o u can think o f ? 
Who are the main users of varicella notification data? 
CoTimonvwahh 
Surveillance staff 
Has national notification system for varicella led to public health action in 
the following: 
Your jurisdiction 
Has the national notification system for varicella led to changes in public 
health policy in the following 
I Unsure 
• No 
• Yes 
Your Jurisdiction 
To your knowledge, has varicella notifications led to the generation of 
national reports? 
Does follow-up occur If the following Individuals are notified varicella 
(chlckenpox) c a s e s ? 
I Unsure 
I No 
I Yes 
Infants Schoolchildren Indigtnous rdivduals 
fteonates ChUien ag«d 1-5 years Pregnant-ftomen Other 
If yes, please select what follow-up Is conducted. 
• Unsure 
• No 
l Y e s 
Clinician interview Venfication of 
vaccination status 
Are varicella (chlckenpox) outbreaks that occur recorded by your 
jurisdiction? 
I Yes 
• No 
I Unsure 
Do you collect any extra information from varicella cases that Is not sent to 
theNNDSS? 
I No 
I Unsure 
In your view, please rate the public health importance of varicella. 
I Extremely Irrjportanl 
I Important 
I Neutral 
I Unimportant 
I Extremely Unimportant 
ACCEPTABILITY 
Do you think notifying varicella is a good use of your time? 
l Yes 
• No 
• Unsure 
Do you thinl( that the current requirements for varicella (chickenpox) case 
reporting in States and Territories is adequate? 
I Yes 
• No 
I Unsure 
SIMPLICITY 
Compared to other notifiable disease, is it easy to report varicella to the 
NNDSS? 
I Yes 
• No 
• Unsure 
Do you think that the flow of information on varicella notifications to and 
from the NNDSS is adequate? 
• Yes 
• No 
• Unsure 
OTHER 
Do you think that varicella should be notifiable in your jurisdiction? 
I Yes 
• No 
I Unsure 
E3.1 Non- Notifying Jurisdictional Stal^eholder Questionnaire 
Instructions on answering 
The National Centre for Immunisation Research and Surveillance (NCIRS) is 
currently undertaking an evaluation of the national varicella notification. 
The aim of the evaluation is to assess the current notification surveillance 
system for varicella zoster in Australia. 
All questions refer to varicella (chickenpox) and varicella (shingle) unless 
otherwise stated. 
All information you provide will be confidential and de-identified. 
The questionnaire should take approximately 5 minutes to complete. 
Question 1. What are the reasons for not making varicella notifiable in your jurisdiction? 
Question 2. In your opinion, what are the strengths of the national system for varicella, 
for Australia overall? 
Question 3. In your opinion, what are the limitations of the national notification system 
for varicella, for Australia overall? 
Question 4. In your opinion, how could the national varicella notification system be 
improved, for Australia overall? 
Question 5. Do you think that varicella should be notifiable in your jurisdiction? 
Question 6. Please give your reasons. 
Question 7. Further comments. 
Thank you for completing the questionnaire 
E4.1 Commonwealth Stakeholder Questionnaire 
Instructions on answering 
The National Centre for Immunisation Research and Surveillance (NCIRS) is 
currently undertaking an evaluation of the national varicella notification. 
The aim of the evaluation is to assess the current notification surveillance 
system for varicella zoster in Australia. 
All questions refer to varicella (chickenpox) and varicella (shingle) unless 
otherwise stated. 
All information you provide will be confidential and de-identified. 
The questionnaire should take approximately 15 minutes to complete. 
Question 1. What is your role in varicella notifications in your jurisdiction? 
Question 2. Please rate you agreement on the following objectives of the national 
notification of varicella: 
Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
The incidence of varicella infection 
in the Australian is being measured. 
-specifically in unimmunised 
children 
-in unimmunised adults 
-in Indigenous children. 
-in Indigenous adults 
Vaccine effectiveness over time 
can be measure by age group. 
Vaccine effectiveness over time 
can be measured by vaccine 
schedule. 
The changes in the epidemiology of 
zoster in Australia are being 
monitored. 
Further connments 
Question 3. Apart from the objectives listed above, are there any other objectives of the 
varicella notification system that you can think of? 
• Yes 
• No 
• Unsure 
Question 4. If yes, please list these objectives. 
Question 5. Are these objectives being met by the current varicella notification 
system? 
• Yes 
• No 
• Unsure 
USEFULNESS 
This section aims to determine how helpful the notification system is to public health 
staff. 
Question 6. Who are the main users of varicella notification data? 
• Jurisdictional Surveillance Officers 
• Jurisdictional Immunisation Coordinators 
• Commonwealth Surveillance staff 
• Commonwealth Immunisation staff 
• Researchers 
• Other 
If other (please specify) 
Question 7. What are the uses of notification data, nationally? 
Question 8. Has national notification system for varicella led to public health action in 
the following? 
Yes No Unsure 
National 
Question 9. Please provide details (if relevant). 
Question 10. Has the national notification system for varicella led to changes in public 
health policy in the following? 
Yes No Unsure 
National 
Question 11. Please provide details (if relevant). 
Question 12. To your knowledge, has varicella notifications led to the generation of 
national reports? 
• Yes 
• No 
• Unsure 
Question 13. Please provide details. 
ACCEPTABILITY 
The aim of this section is to measure how willing you are to participate in the current 
notification system. 
Question 13. In your view, please rate the public health importance of varicella 
• Extremely important 
• Important 
• Neutral 
• Unimportant 
• Extremely unimportant 
Question 14. Do you think notifying varicella is a good use of you time? 
• Yes 
• No 
• Unsure 
Question 15. Please provide details (if any). 
Question 16. Do you think the current requirements for varicella (chickenpox) case 
reporting in States and Territories is adequate? 
• Yes 
• No 
• Unsure 
Question 17. Please provide details. 
the 
national varicella notiTicaiion system < 
SIMPLICITY 
This section aims to ascertain the structure of the system and its ease of operation. 
Question 19. How would you describe the flow of information to the Department of 
Health and Ageing. 
Question 20. In your opinion, do you think it is easy to report notifications to the 
NNDSS? Please explain your answer. 
FLEXIBILITY 
Question 21. How flexible do you think the national notification system is to change (for 
example to detect outbreaks once varicella incidence becomes low)? 
STABILITY 
Question 22. Do you think the notification system is stable in the following areas? 
Yes No Unsure 
Data transfer 
Back-up of data 
Storage of data 
Release of data 
Unscheduled 
outages 
Capacity to run 
efficiently 
Maintenance 
This section seel<s information on your views on the national notification system for 
varicella. 
Question 23. In your opinion, what are the strengths of the national system for varicella, 
for Australia overall? 
Question 24. In your opinion, what are the limitations of the national notifications 
system for varicella, for Australia overall? 
Question 25. In your opinion, how could the national varicella notification system be 
improved, for Australia overall? 
Question 26. Further comments. 
Thank you for complet ing the questionnaire 
E5.1 Detailed case definitions of data sources used 
APSU/PAEDS' ' 
Disease Case definition 
Congenital 
Varicella 
Any stillbirth, newborn infant, or child <2 years w/ho, in the opinion of the 
notifying paediatrician has definite or suspected congenital varicella 
syndrome, with or without defects and meets at least one of the following 
criteha: 
• Cicatricial skin lesions in a dermatomal distribution and/or pox like 
scars and/or limb hypoplasia 
• Development of herpes zoster in the first year of life 
• Spontaneous abortion, termination, stillbirth or early death following 
varicella infection during pregnancy 
Neonatal 
Varicella 
Any infant who, in the opinion of the notifying paediatrician, has neonatal 
varicella based on history (maternal varicella infection in the last 1-4 weeks 
of pregnancy of contact with a varicella infected person after birth), clinical 
and/or laboratory findings in the first month of life without features of 
congenital varicella syndrome. Features include: 
• Pox-like rash which may be papulovesicular, vesiculopustular or 
haemorrhagic and fever. 
• Systemic symptoms may be present. 
Confirmation of diagnosis: 
• Viral antigen/viral isolate from scrapings of the skin lesions or viral 
DNA from lesion fluid. 
• Varicella specific IgM in a serum sample from the neonate or contact 
Severe 
complications 
of varicella 
infection 
Any child aged 1 month - <15 years, hospitalised with varicella and one or 
more of the following complications: 
• Bactaremia/septic shock 
• Toxic shock syndrome/ toxin mediated disease 
• Septic arthritis or other focal purulent collections 
• Necrotising fasciitis 
• Encephalitis 
• Purpura fulminans/disseminated coagulopathy 
• X-Ray evidence of pneumonia 
• Fulminant varicella (multi-organ involvement) 
• Reye's syndrome 
• Ataxia 
Emergency Department visits (personal communication: Sophie Norton) 
Disease Cases 
Chickenpox 
Keywords for chickenpox in diagnoses are coded based on the 
Australian edition of the International Classification of Diseases, 
version 9 and version 10, Clinical Modification (ICD-9-CM and ICD-10-
CM) and the Systemized Nomenclature of Medicine Clinical 
Terminology (SNOMED CT). These classification systems were used 
in during different periods in different hospitals. A chickenpox 
presentation was recorded if it was the first provisional ED diagnosis. 
Shingles 
Keywords for shingles in diagnoses are coded based on the Australian 
edition of the International Classification of Diseases, version 9 and 
version 10, Clinical Modification (ICD-9-CM and ICD-10-CM) and the 
Systemized Nomenclature of Medicine Clinical Terminology (SNOMED 
CT). These classification systems were used in during different periods 
in different hospitals. A chickenpox or shingles presentation was 
BEACH^' 
Disease Cases 
Chickenpox International Classification of Primary Care, version 2(ICPC-2) code 
A72. 
Shingles International Classification of Primary Care, version 2(ICPC-2) code 
S70. 
E6.1 Notifications of chickenpox and shingles, Australia, 2006-201 
NNDSSVZV notifications for chickenpox by month identified that peaks occurred during 
springtime (September/October). During 2009, a peak was also observed in April. As 
peaks in notifications did not occur in January to March, it was concluded that the 
BEACH March to April year could be compared to the calendar year (which is what is 
used for NNDSS data). 
Figure E6.1 Notifications of chickenpox and shingles, Australia, 2006-2012*'^ 
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E7.1 Sensitivity and Specificity of tests used to diagnose varicella zoster 
virus infection 
IE 
Virus antigen detection by IF is a rapid (~ 2 hours)®^ and simple test nnethod that can 
be used for early diagnosis. The test is highly sensitive (97-98%) and highly specific 
(100% when clinical diagnosis is considered the gold standard).®^ 
Virus culture 
Viral isolation through cell culture is a diagnostic test for varicella zoster however can 
be difficult and slow. Test sensitivity is 49 .4- 65% but is also dependent on the speed 
of processing following specimen collection.®^ Additionally, the sensitivity of cell culture 
is affected by how old the lesion is from where the specimen was taken as well as anti-
viral treatment in an individual. Suspected varicella zoster isolates can be confirmed 
with direct IF. 
Serology 
Detection of virus-specific antibodies using paired acute or convalescent sera can be 
used to diagnose varicella zoster infection. However, the reliability of this method is 
lower for varicella zoster (shingles) due to the presence of specific antibodies. 
®^Specimen collection should occur as soon as possible following rash onset to capture 
rising titres.®^ Within days of onset of primary infection, VZV-specific IgM are produced 
in the body but are also produced in approximately 70% of individuals with varicella 
zoster (shingles).®^ Detection of VZV-specific IgM in serum suggests recent infection.®^ 
False negative results for varicella zoster (shingles) may occur during early 
presentation due to waning IgG below detectable levels.®'' A number of sensitive 
enzyme-linked immunosorbent assays (ELISA) are available to measure VZV -specif ic 
antibody including enzyme Immunoassay (EIA), latex agglutination and fluorescent 
antibody to membrane antigen (FAMA).®^ Cross-reactivity between varicella zoster 
virus and herpes simplex virus can occur leading to difficulties in interpreting test 
results.®^ 
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Prologue 
My role and lessons learned 
During the MAE, I was given a number of opportunities to teach. This included Lessons 
From the Field (LFF), a 3.5 hour Introductory to Epi Info™ version 7 workshop 
conducted by the MAE 2012 cohort and providing teaching support during the 2013 
outbreak investigation course. 
My LFF was on measles elimination, a subject that I have had the opportunity to be 
involved in, through participating in the Measles Elimination Working Group. Using a 
framework of measles elimination criteria, I initially thought that it would be worthwhile 
for my colleagues to assess the elimination status of Australia. However, it became 
quite clear early on, that this could not occur as it would involve accessing a lot of 
sensitive data that at the time was being compiled, analysed and interpreted by the 
Measles Elimination Working Group. Instead, I provided data from a hypothetical 
country, with the main objective for my colleagues to follow the framework, and based 
on the compiled evidence, assess whether measles has been eliminated in the country. 
LFF was a really enjoyable component of the MAE, both as a teacher and a student. 
Developing the LFF student guide was a new experience for me and I found it quite 
challenging to create a lesson from scratch, however, I feel that I learnt a great deal 
from it. 
Following initial review by Steph, I learnt that the learning objectives that I had listed 
were not assessable. For example, one objective was 'to learn' which is not 
measurable. Also, I also learnt that my first LFF draft was too time consuming and that 
all activities in the LFF should always go back to the learning objectives. If they were 
not meeting these objectives, it was unnecessary to include them as a question or task. 
Another important lesson learnt was that I needed to be more to be more careful in 
defining terms such as what a 'locally acquired' case was. I realised this, after receiving 
responses from my MAE cohort. A number of them had interpreted this to mean 
acquiring an endemic strain of measles virus. This ultimately impacted on the 
conclusions of whether measles had been eliminated and thus resulted in conflicting 
responses to what I originally had formulated. 
The Epi Info™ version 7 teaching session admittedly was quite a daunting experience. 
Many of the participants were MAE alumni and well known public health experts. I was 
responsible for teaching on questionnaire development. This required preparing the 
student handout and facilitating this session during the workshop (including developing 
a power point presentation). I also had to be familiar with the content from the other 
sessions in the workshop to assist my fellow MAE colleagues. My only experience 
using Epi Info™ version 7 had been during the previous year's outbreak investigation 
course. The requirement to teach others something I had limited experience in, 
resulted in me spending time to ensure I understood the functions of Epi Info™ version 
7. It was also a good opportunity to review my teaching style and communication 
techniques. One important lesson I learnt was that I needed to engage more with 
participants during my session, rather than directing them what to do and telling them 
the answers. I also learnt that it can be challenging to clearly explain concepts to 
others, even when you feel confident in your own knowledge. I hope this will improve 
with more experience teaching others. Ranll kindly nominated to draft an evaluation 
questionnaire for the workshop which is included in the Appendix. 
Lastly, during two sessions in the outbreak investigation intensive course, I assisted the 
course convenor with two case studies. One involved facilitating a case study on 
arboviruses, whilst another was an introduction to Epi Info™. In reflection, this was a 
great opportunity to review my own development over the past year, from being a 
student in this course, to the following year, assisting in the teaching. Similar to the Epi 
Info session, I found it a good opportunity to try to explain concepts to others in a 
concise manner. Another important lesson I learnt was that teaching is not easy. We 
have been fortunate to have such incredible teachers during our MAE who make it look 
effortless, and these teaching experiences made me realise that a lot of hard work and 
planning goes into preparing and facilitating lessons. 
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F1. Lessons from the field- Student guide with answers 
Lessons From the 
Field 
The Verification of Measles Elimination in 
the Western Pacific: Has Country X 
achieved elimination? 
May Chiew 
Master of Philosophy Applied Epidemiology (MAE) Scholar 
Australian National University (ANU) & 
National Centre for Immunisation Research & Surveillance (NCIRS) 
10 June 2013 
The learning objectives for this Lesson From the Field are that by the end of 
this session participants will be able to: 
• describe the difference between disease elimination and disease 
eradication; 
• discuss the framework for the verification of measles elimination; 
• calculate a measles discard rate; 
• estimate R using proportion of imported cases; 
• assess the evidence provided using the framework for verification and 
consider elimination in the context of Country X; 
• determine the feasibility of the framework in a low-resource setting and 
consider barriers that may impede measles elimination; 
• list of the characteristics of measles that makes eradication biologically 
and technically feasible. 
Readings: 
1. World Health Organization (2013). "Framework for verifying elimination of 
measles and rubella." Weekly epidemiological record 9(88): 89-100. 
2. De Serres, G., Gay N. J., et al. (2000). "Epidemiology of transmissible diseases 
after elimination." American Journal of Epidemiology 151(11): 1039-1048. 
(Optional) 
Part 1: Case Study Introduct ion 
Following the completion of your MAE, you have moved to the small idyllic island of 
Country X in the Western Pacific Region to be their newly employed Infectious Disease 
(ID) Epidemiologist. 
Your Director informs you that one of your first roles as the only ID Epidemiologist on 
the island is to gather all the evidence for the Regional Measles Verification Committee 
to assess whether measles elimination has been achieved in Country X. She informs 
you that this work is important, as 2012 was the set target year for elimination and all 
Member States are required to submit the evidence to Western Pacific Regional Office 
(WPRO) by the end of the year. 
Unsure of where to start, she hands you a copy of the March edition of the Weekly 
Epidemiological Record (Reference 1) and recommends that you read the article 
'Framework for verifying the elimination of measles and rubella' and follow the 
framework as a guide to assess the elimination status of Country X. 
Before you start you would like to refresh what disease elimination and disease 
eradication are. 
Question 1. Please define disease elimination and eradication and explain the 
dif ference between the two. (5 minutes) 
Ee Laine 
Eradication = Worldwide interruption of disease transmission with permanent 
reduction to zero incidence of infection as a result of deliberate efforts 
Elimination = The absence of endemic transmission in a defined geographical 
area (e.g. region or country) for >12 months as a result of deliberate efforts. 
Continued intervention measures required for disease elimination, but not for 
necessarily eradication (although ongoing surveillance may be required. Zero 
incidence of disease in eradication, but not in elimination as there may be 
sporadic cases with no evidence of transmission. 
You decide to go through the Framework systematically and consider the 5 lines of 
evidence for the verification of measles elimination: 
1. A detailed description of the epidemiology of measles since the introduction 
of measles in the national Immunisation program 
2. Quality of epidemiological and laboratory surveillance systems for measles 
3. Population immunity presented as a birth cohort analysis with the addition of 
evidence related to an underserved and marginalised groups 
4. Sustainability of national immunisation programmes, including the resources 
for mass campaigns, where appropriate, in order to sustain measles elimination 
5. Genotyping evidence that supports measles virus transmission is interrupted 
In Country X, a national measles vaccination program was rolled out in 2004, where a 
two-dose schedule was funded for children 12 months old (primary dose) and 4 years 
old (booster dose). 
The case definition of a confirmed case of measles in Country X is an individual with 
laboratory confirmation of measles by: Positive serological test for measles IgM 
antibody or; Isolation of measles virus or; Detection of measles-virus nucleic acid by 
polymerase chain reaction (PCR) or; A fourfold or greater rise in measles antibody 
level or IgG seroconversion (except if the individual had received a measles containing 
vaccine eight days to eight weeks before testing). A confirmed case could also be an 
individual with clinical evidence of disease including: a generalised rash lasting >3 days 
and; temperature 38°C and; cough, coryza, or conjunctivitis; and an epidemiologic 
linkage to a confirmed case of measles. 
Line of Evidence 1. A detailed description of the epidemiolopy of measles since the 
introduction of measles in the national immunisation program 
Fortunately, the previous ID epidemiologist conducted descriptive analysis on 
confirmed measles cases in Country X in 2002-2012 and has left the output for you to 
use. 
Graph 1- Notification rate of confirmed measles cases, 2002-2012 Country X 
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Question 2. Please interpret Graph 1. (5 minutes) 
Alexis 
Between 2002-2004 there was a decrease in confirmed measles notifications 
from >5/100,000 to -2/100,000. Following the introduction of the national 
vaccination program in 2004, rates decreased progressively from -2/100,000 in 
2009. There has been a slight increase in notifications since the low in 2009. 
Graph 2- Proportion of cases with a known source of infection by importation 
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Question 3. Please interpret Graph 2. (5 minutes) 
My comments: 
I should have defined what local meant as it was interpreted by many that this 
meant endemically acquired measles. Based on this, Ee Laine provided a good 
interpretation of the graph. 
Ee Laine 
Before 2006, a very high proportion of measles were locally acquired (except in 
2002), indicating endemic transmission. From 2006 onwards, there was a 
continued decline of locally acquired measles, which was taken over by imported 
cases and lmport_related cases. By 2011-12, the majority of cases were 
imported with zero locally acquired cases. The proportion of import_related cases 
has declined from 2006 onwards, suggesting a decline in the chain of local 
transmission from imported cases. 
Table 1. The proportion of cases by known source of infection by year, Country 
X, 2002-2012 
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
Known 
source 
(%) 
70,3 47.3 63.4 55.4 71.8 93.3 95.8 80.0 83.3 84.2 87.5 
Unknown 
source 
(%) 
29.7 52.7 36.6 44.6 28.2 6.7 4.2 20.0 16.7 15.8 12.5 
Question 4. Please interpret the results in Table 1. (5 minutes) 
Rowena 
Prior to 2007 there is less information available about the source of infection with 
between 2 8 - 5 3 % of sources unknown. From 2007 onwards, we have greater 
information regarding source of infection with only 4 - 1 7 % of infections acquired 
from an unknown source. This could possibly be the product of rarer occurrences 
of measles making it more realistic to follow up all suspected cases, or better 
surveil lance follow up of cases following the introduction of the vaccine (although 
if this was the case you'd expect more about source of infection from 2004 
onwards). 
Line of Evidence 2. Quality of epidemiological and laboratory surveillance systems for 
measles 
Country X has a central laboratory which tests for measles. It is conveniently located 
next door to the health department. You organise a meeting with the virologist at the 
laboratory so you can ascertain the quality of laboratory surveillance in Country X. 
Questions: 5 What questions would you ask? (5 minutes) 
Rowena 
Is the lab WHO accredited? 
Which measles testing they do (i.e. PCR, serology and/or IF) and the 
sensitivity and specificity of these tests 
What is the turnaround time to perform the tests and inform public health of 
positive result? 
Are they able to perform measles genotyping? 
Number of measles tests performed including positive and negative 
specimens 
Where are they receiving specimens from (e.g. is it only hospitals or are 
GP's testing too?) 
The virologist is very forthcoming with answering all your questions. 
The laboratory is WHO accredited for serological and virological measles tests and 
services the entire country. Quality assurance mechanisms are in place at the 
laboratory for measles testing and occur annually. Approximate 82% of serological 
results are reported to the laboratory within 4 days of receiving the specimen. 
He also provides you a table of IgM, PCR and IF tests conducted between 2007 and 
2012 (by test type) and the number of tests that were positive. 
T a b l e 2. N u m b e r of pos i t i ve a n d tota l t es ts by test t y p e a n d year ( 2 0 0 7 b e t w e e n 2 0 0 7 - 2 0 1 2 
Year 
2007 2008 2009 2010 2011 2012 
Test type 
Positive Total tests Positive Total tests Positive Total tests Positive Total tests Positive Total tests Positive Total tests 
IgM 5 13 3 6 1 3 1 8 2 11 1 11 
PGR 20 121 12 89 3 100 8 120 11 120 5 79 
IF 5 16 9 40 1 20 3 20 6 20 2 16 
Total 30 150 24 135 5 123 12 148 19 151 8 106 
The reporting rate of non-measles cases (discard rate) = No.negative tests ^ 100,000 
Population estimate 
He also answers all your questions: 
Question 6. Calculate the national measles discard rate for the combined years 
2007-2012. (5 minutes) 
Ee Laine 
Total tests = 150+135+123+148+151+106 = 813 
Total positive tests = 30+24+5+12+19+8 = 98 
Total negative tests = 813-98 = 715 
Total population estimate (2007-2012) = 21641298 
Discard rate = 715/ 21641298 x 100,000 = 3.3 per 100,000 
Question 7. How might sensitivity and specificity of tests impact on the result? 
Are there any other biases you can thinl< of? (5 minutes) 
My comments 
Rowena had an excellent response but did not mention the possible biases. Ee 
Laine pointed out some important biases including the selective testing of cases 
with suspected illness. If testings are only performed on cases with a high index 
of suspicion, this could result in a higher proportion of positive tests. Conversely, 
If testing is done indiscriminately, this may result in a higher proportion of 
negative tests. Additionally, I had in my answer that screening of individuals for 
measles immunity could overestimate the discard rate, if included in this 
analysis. 
Rowena 
A high sensitivity will increase the probability that the test results will be positive 
in people who truly have measles, (i.e. high proportion of true positive results). 
Conversely a test that has lower sensitivity will be more likely to give more falsely 
negative results, falsely labelling people with measles as non-measles cases and 
underestimating cases numbers. 
High specificity will correctly return negative test results in people who don't have 
measles (i.e. High proportion of true negatives). Lower specificity will give more 
false positives (i.e a high proportion of people who don't have measles will have 
lab results indicating they do have measles, thus overestimating measles case 
notifications). 
To find out more about the quality of epidemiological surveillance in Country X, you go 
through a number of annual reports back at the office. You discover that since 2000, 
the investigation of suspected cases of measles and specimens were taken for 81% of 
all suspected cases. Upon looking at your data, you also find that at least one 
confirmed case for every identified outbreak had a specimen that was genotyped. 
Question 8. Based on the evidence you collected about laboratory and 
epidemiologic surveillance, can you conclude that they are of high quality in 
Country X? (2 minutes) 
Ee Laine 
The data reviewed fulfilled the targets outlined in the indicators for quality of lab 
reporting: 
• Discard rate is within the target of >2 cases per 100,000 
• Results reported within 4 days of specimen receipt 
• Over 80% of suspected cases investigated and specimens collected 
(although it is not clear if adequate specimen was taken). 
Furthermore, genotyping information was obtained for at least one confirmed case for 
every identified outbreak. There were also continued improvements in information on 
source of infection. 
To determine the coverage of measles containing vaccine (MCV- primary (MCV1) and 
booster dose {MCV2)), you access the childhood immunisation register. The register is 
estimated to capture 98% of all children under the age of 8 in Country X. You analyse 
two birth cohorts, children aged 2 years (MCV1- to measure the primary dose of 
measles containing vaccine) and children aged 5 years (MCV2- to measure the 
booster dose of measles containing vaccine). Coverage of MCV1 was 92% and MCV2 
89% and based on geography, there was little heterogeneity in coverage around the 
country. 
Question 9. Can you think of any reason that might lead to the underestimation 
of coverage rates? (5 minutes) 
My comments 
This question may have been difficult to answer without knowledge of the caveats to 
immunisation registry data, such as what is experienced in Australia. 
My answer 
It is possible that not all immunisations are recorded by the register and there is 
under-reporting of vaccination status. This was observed in Australia where the 
Australia Childhood Immunisation Register underestimated MCV1 by 3-5% and 
MCV2 by 5-10%. If this is the case in Country X, it is likely that the coverage rates of 
each birth cohort is high (i.e. > 95%). 
Estimating an effective reproduction number using the proportion of imported 
cases 
Complementary evidence of population immunity is the estimation of the reproduction 
number (R). R is the average number of secondary cases that results from an 
infectious case in a particular population. When R= 1, a state of endemic equilibrium 
exists where on average one case results in one secondary infection. When R > 1, the 
number of cases increases from one generation to the next, potentially resulting in an 
epidemic. In comparison, when R is maintained below 1, measles is considered to be 
eliminated. 
One method to estimate R is through the proportion of imported cases (please note: 
the assumption of this method is that measles has already been eliminated - for more 
information on the theory of this method, please refer to Reading 2) 
R = l -
No.of imported cases 
Total no. of cases 
Question 10. Based on the proportion of imported cases (below), estimate the 
reproduction number for individual years 2009-2012 and also the combined 
estimate of R for these years. Please interpret your results. (10 minutes) 
Import status 2009 2010 2011 2012 
Imported 
cases 2 2 10 6 
Total 5 10 16 7 
Alexis 
2009: R= 1 -2 /5 = 0.6 
2010: R= 1-2/10 = 0.8 
2011: R= 1-10/16 = 0.375 
2012: R= 1-6/7 = 0.143 
Total: R= 1-20/38 = 0.474 
R is the average number of secondary cases resulting from an infectious source case. 
With an R less than 1, as these results all are, measles is considered to be eliminated. 
Question 11. Based on the lines of evidence, is their strong evidence that 
population immunity is high? What other measures of population immunity 
exist? (5 minutes) 
Ee Laine 
Based on the vaccine coverage (assuming an under-estimation) and declining R, 
there is some evidence that population immunity is high. However further 
evidence will be needed - for e.g. vaccine coverage in sub-population groups 
(children, adolescents), vaccine effectiveness, outbreak duration, number of 
generations of measles transmission and proportion of import-related cases. 
Other measures of population immunity are seroprevalence surveys, 
supplementary immunisation activities, and those described above. 
Line of Evidence 4. Sustainabilitv of national immunisation proQrammes, including the 
resources for mass campaigns, where appropriate, in order to sustain measles 
elimination 
To determine how sustainable the current measles vaccination program and political 
commitment for measles elimination, you review a number of plans and reports in the 
office in relation to measles. This includes the bi-annual monitoring of the vaccination 
program, a proposal for the evaluation of the program in the coming year, an action 
plan for the financing and sustaining measles elimination and a risk assessment on the 
program. 
Question 12. Are there any other documents that you think may assist in 
enhancing the evidence? (2 minutes) 
Rowena 
Some of these documents may already be included as part of the bi-annual 
monitoring of the vaccine program & action plan but we'd want to make sure that the 
following are included: 
• Country X's budget showing ongoing item(s) dedicated to vaccination 
• Vaccine demand forecasting and stock management 
• Tools assisting standardised program implementation - i.e. 
guidelines/checklists for mass vaccine administration such as in school 
settings. 
Line of Evidence 5. Genotypinp evidence that supports measles virus transmission is 
interrupted 
The previous ID epidemiologist has also produced output on measles genotypes over 
the past decade. 
Graph 3 Number of cases by genotype in Country X, 2002-2012 
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Question 13. Please interpret Graph 3 with reference to the Framework (5 
minutes) 
Alexis 
There was a lot of D8 and D9 in 2002-2005. These were most likely the locally 
circulating strains. Following the introduction of the vaccination program, this has 
changed, and from 2005 the combination of strains each year is quite varied 
suggesting that endemically circulating strains have been replaced by imported 
ones. 
Question 14. After applying the framework for measles elimination and reviewing 
the evidence, do you think that measles has been eliminated from Country X? 
Please give your reasons. (5 minutes) 
My comments 
I received conflicting answers for this question with one colleague concluding that 
despite not having information on a number of Indicators, based on what was 
provided measles can be considered eliminated. I think it reflects the difficulty In 
assessing elimination verifications as all countries have different systems and in 
some way, Indicators in this framework may not be able to fit with each countries 
capacity. 
Ee Laine 
Looking at the essential verification criteria, I think that measles elimination has 
not been achieved in Country X 
• Documentation of the interruption of endemic measles transmission for a 
period of at least 36 months from the last known endemic 
o Criteria not met as there were only two years of absent locally 
acquired measles. 
o Furthermore, for import_related cases, we need to know if 
transmission occurred for how many generations after importation - at 
what point do we define this as sustained transmission that occurred 
locally? 
• the presence of a high-quality surveillance system that is sensitive and 
specific enough to detect imported and import-related cases; 
o Criteria met as there is some evidence of high quality of 
epidemiological evidence (over 80% of source known, over 80% of 
suspected cases investigated and specimens collected) 
• Genotyping evidence that supports the interruption of endemic transmission 
o Criteria not met if the circulating endemic strains (D8 and D9) are not 
found elsewhere in the world. 
• Population immunity presented as a birth cohort analysis with the addition of 
evidence related to any marginalised and migrant groups 
o I think we need vaccine coverage of 95% for measles, so the current 
coverage remains inadequate. Also we do not have sufficient 
information on coverage in specific populations 
Question 15. As measles elimination becomes a priority in less developed 
countries, how feasible do you think these guidelines are in low resource 
settings? (5 minutes) 
Rowena 
For countries getting close to elimination; 
• Groups of susceptible people who live in close proximity (e.g. 
geographical areas of conscientious objectors, non-immune immigrant 
communities) 
• Delay in diagnosis of measles (particular as it becomes rarer and health 
providers no longer recognise symptoms) thus decreasing the ability of 
public health authorities to isolate, vaccinate or administer immunoglobulin 
to prevent further cases. 
• Increased international travel, increasing cases being imported 
• Ability of the virus to infect susceptible hosts (?up to 4 hours after leaving 
a room!) 
For developing countries; 
• Lack of resources including money to fund sustainable vaccination 
program 
• Conflicting priorities (e.g famine, war) 
• Lack of infrastructure (e.g. to store vaccines, accredited labs to test) 
• Lack of political willpower 
Question 16. What do you think are the main barriers to achieving disease 
elimination in a country? (5 minutes) 
Ee Laine 
• Lack of political will, commitment and funding for immunisation program and 
vaccine procurement 
• Lack of a clear national strategy to provide direction and coordinate 
interventions to support elimination 
• Lack of collaboration and partnerships from different groups to implement 
the strategy 
• Lack of adequate infrastructure including laboratory support and surveillance 
• Lack of a mechanism for effective vaccine delivery 
• Lack of demand or distrust from the general public wanting vaccination 
Quest ion 17. What are the propert ies that make the eradicat ion of measles 
feasible? (5 minutes) 
Ee Laine 
Properties related to the disease 
• Humans are the only hosts for the virus and the main mode of transmission 
(i.e. no environmental or animal reservoir) 
• Diagnostic tools available 
• Long lasting immunity resulting from infection or vaccination 
• Presence of a highly effective vaccine 
Properties related to social and political climate 
• Strong political commitment to do so w/orldwide, including funding 
• Global partnerships and coordination towards eradication 
Evidence that it is possible to eliminate the disease in a large geographical area, 
therefore malting it feasible to consider eradication 
End of Lessons From the Field 
Thanks for your t ime! 
F2. Workshops for Communicable Disease Control Conference 2013 
F2.1 Introduction to Epi Info™ Version 7 
Summary of session outline 
Topic Format Time (pn;i) 
Topic 1: Welcome and introduction 
• Introduction - staff and participants 
• Logistics 
Round table 1 . 3 0 - 1 . 4 0 
Topic 2: Introduction to Epi Info and the training 
session 
• Learning objectives 
• Epi Info 
o Overview 
o Capabilities and uses 
• Format of session 
Power point presentation 1 . 4 0 - 1 . 5 5 
Introduction to case study Power point presentation 1 . 5 5 - 2 . 0 0 
Topic 3: Questionnaire and maps 
• Learning objectives 
• Introduction to questionnaires and maps 
• Create form 
• Enter data 
• Create a cluster map 
Power point presentation 
Instruction demonstration 
Participant activities 
2 . 0 0 - 3 . 0 0 
Break for 15 minutes 
Topic 4: Overview of data analysis 
• Classic and visual dashboard 
Power point presentation 3 . 1 5 - 3 . 2 0 
Topic 5: Data analysis using visual dashboard 
• Learning objectives 
• Data import / export, open Epi Info 
dataset 
• Descriptive statistics 
o Frequency tables, summary 
statistics 
• Recode variables 
• Create graphs / epi curve 
. 2x2 tables 
Instruction demonstration 
Participant activities 
3 . 2 0 - 4 . 1 5 
Topic 6: Classic analysis Instruction demonstration 4 . 1 5 - 4 . 3 0 
Topic 7: Stat calc 
• Introduce the range of statistical 
functions and when to use them 
• Use Stat calc to assess if t cases occur 
by chance 
Power point presentation 
Instruction demonstration 
Participant activities 
4 . 3 0 - 4 . 4 5 
Summing up discussions and final questions 
Evaluation forms 
Instructor leads discussion 4 . 4 5 - 5 . 0 0 
F2.2 Ep i ln fo™ 7 workshop presentat ion 
Topic 3 
Questionnaires and IVIaps 
in Epi Info™ 
Instructors: Rowena Boyd and May Chiew 
Session Outline 
• Learning objectives 
• Introduction to questionnaires and mapping 
• Developing a questionnaire 
- a e a t n g a new Project 
-aeafingdrflerenineKl types 
- using trie Check Code Editor 
- finalising andtonnafflng 
• Entering data into a questionnaire 
• Creating a cluster map 
Objectives 
• Create a new Project in Form Designer 
• Create different field types using the Form 
Designer module 
• Add intelligence info Forms 
• Format a questionnaire 
• Use templates in a questionnaire 
• Enter data in different field types 
• Create a cluster map based on information in 
a dataset 
The menu 
Question FteM name Field Type Categohes/Pattem 
Surname surname Text 
Age age Numoer mt 
Date of blilti dob Date DD/MM/YYYY 
Sex sex Legal Values Male 
Female 
Unknown 
Sex sex Comment legal 
vauies 
1-Male 
2-Female 
3-Unknown 
Current smoker 
Past smoker 
Non smoker 
smokingstatus CheckDox 
Didyou consume 
chicken'' 
chicken YesJNo Yes/No 
F2.3 Epi In fo™ Vers ion 7 WorkshopEva lua t ion Quest ionnai re 
This is a short evaluation of the Epi Info 7 course that was run on 18 March 2013. 
Thank you for taking the time to complete this form. The information will be used to 
improve future sessions. 
1. How well organized was the Epi Info™ 7 course? 
• Extremely organized 
• Very organized 
• Moderately organized 
c Slightly organized 
• Not at all organized 
2. How useful to your job was the information presented at the Epi Info™ 7 
course? 
• Extremely useful 
• Very useful 
• Moderately useful 
• Slightly useful 
• Not at all useful 
• Other (please specify) 
3. How much have your skills improved because of training at the course? 
• A great deal 
• A lot 
• A moderate amount 
• A little 
• None at all 
4. How comfortable did you feel asking questions at the course? 
• Extremely comfortable 
• Very comfortable 
• Moderately comfortable 
• Slightly comfortable 
• Not at all comfortable 
5. How friendly were the presenters? 
• Extremely friendly 
• Very friendly 
• Moderately friendly 
• Slightly friendly 
• Not at all friendly 
6. Did the presenters allow enough time for the computer exercises? 
• Much too much 
• Somewhat loo much 
• Slightly too much 
• About the right amount 
• Slightly too little 
• Somewhat too little 
• Much too little 
7. H o w e a s y w a s it to k e e p up w i th the e x e r c i s e s ? 
Extremely easy 
Very easy 
Moderately easy 
Slightly easy 
Not at all easy 
W h a t s u g g e s t i o n s d o you h a v e for imp rov ing th is Ep i I n f o ™ c o u r s e if it w e r e to 
be run a g a i n ? 
Overa l l , h o w sa t i s f ied w e r e you w i th t h e Ep i Info 7 c o u r s e ? 
• Extremely satisfied 
• Moderately satisfied 
• Slightly satisfied 
• Neither satisfied or dissatisfied 
• Slightly dissatisfied 
• Moderately dissatisfied 
• Extremely dissatisfied 
10. If you h a v e a n y c o m m e n t s abou t t h e Epi Info 7 cou rse , p l ease wr i t e t h e m 
be low: 
T H A N K Y O U F O R C O M P L E T I N G T H I S E V A L U A T I O N ! ! 
F2.4 Evaluation of the Introduction to Epi Info 7 workshop 
At the completion of the Epi Info 7 teaching exercise, an evaluation form was handed 
out to all the participants. Ten responses were received. The responses to the 
questions in the evaluation forms appear below: 
1. How well organized was the Epi Info 7 course? 
Two of the ten participants (20%) stated It was "extremely organized", eight (80%) 
stated it was "very organized" and 1 participant (10%) stated it was "moderately 
organized". 
2. Had you used Epi Info before ttiis session (you can tick more than one box)? 
Three participants (30%) answered "Yes - a bit", two participants (20%) 
answered "Yes - but a long time ago", 4 participants (40%) answered "no" and 
one participant (10%) answered "Yes - but a long time ago" and "Yes- but an 
older version" 
3. How useful to your job was the Information presented at the Epi Info 7 course? 
Six participants (60%) answered that it was "very useful" and four participants (40%) 
answered that it was "moderately useful". 
4. How much have your skills improved because of training at the course? 
One participant (10%) answered " a great deal", four participants answered "a 
lot" and four participants (40%) answered a moderate amount. One participant 
did not answer the question. 
5. How comfortable did you feel asking questions at the course? 
Two participants (20%) answered "extremely comfortable" and eight participants (80%) 
answered "very comfortable". 
6. How friendly were the presenters? 
Five participants (50%) answered "extremely friendly" and five participants (50%) 
answered "very friendly" 
7. Did the presenters allow enough time for the computer exercise? 
Eight participants (80%) answered that it was "about the right amount", 1 participant 
(10%) answered that it was "slightly too little". One participant wrote: "varied sometimes 
too little, depended on program playing up" 
8. How easy was it to keep up with the exercise? 
Two participants (20%) answered that it was "extremely easy", four participants (40 %) 
answered that it was "very easy", and four participants (40%) answered that it was 
"moderately easy". 
9. What suggestions do you have for improving the Epi Info course if it were to be 
run again? 
Comments received were: 
• "Larger screen, sometimes difficult to see what presenter was doing. If 
bringing laptop, more information on system requirements" 
• "More exercises to work through" 
• "Invite participants to bring current dataset under investigation" 
• "Keep class size small" 
10. Overall, how satisfied were you with the Epi Info 7 course? 
Six participants (60%) answered that they were "extremely satisfied" and four 
participants (40%) answered that they were "moderately satisfied". 
11. If you have any comments about the Epi Info 7 course, please write them 
below: 
Comments received were: 
• "Thank you...now I'll know where to start when that outbreak hits!!" 
• "Good course materials" 
• "Thanks for allowing this great opportunity. Cheers" 
